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1 PREFACE
Many active pharmaceutical ingredients and their syntheses are often more 
than 20 years old, thus based on a different era of synthesis and also a different 
sense of the purpose of chemistry. In view of more environmentally benign and 
economically attractive processes, their synthetic routes are being improved 
continuously and can still be optimized by the manufacturing companies. 
Within these enhancements, homogenous and heterogenous methodologies 
are investigated by working groups specialized in the field of organo-, metal-
and biocatalysis, with increasing tendency to imitate nature. For example, 
organocatalytic processes are often based on proline derivatives, asymmetric 
synthesis are strengthened by using chiral auxiliars based on amino acids, 
functional-group interconversions (FGI) substitute expensive stoichiometric 
reagents by using cheap cosubstrates as donor or transfer reagents. By 
choosing a desired reaction from a complex cascade, it is often underestimated 
how the reaction system will behave and usually compromises have to be 
made. This can be seen in the general acceptance of certain mandatory 
structures where in some cases even the slightest alteration leads to 
incompatibility and a lack of conversion. The results are undesired enantiomers, 
side-products and maybe also unstable products. However, these drawbacks 
are also quite often readily circumvented by chemical methods. 
Joining this aim for an interdisciplinary change, the overall concept of this work 
was to further increase the implementation of biocatalysis into organic 
syntheses. To elucidate this, the following projects were focused on the 
production of various pharmaceutical target structures like statins, dipeptidyl 
peptidase inhibitors, HIV-1 protease inhibitors, antibiotics and dopamine 
β-hydroxylase inhibitors. By using alcohol dehydrogenases, proteases, lipases, 
aldoxime dehydratases and ene reductases, alternative processes for either well 
established or novel compounds were developed. By adjusting of the preceding 
or subsequent chemical steps, the previously discussed possible restrictions of 
biocatalysis were approached to demonstrate the high value for 
chemoenzymatic processes.
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2 CHEMOENZYMATIC SYNTHESIS OF ROSUVASTATIN
The following project was generously funded by Sandoz GmbH, Kundl, Austria. 
The aim of this collaboration was the establishment of an alternative synthetic 
route for the active pharmaceutical ingredient (API) of Crestor, Rosuvastatin. 
Rosuvastatin, as the name implies, belongs to the drug class of statins which 
are used for the treatment of dyslipidemia, i.e. for lowering the cholesterol 
levels, by inhibiting the enzyme 3-hydroxy-3-methyl-glutaryl-CoA reductase
(HMG-CoA reductase). Several approaches for the synthesis of the generici
were investigated. However, since it is always reasonable to stay with certain 
structures already established in Good Manufacturing Practices (GMPs) from an 
industrial point of view, most of the upcoming experiments were focused on a 
specific route (see Figure 1). Some accompanying ideas were only investigated 
to a minor extend and will appear in the respective chapters without impact on 
the final route. Nevertheless they are included in this work for the purpose of 
encouraging academical research in a broadened fashion, away from 
traditional chemistry towards alternative syntheses.
i A generic is defined as a copy of an established brand drug without the need for animal 
studies, clinical studies or tests regarding the bioavailability, because it is bioequivalent to its 
brand counterpart, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
Figure 1. General project 
overview with target mole-
cules throughout the synthe-
tic route towards Rosuva-
statin.
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2.1 PATENT EXPIRATION OF DRUGS AND THE POTENTIAL OF NEW 
PROCESSES FOR GENERICS
Currently the pharmaceutical industry is facing numerous blockbuster drugs 
losing their patent protection between 2011 and 2016. With the expiration of 
Pfizer’s Lipitor (generic name Atorvastatin), Eli Lilly’s Zyprexa (Olanzapine) and 
a couple of other patents in 2011, no less than 32.2 billion USD in drug sales 
became accessible to low-cost generics in 2012 alone1. In the next three years, 
27 more top-selling drugs will lose their patent protection (see Figure 2). This 
is already and will continue to be an unprecedented boost of process and drug 
development. 
Figure 2. Expired and
scheduled to be expiring
patent protection of 
pharmaceutical blockbusters 
between 2011 and 2016.1
Racemic or undefined compounds 
(green), achiral compounds (red), 
natural products with static
stereochemistry (blue) and 
enantiopure compounds (black)
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A close collaboration between industry and academia lies at hand, with room 
for improvements in all fields of chemistry, including biocatalysis. This is 
already reflected in the rise of publications aimed for new methodologies and 
sustainable organic synthesis for the production of generics. For example, new 
methods for the synthesis of statin side-chains have been developed and 
patented by various companies, e.g. Lek Pharmaceuticals and DSM.2,3 The 
extent of improvement varies from simple crystallization procedures to 
chemoenzymatic total syntheses. Codexis also developed a bienzymatic 
process for the synthesis of ethyl (R)-4-cyano-3-hydroxybutanoate, the chiral 
precursor for the side-chain of Atorvastatin.4 Starting from commercially 
available ethyl 4-chloro-3-oxobutanoate 4, they combined an enantioselective, 
biocatalytic reduction via ketoreductase (KRED) with a substitution process via
halohydrin dehalogenase (HHDH) (see Figure 3). The HHDH initially catalyzes 
the elimination of hydrochloric acid under formation of the chiral epoxide (S)-6
which is then hydrocyanated to the corresponding β-hydroxy nitrile (R)-7. After 
extensive molecular biological alterations, the recombinant enzymes overcame 
the drawbacks of their wild-type’s poor stability and low catalyst loadings, 
leading to a space-time yield of 672 g/L product per day, which was isolated in 
92% yield and had an excellent enantiomeric excess of >99.5% ee. Noteworthy, 
the highly toxic reagent hydrogen cyanide is produced in situ by an automatic 
acid-base titration with aqueous sodium cyanide as titer solution. Although 
sodium cyanide is also highly toxic, the described method allows an easier 
handling of this reagent and prevents the intoxication via inhalation or skin 
resorption. In this case the formation of hydrogen cyanide is coupled to the 
elimination of hydrogen chloride, which in the end reduces the concentration 
of hazardous free hydrogen cyanide to a minimum. Also from Codexis, a 
fascinating biocatalytic ketone reduction for the single stereogenic center of 
the leukotriene receptor antagonist Montelukast sodium (Singulair, Merck) is 
reported (see Figure 4, page 6).5 Usually, oxidoreductases have a very high 
enantioselectivity when specific steric properties of ketone substituents are 
fulfilled. High selectivities are achieved when one of these substituents are 
methyl-, chloromethyl- and ethyl-groups. 
Figure 3. Two-step, three 
enzyme process for the 
precursor of the Atorva-
statin side-chain by MA et 
al..4
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However, only a few examples in literature are highly selective for ketones 
bearing two bulky substituents.6 In the case of Montelukast, the prochiral bulky 
ketone 8 was reduced at a substrate concentration of 100 g/L with quantitative 
conversions, leading to yields of 90-98% and an excellent enantiomeric excess
of >99.9% ee. The expensive cofactor NADP+ (1 mg/g substrate) is regenerated 
in situ with the cosubstrate 2-propanol in a toluene/alcohol/buffer mixture. The 
process currently runs on an impressive 230-kg scale. In the case of the HMG-
CoA reductase inhibitor Rosuvastatin, another novel process was published 
very recently by Lek Pharmaceuticals.7 This process uses whole-cell catalysis 
based on the enzyme 2-deoxyribose-5-phosphate aldolase (DERA) for the 
diastereoselective synthesis of a lactol precursor for the statin side-chain (see 
Figure 5).
By this methodology the two stereogenic centers of the APIi are inserted by 
only one enzyme in a highly enantio- and diastereoselective manner. After 
subsequent protection and oxidation of the lactol 14, the resulting heterocyclic 
aldehyde 16 is then coupled with the phosphine-derivative of the 
i Active pharmaceutical ingredient
Figure 4. Enantioselective 
reduction of a bulky ketone 
for the production of the 
Montelukast precursor (S)-9
by LIANG et al..5
Figure 5. Whole-cell DERA 
process for the enantio- and 
diastereoselective produc-
tion of chiral lactols as 
precursors for statin side-
chains based on aldehydes 
by Lek Pharmaceuticals.7
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heteroaromatic core of the respective drug. The final process had a 
productivity of 50 g*L-1*h-1 with >80% yield and excellent selectivities of >99% 
ee for aldol 12 and >99.8% de for 1,3-diol 13. Nevertheless, there are still some 
difficulties for this lactol strategy. The product needs to be stabilized through 
oxidation of the lactol 14 to its corresponding lactone 15. This oxidation 
process was also realized but shows only up to 84% yield for various oxidants. 
Furthermore, the reaction itself needs to be monitored and controlled since the 
reactants 10 and 11 can act as donor and acceptor, leading to product 
mixtures. This was largely achieved by fed-batch processing and sequential 
addition of reactants to the reaction mixture. Despite these drawbacks, this 
route also demonstrates the versatility and potential of enzymes for the 
industrial production of pharmaceutical compounds. 
2.2 RETROSYNTHETIC STRATEGIES
Based on the preceding work of numerous groups and companies, different 
retrosynthetic routes for the production of enantiomerically pure intermediates 
were investigated in this work, starting in all cases from a prochiral diester of 
type 22 (see Figure 6), which is desymmetrized by a hydrolase. Since the 
heteroaromatic core of Rosuvastatin is achiral and commercially available as 
aldehyde 19, no synthetic strategies for it were examined. The project was 
focused on the production of the enantiomerically pure phosphor reagent 
Figure 6. Retrosynthetic 
approach by hydrolytic de-
symmetrization of prochiral 
glutaric diesters.
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(3R)-2. The corresponding ylide would be synthesized by a substitution 
reaction with a nucleophilic triphenylphosphoranylidene. In general, it would 
be possible to alkylate triphenylphosphine with a corresponding -haloketone, 
but the synthesis of this reactant would be quite complex. Moreover, 
haloketones are often made from the respective carboxylic acid derivatives and 
would therefore not shorten the route but require significantly harsher 
conditions. The activated carboxylic acid derivative (3R)-20 would be generated 
from the carboxylic acid (3R)-21, which itself would be obtained by 
desymmetrization of the prochiral diester 22. The hydrolytic strategy would 
have the benefit of producing intermediates which are already established as 
GMPi compounds. 
Furthermore, a second strategy based on the opposite enantioselectivity of 
lipases was investigated. In this way, the desymmetrization would be achieved 
through aminolysis, leading to amides of type (3S)-26 (see Figure 7) which 
would still be reactive at the desired carbonyl moiety. This way the 
phosphoranylidene intermediate (3R)-2 would also bear the necessary absolute 
configuration. The drawback for an industrial application of an aminolysis is of 
course the lack of information for all intermediates since most of them are 
unknown to literature. However, from an academic point of view, unknown 
compounds can be of even greater interest. As it can always be expected from 
retrosynthetic strategies, inevitable changes had to be made throughout the 
project regarding protective groups and process chemistry. 
i Good Manufacturing Process
Figure 7. Retrosynthetic 
approach by aminolytic de-
symmetrization of prochiral 
glutaric diesters by the use of 
(S)-selective lipases.
[9]
2.3 BIOCATALYTIC DESYMMETRIZATIONS FOR ENANTIOPURE BUILDING 
BLOCKS
The examples given in chapter 2.1 (page 4) for new biocatalytic processes as 
part of chemical syntheses for the production of generics introduced the 
chirality by the addition of a nucleophile, e.g. an enol or a hydride, to a 
carbonyl compound, converting the prochiral substrate into a chiral product. 
The enantiospecificity was based on the binding orientation of the substrate 
and the direction of the nucleophilic attack on the Re or Si face. In the case of a 
desymmetrization process, the stereogenic centers are already present in the 
structure. The selectivity of the enzyme is then determined by the stronger 
binding constant for the two possibly orientations of the. For example, this 
methodology was used by THIEL and DESKA for the combination of a 
biocatalytic acetylation with a chemical ring expansion for the synthesis of 
bifunctionalized N-heterocycles in a highly enantio- and diastereoselective 
manner (see Figure 8).8 The starting material, a symmetric meso-diol of a 
bis-hydroxymethyl-substituted heterocycle 27, is first desymmetrized by 
acetylation with vinyl acetate (28) and a lipase from Mucor miehei as 
biocatalyst. The remaining carbinol moiety is then transformed via an 
aziridinium intermediate 30 to the thermodynamically preferred ring-elongated 
heterocycle 31. While this reaction is based on a meso-compound, ZHANG et al.
successfully desymmetrized disubstituted malonamides of type 32 
(see Figure 9) to their chiral monoamides 33 by using an amidase from 
Figure 8. Biocatalytic de-
symmetrization and che-
mical ring-elongation for 
the synthesis of enantio-
and diastereomerically pure 
bifuntionalized N-hetero-
cycles by THIEL and DESKA.8
Figure 9. Biocatalytic de-
symmetrization of disubsti-
tuted α-aminomalonamides 
by ZHANG et al.9
[10]
Rhodococcus erythropolis.9 The products could be used for the production of 
substituted serine analogues 34 and β,β-disubstituted γ-amino alcohols 35, 
respectively. Various alkyl-substituted substrates 32 were converted in high 
yields of up to 98% and with excellent enantioselectivities of up to >99.5% ee. 
The substrates are readily accessible by alkylation of dialkyl 2-aminomalonates 
and subsequent ammonolysis with aqueous or methanolic ammonia. 
The desymmetrization of prochiral α,α-disubstituted dialkyl malonates 36 
(see Figure 10) was also investigated by TENBRINK et al. as part of a sequential 
one-pot process for the combination with an olefin metathesis reaction in 
aqueous media.10 The cyclic product 38 could be used for the production of 
the unusual, cyclic α-amino acid 39. However, the enantiomeric excess with 
crude pig liver esterase as biocatalyst was poor, leading to the desired 
monoester with only 7% ee. This is nevertheless reasonable as the only 
differentiation between the two substituents is a double bond and no large 
substituent as in most desymmetrization reactions. 
For example, different 3,4-disubstituted meso-pyrrolidines, exemplified by
pyrrolidine 40 (see Figure 11), were desymmetrized by the use of a 
monoamine oxidase (MAO) from Aspergillus niger by KÖHLER et al..11 The FADi-
dependent enzyme oxidizes the pyrrolidine 40 to the corresponding 
1-pyrroline 41 in a highly enantioselective manner. This product can be used 
i Flavin-adenine dinucleotide (FAD)
Figure 11. Biocatalytic de-
symmetrization of pyrroli-
dines with a monoamine 
oxidase (MAO-N) for the 
chemoenzymatic synthesis 
of proline derivatives by 
KÖHLER et al..11
Figure 10. Biocatalytic de-
symmetrization of cyclic 
dialkymalonates after ring-
closing metathesis reaction 
by TENBRINK et al..10
[11]
for a subsequent trans-selective addition reaction, e.g. with trimethylsilyl 
cyanide, to obtain enantiopure aminonitrile 42 or the respective proline 
derivative 43. The substituents at the stereogenic centers are large enough to 
obtain products in high yields of up to 79% with very high enantioselectivities 
of 94-99% ee.
2.4 BIOCATALYTIC HYDROLYSIS OF DIALKYL 3-OXYGLUTARATES
The hydrolytic desymmetrization of diethyl 3-hydroxyglutarate (1a) was already 
investigated by COHEN and KHEDOURI12 using α-chymotrypsin (CHY) and BROOKS
and PALMER13 using both CHY and pig liver esterase (PLE) as biocatalysts. Their 
results were confirmed by SANTANIELLO et al. who compared the selectivities of 
the free dialkyl 3-hydroxyglutarates of type 1 with O-acylated derivatives of 
type 22.14 The latter reported a rather poor enantioselectivity for the 
hydroxyglutarate 44a (see Figure 12) of 55 ± 5% ee in contrast to good to 
excellent enantioselectivities of 84-95% ee for the acylated diesters 44c and 
44d, depending on the alkyl ester, with the diethyl ester being superior to the 
dimethyl ester. When using diethyl 3-hydroxyglutarate and its derivatives with 
α-chymotrypsin, the same enhancement in enantioselectivity was observed in 
this worki
i The enantiomeric excess was determined by coupling of the monoester with optically pure (R)- or 
(S)-1-phenylethylamine, respectively, and subsequent quantification of the diastereomers by 1H-NMR 
spectroscopy and/or chiral normal-phase HPLC (see chapter 8.6).
Figure 12. Desymmetrization 
of dialkyl 3-hydroxyglutarate
and its O-acetyl derivative via
α-chymotrypsin (CHY) and pig 
liver esterase (PLE) by 
SANTANIELLO et al..14
[12]
The mechanism of α-chymotrypsin as serine protease is known in literature and 
can be described generally by the catalytic triad formed between Asp102, His57
and Ser195, with the latter serving as the nucleophile. The substrate, in this case 
the prochiral 3-hydroxy diester, is bound near Ser195 (see Figure 13). This serine 
is activated by the high pKa of the adjacent His57 nitrogen atom. Its pKa is 
elevated in the presence of Asp102 in its carboxylate form. The activated serine 
then acts as a strong nucleophile, attacking the carbonyl of the substrate 46. 
This leads to a tetrahedral intermediate 47, which is stabilized by an oxyanion 
hole formed by the amide protons of the surrounding peptide backbone. The 
carboxylic acid derivative is cleaved under the formation of the acylated 
enzyme 48. In a similar matter, the desired nucleophile is activated by His57 and 
attacks again the carbonyl of the covalently bound substrate 49. It is therefore 
transferred from Ser195 to the nucleophile 51. The catalytic mechanism is 
completed by diffusion of the product to the medium and diffusion of another 
Figure 13. Addition-elimina-
tion mechanism of carboxylic 
acid derivatives via serine 
hydrolases.
[13]
substrate molecule into the enzyme pocket. This is the crucial part of the entire 
reaction because the product could also be recognized as a substrate. Thus, the 
equilibrium of the overall reaction has to be directed towards the desired 
product. With the nucleophile being water, this is readily achieved with the 
resulting product being a carboxylic acid which is deprotonated and 
resonance-stabilized in its carboxylate form, thus inert towards nucleophilic 
attacks. By using alcohols, amines or thiols as nucleophiles, the reaction is 
usually controlled by an excess of the nucleophile or the removal of eliminated 
nucleophile, for example due to a higher vapor pressure or lower solubility in 
the reaction medium. In the present route, water served as nucleophile and the 
irreversibility of the saponification forced the equilibrium to the desired chiral 
monoester. 
ÖHRLEIN and BAISCH reported an enhanced enantioselectivity of α-chymotrypsin 
by using a methoxyacetyl protecting group instead of acetyl.15 It is commonly 
observed that α-heteroatoms are beneficial for the enantioselective binding of 
carboxylic esters and amides to hydrolases. The desymmetrization of diethyl 
3-(methoxyacetyl)-oxyglutarate 52b (see Figure 14) proceeded with an 
enantioselectivity of 98.2% ee. Based on these results, various O-acylated 
derivatives were synthesized in this study to reproduce the excellent 
enantioselectivity with α-chymotrypsin. In addition, varying the size and 
properties of the 3-acyloxy group could also facilitate the product isolation in 
later parts of the synthetic route, preferably by crystallization.
Using a desymmetrization strategy for the production of enantiomerically 
enriched O-TBS-protected 3-hydroxypentanoic monoesters is a challenging 
method in industry. In many cases, the enantioselectivity of a chemical 
desymmetrization is realized by diastereomeric coupling with another 
enantiomerically pure compound, preferably an alcohol or amine. In the case of 
amines, the resulting amides are cleaved by oxidation under harsh conditions. 
KONOIKE and ARAKI on the other hand used the lithium alkoxide 55 (see Figure 
15, page 14) of enantiomerically pure benzyl (R)-mandelate for the 
Figure 14. Enhancement of 
enantioselectivity in the 
presence of an α-heteroatom 
reported by ÖHRLEIN and 
BAISCH.15
[14]
diastereoselective opening of TBS-protected glutaric anhydride 54 with a 
diastereomeric ratio of 9:1 for the (3’R,2R)-diastereomer 56. 16
Subsequently, a three-step purification procedure with hydrogenolysis of the 
monoester 56 was realized. After crystallization of the dicarboxylic acid 57 with 
61% yield and with an excellent diastereoselectivity of 99.9% de, the 
transesterification with sodium methoxide in methanol yielded the desired 
(3R)-TBS-monomethyl ester 58 in enantiomerically pure form. With the 
enantioselective desymmetrization of the prochiral TBS-protected diester by 
the use of hydrolases in this work, the overall yield would probably be 
improved. In addition, the use of chiral auxiliaries and fractionized 
crystallization would be circumvented. Even if the desymmetrization requires a 
different O-derivative, this route would still have the potential to be superior, 
since all modifications would insert or remove parts of bulk chemicals which 
are both cheap and easily accessible. This biocatalytic approach was studied in 
a previous work from NOVÁK et al. in which the TBS-protected dimethyl ester 
59 (see Figure 16) was hydrolyzed by using pig liver esterase.17 Due to the lack 
of information about the reaction time, the activity cannot be discussed. 
Figure 15. Chemical desym-
metrization of prochiral 
TBS-protected glutaric an-
hydride by KONOIKE and 
ARAKI.16
Figure 16. PLE-catalyzed 
desymmetrization of 3-TBS-
DHG with low enantio-
selectivity by NOVAK et al.17
[15]
Nevertheless, the isolated product (3R)-58 showed only a low enantiomeric 
excess of 52% ee after derivatization to its corresponding phenylethylamide 
and analysis of the diastereomeric excess. 
2.4.1 SUBSTRATE SYNTHESIS
The literature-known derivatives were synthesized as benchmark substrates for 
the establishment of analytical methods or the determination of 
enantioselectivity and efficiency of the biocatalysts (see Table 1). Among the 
chosen substrates, diethyl 3-hydroxyglutarate (1a) was also used for the 
synthesis of reference mixtures of enantiomers with around 60% ee. The 
acetate 22a and methoxyacetate 22e were used for comparing the results 
obtained in this work with the literature-reported enantioselectivities of >95% 
ee. The trifluoroacetate 22c was chosen for analytic purposes, e.g. 
determination of product-related conversion and side-product formation by 
19F-NMR spectroscopy, and its smooth cleavage in the following steps. The 
phenylacetate derivative 22d could improve the crystallization of 
intermediates. To circumvent the need for an exchange of the O-acyl moiety, 
substrate 22f, bearing a tert-butyldimethylsilylether protective group, was also 
investigated. As a synthon with similar sterical influence, the tert-
butyloxycarbonyl- (Boc-) protected compound 22b was another promising 
candidate. And finally, since the silyl ether is later cleaved to silanol, which 
cannot be separated by liquid-liquid extraction, the tetrahydropyranyl 
Table 1. Protective groups for 
the secondary alcohol of 
diethyl 3-hydroxyglutarate
(a) Acetyl (Ac), tert-butyloxycarbonyl 
(Boc), trifluoroacetyl (TFA), phenyl-
acetyl (PhAc), methoxyacetyl
(MeOAc),tert-butyldimethylsilyl (TBS), 
tetrahydropyran-2-yl (THP) (b) Deter-
mined by integration of 1H-NMR 
signals for 1a and O-derivatives (c) 
Pyridinium p-toluenesulfonate
Entry 22 Ra X Cat. (mol%) Solvent
Time 
[h]
Temp. 
[°C]
Conv.
[%]b
Yield
[g (%)]
1 a Ac OAc Zn(ClO4)2 (0.1) - 2 20 >95.0 0.84 (85.3)
2 b Boc OBoc Zn(OAc)2 (10.0) - 6 60 >95.0 1.11 (91.2)
3 c TFA OTFA Zn(ClO4)2 (1.0) - 2 20 >95.0 1.07 (89.1)
4 d PhAc Cl - - 16 0-20 >95.0 5.30 (82.2)
5 e MeOAc Cl Pyridine (110) CH2Cl2 24 0-20 92.1 3.54 (64.0)
6 f TBS Cl 1H-imidazole (150) THF 24 20 >95.0 0.58 (36.4)
7 g THP - PPTSc CH2Cl2 21 20 >95.0 1.68 (58.3)
[16]
derivative 22g was another alternative. Literature shows almost similar reaction 
properties for THP and TBS.18 Notably, THP has the benefit of being hydrolyzed
under mild conditions to 5-hydroxypentanal, an aldehyde which could be easily 
separated by liquid-liquid extraction with bisulfite solutions. As can be seen in 
Table 1 (page 15, entries 1-5), the conversion and isolated yields of these 
substrate syntheses are good to excellent in almost all cases. 
Remarkable is the synthesis of the acetate derivative 22a (entry 1), which was 
achieved under solvent-free conditions with zinc perchlorate hexahydrate in 
acetic anhydride. However, after analyzing the time-dependent conversion rate 
of the reaction by direct 1H-NMR integration without work-upi (see Figure 17), 
the mechanism is more likely autocatalytic. The exponential reaction rate after 
almost no conversion for two hours suggests an unidentified catalytic side-
reaction, in this case probably by acetic acid formed during the reaction. The 
low catalyst loading of 0.1 mol% zinc perchlorate is presumably the chain 
reaction starter with acetic acid as BRÖNSTED acid catalyst (see Figure 18).
Furthermore, the crude product could was used without purification. The only 
side-product acetic acid was neutralized with a base before adding the 
biocatalyst for the subsequent desymmetrization.
i The absence of solvent, the non-paramagnetic metal catalyst and the nearly stoichiometric amount of reagent 
made this reaction convenient for monitoring by 1H-NMR. 
Figure 18. Proposed 
mechanism of acylation 
with acetic anhydride under 
solvent-free conditions with 
parallel LEWIS-acid (blue) 
and BRÖNSTED-acid catalysis 
(red).
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Figure 17. Time-course of 
the acetylation of 1a with 
zinc perchlorate in acetic 
anhydride. 
[17]
2.4.2 ANALYTICAL METHODS FOR THE DETERMINATION OF THE ACTIVITY 
AND ENANTIOSELECTIVITY OF HYDROLASES
Hydrolytic reactions were conducted in a Titrino apparatus for maintaining the 
weak basic pH of 8.0 throughout the reaction. The formed carboxylic acid was 
neutralized by titration of aqueous sodium hydroxide solution (0.2 - 4.0 M). The 
consumption of titer was automatically recorded and direct proportional to the 
amount of product formed (see Figure 19). The conversion was additionally 
confirmed after extractive work-up by 1H-NMR analysisi of the crude product 
(see Figure 20). The enantiomeric excess was determined according to 
literature protocols by coupling of the acetylated monoester 45b
(see Figure 21, page 18) with an enantiopure chiral amine, i.e. (S)- or 
(R)-1-phenylethylamine 61, respectively. The formed diastereomers of type 62 
were analyzed by 1H-NMR spectroscopy and chiral normal-phase HPLC for 
their diastereomeric excess, which is equal to the enantiomeric excess of the 
monoester.
In general the enantiomeric excess of a compound should be measured 
without derivatization since most of the common coupling reagents have a 
slight tendency to isomerize chiral centers in the vicinity of the coupling bond.
Experimental data for many reagents can be found in literature which suggest 
i Most of the signals do not shift sufficiently for differentiation of product and starting material. 
Integration of ethyl signals gave poor reproducibility. Exceptions suitable for integration after 
Lorentz fitting are shown in Figure 20.
Figure 19. Exemplary titration 
graph for the hydrolytic 
desymmetrization in aqueous
buffered solutions.
Figure 20. 1H-NMR signals 
suitable for the determination 
of conversion for the 
hydrolytic desymmetrization. 
Tetramethylsilane (TMS, δ = 0.0 ppm) 
was used as shift reference prior to 
stacking.
[18]
an expectable error of at least 1.0 % ee for the remaining enantiomeric 
excess.19 Unfortunately, the investigated monoesters have only aliphatic 
hydrocarbons and carboxylate derivatives with only minimal absorbance of 
UV/Vis wavelengths. Thus, the previously mentioned error margins were taken 
as they were the monoester 45b was derivatized to its diastereomeric 
phenylethylamide of type 62 by using the coupling reagent T3P 
(tris-n-propylphosphonic anhydride, see Figure 21, page 18). Due to its low 
tendency to epimerize the coupling compounds, the resulting diastereomeric 
excess should be close to the actual enantiomeric excess of the monoester. 
The subsequent deacetylation of the O-protecting acetate was basically 
monitored accordingly by consumption of titer for maintaining the pH. 
Unfortunately there was evidence of base-catalyzed elimination of acetic acid 
due to the high molarity of the titer. Since this side-reaction would both 
eliminate the acetyl signal in 1H-NMR spectra and disturb the methylene 
signals, the product-related conversion was determined by integration of the 
chiral carbinol 60 (4.47 ppm, see Figure 22, page 19). The absence of the acetic 
ester leads to a strong shift towards high-field. Since the free carbinol 60 is 
also reactive under the coupling reactions for the determination of the 
enantiomeric excess, the product was first acetylated again with excess acetic
anhydride and then coupled with T3P and phenylethylamine to check for 
isomerization. The HPLC separation of isomers was conducted according to the 
method described for the desymmetrization. 
Figure 21. Exemplary HPLC 
chromatogram of diastereo-
meric phenylethylamides by
T3P coupling.
Diastereomerically enriched mixture 
of (2’S,3R)-phenylethylamide (red, 
96.8% de) in comparison with its 
(2’R,3R)-isomer (grey) as reference.
[19]
Since the crude products were used without further purification, quantitative
analysis of the 1H-NMR spectra had to be made. Ideally, a convenient NMR 
standard, which is not compartmented in a glass capillary, should have a high 
purity and a distinctive signal in an isolated region of the spectrum. Such an 
isolated area would be between 4.60 and 5.30 ppm in both spectra (see Figure 
22).
Signals in this region can be seen for benzylic methylene compounds such as 
benzylamine and benzyl alcohol. For a more convenient handling and 
purification, p-chlorobenzyl alcohol was used. This compound is crystalline, 
commercially available in high purity of >99.9% and has a distinctive singlet at 
4.68 ppm in CDCl3. The product content and its purity were therefore 
calculated by the weigh-in of NMR standard and the mass ratio of the mixture 
according to the following equations:
PC = m (pClBnOH) ∗
 ()∗()
 ()
/
 ()∗ ()
 ()
PP =
PC
m (Crude product)
PC = Product content [mg]
m (pClBnOH) = weigh-in NMR standard [mg]
Int (pClBnOH) = Integral for p-chlorobenzyl 
alcohol NMR signal (4.68 ppm)
M (pClBnOH) = Mol. weight (pClBnOH) = 
142.58 g/mol
Int (Product) = Integral for product NMR 
signal
M (Product) = Mol. weight (Product) [g/mol]
PP = Product purity [%]
m (Crude product) = weigh-in crude product 
[mg]
Figure 22. 1H-NMR spectra 
with an internal standard for 
quantitative analysis of the 
product content.
[20]
2.4.3 BIOCATALYTIC DESYMMETRIZATION OF DIALKYL 
3-HYDROXYGLUTARATES BY α-CHYMOTRYPSIN
The synthesized derivatives of diethyl 3-hydroxyglutarate were all subjected to 
the desymmetrization with α-chymotrypsin20(Figure 23) as already proven 
active biocatalyst. The reactions were performed with a Titrino apparatus, 
which simultaneously measures the pH of the aqueous reaction mixture and 
titrates with a given solution of base to neutralize the product and maintain the 
pH, a prerequisite for maintaining a high enzyme activity. Unfortunately, the 
already TBS-protected substrate 22f, did not show any conversion
(see Figure 24). This is congruent with common observations throughout 
biocatalysis that bulky substituents in the vicinity of the reactive carbonyl 
structure can have a strong impact on both activity and selectivity of the 
enzyme, if not completely inhibiting the desired reaction. The absence of 
activity during the α-CHY-catalyzed desymmetrization was also observed for 
the bulky O-protected derivatives in this work, i.e. the phenylacetate 22d, the 
tert-butyloxycarbonate 22b and the tetrahydropyran-2-yl acetal 22g, which 
showed no conversion. Aside from bulkiness, the trifluoroacetate 22c revealed 
itself as highly labile towards hydrolysis in aqueous buffer solutions, which was 
the major reactivity observed for this compound. 
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Figure 23. Crystal structure 
of the α-chymotrypsin dimer 
with the complexed inhibitor 
phenylethane boronic acid 
(BLEVINS and TULINSKY).20
Figure 24. Biocatalytic de-
symmetrization of 3-DHG and 
O-protected derivatives by 
α-chymotrypsin (α-CHY).
O-protected derivatives: tert-butyl-
dimethylsilyl (TBS), tert-butyloxycar-
bonyl (Boc), tetrahydropyran-2-yl 
(THP), tri-fluoroacetyl (TFA); side 
products: deprotected monoester 
(MeOAc), deprotected diester (TFA).
[21]
The product of this hydrolysis is in fact the O-unsubstituted diethyl 
3-hydroxyglutarate 1a and is further converted by α-chymotrypsin with poor 
enantioselectivity (see Figure 12, page 11). As it was expected, the acetate 22a
and methoxyacetate 22e showed high activity in combination with excellent 
enantioselectivities of >95% ee. Interestingly, the methoxyacetate 22e also 
showed significant hydrolysis to the 3-hydroxy monoester of type 60 up to 
21%. This was also considered beneficial for the exchange to the TBS protective 
group. Surprisingly, the second hydrolysis could not be enhanced by 
prolonged reaction times or higher basicity of the reaction medium. The 
chemical saponification of the methoxyacetate 21e led to significant loss of 
yields due to parallel saponification of the remaining ethyl ester. The sole 
substrate exhibiting the desired reactivity was indeed the acetate 22a, which 
did not show any side-reactions. Occasional appearance of an α,β-unsaturated 
diester by base-induced elimination of acetic acid was observed for highly 
concentrated titer (4.0M sodium hydroxide) and was prevented by slow 
titration or higher dilution of titer. 
2.4.4 DEACYLATION OF THE 3-ACYLOXY MOIETY
The deprotection of O-acylated carbinols in the presence of other esters was 
quite challenging. Standard wet-chemical approaches by acid- or base-
catalyzed hydrolysis were futile since the hydrolysis of the second alkyl ester 
led to the loss of chirality and thus decreased the yield of the desired 
monoester. Although α-chymotrypsin showed the desired activity for the 
methoxyacetyl substrate with around 20% conversion (see Figure 24, page 20), 
the hydrolysis could not be enhanced by either prolonged reaction time or 
higher enzyme amount. Therefore, a selection of hydrolases was screened for 
activity but none of them showed any conversion (see Table 2, entries 3-5, 
page 22). A lipase-catalyzed transesterification with various alcohols was also 
investigated (see Table 2, entries 1-2, 6-8, page 22). Candida antarctica lipase B 
showed moderate activity up to 30% product-related conversion. Nevertheless, 
the conversion was never quantitative, leading to a mixture of acylated and 
deacylated monoester which would have to be separated by column 
chromatography. The most promising solution was found with an industrially 
applied hydrolase for the specific cleavage of an acetyl group from 
cephalosporin C, thus named cephalosporin C acetylesterase (CAE, see Figure
25, page 21).21 The enzyme was originally isolated from Bacillus subtilis and 
overexpressed in recombinant E. coli. It was further immobilized on a 
commercial carrier for the large-scale production of deacetyl-7-amino-
Figure 25. Crystal structure 
of cephalosporin C deacetyl-
ase from Bacillus subtilis
complexed with acetate
(VINCENT et al.).21
[22]
cephalosporanic acid (HACA) by combination with a D-amino acid oxidase 
from Trigonopsis variabilis.22
Entry
Substrate
[mmol]
Biocatalyst
(g)
Additive 
(eq.)
Substrate
[M]
Conversion
[% (h)]
Yield
[g (%)]
1 10.0
CAL-B 
(1.00)
EtOH 
(2.00)
1.43 22.0 (15.5) n.d.
2 10.0
CAL-B 
(1.00)
EtOH 
(10.0)
1.43 30.1 (76.5) n.d.
3 1.25
Amano PS 
SD (0.05)
- 0.05 4.76 (24.0) n.d.
4 1.25
Amano AK 
(0.05)
- 0.05 7.41 (24.0) n.d.
5 1.25
Amano 
AYS (0.05)
- 0.05 4.76 (24.0) n.d.
6 5.00
CAL-B 
(0.50)
EtOH 
(17.1)
0.50 5.66 (24.0) n.d.
7 5.00
CAL-B 
(0.50)
EtOH 
(34.2)
0.50
<1.00 
(24.0)
n.d.
8 4.58
CAL-B 
(0.20)
MeOH 
(5.38)
0.76
<1.00 
(24.0)
n.d.
9 5.00
CAE 
(0.05)
- 1.00 12.3a (18.5) n.d.
10 10.0
CAE 
(0.05)
- 1.00 89.5 (5.5)
1.47 
(74.8)b
11 40.0
CAE 
(0.50)
- 0.80 >95.0 (4.5)
5.43 
(77.0)b
12 48.5
CAE 
(0.50)
- 4.00 >95.0 (8.0)
4.28 
(50.1)b
In the case of the acetylated monoester (3R)-45b, CAE showed complete 
conversion in aqueous buffer, even in the presence of stoichiometric amounts 
of ethanol, which corresponds to the product mixture of the desymmetrization 
(see Table 2, entries 11-12, page 22). Remarkably, only the acetate is cleaved 
while the ethyl ester remains untouched. Control experiments with 1a and the 
acetate-protected diester 22a showed no conversion and full conversion to 
3-DHG, respectively (see Figure 26, page 23). In any case, desymmetrization 
did not occur with CAE. The fact that Cephalosporin C acetylesterase accepts 
carboxylates while most hydrolases are only active for esters and amides makes 
this enzyme extremely valuable. 
Table 2. Removal of the 
O-acetyl protective group by 
the use of hydrolases.
(a) The pH was not maintained in 
this first experiment and decreased 
to 3-4 which might have led to 
inactivation of the enzyme (b) Due 
to high solubility of the product in 
water the extractive work-up led 
only to moderate yields.
[23]
Table 2 (page 22) shows the examined hydrolases for hydrolysis and 
alcoholysis of the O-acetyl group. After the experiments with CAE 
demonstrated quantitative conversion and excellent regioselectivity, no further 
hydrolases were screened.
2.4.5 INVESTIGATION OF OPTIMUM PARAMETERS FOR THE BIOCATALYTIC 
DESYMMETRIZATION AND DEACETYLATION
The establishment of a bienzymatic synthesis for the enantioselective 
production of ethyl (3R)-hydroxyglutarate from the prochiral O-acetylated 
diethyl 3-hydroxyglutarate was already a great. Nevertheless, the productivity
of the process needed to be improved by modifying various parameters
(see Figure 27). Since the experiments were always terminated after 100% 
consumption of theoretical titer amount, comparing the reactions by 
conversion alone would be difficult. The reaction time itself would also be 
Figure 27. Optimization of 
reaction parameters for cost-
effective production of 
enantiomerically enriched 
monoesters by hydrolytic 
biotransformations
Figure 26. Control experi-
ments for a possible desym-
metrization of dialkyl 3-oxy-
glutarates by cephalosporin 
C acetylesterase (CAE).
[24]
ambiguous since it depends on the absolute amount of substrate in the given 
experiment, which was altered in the range of 50 mM to 4.0 M. Thus, the 
following results will be given in calculated data for the volumetric productivity 
of a reactor under the respective reaction conditions (g/(L*d), grams of product 
per liter of reaction medium per day), which would be identical to the space-
time-yield under continuous operation. Since the biocatalyst has the highest 
cost factor, additional values of both catalyst concentration (g/L, grams of 
enzyme formulation per liter of reaction medium) and catalyst loading 
(g(Sub)/g(CHY), grams of substrate per gram of enzyme formulation of -
chymotrypsin or its mixture with trypsin) will be presented. The cost-related 
amount of enzyme formulation necessary for the production of one kilogram
of product per day can be directly estimated from the ratio of the volumetric 
productivity (blue) to the catalyst concentration (red) and is therefore not 
presented separately.
2.4.5.1 SUBSTRATE STRUCTURE
The effect of the 3-hydroxy protective group was already discussed in chapter 
2.4.3 (page 20). It accelerated the hydrolytic reaction and enhanced the 
enantiomeric differentiation of -chymotrypsin from moderate 60% ee to 
excellent >98% ee. Also of importance was the kind of alkyl ester used for the 
reaction. The readily available diesters of 3-hydroxyglutarate are the dimethyl 
1b and diethyl ester 1a, respectively, with the diethyl ester being the more 
economical one. However, the commercially available building block of the 
Rosuvastatin side-chain, the chiral phosphor ylide, consists of the 
corresponding methyl ester. Thus both dialkyl esters were compared for their 
productivity in the biocatalytic desymmetrization (see Figure 28).
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[25]
The free hydroxyesters were converted in nearly the same reaction rates at 
0.25 mol/L substrate concentration, whereas the corresponding O-acetyl esters 
showed a strong dependency on the chain length. The acetylated diethyl ester 
was desymmetrized with more than 40% higher activity at 4.0 mol/L substrate 
concentration. Since this substrate was converted The influence of the alcoholic 
side-product on the enzyme activity was not investigated.
2.4.5.2 SUBSTRATE CONCENTRATION
Biocatalytic reactions are often limited by the necessity of a low substrate 
concentration. This is due to the fact that many enzymes tend to be inhibited 
by a high excess of substrate, especially if the product has also high binding 
constants in the active center. In the case of hydrolases, this inhibition is often 
prevented by the strong difference in polarity of substrate and product. This 
fact also explains the significant higher reaction rates of hydrolases in relation 
to oxidoreductases, for example. The enzyme with the highest known reaction 
rate is the acetylcholine esterase with a turn-over frequency (TOF) of >10,000 s-
1.23 The substrate concentration of the biocatalytic desymmetrization of diethyl 
3-acetoxyglutarate 22a was successfully improved from 50 mM to 4.0 M, which 
corresponds to a theoretical product concentration of >800 g/L. at 100% 
conversion (see Figure 29). 
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substrate concentrations of 
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22a and improved process 
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[26]
Notably, the solubility of the substrate in the aqueous reaction mixture is rather 
low, leading to a biphasic system in almost 1:1 volumetric ratio 
(buffer/substrate). Further upscaling to 5.0 M and even 6.0 M showed a 
dramatic decrease in activity (see Figure 29, page 25, ratio of volumetric 
productivity (blue) to catalyst concentration (red)). However, this could also be 
due to the increased viscosity of the reaction mixture and the aggravated 
titration under pH control. Nevertheless, the concentration of 4.0 M was 
sufficient for industrial applicability. Furthermore, the productivity was 
tremendously improved by combining a moderate catalyst concentration of 
80 g/L with a low catalyst loading of 12.3 g diethyl 3-acetoxyglutarate per g of 
α-chymotrypsin (see Figure 29, page 25, green square). 
2.4.5.3 ENZYME FORMULATIONS
There are numerous suppliers of α-chymotrypsin, comprising a variance of 
purified or crude enzymes as well as mixtures of α-chymotrypsin and trypsin. 
To evaluate the efficiency of these formulations for the desymmetrization route 
and the need of a recycling procedure for the homogenously dissolved 
biocatalyst, different enzyme formulations were examined. Of great interest 
was the usability of 1:1 α-chymotrypsin/trypsin mixtures, which are 
considerably cheaper than the isolated enzyme. Additionally, three proteins 
which were isolated from the purified α-chymotrypsin formulation by 
coworkers of the HUMMEL group were also used.
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[27]
The major concern of these experiments was the enantiomeric excess of the 
product, since protein impurities could lead to side-reactions and a lower 
enantioselectivity. Fortunately, neither the presence of trypsin nor the isolation 
of one of the three proteins in the purified α-CHY altered the enantioselectivity 
to a notable extent. All formulations showed an excellent enantioselectivity of 
around 97% ee (see Figure 30, page 26). Even more, the economically more 
attractive α-chymotrypsin/trypsin mixtures also showed the desired high 
productivities of >800 g/L (Biozym) and >500 g/L (BBI). The need for 
2.0 - 2.5 equivalents of enzyme amount for the mixture of Biozym in relation to 
the purified enzyme is readily amortized by its substantially lower prizing.
2.4.5.4 EFFECTS OF SALTS AND ADDITIVES ON THE VOLUMETRIC PRODUCTIVITY
Apart from the substrate and the enzyme itself, the reaction could also be 
affected by other solutes. When conducting the reaction in pure water instead 
of buffer, the reaction rate decreased slightly, suggesting a dependency on the 
ionic strength of the reaction medium, or the fluctuation of pH in the absence 
of a buffered medium (see Figure 31). The choice of additives was imposed by 
the combination with the preceding acetylation as well as the use of isolated 
proteins of a commercial α-chymotrypsin formulation. 
The solvent-free acetylation led to a crude product comprising the acetylated 
diester and stoichiometric amounts of acetic acid, a small excess of acetic 
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Figure 31. Effect of additives 
on the productivity of the 
biocatalytic desymmetriza-
tion of 22a with α –chymo-
trypsin.
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[28]
anhydride (0.1 equivalents) and the catalytic amount of zinc perchlorate 
(0.001 equivalents). After dissolving this crude product in aqueous buffer and 
neutralizing the side-products with an aqueous sodium base (carbonate, 
bicarbonate or hydroxide, 1.2 equivalents), the reaction medium with 1.0 mol/L 
substrate would consequently have an additional ionic strength of dissolved 
1.2 mol/L sodium acetate prior to the addition of the biocatalyst (see Figure 
31, page 27, entry 3). The effect of catalytic amounts of zinc perchlorate was 
also studied separately (entry 5). Coworkers of the HUMMEL group isolated 
three proteins from the purified α-chymotrypsin batch (Biozym) which was 
used for the majority of the given experiments. The final separation step was 
done with an eluent of aqueous ammonium sulfate (1.0 mol/L). Since 
ammonium sulfate does not only increase the ionic strength but also lower the 
solubility of proteins, its effect on the reaction was also examined (entry 6). All 
additives were tested under the same reaction conditions with 1.0 mol/L 
substrate concentration and 100 mg of α-chymotrypsin. The effect on the 
volumetric productivity of the reaction, defined as the amount of product (in 
grams) per liter of reaction medium and per day, is illustrated. The highest 
reaction rate is observed under the standard reaction conditions in aqueous 
buffer. Catalytic amounts of zinc perchlorate show nearly the same decrease as 
the reaction in pure water (entries 5 and 7). In contrast to that, the presence of 
sodium acetate and ammonium sulfate did have a strong influence on the 
productivity, however arbitrarily related to their respective concentrations 
(entries 3, 4 and 6). Interestingly, sodium chloride had nearly no effect on the 
reaction, even at relatively high concentration of 1.2 mol/L (entry 2). 
This discrepancy could suggest ionic effects related to the HOFMEISTER series, 
with the acetate, ammonium and sulfate ions leading to a lower solubility of 
the biocatalyst and/or an increase in surface tension and therefore weaker 
mixing of the substrate phase with the aqueous phase (see Figure 32).24
However, doubling of the acetate concentration did not show any effect on the 
reaction, contradicting the proposed ionic effects. Summing up these results, 
the effects of ionic additives on the volumetric productivity did not show a
clear tendency. In general, the highest productivity was achieved in aqueous 
phosphate buffer (50 mM, pH 8.0, entry 1) without other solutes but was 
almost unchanged in the presence of sodium chloride (see Figure 31, page 27, 
entry 2).
Figure 32. Hofmeister series 
of cations and anions altering 
the properties of dissolved 
proteins and the solvent in 
aqueous solutions from high 
stability (cosmotropes) to 
high solubility (chaotropes) 
accompanied by a decree-
sing surface tension. 
[29]
2.5 ENANTIO- AND DIASTEREOSELECTIVE AMINOLYSIS OF CHIRAL CARBON 
ACID ESTERS
Apart from resolving carbonacid esters by enantioselective hydrolysis in 
aqueous media, some hydrolases are also capable of resolution processes in 
organic media. This way the corresponding donor can be changed from water 
to all kinds of nucleophiles, e.g. alcohols, amines or thiols. Furthermore, most 
of these lipases are fairly stable in organic media and at elevated temperatures. 
Comprehensive work in the field of lipase-catalyzed aminolysis of chiral 
carbonacid esters has been done by GOTOR et al., mostly by using commercially 
available lipases from Candida sp.. 25,26
For instance, the resolution of α-halo esters of type 64 (see Figure 33) was 
achieved with a lipase from Candida cylindracea (CCL) in n-hexane as reaction 
medium at low or elevated temperatures.26 This process is of particular 
importance since halogenated esters would also alkylate the amine under 
common amide synthesis conditions. With CCL, primary amines of type 65
react with excellent enantioselectivities under formation of the corresponding 
amides. Notably, the enantiomeric excess is strongly dependent on the alkyl 
ester of the substrate 64 and the structure of incorporated amine. Even 
aromatic amines can be used, e.g. p-methoxyaniline, with high yields and 
excellent enantioselectivites of >95% ee (66d). In addition, GARCIΑ-URDIALES et 
al. reported the enantioselective ammonolysis of ethyl 4-chloro-3-hydroxy-
butanoate 67 (see Figure 34, page 30) in various ammonia-saturated organic 
solvents in the presence of lipase B from Candida antarctica.27 These reports 
indicate clearly that lipases show enantioselectivity for α- and β-stereogenic 
centers, with a strong dependency on the structure of the nucleophile. The 
enantiomeric excess improves with increasing polarity of the nucleophile, with 
ammonia and primary achiral amines giving the highest selectivities.
Figure 33. Lipase-catalyzed 
enantioselective aminolysis 
of α-halocarboxylic acid 
esters by GOTOR et al.26
[30]
Remarkably, α-chiral amines are also applicable, giving diastereomers in 
enriched mixtures, as shown by VÖRDE et al. for the diastereoselective 
aminolysis of racemic ethyl 2-methyloctanoate with enantiomerically pure 
(R)- or (S)-1-phenyl-ethylamine.i28 Unfortunately, the diastereomeric excess was 
only low to moderate, with the best result being 54% de at 3% conversion in 
dioxane. Due to the necessity for enantiomerically pure amine, this 
diastereomeric approach was not investigated in the present work.
2.5.1 LIPASE-CATALYZED DESYMMETRIZATION BY AMINOLYSIS WITH 
VARIOUS PRIMARY AND SECONDARY AMINES
RIISE MOEN et al. successfully desymmetrized diethyl 3-hydroxyglutarate with 
lipase B from Candida antarctica (CAL-B) through hydrolysis in aqueous 
buffer.29 Remarkably, CAL-B shows enhanced activity and enantioselectivity in 
comparison to α-chymotrypsin for 1a as substrate. Furthermore, the 
immobilized catalyst can readily be recycled by filtration and resuspension in 
buffer. However, the enantiopreference of CAL-B is inverted in comparison to 
α-chymotrypsin, leading to the corresponding (S)-enantiomer of the
monoester 60 by hydrolytic desymmetrization. In contrast to that, LÓPEZ-GARCÍA
et al. successfully used primary amines in the desymmetrization, leading to 
their corresponding amines with high conversions and good to excellent 
enantioselectivities of 88-99% ee (see Error! Not a valid bookmark self-
reference.). 30 Notably, also the O-unprotected diester of 3-hydroxyglutarate 
was converted in 98% and with >99% ee. This is important as it opens the 
possibility of introducing the tert-butyldimethylsilyl protective group after the 
desymmetrization. Based on these preceding reports, the aminolytic 
desymmetrization was further investigated in this work. The inverted selectivity 
of the lipase for producing the (3S)-amide was still a drawback. 
i According to their publication the reaction is enantioselective. However, they obtain different conversions and 
selectivities for (R)- and (S)-amine. Therefore the reaction with CAL-B should be defined as diastereoselective.
Figure 34. Lipase-catalyzed 
enantioselective ammono-
lysis of β-hydroxycarboxylic 
acid esters by GARCIA-
URDIALES et al.27
[31]
By using sterically demanding nucleophiles, the lipase-catalyzed 
desymmetrization would initially generate the undesired (S)-enantiomer 
(3S)-26, but with increased reactivity for the remaining ethyl ester. 
Consequently, the substitution reaction with the phosphoranylidene would 
then again yield the desired (R)-enantiomer of the stabilized ylide (3R)- 2
(see Figure 36).
Benzyl amine was regarded as a promising and sterically demanding amine for 
this methodology. Additionally, the benzyl group would certainly facilitate 
UV/Vis analysis of most intermediates. The desymmetrization of 1a with 
benzylamine was successfully realized in this study, with quantitative 
conversion and an excellent enantioselectivity of >93% ee (see Table 3,
page 32, entries 1-5). Besides, the corresponding amide is readily purified by 
recrystallization in MTBE. 
Figure 36. Enantiopreference 
of biocatalytic desymmetri-
zations via α-chymotrypsin 
and Candida antarctica
lipase B with water and 
amines, leading to the 
stabilized phosphor ylides 
with the desired absolute 
configuration.
Figure 35. Enantioselective 
desymmetrization of 3-sub-
stituted dimethyl glutarates 
with benzylamine in dioxane 
by LÓPEZ-GARCÍA et al.30
[32]
What remained questionable was the reactivity of the benzylamide during the 
following synthetic steps. For example, ASENSIO et al. tosylated N-benzyl 
acetamide in 60% conversion by using the lithium amidate.31 This lithium 
amidate of type 71 could also be formed in the present synthesis by an acid-
base equilibrium during the ylide substitution (see Figure 37, page 33). This 
species could then also cyclize intramolecularly and form a number of 
undesired side-products of type 72 and 73. To circumvent this problem, a 
couple of secondary amines were also examined for the biocatalytic 
desymmetrization (see Table 3, entries 6-12). Most of them were indeed active, 
nevertheless generally to only minor extent. This is in accordance with some 
results by DHAKE et al. for piperidine.32 Its low activity for aminolytic ester 
substitution was also reproduced in the present work (entry 12). Interestingly, 
pyrrolidine and morpholine showed higher conversion of 56% and 35%, 
respectively (see Table 3, page 32, entries 8-9). The benefit of morpholine was 
a crystalline product which was readily purified by recrystallization in light 
petroleum ether. The reaction with pyrrolidine demonstrated the limits of 
lipase-catalyzed desymmetrization. At a reaction temperature of 60°C with the 
donor as solvent in more than 10-fold molar excess, the reaction went straight 
through to the bisamide (see Table 3, page 32, entry 11).
Table 3. Lipase-catalyzed 
aminolysisa of 3-DHG with 
various primary and secon-
dary amines in organic 
solvents.
(a) General reaction conditions: 
1.0 eq. amine (except entry 10), 
0.5 M substrate concentration (b) 
Double aminolysis to the 
corresponding prochiral bis-amide.
Entry R1 R2
22
[mmol]
CAL-B
[mg]
Temp.
[°C]
Solvent
Conv.
[%]
Yield
[g(%)]
1 H Bn 2.00 180 20 dioxane >95 0.52 (98.9)
2 H Bn 2.00 180 20 THF >95 0.47 (89.3)
3 H Bn 2.00 180 20 MTBE >95 0.49 (93.1)
4 H Bn 2.00 180 20 toluene 84.0 n.d.
5 H Bn 10.0 907 20 MTBE >95 2.20 (83.1)
6 Me Bn 10.0 900 reflux MTBE 7.2 0.16 (5.6)
7 Et Et 2.00 180 reflux MTBE 0 -
8 morpholine 10.0 900 reflux MTBE n.d. 0.86 (35.0)
9 pyrrolidine 5.00 110 20 MTBE 55.9 n.d.
10 pyrrolidine 5.00 0 20 MTBE 22.0 n.d.
11 pyrrolidine 5.00 110 60 pyrrolidine >95.0b n.d.
12 piperidine 5.00 113 reflux MTBE 32.0 n.d.
[33]
Judging from the absence of this second aminolysis for primary amines, the 
reactivity of secondary amines for uncatalyzed aminolysis does in fact play an 
important role for the optical purity of the product. For this reason the reaction 
between diethyl 3-hydroxyglutarate and pyrrolidine was reproduced without 
biocatalyst (entry 10). After the same reaction time as the lipase-catalyzed 
reaction and the respective work-up procedure, the crude product was 
analyzed by NMR spectroscopy. The conversion of the uncatalyzed reaction in 
MTBE at room temperature was determined to be 22%. By taking this 
uncatalyzed conversion to the racemic monoamide into consideration, the 
moderate enantiomeric excess of 59.1% ee (see Figure 40, page 35) at 55.9% 
conversion (see Table 3, page 32, entry 9) could actually be significantly higher, 
more precisely up to 97.6% ee. This would be in good agreement for the 
excellent enantioselectivity observed when using benzyl amine as donor 
reagent (>93% ee, see Figure 39, page 34). 
2.5.2 ANALYTICAL METHODS FOR THE DETERMINATION OF CONVERSION
AND ENANTIOSELECTIVITY
The conversion of the prochiral diester to its chiral monoamide was determined 
according to the method described for hydrolytic products (see chapter 2.4.2, 
page 17) by integration of significant signals in the 1H-NMR spectrum. 
In situ-monitoring of the reaction progress by titration, which was applicable 
for hydrolytic reactions, was not possible for these reactions. The reaction 
products, i.e. the chiral monoamide, remaining prochiral diester as well as the 
substituted alcohol, cannot be detected by such methods. A possibility would 
Figure 37. Possible intra-
molecular side-reactions by 
introducing primary amides 
in the synthetic route. 
[34]
be an alcohol dehydrogenase-coupled oxidation of the carbinol to the 
corresponding aldehyde and quantification via photometric assays with 
carbonyl-detecting reagents. Since the reaction proceeds in MTBE this 
approach would need an alcohol dehydrogenase tolerant to organic solvents. 
Since this methodology was not available in this work, the conversion of all 
aminolytic reactions were solely analyzed by isolated product quantification 
and NMR integration (see Figure 38).
Despite literature-known methods for HPLC analysis of the chiral monoamides, 
only the N-benzyl amide (see Figure 39) and the N-pyrrolidino amide 
(see Figure 40, page 35) were successfully separated on chiral HPLC for the 
determination of the enantiomeric excess. 
Figure 39. HPLC chromato-
gram of the enantiomerically 
enriched N-benzylamino 
monoester 
Figure 38. NMR spectra of 
the prochiral substrate and 
the enantiomerically 
enriched N-benzylamino 
monoester after purification.
[35]
Both separations were sufficient for integration, however should be improved 
for further studies on aminolytic desymmetrizations of 3-DHG, including 
separation of substrate and diamide, which was observed at higher reaction 
temperatures and excess amine (see Table 3, page 32, entry 10). Analysis by 
quantitative HPLC measurement should be possible by simple filtration of the 
immobilized biocatalyst and direct measurement of the MTBE reaction solution. 
This methodology was not further investigated in the present work.
2.6 SUBSEQUENT CHEMICAL ROUTE TO AN ENANTIOPURE KEY 
INTERMEDIATE
Up to now the absolute configuration was introduced by a biocatalyst in 
excellent selectivity. The task for the following chemical reactions 
(see Figure 41, page 36) was to achieve high conversions and yields under 
retention of the absolute configuration and without any racemization of the 
stereogenic center. The biocatalytic deacetylation proceeded without 
epimerization and yielded the desired deprotected (3R)-monoester 60 in 
quantitative conversion and excellent yields of up to 95%. The optical purity 
was determined to be >97% ee according to the method described in chapter 
2.4.3 on page 18. Since the monoesters with the free hydroxy group and the 
acetyl-protecting group were obtained with excellent enantiomeric excess, the 
following steps were conducted for both of them in parallel. 
Figure 40. HPLC chromato-
gram of the enantio-
merically enriched N-pyr-
rolidino monoester. 
[36]
2.6.1 PROTECTIVE GROUP CHEMISTRY FOR THE 3-HYDROXY GROUP
The subsequent activation of the monoester was going to be done by 
nucleophilic substitution, thus the potentially nucleophilic secondary alcohol
had to be masked. A common protecting group in this case is the tert-
butyldimethylsilyl ether, which is highly stable towards strongly basic reaction 
conditions and nucleophilic substitution. This protective group is also used in 
the literature-known synthesis of Rosuvastatin.16 Usually, tert-butyl-
dimethylchlorosilane 74 is activated in situ in the presence of 1H-imidazole 75
(see Figure 42). The intermediate 76 is then used to silylate a nucleophile, 
which in this case is the secondary alcohol of (3R)-60. However, after extraction 
of the crude product, the appearance of a by-product was observed. By 
Figure 41. Chemical derivati-
zation of enantiomerically 
enriched monoesters to their 
corresponding phosphor 
reagents
Figure 42. Reaction scheme 
for the TBS protection of 
ethyl (3R)-hydroxyglutarate
[37]
analysis of the 1H-NMR spectra and the reaction mechanism, the impurity was 
identified as the corresponding silyl ester (3R)-77. 
The procedure was therefore changed to an excess of chlorosilane 74 and a 
subsequent hydrolysis in aqueous basic medium as previously described by 
SCHOENHERR et al.. 33 The literature protocol was partially changed since the 
reported 6-fold excess of inorganic base seemed to be exaggerated. The 
hydrolysis was successfully achieved with 0.5 equivalents of inorganic base to 
maintain the basic pH in the solution. In addition, the aqueous work-up after 
silylation, which was done in the literature procedure, was eliminated since it 
was redundant. Under the optimized reaction conditions (see Table 4), the 
desired TBS-protected monoester (3R)-21b was isolated as a mixture with 
residual silanol. Although the protection group is labile to acidic pH, the 
aqueous phase needed at least pH 5 to obtain yields above 60% after three 
extractions. Saturation with sodium chloride led to an increased yield of both 
product and silanol. This impurity could only be partly removed by distillation, 
preferably in its hemihydrate form.34 Even at high vacuum and elevated 
temperatures the viscosity of the product made it hard to completely distillate 
the remaining silanol. Since it was not clear how this impurity would affect the 
following reactions, the crude product was initially used without further 
purification.
Table 4. TBS-protection of 
ethyl 3-hydroxyglutarate in 
various organic solvents
(a) The conversion is determined 
after basic hydrolysis of the silyl 
ester and subsequent extraction 
from the acidified aqueous phase (b) 
Calculated from the crude product 
by quantitative NMR analysis with 
p-chlorobenzyl alcohol as internal 
standard.
Entry
60
[mmol]
TBS-Cl
(eq.)
1H-imidazole 
(eq.)
Solvent
T 
[°C]
Time 
[h]
Conversion a
[% (h)]
Yield
[g (%)]
1 5.00 2.20 6.00 THF 20 17 >95 2.26 (75)
2 10.0 1.10 3.00 MTBE 20 26 43 n.d.
3 5.00 1.50 2.50 MTBE reflux 12 59 n.d.
4 5.00 2.00 3.00 MTBE reflux 20 89 1.82 (52)
5 30.8 2.20 2.20 MTBE reflux 6 87 10.5 (51)
6 40.0 2.20 2.20 2-MeTH 80 18 32 n.d.
7 100 2.00 2.00 THF 20 21 >95 9.80b (24)
8 117 2.00 2.00 EtOAc 20 19 78 n.d.
9 100 2.00 2.00 THF 20 17 >95 16.8b (58)
[38]
PROTECTIVE-GROUP CHEMISTRY FOR DESYMMETRIZED MONOAMIDES
The TBS-protection of desymmetrized primary and secondary amides was 
realized according to the above mentioned method. Since amides have only 
low solubility in water, the extraction could be done at a basic pH of around 8. 
This way, the acid-labile protective group did not hydrolyse during the work-
up. Unfortunately, the product was again mixed with silanol. All amides were 
purified via column chromatography on silica to remove the remaining 
side-product (see Table 5). Notably, the primary amide positions were not 
silylated under the reaction conditions.
Entry R1 R2
TBS-Cl 
(eq.)
1H-Imidazole
(eq.)
Conv.
[%]
Isol. yield
[g(%)]
1 H Bn 1.1 3.0 >95.0 0.49 (64.5)
2 Me Bn 2.0 3.0 >95.0 0.20 (66.0)
3 Morpholine 2.0 3.0 >95.0 0.12 (83.4)
2.6.2 ACTIVATION OF THE CARBOXYLIC ACID
The phosphor ylide was going to be generated via nucleophilic substitution, so 
the O-protected carboxylic acids had to be activated. Some common activation 
methods for carboxylic acids were investigated for this purpose. The 
monoesters were transformed into the corresponding acid chlorides or mixed 
anhydrides of type 78 (see Figure 43, page 39) as suggested by some 
literature protocols.35 Whereas the formation of the acid chloride seemed to be 
the more convenient method, the purification of the crude product was not 
trivial. The analysis of the crude product also revealed the presence of various 
impurities which could not be identified within this work. In contrast to that the 
Table 5. TBS-protection of 
various enantiomerically en-
riched β-hydroxyamides
[39]
reaction with methyl chloroformate for the synthesis of the mixed anhydride 
with a carbonate leaving group proved itself to be straightforward. The 
quantitative conversion was determined by 13C-NMR analysis for the acid 
chloride since the only clear observable difference in NMR spectroscopy is the 
low-field shift of the carboxyl-carbon.
In the case of the methyl carbonate derivative, the conversion was also 
quantitative. Even after purification on silica to remove residual silanol from the 
preceding reaction, the pure compound showed a methyl integral not 
corresponding to the theoretical number of protons. This could be explained 
by a mixed anhydride of type 78 (see Figure 43) of two monoesters.
Since the two carboxylates share a C2-axis, diastereomeric shifts are not 
observable. The integrals determined by manual integration suggested the lack 
Table 6. Synthesis of acti-
vated carbonacid derivatives
by literature-known proto-
cols
Figure 43. Reaction scheme 
for the synthesis of activated 
carboxylic acid derivatives
Entry
R
(mmol)
Reagent 
(eq.)
Additive (eq.)
Solvent 
(°C)
Conv.
[% (h)]
Yield
[g (%)]
1 Ac (1.60) ClCOOMe (1.25) TEA (1.50) Toluene (-40) 86.3 (0.5) 0.29 (60.6)
2 Ac (5.00) ClCOOMe (1.25) TEA (1.50) MTBE (-40) >95.0 (0.5) 0.94 (68.1)
3 Ac (4.00) C2O2Cl2 (1.30) DMF (0.01) DCM (0-20) >95.0 (4.0) n.d.
4 TBS (3.77) (H3C)3CCOCl (1.03) TEA (1.03) THF (0) 0.0 (3.0) -
5 TBS (3.44) TosCl (1.10) TEA (1.10) MTBE (20) 0.0 (24.0) -
6 TBS (2.00) ClCOOMe (1.65) TEA (1.25) MTBE (-60) >95.0 (1.0) 0.28 (33.8)
7 TBS (15.0) ClCOOMe (1.50) TEA (2.00) MTBE (-70) 78.7 (2.0) 5.64 (n.d.)
8 TBS (12.6) ClCOOMe (1.50) TEA (2.00) MTBE (-70) 91.7 (2.0) 3.17 (66.1)
9 TBS (5.00) ClCOOMe (1.50) TEA (2.00) MTBE (-70) 91.0 (16.5) 1.16 (66.8)
[40]
Signal shift [ppm] 4.56 4.13 3.90 2.74 2.57 1.27 0.85 0.09
Number of protons 1 2 3 2 2 3 9 6
Position 3 5 1 2 4 6 8 7
Calculated protons 1.02 1.98 3.38 1.90 1.92 3.18 8.26 5.96
STDEV 0.06 0.13 0.20 0.11 0.12 0.19 0.50 0.36
STDEV [%] 6.1 6.5 6.1 6.1 6.1 6.1 6.1 6.1
of protons for the methylcarbonate signal, but the analysis of the Lorentz-fitted 
spectrum36 suggested quite the opposite (see Table 7, page 40). The number 
of protons for each position was determined by normalizing each signal 
separately to its theoretical value and calculating an average of all other signals 
as well as the standard deviation (STDEV). The latter was determined to be 
6.1 - 6.5% for every integral. This leads to the conclusion that the integral of 
the methylcarbonate (see Table 7, 3.90 ppm) cannot account for quantification 
of the proposed impurity 78 (see Figure 43, page 39). The corresponding 
spectrum of the acetate-protected mixed anhydride showed an enhanced 
standard deviation of 4.3% (see Table 8, page 41) for every signal. Despite the 
fact that the manual integration suggested a lack of desired product, the 
validation by Lorentz-fitting stood again in contrast.  
These findings indicate that integration of 1H-NMR spectra for the 
quantification of impurities is only reliable to a moderate extend. In general, 
the activation with methyl chloroformate was superior to the formation of the 
acid chloride, in terms of conversion and purity of the intermediate. There was 
also no concrete evidence of a formation of the proposed anhydride 78 from 
two monoester molecules. Pivaloyl and p-toluenesulfonyl chloride were also 
Table 7. Analysis of the 
1H-NMR spectrum of the 
mixed TBS-anhydride
[41]
Signal shift [ppm] 5.51 4.16 3.92 2.91 2.74 2.05 1.27
Number of protons 1 2 3 2 2 3 3
Position 3 5 1 2 4 6 7
Calculated protons 1.03 1.98 3.00 1.97 1.95 2.83 3.28
STDEV 0.04 0.09 0.13 0.08 0.08 0.12 0.14
STDEV [%] 4.3 4.3 4.3 4.3 4.3 4.3 4.3
tested for the activation of the monoesters but exhibited no product-related 
conversion in the crude product. Whether this resulted from low reactivity or 
due to hydrolysis during the extractive work-up was not determined. The 
literature procedure was done in toluene, with triethylamine as assisting base 
for the neutralization of the byproduct hydrochloric acid. Interestingly, 
triethylamine hydrochloride precipitated out of the reaction mixture when tert-
butyl methyl ether (MTBE) was used as reaction solvent. The precipitation was 
not quantified but could be useful for further reaction optimization and 
combination with preceding or following reaction steps.
2.6.3 PREPARATION OF THE STABILIZED PHOSPHOR YLIDE
The C=C bond formation of an aldehyde with phosphor ylides based on 
phosphoranylidenes or phosphonates are known as WITTIG and HORNER-
WADSWORTH-EMMONS (HWE) reaction, respectively. These two reactions have 
similar reaction mechanisms. In general, both reactions produce predominantly 
E-alkenes. The main difference between WITTIG and HWE reagents lies in their 
Table 8. Analysis of the 
1H-NMR spectrum of the 
mixed O-acetyl anhydride
[42]
basicity and nucleophilicity. The β-carbonyl moiety leads to an increased 
stability of the reagents. The benefit of the WITTIG reagent is its reactivity even 
in the absence of additional base. Most notably is a recent publication of BENCH 
et al. on the synthesis of phosporanylidenes of type 81 (see Figure 44, page 
42) from acetone and phosphines of type 79 by using a biconcave cobalt 
perfluorophthalocyanine (80) and oxygen, leading to the desired ylide with 
water as the only by-product.37 Despite it being an initial study with no 
sophisticated data for lab scale procedures, this surely opens new possibilities 
for stabilized WITTIG reagents without the need for α-halogenated ketones. 
Commonly, WITTIG reagents can be prepared by two general strategies. The 
alkylation of trisubstituted phosphines of type 82 (see Figure 45) is by far the 
most convenient way and has been established for various C=C coupling 
reactions. In the case at hand the formation of such an α-haloketone 83
starting from a carboxylic acid derivative would require certain harsh conditions 
which are unfavorable for an industrial application. Therefore, the method of 
choice was the substitution of a carboxylic ester derivative 88 with a 
trisubstituted phosphoranylidene 87. This reagent is formed in situ by 
deprotonation of trisubstituted phosphonium halides 86 in the presence of 
strong bases, e.g. n-butyllithium or lithium N,N-diisopropylamide. 
Figure 44. Synthesis of 
stabilized WITTIG reagents by 
cobalt (II)- perfluorophthalo-
cyanine-catalyzed oxidative 
coupling of acetone with 
phosphines in the presence 
of oxygen (BENCH et al.).37
Figure 45. Common strate-
gies for the synthesis of 
stabilized WITTIG reagents
[43]
Since the latter is mostly used for its coordinating counter ion, n-butyllithium 
was used for complete deprotonation and its irreversibility caused by the 
formation and evaporation of n-butane and therefore shifting of the acid-base 
equilibrium to the desired product. The progress of the reaction can even be 
monitored by plain sight. The colorless phosphonium halide 89 (see Figure 46) 
is suspended in THF while the corresponding ylide 90 is highly soluble. 
Moreover, due to delocalization with the aromatic rings and the phosphorous 
d-orbital, the reagent solution has an intense orange color. The complete 
conversion is monitored by the change of a suspension to a deep orange 
solution. This is also a convenient indicator for remaining base, which in the 
case of n-butyllithium would lead to undesired side-reactions. To circumvent 
this, the reaction solution should always maintain a small amount of dispersed 
phosphonium salt. After addition of the activated carboxylate of type 20 or 22, 
the substitution reaction leads to decoloration of the solution. Unfortunately, 
the substitution product has acidic α-protons which neutralize one equivalent 
of reagent. For this reason the reaction had to be done with an at least 2-fold 
amount of reagent. It was not tested if the precipitating starting material 89 
could be isolated by filtration and reused for another batch, however it seems 
reasonable. Apart from the reaction with the activated carboxylic acid 
derivatives (see Table 9, page 44, entries 4, 7-9), the ylide was also formed 
from the corresponding prochiral TBS-protected diethyl ester to obtain the 
racemic compound (entry 5). As expected, the ethyl ester had a low reactivity 
with 90 and only 27% product-related conversion was observed. Interestingly, 
the same reaction with the HWE phosphonate 92 (entry 6) showed complete 
conversion but also side-product formation and loss of chirality by silanol 
elimination, suggesting lower selectivity for the desired product.
Figure 46. Synthesis of 
stabilized WITTIG and HWE 
reagents by nucleophilic 
substitution of carboxylic 
acid derivatives
[44]
Entry
Reagent 
(eq)
20 (R1)
(mmol)
X
Solvent 
(°C)
Conv.
[% (h)]
1
Ph3PCH3Br 
(2.0)
H 
(3.60)
BnNHa
THF/toluene 
(-55)
n.d.b
2
Ph3PCH3Br 
(2.0)
2-THP 
(2.30)
BnNHa
THF 
(-55)
n.d.b
3
Ph3PCH3Br 
(2.0)
Ac 
(2.50)
Cl
THF 
(-55)
n.d.c
4
Ph3PCH3Br 
(2.0)
Ac 
(2.30)
MeOCO 
THF 
(-55)
n.d.c
5
Ph3PCH3Br 
(2.0)
TBS (22)
(1.00)
EtO
THF 
(-15)
27.0 
(3.0)
6
(MeO)2POCH3
(4.0)
TBS (22)
(2.00)
EtO
THF 
(-78)
74.0 
(2.5)d
7
Ph3PCH3Br 
(2.0)
TBS 
(0.80)
MeOCO
THF/toluene 
(-70)
61-69e
(3.0)
8
Ph3PCH3Br 
(2.5)
TBS 
(3.67)
MeOCO
THF 
(-78)
n.d.f
9
Ph3PCH3Br 
(2.5)
TBS 
(9.00)
MeOCO
THF 
(-78)
n.d.f
The enantiomerically enriched phosphor ylide (3R)-2a is an important 
intermediate since the established industrial route to Rosuvastatin is based on 
the following WITTIG reaction. It is also the commercially available intermediate 
(methyl ester) and thus the benchmark for the desired novel process. The 
remaining impurities led to no satisfying crystallization, regardless of the 
investigated solvents. 
Table 9. Synthesis of 
phosphor ylides as WITTIG
and HWE reagents
(a) (S)-enantiomer through lipase-
catalyzed aminolysis (b) not 
determined; the lower pKa of protic 
moieties (NH < OH < methylene) 
led to various side-products which 
could neither be isolated nor 
identified (c) not determined; the 
strongly basic methylene 
compound led to major elimination 
of acetic acid with the loss of 
chirality (d) quantitative conversion 
of the starting material, mixture of 
at least four products incl. 
elimination products with loss of 
chirality, 26% product-related 
conversion (e) conversion was 
determined by the conversion of 
aldehyde in the subsequent WITTIG
reaction, incl. correction of 1.1 eq. 
aldehyde and 97% conversion of 
the reference reaction (f) not 
determined, isolation methods 
were tested but unsuccessful
Figure 47. HPLC chromato-
gram of enantiomerically 
enriched TBS-protected 
phosphoranylidene ethyl 
ester after preparative TLC 
purification and calculation 
of the enantiomeric excess
[45]
Therefore, the compound was used without further purification in the following 
WITTIG reaction. The product-related conversion was determined by calculating 
the conversion of heteroaromatic aldehyde consumed in the subsequent 
reaction. The small excess of ylide (1.1 equivalents) in the reaction procedure 
was also taken into account. Nevertheless, since the optical purity of this ylide 
is crucial for the route, the crude product (see Table 9, page 44, entry 9) was 
partially purified by preparative thin-layer chromatography on silica and 
analyzed by chiral HPLC to reveal an excellent enantiomeric excess of 98.2% ee 
(see Figure 47, page 44), which was considered sufficient for the following 
steps.
2.7 SYNTHESIS OF THE ACTIVE PHARMACEUTICAL INGREDIENT 
ROSUVASTATIN
The heteroaromatic core of Rosuvastatin is commercially available as the 
corresponding aldehyde 19 (see Figure 48), which can be used directly for the 
Figure 48. Patent procedure 
for the production of 
Rosuvastatin calcium from 
heteroaromatic aldehyde.38
[46]
WITTIG reaction. The product (3R)-18 is then deprotected for a 
diastereoselective reduction of the remaining carbonyl group. Subsequently, 
the alkyl ester of Rosuvastatin ((3R,5S)-3) is saponified to obtain the sodium 
salt of the API. The patented procedures by WATANABE et al. had some 
hazardous conditions which were objectable, like the deprotection of the silyl 
ether by hydrogen fluoride or the use of acetonitrile as solvent.38 Notably, a 
recently published solvent guide from Sanofi Aventis defines acetonitrile as the 
preferable aprotic polar solvent for industrial processes.39 Furthermore, the 
stoichiometric use of reducing agent and LEWIS base for the diastereoselective 
reduction of the β-hydroxyketone (3R)-17 were investigated for an alternative 
route via alcohol dehydrogenases.
2.7.1 WITTIG REACTION WITH THE HETEROAROMATIC CORE OF
ROSUVASTATIN
The WITTIG reaction for the C=C coupling of the heteroaromatic aldehyde 19 
and the phosphor ylide of type (3R)-2a was first reproduced with commercially 
available methyl ester (see Table 10, entries 1-4, 6). Since the stabilized WITTIG
reagent does not need additional base, the reaction proceeded smoothly in a 
mixture of both compounds, with the ylide in slight excess of 1.1 equivalents. In 
contrast to the literature procedure38, the present study also used protic 
solvents (entries 3-5) and even water (entry 2) which were proven to be
Table 10. WITTIG reaction 
with phosphoranylidene and 
heteroaromatic aldehyde
(a) acetonitrile (MeCN), potassium 
phosphate buffer (KPB), 2-propanol 
(iPA), tert-butyl methyl ether (MTBE)
(b) Determined by 1H-NMR integra-
tion from the crude product (c) 
Purified by column chromatography 
on silica.
Entry R1 R2
19
[mmol]
Solventa Conv.b (time) [% (h)]
Isolated yieldc
[g (%)]
1 TBS Me 0.90 MeCN 69.2 (12) n.d.
2 TBS Me 0.90 H2O 68.5 (12) n.d.
3 TBS Me 0.90 KPB/iPA 97.2 (12) 0.43 (78.6)
4 TBS Me 2.85 iPA 97.4 (8.5) 1.43 (82.6)
5 TBS Et 0.49 iPA 78.8 (6.0) n.d.
6 TBS Me 28.9 MTBE 98.0 (18.0) n.d.
[47]
convenient solvents. 
Remarkably, the reaction seems to be accelerated in protic solvents, possibly 
due to the stabilization of the betain intermediate. In view of a possible 
biocatalytic reduction with alcohol dehydrogenases, a mixture of buffer and 2-
propanol (3:1 v/v) was also successfully used for the reaction. The presence of 
2-propanol is a convenient way of substrate-coupled regeneration of the 
expensive cofactor nicotinamide adenine dinucleotide (NADH). The only side-
product of the WITTIG reaction and therefore the sole impurity, 
triphenylphosphine oxide, was separated by column chromatography for 
analytical purposes. Its effect on biocatalytic reductions was not investigated. 
To eliminate a possible inhibitory activity, the phosphine oxide was always 
removed in the initial experiments. The moderate conversion for the 
synthesized TBS-protected phosphoranylidene (3R)-2a is due to the conversion 
of the preceding ylide formation. Most likely the ethyl ester reacted to the 
same extent with the aldehyde 19 as the commercial methyl ester. Thus, the 
lower conversion was reasoned with the lower content of ylide reagent of only 
about 70-80 mol-%. The presence of a fluorine substituent in the aldehyde is 
helpful when analyzing the following reaction steps by NMR spectroscopy. In 
the proton-decoupled 19F-NMR spectra, the fluorine signal shifts sufficiently to 
determine product formation, but only qualitatively due to the necessary 
proton-decoupling (see Figure 49). The recorded spectra after purification via
column chromatography show a high-field shift for the product relative to the 
aldehyde. An unidentified side-product is also visible between 108.2-108.4 
Figure 49. Proton-decoupled 
19F-NMR spectra of the WITTIG
reaction and the hetero-
aromatic aldehyde as 
reference.
[48]
ppm, which could not be separated from the product, but was separated after 
the following step.
2.7.2 DEPROTECTION OF THE 3-HYDROXY GROUP
The O-protective group chemistry is necessary for ylide formation and possibly 
also prevents the product from reacting with excess ylide. However, after the 
WITTIG reaction, the protecting group became obsolete and even a hindrance 
for the following reduction. It was therefore removed to obtain the chiral β-
hydroxyketone as starting point for the following diastereoselective reduction. 
Although most of the literature-known procedures for the removal of tert-
butyldimethylsilyl ethers use the extremly toxic hydrogen fluoride or easier to 
handle fluoride salts, silyl ethers also tend to hydrolyse in acidic aqueous 
media. This hydrolytic approach is of course more desirable for an industrial 
process in regard of process safety. Hence, the TBS group was successfully 
hydrolyzed by the use of both tetra-n-butylammonium fluoride or a mixture of 
hydrochloric acid and ethanol, with quantitative conversions and excellent 
yields (see Table 11, page 49). 
Apart from the toxicity of fluoride, the two discussed methodologies differ also 
in their course of action (see Figure 50). The fluoride acts as a nucleophile and 
attacks directly at the silicon due to its ability to incorporate d-orbitals. The 
Figure 50. TBS-deprotection 
mechanisms of fluoride 
reagents and aqueous acid 
solutions
[49]
formed trigonal bipyramidal intermediate 96 eliminates the highly stable
tert-butyldimethylfluorosilane (97). This reaction is driven by the Si-X bond 
strengths, which can be seen in their respective dissociation energies. For  
trialkylsilylethers, the Si-O bond has a dissociation energy of around 122 
kcal/mol, while the trialkylfluorosilanes are in the region of 158 kcal/mol.40 The 
free carbinol 99 is then formed by aqueous work-up of the TBA salt 98. The 
hydrolytic approach starts with the electrophilic attack of a proton to the 
oxygen of the silylether 95, leading to the intermediate 100. The tert-
butyldimethylsilyl cation 101 is stabilized by its high electron density and the 
+I effects of the alkyl substituents. The carbinol 99 is eliminated and the silyl 
cation reacts with nucleophiles in the solution, e.g. ethanol or water. Both 
methods will produce the desired free carbinol 99 under retention of the 
stereogenic information.
Entry
(3R)-18a
[mmol]
Reagent Solvent
Conversion
[%]
Yield
[g(%)]
1 0.69 TBAF THF >95.0 n.d.
2 2.30 HCl EtOH >95.0 1.00 (88.1)
The product of the hydrolytic deprotection was purified by column 
chromatography since all protic components, including
tert-butyldimethylsilanol and its hemihydrate, had to be removed prior to the 
following reduction with sodium borohydride. This could become unnecessary
if a biocatalytic reduction can be realized since the biocatalyst would naturally 
be highly chemoselective towards ketone reduction. Hence, it would be 
possible to use crude products and eliminate another necessary purification 
step.
Table 11. TBS-deprotection 
of WITTIG reaction products
by fluoride and acidic 
treatment
[50]
2.7.3 DIASTEREOSELECTIVE REDUCTION VIA ALCOHOL DEHYDROGENASES
The biocatalytic reduction by the use of an alcohol dehydrogenase (ADH) was 
bilaterally investigated together with researchers from the HUMMEL group who 
screened alcohol dehydrogenases of various organisms for the enantioselective 
reduction of both O-protected and free β’-hydroxy enones of the Rosuvastatin 
methyl ester. Preliminary experiments were focused on a general activity for 
the corresponding substrate. To the best of our knowledge, a similar 
biotransformation was only achieved once for the cyclic β-silyloxy ketone 103
(see Figure 51) by BORTHWICK et al..41 They screened alcohol dehydrogenases 
from various organisms for the diastereoselective reduction of 103. Active 
biocatalysts from Mucor racemosus and Mucor circellinoides showed the desired 
selectivity for the syn-product 104, with an ADH from M. circellinoides as the 
superior one. After optimization of the reaction conditions, they were able to 
reduce the cyclic ketone 103 at 5 g/L substrate concentration with 62% yield
and an excellent diastereoselectivity of >98% de.
The presence of the p-fluorophenyl moiety in Rosuvastatin and its specific shift 
in 19F-NMR spectra made it possible to analyze the screening samples for 
product-related conversion. Usually, ADH screening assays are photometric 
measurements of the conversion-dependent decrease of NAD(P)H absorbance. 
However, side product formations or depletion can also lead to a decrease of 
absorption and falsify the results. Therefore, samples with positive photometric 
activity were extracted with MTBE and additionally analyzed by 19F-NMR 
spectroscopy. Unfortunately, as depicted in Table 12 (page 51), none of the 
tested alcohol dehydrogenases were able to reduce the O-TBS protected 
β’-hydroxy enone. This is much likely due to the increased bulkiness of the 
tert-butyldimethylsilyl ether. 
Figure 51. Diastereoselective 
reduction of a bulky β-silyl-
oxy ketone using an alcohol 
dehydrogenase (BORTHWICK
et al.).41
[51]
Entry a Organism
Activity b (+ / -) for
(3R)-18ac (3R)-17ac
1 Kocuria rosea - -
2 Rhizobium rhizogenes - -
3 Lactobacillus paracasei ssp. tolerans - -
4 Streptococcus thermophilus - -
5 Brochotrix thermospecta - -
6 Lactobacillus kefir - -
7 Dactylosporangium fulvum - -
8 Dactylosporangium roseum - -
9 Streptococcus ferus - -
10 Dactylosporangium thailandense - -
11 Rhizopus oryzae - -
12 Aspergillus oryzae - -
13 Weissella confusa (Lactobacillus confusus) - -
14 Bacillus subtilis ssp. spizizenii - -
15 Streptomyces antibioticus - -
The protective group was removed and the free β-hydroxyketone was used in 
another screening with the same organisms. Even for this more accessible 
substrate, no active biocatalyst was identified.
2.7.4 DIASTEREOSELECTIVE REDUCTION UNDER LEWIS-ACID COORDINATION
The chemical pathway to Rosuvastatin methyl ester was achieved by the 
NARASAKΑ-PRASAD reduction.42,43 This reaction is specifically used for the 
diastereoselective reduction of β-hydroxyketones to their corresponding syn-
diols by the use of sodium borohydride. The enantioselectivity is achieved by 
incorporation of a LEWIS acid like diethyl methoxyborane 106 in stoichiometric 
amounts (see Figure , page 52). 
Table 12. ADH-Screeninga,b for 
the reduction of TBS-protected 
or free β’-hydroxy enones of 
Rosuvastatin methyl ester.
(a) General reaction conditions: 5 mM 
substrate (solution in tert-butyl 
methyl ether), 0.5 M triethylamine, 
1 mM MgCl2, 1 mM NAD+, 1 mM 
NADP+, D-Glucose, GDH, 30 °C, 
overnight (b) Determined by analysis 
of the 19F-NMR spectrum. “+” corres-
ponds to a new peak occurring after 
the enzymatic reaction. (c) For the 
definition of Ar see Figure 49, page 
47.
[52]
An ethyl substituent is eliminated as ethane during the coordination of the 
chiral carbinol 17. The boronate 108 then acts as sterical hindrance and directs 
the Re-face attack of the usually unselective borohydride. The resulting borate 
111 is then oxidatively cleaved by hydrogen peroxide for retention of the 
absolute configuration. Although the literature mechanism suggests the 
substitution of both ethyl groups by two β-hydroxy ketone molecules, each of 
them acting as bulky steric hindrance for the Si face of another, the highest 
diastereomeric excess was achieved with a stoichiometric amount of lewis acid 
at a low temperature of -78°C. Nevertheless, since the heteroaromatic core of 
Rosuvastatin is very bulky, the coordination of the second molecule could still 
have been incomplete prior to the addition of sodium borohydride, thus 
leading to a lower selectivity of the hydride transfer. 
Figure illustrates a minimized energy model of the 1:1 substitution 
intermediate for stoichiometric amounts of borane. The coordination of the 
carbonyl oxygen to the boron atom leads to a boat configuration with blocked 
Si face. The hydride transfer is restricted to the Re face, thus producing the 
1,3-syn-diol. At higher temperatures, the vibrational energy seems to be high 
enough to promote the corresponding chair conformation with opening of the 
Si face for hydride transfer. In general, the diastereomeric excess was enhanced 
by an increased amount of coordinating borane 106 as well as minimizing the 
enthalpy of the system by operating at low temperatures. It is reasonable that 
Figure 53. Reaction inter-
mediate 109 (Figure ) with 
polarized carbonyl (black) and 
open Re face (minimized 
energy model)
Figure 52. Diastereoselective 
NARASAKA-PRASAD reduction 
and oxidative cleavage for the 
synthesis of Rosuvastatin 
methyl ester.
[53]
the diastereoselectivity can be maximized by prolonged period of reagent 
addition between the LEWIS acid and the borohydride.
Entry
17/18 (R)
[mmol]
Additive 
(eq.)
Solvent 
(°C)
Conv. (time)
[%(h)]
d.r.
Yield
[g (%)]
1
TBS 
(0.06)
-
THF 
(0)
>95 (1.0) 80:20 n.d.
2
H 
(2.30)
Et2BOMe 
(0.5)
THF 
(-15)
>95 (1.0) 66:34 1.20 (n.d.)
3
H 
(2.00)
Et2BOMe 
(0.5)
THF 
(-70)
>95 (2.0) 65:35 0.92 (n.d.)
4
H 
(1.00)
Et2BOMe 
(1.0)
THF 
(-15)
>95 (1.0) 80:20 n.d. (-)
5
H 
(1.00)
Et2BOMe 
(1.0)
THF 
(-70)
>95 (1.0) >98:2 n.d. (-)
Remarkably, the unselective reduction of the TBS-protected enone showed a 
diastereomeric excess of 60% de at 0°C, whereas the diastereoselectivity for the 
NARASAKA-PRASAD reduction was also 60% de at -15 °C and stoichiometric 
amounts of LEWIS acid. The bulky silyl ether seems to have a similar directing 
effect as the boronic ester.
2.8 DEVELOPMENT OF THE PROCESS CHEMISTRY
After the validation of all separate steps for the synthesis of Rosuvastatin alkyl 
ester, the experiments were focused towards a higher efficiency. The obvious 
drawback of the previous chapters was the purification of certain intermediates 
by column chromatography. This method is not feasible for large-scale 
production of APIs. Therefore, multiple strategies for the elimination of 
purification steps and the reduction of waste were examined.
Table 13. Diastereoselective 
reduction of β-chiral enone 
with NaBH4 and with or 
without LEWIS-acid coordi-
nation.
[54]
2.8.1 RECYCLING OF BIOCATALYSTS
A common method for the reduction of costs and waste in biocatalysis is the 
recycling of the catalysts. This is reasonable for low catalyst loadings 
(mol substrate / mol catalyst), when the costs for the biocatalyst surpass the 
costs for the product itself. The necessity of purified biocatalysts for a high 
chemo- or enantioselectivity could also favor a recycling procedure, due to 
their sometimes cost- and work-intensive purification. Moreover, high 
tolerance to organic media would in general facilitate recycling of the 
biocatalyst by extraction or filtration. For example, lipases are often 
immobilized on heterogeneous carriers like acrylic resins (Candida antarctica
lipase B) or diatomite (Amano PS SD, Pseudomonas cepacia or Burkholderia 
cepacia). This way the catalysts can be compartmented in a packed-bed reactor 
or continuously stirred tank reactor (CSTR), while the substrates are dissolved in 
an organic solvent and pumped through the immobilisate. 
Entry Spec. Activity A Rel. activityd A Spec. Activity B Rel. activityd B
[U/g]b,c [%] [U/g]b,c [%]
1 101 (100) 100 88.9 (100) 100
2 99.1 (98.1) 98.1 88.3 (99.3) 99.3
3 83.2 (82.4) 82.4 79.9 (89.9) 89.9
4 46.6 (46.1) 46.1 79.4 (89.3) 89.3
5 25.6 (25.3) 25.3 79.0 (88.9) 88.9
However, continuous processes with hydrolytic reactions are difficult to realize 
since the maintaining of basic pH is mandatory. By pumping the 
Table 14. Recyclinga of homo-
genous and heterogeneous 
biocatalysts in the production of 
(3R)-EHG.
(a) Each cycle was terminated after 
reaching >95% conversion judging by 
the titration curve of aqueous base; 
α-Chymotrypsin (CHY, A) was recycled 
by filtration over an ultrafiltration (UF) 
membrane and diluted with new 
reaction medium; Cephalosporin C 
acetylesterase (CAE, B) was used in 
immobilized form, separated by 
filtration over a glass frit and 
resuspended in the next UF membrane 
filtrate. (b) One unit is herein defined as 
one μmol of substrate converted per 
minute related to full conversions 
instead of initial reaction rates (c) 
Grams of enzyme formulation (purified 
(A) / immobilized (B) (d) Remaining 
activity relative to preceding cycle.
[55]
substrate/product mixture through an enzyme column, the pH is permanently 
lowered and the biocatalysts in the rear part of the column are inactivated, if 
not denaturized. Hence, the single batch reactor with an automatic titration 
with aqueous base is combined with a filtration step to remove the biocatalyst 
from the product solution. After resuspension in buffer solution, the biocatalyst 
is reused. For homogenous biocatalysts, this filtration can be realized by an 
ultrafiltration membrane, usually with a molecular weight cut-off of around 
25% of the catalyst’s molecular weight. Since α-chymotrypsin was used in 
homogenous solution, an ultrafiltration was implemented to recycle the 
biocatalyst. After 24 hours of desymmetrization reaction, the solution is 
pumped through an ultrafiltration membrane in a stirring cell (0.6 bar argon 
gas, 5.6 bar internal pressure). Table 14 (page 54) shows the remaining 
activities of α-chymotrypsin (A, Biozym, purified) within each desymmetrization 
cycle. A continuous decrease of activity was observed over five cycles, which 
implies the need for at least partial supplementation of biocatalyt after each 
cycle. The filtrate was directly used for the deacetylation reaction with 
cephalosporin C acetylesterase (CAE) while the filter residue was taken up in 
aqueous buffer and directly used for the next reaction batch. The deacetylation 
catalyst in its immobilized form was recycled by filtration over a glass frit (Por4, 
16 um) and resuspension in the filtrate of the next desymmetrization reaction. 
This procedure was repeated until five reaction cycles were completed. The 
results show almost complete retention of starting activity for the first two 
cycles of the immobilized cephalosporin C acetylesterase (B, see Table 14, 
page 54, entries 1-2). After storage at 4-8°C for two weeks, the next cycle 
showed a decrease of activity (Entry 3), while the following cycles were again in 
the range of the third cycle (entries 4-5). This could be explained by the 
absence of buffer solution between cycles 2 and 3, whereas its presence seems 
advantageous for the stability of the immobilized enzyme.
2.8.2 WORK-UP PROCEDURES CIRCUMVENTING CHROMATOGRAPHY
The main reasons for column chromatography were the elimination of silanol 
from the silyl ether protection step and the deprotection of this silyl ether after 
the WITTIG reaction. In addition, triphenylphosphine oxide had to be removed 
after the WITTIG reaction. 
Figure 54. Stirring cell with 
ultrafiltration membrane for the 
removal of dissolved α-chymo-
trypsin after the desymmetri-
zation reaction.
[56]
SILANOL REMOVAL FROM CRUDE PRODUCTS
For moderate volatile impurities like tert-butyldimethylsilanol, a distillation 
could be reasonable as purification method. With a boiling point of 109 °C 
under atmospheric pressure, this seems also facile to achieve. However, the 
high viscosity of the TBS-protected monoester as well as the β-hydroxy ketone 
of Rosuvastatin made it very difficult. Remarkably, the silanol could be partly 
removed via distillation and condensed as colorless oil and colorless needles. 
The reason for crystallization is the formation of a silanol hemihydrate with 
residual water. This hydrate was serendipitously discovered by BARRY et al.34
after the precipitation of colorless needles from recrystallization liquor. 
They determined the crystal structure by X-ray diffraction and calculated a 
rather low density of 0.996 g/cm³ which explains its volatility. This hemihydrate 
was removed by either precipitation at low temperatures and subsequent 
filtration (residual content <20%) or by high vacuum distillation from crude 
productsi (residual content <10%). Moreover, xylene was successfully utilized in 
an azeotrope distillation (b.p. 110°C, atm.) to remove the silanol and its 
hemihydrate to a residual content of <5%. The determination of purity was 
achieved by quantitative 1H-NMR analysis of the silylated product and tert-
butyldimethylsilanol as reference (see Figure 55, page 56).
TRIPHENYLPHOSPHINE OXIDE REMOVAL FROM CRUDE PRODUCTS
Since triphenylphosphine oxide (TPPO) is not volatile, distillation was not an 
option. However, TPPO shows poor solubility in certain organic solvents, e.g. 
MTBE. At low temperatures, precipitation and filtration sufficed for the removal 
of >90% TPPO impurities in the first cycle. Additional impurities prevented 
i A separate cooling trap for the hemihydrate is strongly recommended. Membrane pumps and 
the nearest lab technician responsible for replacing the membranes will most likely agree.
Figure 55. 1H-NMR segment of 
TBS-protected mixed anhydride 
and tert-butyldimethylsilanol as 
reference for purity control
[57]
further precipitation of TPPO. It has a very distinctive 31P-NMR shift at 29.8 
ppm (relative to Me3PO4 in acetone-d6, 4.00 ppm) which was used to 
qualitatively determine its absence or presence, respectively.
Since the phosphorous Nuclear-Overhauser-Effect (NOE) is inconsistent, 
integration of 31P-NMR spectra is inconclusive. Fortunately for the case of 
Rosuvastatin, the few aromatic signals of the p-fluorophenyl substituent do not 
overlay with the TPPO signals in the 1H-NMR (see Figure 56). Therefore, 
quantitative analysis of remaining TPPO was done via integration of the latter
in relation to the internal standard p-chlorobenzyl alcohol which was already 
described in chapter 2.4.2 for the quantification of the desymmetrized 
monoesters.
2.8.3 MULTI-STEP REACTIONS WITHOUT ISOLATION OF INTERMEDIATES
Most of the patented processes for the production of APIs were initially 
designed for a high yield of the target molecule. To reach this goal, solvents for 
each reaction were often selected for solubility reasons or beneficial effects on 
the reaction progress. For example, the use of diethyl ether for Grignard 
reactions, dispite its hazardousness, is still common sense. In many cases, the 
reaction proceeds only with symmetrical, aliphatic and unbranched ethers. Di-
n-butylether was also successfully used in such reactions. However, its high 
boiling point of 110°C is a drawback for volatile products. In regard of more 
sustainable process chemistry, generic processes now use solvents with low 
environmental impact, like ethyl acetate, alcohols or ideally water. In addition, 
separate steps with the same compatibility towards a certain solvent can be 
combined in a sequential one-pot or even tandem synthesis. In the recent past, 
some major breakthroughs were achieved by this solvent engineering 
Figure 56. 1H-NMR segment of 
the WITTIG product and 
triphenylphosphine oxide as 
reference for purity control
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approach, reducing the amount of total solvent used in the downstream 
processing. 
For example, researchers from Pfizer improved their synthesis of Sertraline 
hydrochloride by using ethanol as the sole solvent (see Figure 57).44 By 
elimination of all intermediary isolation steps, the process was converted from 
a three-step synthesis in THF, toluene, hexanes and ethanol to a three-step 
one-pot process in only ethanol with isolation of the API as mandelate salt. 
Starting from this aim, the reactions for the synthesis of Rosuvastatin were 
tested in various solvents for the assessment of compatible reactions. During 
this analysis, some advantageous properties were also discovered. For example, 
the biocatalytic processes for the desymmetrization and deacetylation of 
diethyl 3-acetoxyglutarate both used an aqueous buffer system at pH 8.0 and 
were therefore compatible without an extractive work-up (see Figure 57, 
page 59). Furthermore, the acetylation of 1a proceeded without any solvent. 
Thus, the first reaction was also combined with the biocatalytic reaction by 
simple addition of aqueous reaction medium and neutralization of the 
remaining byproduct, acetic acid, by neat sodium carbonate. The additional salt 
loading and increased ionic strength did not exhibit any inhibitory effects for 
neither of both biocatalytic reactions (see chapter 2.4.5.4, page 25). 
Figure 57. Solvent enginee-
ring for an improved 
production of Sertraline 
mandelate by TABER et al.44
[59]
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DERIVATIZATION FOR THE SYNTHESIS OF THE TBS-PROTECTED MIXED ANHYDRIDE
The resulting free β-hydroxyacid is then extracted and tert-butyldimethyl-
silyl-(TBS-) protected (see Figure 58, page 60). This formation of silyl ether is 
compatible with ethyl acetate, MTBE and other water-immiscible solvents, 
which could be used for extraction of the β-hydroxy carboxylic acid. The 
silylation in MTBE did not only afford the desired mixture of silyl ether and silyl 
ester, it also showed low solubility for imidazole salt byproducts and the 
silanol, making it possible to purify the crude product by filtration of 
precipitating impurities at low temperatures. Addition of the 
THF/methanol/water mixture and potassium carbonate led to a biphasic 
system, which was sufficient, however slower for the hydrolysis of the silyl ester. 
Again, the extractive work-up could be combined with MTBE. Since methanol 
had to be removed prior to the addition of methyl chloroformate because of its 
own reactivity, this was the first step which needed to be completely dried. The 
Figure 57. Multi-step synthesis 
for the production of 
enantiomerically pure (3R)-60 in 
comparison to the separate 
steps (square).
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previously discussed silanol hemihydrate was also reactive under the following 
conditions, reducing the excess of chloroformate to below stoichiometric 
amounts. This purification seemed to be mandatory and was also tolerable 
after four consecutive steps without necessary purification. The activation of 
the TBS-protected monoester was also realized in MTBE, with the additional 
benefit of triethylamine hydrochloride as the sole impurity being hardly 
soluble. Again, this reaction solution was readily purified by precipitation and 
filtration at low temperatures. Excess of methyl chloroformate was still present 
and needed to be quenched and removed via addition of aqueous sodium 
bicarbonate solution and phase separation. The compatibility of the ylide 
formation in MTBE was not tested. 
SYNTHESIS OF ROSUVASTATIN METHYLESTER FROM THE ENANTIOPURE PHOSPHOR YLIDE
The synthesis of Rosuvastatin methyl ester starting from the commercial ylide 
was also investigated for possible enhancement regarding solvents 
(see Figure 59, page 61). Since MTBE had proven itself to be highly versatile as 
reaction and extractive solvent, it was also chosen for this examination. The 
WITTIG reaction already turned out to be proceeding in any examined organic
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Figure 58. Solvent enginee-
ring for the subsequent 
derivati-zation to the TBS-
protected mixed anhydride. 
Comparison of the multi-step 
synthesis and the isolated 
reaction steps (square).
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solvent, with higher reaction rates observed in protic solvents or mixtures with 
water. The deprotection of the silyl ether 18a in aqueous media produced the 
corresponding silanol as persistent impurity. Thus, an alcoholic medium 
seemed favorable to transetherate the protecting group into a more 
convenient impurity, which could possibly be removed via evaporation. The 
following diastereoselective reduction of 17a was usually conducted in a 
methanolic THF medium. Therefore, the use of MTBE and ethanol as the only 
solvents was reasonable. 
While the WITTIG reaction proceeded as expected, the deprotection of the silyl 
ether did not. The conversion was not quantitative and led to a mixture of β-
silyloxyketone and β-hydroxyketone. The coordination of LEWIS-acid was 
therefore restricted to the deprotected hydroxy group and the 
diastereoselective reduction produced the desired (5S)-carbinol 3 in only 
60% de. After oxidative cleavage with hydrogen peroxide and additional acidic 
workup to remove remaining silylether, the content of Rosuvastatin methyl 
ester was quantified via 1H-NMR spectroscopy. The low conversion for the 
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Figure 59. Solvent enginee-
ring for the production of 
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anylidene. Comparison of the 
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(square).
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deprotection step could probably be circumvented by a prolonged reaction 
time, hence leading to quantitative elimination of silanol. The 
diastereoselectivity of the subsequent reduction would thus be enhanced 
compared to the already determined 96% de under these reaction conditions.
2.8.4 CRYSTALLIZATION OF INTERMEDIATES
The desymmetrization with α-chymotrypsin showed an excellent 
enantioselectivity of >97% ee for the desired monoester. To further increase 
the optical purity of the desired phosphorous ylide, a fractionized 
crystallization was also examined (see Figure 60). 
Since four intermediates are carboxylic acids, the crystallization with different 
amines was reasonable. Among commonly used amines for the enrichment of 
chiral carboxylic acids are dicyclohexylamine 113, tert-octylamine 115 and 
dehydroabietylamine 114, which were used in this study (see Table 15). 
Moreover, chiral amines such as 1-phenylethylamine 116 can also be applied 
for diastereopreferencial crystallization. The intermediates 45b, 60 and 21b
were successfully crystallized with dicyclohexylamine from a mixture of MTBE 
and n-hexane, unfortunately, due to fast crystallization, with an unsatisfying 
rise of optical purity to a maximum of 98% ee. Notably, the dicyclohexylamine 
salt of the TBS-protected monoester 21b was also used directly for the 
chloroformate activation reaction (see Figure 61, page 63). 
Figure 60. Intermediates 
bearing carboxylic acid 
moieties and amines examined 
in crystallization of 
enantiomeri-cally enriched and 
purified ammonium salts.
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Entry R1-COOHa R2R3NH Cryst.
Isol. Yield
[g (%)]
eeb
[%]
1 (3R)-45b 113 + 0.70 (38.1) 98.0
2 (3R)-45b (RS)-116 - - -
3 (3R)-60 113 + 0.95 (57.9) 97.2
4 (3R)-60 (+)-114 + 1.89 (71.3) 98.4
5 (3R)-60 (RS)-116 - - -
6 (3R)-21b 113 + 1.15 (53.0) n.d.
7 (3R)-21b (+)-114 - - -
8 (3R)-21b (RS)-116 - - -
9 Rosuvastatin 115 - - -
The byproduct dicyclohexylamine 113 precipitated as hydrochloride from the 
MTBE reaction mixture. Due to its cationic species, it was also inert towards 
carbamate formation. However, the reaction showed only 84% conversion, 
possibly due to the sterically demanding cyclohexyl groups. This reaction was 
not further investigated, but gives rise to an improved purification method for 
the silylation in combination with the carboxylic acid activation. 
Table 15. Purification of 
carboxylic acid intermediates 
by crystallization of their 
ammonium salts 
(see Figure 60, page 62).
(a) 4.6 mmol, except for entries 4 and 
7 (5.8 mmol) (b) Determined after 
acidic work-up and phenylethylamine 
derivatization.
Figure 61. Advantageous use 
of a crystallization procedure 
for (3R)-TBS-EHG (21b) in 
view of purity control for the 
mixed anhydride
[64]
2.9 CONCLUSION AND OUTLOOK
The present study on a biocatalytic desymmetrization route to the blockbuster 
drug Rosuvastatin, which had an annual world market sale of 6.253 billion US 
dollars in 2012, demonstrated the difference between an ideal process on 
paper and the often more complex chemistry of the realized synthesis. The 
initial route was adjusted several times to circumvent chemical as well as 
biocatalyst weaknesses. Nevertheless, the final route to the enantiomerically 
enriched key intermediate, the chiral phosphoranylidene 93, was successfully 
realized with high yields, excellent enantioselectivities and numerous 
improvements which made this process sophisticated enough to be of high 
industrial value. The most notable fact is that the bienzymatic process to 
ethyl (3R)-hydroxyglutarate (60), which was necessary to increase the 
enantioselectivity of the hydrolase α-chymotrypsin from moderate 60% ee to 
excellent >97% ee, is also the most stable part of the route (see Figure 62). The 
substrate concentration of 4.0 mol/L of 22a was even more fascinating, as it is 
in fact a binary mixture of aqueous reaction buffer and an organic substrate 
phase of around 1:1 volumetric ratio. By combining the highly enantioselective 
desymmetrization and a subsequent chemoselective deacetylation with 
cephalosporin C acetylesterase (CAE), the enantiomerically enriched ethyl 
(3R)-hydroxyglutarate (60) was produced in more than 350 g/L, which is 
remarkable for a biocatalytic process.
The subsequent derivatization to the enantiomerically enriched ylide (3R)-93b 
(see Figure 63, page 65), which was used as a benchmark intermediate for the 
industrial feasibility of the process, was established using literature-known 
protecting groups and activated carboxylic acid derivatives. The desired ylide 
could not be isolated in pure crystalline form. However, the content of ylide 
was determined by the conversion of aldehyde in the following WITTIG reaction 
(see, page 66). With respect to the already established WITTIG reaction with the 
Figure 62. Bienzymatic pro-
cess for the production of the 
enantiomerically enriched 
monoester (3R)-60 at high 
substrate concentrations.
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commercial ylide and the need for 1.1 equivalents of reagent, the conversion of 
aldehyde revealed an ylide content of 78-87%. The ylide was partially purified 
by preparative TLC and analyzed via chiral HPLC. The enantiomeric excess was 
calculated to be 98.2% ee, an optical purity which was considered to be 
sufficient for an industrial application. 
Another major achievement of this work was the combination of compatible 
reactions by solvent engineering and the elimination of purification steps. By 
doing so, the overall synthetic route was basically reduced to a single necessary 
purification of intermediate (3S)-20 in 9 consecutive steps (see Figure 64, 
page 66). Nevertheless, this purification is not trivial, with the tert-
butyldimethylsilanol as the major impurity. Within this work, a possible solution 
for this problem was found in the crystallization of the preceding product by 
the use of dicyclohexylamine. The corresponding ammonium salt can be 
purified by recrystallization and used directly for the following anhydride 
formation. This is only one of numerous future improvements which revealed 
themselves during this project. From an enzymatic point of view the top 
priority for upcoming improvements would without a doubt be an alcohol 
dehydrogenase which reduces the β-hydroxyketone 113 in high 
diastereoselectivity, eliminating stoichiometric amounts of 
diethylmethoxyborane and sodium borohydride. Since the preceding WITTIG
reaction is enhanced by aqueous or protic solvents, the reaction medium 
would most likely be compatible. Furthermore, the chemoselectivity of a 
biocatalyst instead of hydride reagents would be advantageous for present 
impurities. 
Moreover, the route to the enantiomerically enriched O-protected monoester 
could tremendously be shortened by a hydrolase accepting the TBS protecting 
group on the prochiral starting material 1a without losing activity or 
enantioselectivity. The TBS group is also the weakest point of this route from a 
chemical point of view, since its insertion and removal is bound to silanol 
Figure 63. Final route for the 
production of chiral 
phosphoranylidene (3R)-93b
[66]
impurities which are not easy to eliminate and also not inert towards some of 
the reaction conditions. Since the tetrahydropyran-2-yl group has the same 
stability properties but can be converted into an extractable aldehyde, it would 
certainly be the more favorable choice.
Finally, a desymmetrization process by a lipase-catalyzed aminolysis with 
primary and secondary amines was investigated (see Figure 65). Lipase B from 
Candida antarctica was successfully used to desymmetrize 1a with 
benzylamine, in good yields of 83% and very good enantioselectivity of 
93% ee. However, the presence of a relative acidic amide proton led to 
significant side-product formation during the ylide synthesis.
Figure 64. Overall synthetic 
route of Rosuvastatin calcium 
with only one mandatory 
purification step (blue).
Figure 65. Lipase-catalyzed 
desymmetrization of 1a with 
primary and secondary 
amines.
[67]
Changing the enzymatic desymmetrization to secondary amines was only 
moderately successful, accompanied by an uncatalyzed chemical aminolysis at 
even room temperature and therefore a low enantiomeric excess of the chiral 
monoester. By using pyrrolidine as nucleophile, a moderate optical purity of 
60% ee was achieved in parallel to an uncatalyzed aminolysis yielding a 
racemate. The reaction was reproduced in an uncatalyzed experiment and the 
result was used to recalculate the enantioselectivity of the isolated enzymatic 
process. Under the premise of equal reaction conditions, the enantioselectivity 
was determined to be 97.6% ee. These are most promising results for future 
work in the chemoenzymatic synthesis of pharmaceutical building blocks and 
generics.
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3 OVEREXPRESSION AND APPLICATION OF ALDOXIME 
DEHYDRATASES FOR THE SYNTHESIS OF ENANTIOPURE NITRILES AS 
PHARMACEUTICAL BUILDING BLOCKS
This project was a collaboration project between the organic synthetic working 
group of Prof. Harald Gröger (Organic Chemistry I, Bielefeld University, 
Bielefeld, Germany) and the molecular biology working group of Prof. Yasuhisa 
Asano (Enzyme Laboratory, Toyama Prefectural University, Kosugi, Toyama, 
Japan). It was generously funded with a Pre-Doctoral Fellowship by the Japan 
Society for the Promotion of Science (JSPS) on recommendation of the German 
Academic Exchange Service (DAAD). The following experiments were 
conducted during a six-months research stay at the japanese host institution 
from January 2013 – July 2013. The main interest focused on a possible 
application of aldoxime dehydratases, a recently discovered enzyme belonging 
to the class of lyases, for the enantioselective synthesis of nitriles (see 
Figure 66). 
Figure 66. General project 
overview for the synthesis of 
enantiopure nitriles by 
biocatalytic aldoxime de-
hydration.
[71]
3.1 ENANTIOSELECTIVE SYNTHESIS OF α-CHIRAL NITRILES AS BUILDING 
BLOCKS IN THE PHARMACEUTICAL INDUSTRY
Nitriles as carbonyl synthons can be widely applied in the manufacture of 
carboxylic acids, amides, amines and ketones (see Figure 67). This is based on 
the straightforward introduction of the nitrile group by nucleophilic 
substitution of alkyl halides with the pseudohalide cyanide or the addition of 
cyanide to aldehydes, e.g. for the STRECKER synthesis of α-amino acids.45 The 
nucleophilic substitution of alkyl halides follows a second order mechanism 
under complete inversion of the preceding absolute configuration, enabling 
the synthesis of enantiomerically pure nitriles. 
Nevertheless, enantiomerically pure alkyl halides are generated from their 
corresponding enantiomerically pure carbinols. This need for optically pure 
starting materials is a crucial drawback. Furthermore, the convenience of this 
nucleophilic carbonyl derivative is overshadowed by the reagents toxicity. 
Methodologies to circumvent the use of cyanide have been published in recent 
years, but to the best of the author’s knowledge, none of the following 
reactions is currently conducted on industrial scale. CZEKELIUS and CARREIRA
successfully converted enantiomerically enriched β-chiral nitroalkanes of type 
117 to their corresponding nitriles of type 119 by a chemical two-step 
elimination strategy (see Figure 68, page 71).46
Figure 67. Derivatization of 
chiral nitriles towards 
pharmaceutically relevant 
building blocks.
Figure 68. Two-step 
chemical derivatization of 
β-chiral nitroalkanes to 
α-chiral nitriles by CZEKELIUS
and CARREIRA.46
[72]
No optical purities are given for the overall process, which would be the most 
interesting information since the intermediate of type 118 and the product 119
should more or less be epimerizable under the reaction conditions. For the 
reason that enantiopure β-chiral nitroalkanes are not trivial to synthesize, this 
methodology is certainly restricted. Very recently, CHOI and FU reported an 
enantioselective, nickel-catalyzed NEGISHI cross-coupling reaction with chiral 
bidentate ligands of type (S,S)-121 (see Figure 69).47
Another metal-catalyzed process for the production of chiral nitriles was 
realized by a copper hydride reduction of α,β-unsaturated nitriles of type 123
with the use of a JOSIPHOS ligand (124) and stoichiometric amounts of 
hydrosilanes (see Figure 70).48
Very recently, an organocatalytic enantioselective synthesis of chiral α-aryl 
nitriles has been developed by coworkers of the LIST group (see Figure 71, 
page 73).49 Starting from racemic nitriles, they synthesized prochiral silyl ketene 
imines of type 126 which are subsequently protonated by a chiral organic 
phosphate 127. The stoichiometric proton donor is methanol which is itself 
silylated in return. 
Figure 69. Enantioselective 
C-C coupling reaction of 
racemic α-bromonitriles 
(rac-120) with zinc 
organyles in the presence of 
enantio- and diastereo-
merically pure bidentate 
ligands by CHOI and FU.47
Figure 70. Enantioselective 
reduction of β-substituted 
cinnamonitriles 123 by a 
copper hydride with 
JOSIPHOS (124) as chiral 
ligand and stoichiometric 
amounts of hydrosilanes as 
hydride donor by LEE et al..48
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A biocatalytic alternative to these metal- and organocatalytic approaches has 
also been reported by KOSJEK and her coworkers from Merck, reducing
α,β-unsaturated nitriles of type 129 with an enoate reductase.50 The 
stoichiometric hydride donor in this case is sodium phosphite, which recycles 
the oxidized nicotinamide cofactor (NAD(P)+) to its reduced form by a 
phosphite dehydrogenase (PTDH)51 present in the reaction mixture 
(see Figure 72).
POSSIBLE IMPLEMENTATION OF AN ALDOXIME DEHYDRATION IN THE PRODUCTION OF
ACTIVE PHARMACEUTICAL INGREDIENTS
Beside the use as a precursor for previously discussed chiral structures, nitriles 
are also implemented directly as pharmacologically active structures in drugs 
such as Vildagliptin, Saxagliptin and Sapacitabine (see Figure 73). While the 
first two compounds are used as dipeptidyl-peptidase 4 inhibitors for the 
Figure 72. Enantioselective 
reduction of α,β-disub-
stituted α-aryl acrylonitriles 
of type 126 with an enoate 
reductase by KOSJEK et al.50
Figure 71. Enantioselective 
protonation of silyl ketene 
imines with the use of 
organocatalysts by GUIN et 
al.49
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treatment of diabetes, the latter is currently in the clinical phase III for the 
treatment of leukemia. The inhibitory effect towards peptidases is based on the 
structure of the nitrile as a carbonyl synthon. The peptidase acts on the nitrile, 
transforming it into an unreactive enzyme-aldimine complex.
In the case of Vildagliptin, the chiral nitrile is derived from L-proline amide by 
trifluoroacetic anhydride dehydration. This is advantageous as L-proline is 
commercially available in enantiomerically pure form. For more complex 
structures like Saxagliptin or Sapacitabine, the proline-type or furanose-type 
structure syntheses become sophisticated and replaceable. As aldoximes can 
be produced by the condensation of aldehydes with hydroxylamine, the 
relevant structures could be generated from their corresponding aldehyde 
derivatives, which will be discussed in chapter 3.3 (page X).
3.2 ENANTIOSELECTIVE BIOCATALYTIC DEHYDRATION OF ALDOXIMES
All of the methods above have certain drawbacks of either using 
enantiomerically pure precursors or enantiomerically pure metal-catalysts. 
Additionally, the substrate structures are sometimes a prerequisite, e.g. the α,β-
substitution pattern for enoate reductases. Therefore, finding a catalyst which is 
able to accept a wide range of molecular structures and combining it with a 
feasible substrate synthesis is of high interest. By using an aldoxime 
dehydratase, the synthetic pathway based on aldehydes could have additional 
advantages, such as a nearly perfect atom economy (see Figure 74) and the 
absence of stoichiometric reagents or expensive cofactors. 
Figure 73. Active pharma-
ceutical ingredients possess-
ing α-chiral nitrile moieties.
Figure 74. General synthetic 
route for the synthesis of 
enantiomerically pure 
nitriles starting from racemic 
aldehydes.
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3.2.1 STATE OF THE SCIENTIFIC KNOWLEDGE OF THE ALDOXIME 
DEHYDRATASE MECHANISM
Aldoxime dehydratases were first characterized by ASANO and KATO during the 
investigation of the aldoxime-nitrile pathway in plants and microorganisms.52,53
This pathway describes a part of the degradation of α-amino acids to their 
corresponding lower homologues of nitriles, which are further degraded to 
carboxylic amides and acids. The understanding of these biological pathways is 
of importance for the synthesis of bio-based structures or the development of 
new catalytic systems. The formal dehydration of aldoximes to their nitriles is 
catalyzed by a ferrous (Fe2+) heme unit, with protic amino acid side-chains like 
histidine and serine in the vicinity.54,55 The oxidation state of the iron heme was 
investigated by various groups and their results suggest the necessity of 
ferrous (Fe2+) heme rather than ferric (Fe3+) heme for successful catalysis. 
Moreover, flavin mononucleotide (FMN) or reducing agents like sodium sulfide
are necessary for high activity. This effect implies an oxidative inactivation of 
the active center to the ferric (Fe3+) state, either by the reaction itself or in a 
side-reaction with molecular oxygen. 
In addition, the ligand binding was determined by several crystal structures of 
aldoxime dehydratases from Pseudomonas chlororaphis (OxdA, see Figure 75, 
page 75)55 or Rhodococcus erythropolis (OxdRE, see Figure 76)54, with the 
aldoxime directly bound to the ferrous heme unit with its nitrogen atom. It has 
been reported that the reaction only proceeds with this binding conformation 
and does not occur for the binding of the aldoxime oxygen. This inactive 
binding motif is mainly observed for the ferric oxidation state, which was 
artificially induced by oxidation. Furthermore, NOMURA et al. elucidated the 
mechanism by crystal structure and spectroscopic analysis and postulated an 
iron-(IV) carbimide intermediate.55 They also examined mutants obtained by 
alanine exchange for increase or decrease of enzymatic activity. As it is 
predictable, histidine (His320) and serine (Ser219) were obligatory for activity (see 
Figure 77) and their substitution to alanine led to complete loss of activity. 
Also, an adjacent arginine residue (Arg178) enhanced the reaction by a 5-fold 
rate, completing a catalytic triad responsible for the elimination of the 
aldoxime hydroxy group. Other residues in the vicinity of the active center were 
also exchanged by alanine but showed only minor effects on the residual 
activity. Notably, the exchange of a tyrosine led to a 1.7-fold increase of activity 
related to the wild-type. This could be explained by expansion of the active 
center and a correlating facilitated substrate binding.
Figure 75. Crystal structure of 
the biological assembly of 
aldoxime dehydratase from 
Pseudomonas chlororaphis
(OxdA) in complex with 
butyraldoxime (NOMURA et 
al.).55
Figure 76. Crystal structure of 
the biological assembly 1 of 
aldoxime dehydratase from 
Rhodococcus erythropolis
(OxdRE) in complex with 
propionaldoxime (SAWAI et 
al.).54
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Looking at the proposed reaction pathway starting from aldehydes and 
hydroxylamine it seems favorable to generate the aldoxime in situ by 
spontaneous condensation in aqueous medium. Unfortunately, XIE et al. 
demonstrated in a scaled-up process (0.75 M substrate concentration) for the 
synthesis of 3-phenylpropionitrile that the aldoxime dehydratase is inhibited by 
both aldehyde and hydroxylamine, even as residual impurities from a separate 
aldoxime formation.56 Remarkably, a simple washing of the crude product with 
water was sufficient to remove excess hydroxylamine. 
3.2.2 OVEREXPRESSION AND PURIFICATION OF RECOMBINANT ALDOXIME 
DEHYDRATASES
From an academic point of view it was important to have a reference reaction 
to gain insights into the reaction, preferably an already established substrate. 
The dehydration of phenylacetaldoxime was chosen as the higher chiral 
homologue 2-phenylpropionaldoxime, more specifically its corresponding 
aldehyde, is commercially available. The achiral reference substrate was 
converted with a remarkably high activity of up to 14,000 units per liter of 
culture (U/Lcult)57 by an aldoxime dehydratase from Bacillus sp. OxB-1, 
overexpressed in recombinant E. coli, which was therefore used as a reference 
catalyst system. Notably, the overexpression in the heterologous host amplified 
the wild-type activity by more than thousand-fold. In preceding studies by 
KATO et al. it was already reported that this aldoxime dehydratase from Bacillus
sp. (OxdB) showed no activity towards 2-phenylpropionaldoxime.58
Nevertheless, this substrate was also investigated. Other chiral aldoximes were 
also to be tested in the present work, none of them being screened before. The 
Figure 77. Proposed overall 
dehydration process based 
on the crystal structure of 
OxdA and necessary protein 
residues from alanine 
exchange studies by 
NOMURA et al..55
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biocatalyst was overexpressed according to the literature procedures and used, 
unless stated otherwise, as resting cell suspension in phosphate buffer (KPB).
The heterologous host system E. coli HB101, already transfected with the 
plasmid pOxD-9OF, was used in the present study.57 The aldoxime dehydratase 
was additionally purified for comparison with other formulations, e.g. resting 
cells, acetone-dried cells and the cell-free extract after sonication. The 
purification procedure was first described by KATO and ASANO57 and was 
reproduced to yield purified OxdB with the reported literature activity (8.35 
U/mg, 8.55 U/mg WTi), however with a relatively low overall yield of 5.7 mg. 
The cell-free extract was purified by ammonium sulfate precipitation (40-70% 
saturation), DEAE- and Butyl-Toyopearl ion-exchange chromatography as well 
as a preparative gel-filtration chromatography on a Superdex 200 (16/600)
i WT = wild-type
Figure 78. SDS-PAGE of the 
purification procedure of 
OxdB from rec. E. coli HB101 
/pOxD-9OF; 8-30 μg protein 
were placed on each lane. 
MP = Marker proteins (Phosphor-
ylase b (97.4 kDa), Serum albumin 
(66.2 kDa), Ovalbumin (45.0 kDa), 
Carbonic anhydrase (31.0 kDa), 
Trypsin inhibitor (21.5 kDa), 
Lysozyme (14.4 kDa)), Cell-free 
extract (1), 40-70% (NH4)2SO4
precipitate (2), DEAE-Toyopearl 
(3), Butyl-Toyopearl (4), Superdex 
200 16/600 (5).
Table 16. Purification steps
for OxdB from recombinant 
E. coli HB101 / pOxD-9OF.
Entry Method
Total 
Protein 
(mg)
Specific 
activity 
(U/mg)
Total 
activity (U)
Recovery
(%)
Purification
(fold)
1 Cell-free extract 1357 0.21 279.2 100 1.0
2 40-70% (NH4)2SO4 958.8 0.23 220.5 79.0 1.1
3 DEAE-Toyopearl 244.0 0.34 82.96 29.7 1.6
4 Butyl-Toyopearl 42.97 1.80 77.35 27.7 8.6
5 Superdex 200 5.690 8.47 48.19 17.3 40
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column connected to an ÄKTA purifier unit. After the final purification step an 
SDS-PAGE analysis (see Figure 78, page 77) showed a single band at 
approximately 40 kDa molecular weight, corresponding to the literature value 
of OxdB from Bacillus sp. (40,000 Da)58. The first ion-exchange chromatography 
on a N,N-(diethylamino)ethyl-Toyopearl (DEAE-Toyopearl) removed more than 
70% of total extractable protein of the cell-free extract (see Table 16, entry 3). 
Although the pooled fractions 10 - 17 (244.0 mg) contained all of the active 
protein (see Figure 79), almost 63% of the total activity was lost during the 
procedure. This shows the rather weak stability of OxdB after separation from 
its recombinant host cell. 
The subsequent purification step on a Butyl-Toyopearl ion-exchange column 
could further remove inactive proteins, with the pooled fractions 16 - 20 
(see Figure 80) maintaining more than 93% of total active protein. However, 
the resolution of this procedure seems quite poor, hence the need for small 
volume fractions.
The final gel-filtration chromatography successfully removed the remaining 
inactive protein contaminants. Due to its poor resolution (see Figure 81,
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Figure 79. DEAE-Toyopearl 
purification of OxdB. Each 
fraction was analyzed by 
Bradford assay and sub-
sequent biotransformation 
for protein content and 
specific activity towards 
Z-phenylacetaldoxime.
Figure 80. Butyl-Toyopearl 
purification of OxdB. Each 
fraction was analyzed by 
Bradford assay and sub-
sequent biotransformation 
for protein content and 
specific activity towards 
Z-phenylacetaldoxime.
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page 79) and the instability of the protein, nearly 38% of total active protein 
from Butyl-Toyopearl was lost in this process. The purified OxdB solution 
(fraction 17) showed a specific activity of 8.47 U/mg for Z-phenylacetaldoxime 
under the literature-assay conditions. The purified OxdB remained unstable, 
losing its entire remaining activity over the following 120 hours. 
Therefore, whole-cell catalysis seems to be the preferable method for using 
aldoxime dehydratases, at least up to date. In contrast to the purified enzyme, 
whole-cells are also superior in regard of their separation from 
biotransformations, their reusability, if staying intact, and their heightened 
stability in solution. In addition, acetone-dried cells of E. coli HB101 / 
pOxD-9OF were prepared according to a literature protocol from ASANO for the 
preparation of acetone-dried whole-cells of a phenylalanine dehydrogenase.59
Figure 81. Superdex 200 
(16/600) purification of 
OxdB. Fraction 17 was 
analyzed by Bradford assay 
and subsequent biotrans-
formation for protein 
content and specific activity 
towards Z-phenylacetald-
oxime.
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Figure 82. Storage stability 
of different enzyme 
formulations of recombinant 
E. coli HB101/pOxD-9OF.
Abbreviations: acetone-dried cells 
(ADC), resting cell suspension (RC), 
cell-free extract (CFE)
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Impressively, these acetone-dried cells maintained about 90% of the initial 
specific activity for more than four months while being stored at -20 °C
(see Figure 82, page 79). This is a promising factor on possible future
applications on industrial level, since the preparation of the whole-cells can be 
separated from the manufacturing of chiral nitrile compounds.
3.2.3 SUBSTRATE DIVERSITY AND STEREOPREFERENCES FOR ACHIRAL 
ALDOXIMES
A crucial point for many enzymatic reactions is the substrate spectrum. For 
example, lipases react significantly faster with apolar substrates like carboxylic 
esters or alcohols than amides or carboxylates. Alcohol dehydrogenases have 
often a higher selectivity for ketones bearing small substituents. Since the 
aldoxime dehydration is part of the microbial degradation of α-amino acids, it 
is reasonable to presume that all amino acid side-chains, whether aliphatic or 
aromatic, are accepted as substrate structures. In fact, this seems to be the case 
for aldoxime dehydratases, as they were already proven to be highly versatile in 
this manner. Many aliphatic, aromatic, even heteroaromatic aldoximes were 
successfully screened with aldoxime dehydratases from Bacillus sp.56,58, 
Rhodococcus sp.60,61,62,63, Pseudomonas sp.64 and Fusarium sp.65 (see Table 17). 
While the synthesis of Z-phenylacetaldoxime, the standard substrate for the 
Entry Substrate Oxd
Km
[mM]
Rel. activity
[%]
1 Z-phenylacetaldoxime Bacillus sp. OxB-1 0.872 100
2 Z-3-phenylpropionaldoxime Bacillus sp. OxB-1 1.36 62.9
3 E/Z-n-capronaldoxime Bacillus sp. OxB-1 6.12 57.1
4 E/Z-indoleacetaldoxime Bacillus sp. OxB-1 2.42 39.3
5 Z-napthacetaldoxime Bacillus sp. OxB-1 0.846 4.48
6 E/Z-2-phenylpropionaldoxime Rhodococcus sp. N-771 n.d. 232
7 E/Z-cyclohexanecarbaldoxime Rhodococcus sp. N-771 n.d. 610
8 E/Z-Isobutyraldoxime Rhodococcus sp. N-771 n.d. 67.1
9 Z-3-phenylpropionaldoxime R. globerulus A-4 2.31 253
10 E/Z-2-phenylpropionaldoxime R. globerulus A-4 11.9 19.7
Table 17. Exemplary sub-
strate spectrum for 
aldoxime dehydratases 
based on literature 
reports.56,58,60-63
[81]
aldoxime dehydratase from Bacillus sp. OxB-1, is significantly affected by the 
preferential crystallization of the Z-isomer over the E-isomer, most of the other 
aliphatic aldoximes can only be generated as E/Z-mixtures, with 
thermodynamic preference for the E-aldoxime. Aromatic aldoximes are an 
exception since the overlap with the aromatic system is impeding the E/Z-
isomerism. The stereopreference of E- and Z-aldoximes was first described by 
KATO et al., showing that OxdB has a higher activity for Z-aldoxime dehydration 
at 30 °C.58 What was surprising during this study is the fact that a handful of 
chiral aldoximes was initially screened for activity and also enantioselectivity. 
These chiral aldoximes, i.e. E/Z-2-phenyl-propionaldoxime and mandelic 
aldoxime, were determined to be either not active or leading to a racemic 
mixture of the corresponding nitriles.58,63 Nevertheless, since these results were 
only based on two chiral substrates and a couple of already identified aldoxime 
dehydratases, the present study was conducted for a number of additional 
chiral aldoximes and was initially focused on the screening for more active 
microorganisms.
3.3 CHIRAL SUBSTRATE SYNTHESIS AND REFERENCE COMPOUNDS
The previously discussed pharmaceutical target structures (chapter 3.1, 
page 79), more precisely their necessary aldehyde precursors, could be 
synthesized through a hydroformulation approach (see Figure 83). This 
hydroformulation, also known as Oxo synthesis or ROELEN reaction, adds 
carbon monoxide to an olefin under reductive conditions with molecular 
hydrogen to form aldehydes.66
It is widely applied in industry and efforts were also made to transfer this 
valuable method to aqueous or biphasic reaction mixtures, like the 
RHÔNE-POULENC process for the production of n-butanal from propene.67
Figure 83. Retrosynthetic 
approach based on a 
hydroformulation process 
for the synthesis of 
obligatory aldehyde pre-
cursors.
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Interestingly, not only alkenes but protected enamines and enol ethers can be 
hydroformulated. For example, LEIGHTON and O’NEIL successfully 
hydroformulated cyclic enol acetals of type 131 for the synthesis of polyol 
aldehyde structures 132 of natural compounds (see Figure 84).68
However, in this work, the biotransformation of racemic aldoximes was first 
investigated by using commercially available aldehydes (see Figure 85). The 
synthesis of aldoximes from their corresponding aldehydes can be realized 
under numerous conditions more or less optimized for the corresponding 
aldehydes. The methods range from simple mixing of aldehyde and 
hydroxylamine, or one of its readily available and easier to handle salts, to 
heterogenous catalysis with a solid inorganic base under solvent-free 
conditions, or just with stirring over molecular sieves. There are more than 
enough methodologies to generate aldoximes in excellent yields, even in 
aqueous media facilitating combination with an enzymatic reaction in a 
one-pot process.
However, since it was already intensively investigated by KATO et al.58 that the 
aldoxime dehydratase from Bacillus sp. OxB-1 shows different activities for
E- and Z-aldoximes of the same aldehyde, it seemed reasonable to explore 
Figure 84. Hydroformyla-
tion of exocyclic enol ethers 
for the synthesis of aliphatic 
polyol aldehydes by 
LEIGHTON and O’NEIL.68
Figure 85. Substrate syn-
thesis of α- and β-chiral 
aldoximes for the screening 
of enzymatic activity of 
OxdB and a possible 
enantioselectivity.
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synthetic conditions to generate either one isomer or the other, separately. In 
some cases, predominantly aromatic aldehydes but also for 
phenylacetaldehyde, the isomers differ not only in their enzymatic activity but 
also in their physicochemical properties, e.g. melting points or solubility. For 
phenylacetaldehyde, the Z-aldoxime was isolated from a mixture through 
fractionized crystallization. The literature also offers a number of 
methodologies specifically designed to synthesize aromatic Z- or E-aldoximes, 
which were also tested for applicability in this work.
The broad substrate spectrum of aldoxime dehydratases made it possible to 
vary the structures of chiral aldoximes to get a wide, however rational view on 
stereopreferences. For this matter, five small and structurally different 
aldehydes were used as starting materials (see Figure 85, page 82). The closest 
α-chiral aldehyde related to the standard substrate phenylacetaldehyde is 
2-phenylpropionaldehyde (132a) with an additional methyl substituent. This 
substrate was tested by KATO et al. and showed no activity for the aldoxime 
dehydratase from Bacillus sp. (OxdB) 58 and no selectivity for OxdRE
(Rhodococcus erythropolis)56. Regardlessly, it was still chosen for screening 
purposes in the present study. High activities for aromatic aldoximes in 
preceding studies suggested a general acceptance of cyclic structures directly 
bound to the carbaldoxime. Thus, 3-cyclohexene-1-carbaldehyde (132b) was 
examined as a chiral cyclic substrate. The flexibility of cycloalkanes can 
sometimes complicate the analysis. Therefore, the rigid 5-norbornene-2-carb-
aldehyde (132c) was used as an analog to 132b, without the ability to change 
the ring conformation and coincidentally enhance structure complexicity. 
Furthermore, the impact of a heteroatom was tested in view of biologically 
active chiral nitriles based on proline derivatives. However, unprotected 
pyrrolidine derivatives could not be synthesized in the present study. Hence, 
tetrahydrofuran-2-carbaldehyde (132d) was chosen as a substitute. 
Remarkably, addition of the synthesized compounds to the growing medium of 
OxdB resulted in complete inhibition in all but one cases. As can be seen in 
Figure 86, the cells of E. coli HB101 / pOxD-9OF grew also on a medium 
containing tetrahydrofuran-2-carbaldoxime 133d (5 mM). The reason for this 
specific tolerance was not determined. Last but not least, identifying mid-range 
selectivities for aldoxime dehydratases were also of interest so that 
3-phenylbutyraldehyde (132e) was chosen as well. Its stereogenic center is an 
additional methylene group away from the aldoxime. With this set of structure-
and electronically diverted compounds, standard protocols for the formation of 
aldoximes and their corresponding racemic nitriles were conducted.
Figure 86. Agar plate with 
grown recombinant E. coli 
HB101 / pOxD-9OF on LB 
medium containing 5 mM 
tetrahydrofuran-2-carbald-
oxime.
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3.3.1 RACEMIC ALDOXIMES THROUGH CONDENSATION OF RACEMIC 
ALDEHYDES WITH HYDROXYL AMINE
It is commonly known in literature that aldehydes and hydroxylamine 
spontaneously condensate to the corresponding aldoxime under the 
elimination of water. This process is nearly solvent-independent. However, the 
solubility of the reagent could play an important role in terms of conversion 
and isolation. Hydroxylamine is highly hazardous in its free form, with reports 
stating explosions at around 70 °C. Even more, aqueous solutions were 
reported to explode at 100 °C. Since hydroxylamine salts are readily available 
and easier to handle, the reagent was formed in situ with an adequate base. In 
view of an environmentally benign process the reaction was first tested in pure 
water with hydroxylamine salts like chloride and phosphate. Inorganic bases 
like sodium acetate, sodium hydroxide or sodium carbonate were used due to 
their high solubility in water. However, sodium hydroxide was ruled out for the 
possibility of a CANNIZZARO-type side-reaction and the disproportionation of 
starting material. Sodium acetate reacted as desired, but the byproduct acetic 
acid needed to be removed via extensive washing or in high vacuum. The most 
convenient base was in fact sodium carbonate, leading to the evolution of 
gaseous carbon dioxide and thus facilitating the isolation process. In this case, 
the corresponding aldoxime was extracted from an aqueous sodium salt 
solution of the hydroxylamine salt counter ion. 
Entry 132 R1 R2
Conversion
[%]
E/Za
Isol. Yieldb
[g(%)]
1 a Ph Me >95 72:28 8.46 (94.5)
2 b 1-Cyclohex-3-ene >95 65:35 3.63 (96.8)
3 c 2-Norborn-5-ene >95 55:45c 2.40 (44.1)
4 d 3-Tetrahydrofuran >95 50:50 3.93 (75.9)
5 e 2-Ph-Pr H >95 50:50 3.03 (82.5)
Table 18. Substrate 
synthesis of racemic 
aldoximes by condensation 
of racemic aldehydes with 
hydroxyl-amine.
(a) Determined by integration of 
1H-NMR spectra (b) Purification
via column chromatography or 
Kugelrohr distillation (c) NMR 
analysis showed a diastereomeric 
excess of 40% de for the 
α-stereogenic center.
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Interestingly, all aldehydes showed nearly quantitative conversion despite their 
overall poor solubility in the reaction medium water. In addition, the low 
solubility of the aldoximes was useful for an extractive isolation of the crude 
product. Except for substrate E/Z-133d, all aldoximes were purified by column 
chromatography on silica with different eluent mixtures of n-hexanei and ethyl 
acetate. E/Z-Tetrahydrofuran-2-carbaldoxime (E/Z-133d) was purified by 
Kugelrohr distillation. This methodology was also applicable for other 
substrates, but the heating of the compounds led to almost 1:1 mixtures of E-
and Z-aldoxime, aggravating the establishment of analytical methods later on. 
Notably, the bicyclic substrate 133c showed a diastereomeric excess of 40% de 
for the α-stereogenic center. This can be seen in its proton NMR spectrum 
since the additional two stereogenic centers of the bridged rings lead to four 
distinctive diastereomers (Figure 87). 
This diastereomeric excess is based on the production of the starting material 
132c. These norbornene derivatives are prepared via DIELS-ALDER reaction (see 
Figure 88) between cyclopentadiene (132) and a MICHAEL acceptor of type 
134. DIELS-ALDER reactions are endo-selective by definition, which would give 
the corresponding (2R)-diastereomer of 135 in high excess.  Detailed analysis 
of 1H-NMR and two-dimensional correlation spectra (1H-COSY) were used for 
the determination of the chemical shifts of all diastereomers (see Figure 89, 
page 86). Unfortunately, with two different bridgeheads of the bicyclus, 
i The use of toxic n-hexane was due to the solvent stock of the host institution. The separation 
should be reproducible with less hazardous cyclohexane/ethyl acetate mixtures.
[86]
regioisomers of the 2-carbonyl moiety cannot be discriminated in NMR 
spectroscopy but will most likely be discriminated by the biocatalyst.
Hence, the separation of eight isomers would have been necessary to analyze 
the biotransformation. In the present study, this separation could not be 
realized. Therefore, the following results obtained during the biotransformation 
of 5-norbornene-2-carbaldoxime (133c) could not be interpreted conclusively.
3.3.2 RACEMIC NITRILES BY PHOSPHINE OXIDE-CATALYZED DEHYDRATION
The reference compounds, the corresponding racemic nitriles, were
synthesized according to a literature protocol from DENTON et al. for the 
triphenylphosphine oxide (135)-catalyzed dehydration of aldoximes (see 
Figure 90, page 87).69 There are actually a couple of methods known in 
literature for the catalytic dehydration of aldoximes; however most of them are 
unselective. They are based on the substitution of the aldoxime hydroxy group 
by chloride and subsequent elimination of hydrochloric acid. This process also 
shows the limitation for these reactions, since basically all alcohols in the 
Figure 88. DIELS-ALDER reac-
tion of cyclopentadiene and 
α,β-unsaturated carbonyl 
compounds leading to 
diastereomerically enriched 
endo-products.
Figure 89. Identification of 
all 1H-NMR shifts for the 
separated diastereomers by 
1H-COSY spectra. 
Enantiomers of the aldoxime 
moiety, thus additional four 
isomers, cannot be 
discriminated by proton 
NMR spectroscopy.
[87]
starting material will be converted as well. Additionally, nucleophilic positions 
have to be masked by protecting groups.  There is not one enantioselective 
dehydration process known in literature, which could generate enantiomerically 
pure nitriles from racemic aldoximes. 
Entry 133 R1 R2
Conversiona
[%]
Isol. Yieldb
[g(%)]
1 a Ph Me >95.0 0.20 (30.5)
2 b 1-Cyclohex-3-ene >95.0 0.14 (58.3)
3 c 2-Norborn-5-ene >95.0 0.32 (73.6)
4 d 3-Tetrahydrofuran >95.0 0.36 (74.1)
5 e 2-Ph-Pr H >95.0 0.42 (94.5)
Figure 90. Phosphine oxide-
catalyzed dehydration pro-
cess for the synthesis of 
racemic reference com-
pounds.
Table 19. Reference com-
pounds by phosphine-oxide 
catalyzed dehydration of 
aldoximes.
(a) Determined by integration of 
1H-NMR spectra (b) Purification
via column chromatography or
Kugelrohr distillation.
[88]
The reactive species in the given protocol is most likely an intermediary 
chlorotriphenylphosphonium ion 137, which is substituted by the aldoxime 
133 to generate the unstable aldoximophosphonium ion 138, which produces 
the desired nitrile of type 139 under elimination of triphenylphosphine oxide 
(135) and a proton. The overall reaction is impressively sophisticated, with 
three gaseous byproducts (CO, CO2, HCl) as the driving force. All aldoximes 
were converted quantitatively and purified via column chromatography on 
silica or Kugelrohr distillation, respectively. As they were only used as analytical 
reference compounds, the isolated yield was not considered an issue and 
cannot be used for comparison with the yield of the biocatalytic 
transformation. Table 16 (page 87) shows the results of the unselective 
dehydration of the investigated chiral aldoximes.
3.4 ANALYTICAL METHODS FOR CONVERSION AND SELECTIVITY
The establishment of analytical methods for the determination of both enzyme 
activity and enantioselectivity is always the initial key for investigating 
biocatalysts. Depending on the respective substrate or product structures, this 
can be achieved either in situ or after extractive work-up. As usual, the main 
advantage of in situ analysis is the higher sample throughput and the 
unchanged mixture content. The literature protocol for the standard substrate 
is based on quantitative product determination in the aqueous reaction 
solution by reversed-phase HPLC (acetonitrile/water mixtures as eluent). The 
enantiomeric excess was subsequently determined by extraction of the 
products into an organic solvent, i.e. methyl tert-butylether (MTBE), and 
analysis thereof on a normal-phase chiral HPLC column (n-hexane/2-propanol 
mixtures as eluent).
3.4.1 E/Z-2-PHENYLPROPIONALDOXIME / 2-PHENYLPROPIONITRILE
The closest phenylacetaldoxime (PAOx) – related substrate also had the benefit 
of bearing an aromatic ring, which facilitated the HPLC analysis by UV 
absorption. The product-related conversion could therefore be determined in 
situ by separating the reaction mixture on a reversed-phase column with an 
eluent of 30% acetonitrile in water (see Figure 91). Furthermore, after 
verification with reference mixtures, by-products were identified, i.e. hydrolysis 
[89]
to the corresponding aldehyde and formation of its hydrate. The equilibrium 
between those impurities impeded the quantitative analysis of the hydrolytic 
side-reaction.
The separation of all isomers of substrate and product on a Chiralcel OJ-H 
column was beneficial for the kinetic analysis within E/Z-mixtures. In addition,
after separating the enriched product from non-quantitative 
biotransformations, the absolute configurations of all isomers were successfully 
determined by comparison of the optical rotary power with a literature 
reference for (R)-139a (see Table 20).70
Figure 91. Reversed-phase
HPLC analysis of the 
reaction mixture of the 
aldoxime dehydratase-cata-
lyzed synthesis of 2-phenyl-
propionitrile (139a).
Peaks: 2-phenylpropionaldehyde 
and hydrate (green), E-2-phenyl-
propionaldoxime (orange), 
Z-2-phenylpropionaldoxime (red), 
2-phenylpropionitrile (blue).
Figure 92. HPLC analysis of 
the extracted product 
mixture of the aldoxime 
dehydratase-catalyzed syn-
thesis of 2-phenylpropio-
nitrile (139a).
Peaks: 2-phenylpropionitrile 
(blue), E-2-phenylpropionaldox-
ime (orange), Z-2-phenylpropion-
aldoxime (purple).
[90]
Entry
Isolated 
compound
Isolated yieldb
[mg (%)]
ee
[%]
[]
D
23
(c, CDCl3)
c
1 (S)-139a 68.4 (52.1) 65.2 - 4.40 (2.25)
2 E-(R)-133a 61.6 (41.2) >99.8 - 7.57 (1.32)
3 (R)-139a 34.2 (13.0) 67.3 + 5.57 (0.85)
Since the distribution coefficients for the extraction of the product mixture 
were not equal for all compounds, the conversion was not determined on chiral 
normal-phase HPLC. The enantiomeric excess for each component could be 
determined since enantiomers do not differ in their biphasic distribution. 
3.4.2 E/Z-CYCLOHEX-3-ENE-1-CARBALDOXIME / CYCLOHEX-3-ENE-1-
CARBONITRILE
Stereogenic centers in cyclic substrates can be quite interesting when it comes 
to ring inversion processes depending on the substitution. For cyclohexene 
derivatives, different substituent effects were studied by LAMBERT et al..71 As a 
rule of thumb, electron-withdrawing groups (EWG) enhance ring inversion by 
stabilizing the planar intermediate. For the present study on enantioselective 
aldoxime dehydration this can be rather challenging since substrate and 
product both have an EWG. In the case of cyclohex-3-ene-1-carbonyl 
derivatives, this could lead to epimerization of the product, independent of an 
enantiopreference of the aldoxime dehydratase. The conversion was 
successfully quantified by reversed-phase HPLC analysis of the reaction mixture 
(see Figure 93, page 91).
Table 20. Identification of 
isolated productsa and 
remaining substrates by 
measurement of the optical 
rotary power.
(a) Lit. value for (R)-2-phenyl-
propionitrile [a]D20 = +9.5 (c 2.4, 
CHCl3) (b) Determined after 
column chromatography on silica 
(c) Determined from 1H-NMR 
samples.
[91]
Unfortunately, the enantiomeric excess could not be determined by UV 
detection on a chiral HPLC. This missing link was closed by a chiral GC column 
and flame-ionization detection (FID). While the product could be readily 
separated into both enantiomers, the chiral aldoximes could not be separated 
(see Figure 94). In addition, due to the lack of literature values for the optical 
rotary power of the components, the major enantiomer of the product could 
not be identified yet.
Figure 93. HPLC analysis of 
the reaction mixture of the 
aldoxime dehydratase-
catalyzed synthesis of 3-
cyclohexene-1-carbonitrile 
(139b).
Peaks: 3-cyclohexene-1-carb-
aldehyde (green), Z-3-cyclo-
hexene-1-carbaldoxime (orange), 
E-3-cyclohexene-1-carbaldoxime 
(purple), 3-cyclohexene-1-carbo-
nitrile (blue).
Figure 94. GC analysis of 
the product mixture of the 
aldoxime dehydratase-
catalyzed synthesis of 3-
cyclohexene-1-carbonitrile.
Spectra: Reference mixture of
rac-3-cyclohexene-1-carbonitrile 
(left) and biotransformation with 
OxdB (right).
[92]
3.4.3 E/Z-5-NORBORNENE-2-CARBALDOXIME / 5-NORBORNENE-2-
CARBONITRILE
The previously discussed ring inversion can be suppressed by further 
substituents. In addition, bridging of the aliphatic ring system can also be 
useful. The restriction of conformational interchange and increase of structure 
complexity was initially chosen for a better understanding of the enzyme 
kinetics. 
Nevertheless, the different bridgeheads of this bicyclic substrate led to the 
formation of eight substrate isomers, a complex mixture that could not be fully 
separated within this project.
Figure 95. NMR analysis of 
the racemic mixture of 
5-norbornene-2-carbo-
nitrile (139c) with two 
distinguishable diastereo-
mers and two regioisomers, 
presumably in 1:1 ratio.
Figure 96. HPLC analysis of 
the reaction mixture of the 
aldoxime dehydratase-
catalyzed synthesis of 
5-norbornene-2-carbonitrile 
(139c).
Peaks: 5-norbornene-2-carb-
aldehyde (green), Z-5-norbor-
nene-2-carbaldoxime and dia-
stereomer (orange), E-5-norbor-
nene-2-carbaldoxime and diaste-
reomer (purple), 5-norbor-
nene-2-carbonitrile (blue).
[93]
The NMR spectrum of the TPPO-catalyzed dehydration reaction confirms the 
enrichment of endo-components in about 5:1 ratio (see Figure 95, page 92). 
Unfortunately, the regioisomers of these compounds, cannot be regarded as 
equal for OxdB binding. The four stereoisomers could not be separated by any 
available method during this study. HPLC analysis of the reaction mixture on a 
reversed-phase HPLC column demonstrated the need for a different assay to 
determine conversion and enantiopreference of aldoxime dehydratases for 
these bicyclic structures (see Figure 96, page 92). 
3.4.4 E/Z-TETRAHYDROFURAN-3-CARBALDOXIME / TETRAHYDROFURAN-
3-CARBONITRILE
In view of the chemoenzymatic synthesis of pyrrolidine derivatives for the 
production of dipeptidyl-peptidase inhibitors like Vildagliptin, a heterocyclic 
substrate was also investigated.72 In this work, tetrahydro-
furan-3-carboxaldehyde 132 was used as a commercially available substitute. 
This substrate showed an enhanced solubility in aqueous reaction media and 
was also the sole compound which did not inhibit growth of the recombinant 
E. coli cells on an agar plate. The purification of substrate and reference 
compound was established by Kugelrohr distillation, thus leading to nearly 1:1 
mixtures of E/Z-aldoxime 133d, aggravating the differentiation by UV 
absorption analysis. 
Figure 97. HPLC analysis of 
the reaction mixture of the 
aldoxime dehydratase-cata-
lyzed synthesis of tetra-
hydrofuran-3-carbonitrile 
(139d).
Peaks: Tetrahydrofuran-3-carb-
aldehyde (green), Z-tetrahydro-
furan-3-carbaldoxime (orange), 
E-tetrahydrofuran-3-carbaldoxime 
(purple), tetrahydrofuran-3-carbo-
nitrile (blue).
[94]
However, based on the fact that Z-aldoximes have a higher UV extinction 
coefficient than E-aldoximes, the HPLC analysis of a 1:1 mixture could be used 
for the assignment of E- and Z-conformation (see Figure 97, page 93).
Also in this case, HPLC analysis by UV detection was troublesome since nitriles 
have nearly no UV absorption. Again the solution of this analytical problem was 
found in chiral GC analysis and FID spectra (see Figure 98).
3.4.5 E/Z-3-PHENYLBUTYRALDOXIME / 3-PHENYLBUTYRONITRILE
This β-chiral substrate had again an aromatic moiety and was therefore readily 
observed by UV absorption on both reversed-phase and normal-phase HPLC. 
Figure 98. GC analysis of 
the reaction mixture of the 
aldoxime dehydratase-cata-
lyzed synthesis of tetra-
hydrofuran-3-carbonitrile 
(139d).
Spectra: Reference mixture of 
rac-tetrahydrofuran-3-carbonitrile 
(left) and biotransformation with 
OxdB (right).
Figure 99. Reversed-phase
HPLC analysis of the 
reaction mixture of the 
aldoxime dehydratase-cata-
lyzed synthesis of 3-phenyl-
butyronitrile (139e).
Peaks: 3-Phenybutyraldehyde 
(green), Z-3-phenylbutyraldoxime 
(orange), E-3-phenylbutyraldox-
ime (purple), 3-phenylbutyronitrile 
(blue).
[95]
Interestingly, the aldoxime formation led in all cases to 1:1 mixtures of E- and
Z-isomers. In combination with the higher molar extinction of the Z-isomer, 
this was again beneficial for the assignment of isomers by UV absorption 
(see Figure 99).
The separation of enantiomers was also successfully achieved in this study 
(see Figure 100). Unfortunately, no literature data for the identification of the 
preferred enantiomers was available. The enantiopreference will therefore be 
given as the major-enantiomer. This substrate is also of interest from another 
point of view. Since the stereogenic center is not enolizable, a possible 
epimerization of the product for α-chiral nitriles can be ruled out and the 
enantiomeric excess should be directly related to the biocatalyst.
3.5 CASE STUDIES REVEALING A CONFORMATION-DEPENDENT SELECTIVITY
After the establishment of analytical methods for the product-related 
conversion of the aldoxime dehydratase-catalyzed synthesis of chiral nitriles, 
the compounds were tested for their specific activity in relation to the achiral 
standard substrate Z-phenylacetaldoxime. For these initial preparative 
screening experiments, E/Z-mixtures were examined by the literature protocol 
of KATO et al.58 Surprisingly, the allegedly inert substrate E/Z-2-
phenylpropionaldoxime (133a) was infact highly active for the aldoxime 
dehydratase from Bacillus sp. OxB-1 (see Table 21, page 96, entry 1). With 
around 3,200 U/L of culture, the relative activity was about 23 % at 30 °C, with 
full conversion determined by quantitative HPLC analysis. The substrate was 
also tested for another aldoxime dehydratase from Rhodococcus sp., which was 
Figure 100. Normal-phase 
HPLC analysis of the extracted 
product for the determination 
of the enantiomeric excess of 
3-phenylbutyronitrile (139e).
Peaks: 3-Phenylbutyraldehyde (green) 
3-phenylbutyronitrile (blue), Z-3-phe-
nylbutyraldoxime (orange), E-3-phe-
nylbutyraldoxime (purple).
[96]
reported to be active yet unselective for this compound.63 The specific activity 
was also high in this case, but even lower than for the OxdB biotransformation 
(entry 2). To reduce the enzymatic activity and investigate a possible 
enantiopreference of the enzyme, the screening was also done at a lower 
temperature of 8 °C. The activity decreased to about 1/18 of its initial activity at 
30 °C (entry 4).
Entry 133 Oxda
Temp.
[
o
C]
Total 
activityb
[U/L
culture
]
Whole-cell
activityc
[U/mg]
1 a OxdB 30 3,190 -
2 a OxdRG 30 2,010 -
3 a OxdB 30 - 0.13
4 a OxdB 8 170 -
5 b OxdB 8 30 -
6 c OxdB 8 81 -
7 d OxdB 8 n.d. -
8 e OxdB 8 205 -
In addition, the other chiral substrates were also tested at this reaction 
temperature and showed significantly lower activites, nevertheless sufficient for 
preparative experiments. The only compound which could not be analyzed for 
conversion was tetrahydrofuran-3-carbaldoxime (133d), which was therefore 
not investigated in more detail. Notably, the more complex structure of 
5-norbornene-2-carbaldoxime (133c) showed a higher activity than its 
unbridged counterpart 133b (entries 5 and 6). This indicates conformational 
changes during the binding of 3-cyclohexene-1-carbaldoxime (133b), slowing 
down the dehydration process. 
Table 21. Microscale 
screening for active 
biocatalysts at elevated and 
lower temperatures
(a) OxdB = HB101 / pOxD-9OF, 
OxdRG = BL21 Star DE3 / pOxdS17 
(b) Determined by quantitative 
HPLC measurement after 60 
seconds reaction time (c) Units per 
mg of acetone-dried cells, not 
purified protein.
[97]
3.5.1 BIOCATALYTIC SYNTHESIS OF ENANTIOMERICALLY ENRICHED NITRILES 
BY THE USE OF ALDOXIME DEHYDRATASES IN RECOMBINANT E. COLI
The screening experiments were promising for the preparative synthesis of the 
chiral nitriles. To get a more detailed insight into the time-course of the 
reaction and to clarify important parameters like the KM value or a product 
inhibition, the biotransformations were scaled up from 0.5 mL to 5.0 mL., in 
some cases even to 50 mL. This allowed the analysis of more than one aliquot 
of the reaction mixture after certain timeframes. More importantly, by 
observing the enantiomeric excess of the formed nitrile over time, a fascinating 
r appeared. The enantiomeric excess of the product was shifting over the 
course of the reaction. This was first observed during a biotransformation of 
E/Z-2-phenylpropionaldoxime with a diastereomeric ratio of 4:1 (E/Z, see 
Figure 101). At a substrate concentration of 5 mM, which was the standard 
concentration in the screening experiments, an initially high ee value decreased 
during the first minutes of the biotransformation. Nevertheless, the ee value 
increased again after reaching about 20% conversion. 
Figure 101. Time-course of 
the aldoxime dehydratase 
catalyzed synthesis of 
2-phenylpropionitrile 
(139a).
[98]
By taking a closer look at the chiral HPLC spectra during the reaction progress, 
it was observed that both Z-enantiomers are converted, with kinetic 
differentiation, but in general, leading to a racemate at full conversion. In 
contrast to that, the E-aldoxime was only converted with a certain absolute 
configuration, which was later determined according to Table 20 (page 90). 
The remaining enantiomer of the E-aldoxime was not converted, even after 24 
hours in the presence of biocatalyst (see Figure 102). This was somehow 
surprising as the same experiment at an elevated temperature of 30 °C led to 
full conversion and a perfect racemate. 
Under the given circumstances this could be explained by an isomerization 
process between E- and Z-aldoximes in a thermodynamically controlled 
equilibrium (see Figure 103). The corresponding Z-isomer would then be 
active for Oxd dehydration and thus lead to full conversion and a racemic 
product.
Figure 102. Chiral HPLC 
chromatograms from the 
time-course of the aldoxime 
dehydratase-catalyzed syn-
thesis of 2-phenylpropio-
nitrile (139a).
(a) Reference mixture of 
rac-2-phenylpropionitrile and 
E/Z-2-phenylpropionaldoxime 
(9:1) (b) Reaction mixture after 
30 minutes (c) Reaction mixture 
after 2 hours (d) Reaction mixture 
after 24 hours
Figure 103. Thermodynami-
cally controlled isomeri-
zation of inert E-(R)-aldox-
ime to active Z-(R)-aldoxime 
and subsequent dehydra-
tion by OxdB.
[99]
Besides the enantioselectivity of the aldoxime dehydration, it was also 
investigated if the substrate concentration could be enhanced. Running the 
biotransformation at 5 mM aldoxime concentration, which corresponds to less 
than 1 g/L, would certainly be irrelevant for an industrial application. Therefore, 
the reaction was scaled up to 10 mM, 25 mM, 50 mM and 100 mM. The 
conversion rate decreased with increasing substrate concentration, but not 
proportional to the product concentration, suggesting a substrate inhibition 
above around 20 mM (see Figure 104).
Even more intriguing was the enantiomeric excess of the product obtained 
during the scale-up experiments. At low conversions, the absolute 
configuration of 2-phenylpropionitrile was inverted. The product was isolated 
by column chromatography and the opposite configuration was confirmed by 
measuring the optical rotary power (see Table 20). The inverted 
enantiopreference can be explained by the high substrate concentration of 50 
mM. At this concentration, presumably all components of the mixture are 
above their Km or even double Km value, hence being converted in the highest 
possible reaction rates. Judging from the kinetic differentiation on the chiral 
HPLC spectra (see Figure 102, page 98), the Z-aldoxime is converted at first, 
with the Z-(R)-enantiomer being faster converted than its enantiomer. Due to 
the inhibition at around 2.4 % (see Figure 104, 50 mM) this led to an enhanced 
conversion of Z-(R)-aldoxime and thus the preferred synthesis of 
(R)-2-phenylpropionitrile. 
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Conversion [%] nitrile Selectivity [%] ee
Figure 104. Scale-up of the 
biotransformation for the 
synthesis of 2-phenyl-
propionitrile (139a).
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3.5.2 ENANTIOSELECTIVITY CHANGE ACCORDING TO E/Z-CONFORMATION
Based on the preceding findings it was necessary to separate the aldoxime 
diastereomers and reproduce the experiments with isomerically pure 
compounds. The separation of E- and Z-aldoximes by column chromatography 
seemed manageable and was successfully achieved with the crude product of 
the aldoxime condensation. Two fractions were obtained with sufficient purity 
of E-rac-2-phenylpropionaldoxime (98% de) and Z-rac-2-phenyl-
propionaldoxime (84% de). Better separation should be achievable by using a 
UV detector, which was not available during this study. The biotransformations 
with OxdB were reproduced and showed the same behavior as with the 
mixtures (see Figure 105). While Z-rac-133a was at first converted with a high 
enantioselectivity for the (R)-enantiomer, the (S)-enantiomer was subsequently 
transformed to obtain a nearly perfect racemate of 139a at full conversion. 
Since 4% of inert E-(R)-aldoxime was present in the substrate, the reaction 
stopped at 96% conversion and with an enantiomeric excess of 4% ee for the 
(S)-nitrile.  On the other hand, the enzymatic dehydration of E-rac-133a at 8 °C 
led to the predicted full conversion of E-(S)-133a to its corresponding (S)-nitrile 
139a and no conversion of E-(R)-133a. Due to the residual 1% of Z-aldoxime in 
the substrate, the product showed a lower, however still excellent enantiomeric 
excess of 98% ee for the (S)-nitrile.
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Figure 105. Biotransfor-
mation of isomerically 
enriched E- or Z-131a by 
OxdB at low temperature 
(8°C).
[101]
3.5.3 QUALITATIVE KINETICS FOR THE CONVERSION OF RACEMIC E- AND Z-
ALDOXIMES
With the literature-unknown and now identified enantioselectivity of the 
aldoxime dehydratase from Bacillus sp. OxB-1 in recombinant E. coli for the 
conversion of E-2-phenylpropionaldoxime, the other chiral substrates 133b-e
were also investigated (see Figure 106). Since their enzymatic activity was 
already proven in the microscale experiments, the following-up 
biotransformations were focused on a change in enantioselectivity during the 
time-course of the reaction. This phenomenon can be used as a direct 
implication of diastereomeric differentiation. Due to the schedule of the 
research stay at the host institution, only qualitative results were obtained.
E/Z-3-CYCLOHEXENE-1-CARBALDOXIME (133B)
As it was already mentioned for the initial experiments, the ring inversion of 
3-cyclohexene derivatives could alter the enantiomeric excess of the remaining 
substrate and the corresponding nitrile. Apart from this, the non-linear 
behaviour of the enantiomeric excess during conversion observed for 2-
phenylpropionaldoxime was also present in the biotransformations with E/Z-3-
cyclohexene-1-carbaldoxime. Unfortunately, the E/Z-mixture could not easily 
be separated and the highest purity of E-133b achieved was an E/Z ratio of 
89:11 after column chromatography. Nevertheless, even with using a substrate 
mixture of 133b with an E/Z ratio of 2.2:1, non-linear behaviour was indeed 
observable (see Figure 107, page 102), with an initial high selectivity for one 
enantiomer. Even more intriguing were the final conversion of 76% and the 
final enantiomeric excess of 17% ee.
Figure 106. Additional 
chiral substrates for the 
investigation of a non-linear 
behaviour of the enantio-
meric excess.
[102]
The reaction did not proceed any further, which again suggests the existence 
of an inert aldoxime enantiomer. Due to the lack of literature references, the 
absolute configuration of the major enantiomer of 139b could not be 
identified yet. This result is very surprising since the only differentiation of the 
biocatalyst is the unsaturated bond in the cyclohexene ring (see Figure 108). 
More studies on this substrate will be done in the future, as it would certainly 
have an impact on the synthesis of enantiomerically pure cyclic nitriles.
E/Z-5-NORBORNENE-2-CARBALDOXIME (133C)
Implementing a bridged 3-cyclohexene as substrate seemed favorable to 
prevent the decrease of the enantiomeric excess by ring inversion. However, 
during the analysis of the starting material it became clear that the mixture of a 
total of eight isomers would be extremely difficult. Since the isomers could not 
be separated on chiral HPLC, it was not distinguishable which isomers are 
preferably converted by the enzyme. What could be determined, however, was 
again a non-quantitative conversion of the substrate and a final enantiomeric 
excess of 66% ee, which was in the range of the enantiomeric excess of the 
starting material (see Figure 109, page 103). This leads to the conclusion that 
there are at least some isomers which are not converted by the biocatalyst, but 
their identities remain unclear up to now.
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Figure 107. Biotransfor-
mation of isomerically 
enriched E-133b by OxdB at 
low temperature (8°C).
Figure 108. Chiral discrimi-
nation of E/Z-3-cyclohex-
ene-1-carbaldoxime (131b) 
by only one unsaturated 
bond (emphasized).
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E/Z-TETRAHYDROFURAN-3-CARBALDOXIME (131D)
Since the aim of this project was also the synthesis of pharmaceutically relevant 
heterocyclic nitriles of type 140 (see Figure 110), substrate 133d was of great 
interest to get insights into the biocatalytic transformation of heteroaromatic 
cyclopentane structures. 
Unfortunately, the specific activity could only be determined by reversed-phase 
HPLC after reaching about 20% conversion at 5 mM due to the low molar 
extinction of the product 139d. Nevertheless, the reaction was monitored for a 
change in enantioselectivity non-proportional to the conversion of 133d. The 
aldoxime dehydratase from Bacillus sp. OxB-1 showed no enantioselectivity by 
GC analysis of the product mixtures. At any stage of the reaction, a racemate 
was obtained (see Figure 111, page 104).
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Figure 109. Biotransfor-
mation of isomerically 
enriched E/Z-133c by OxdB
at low temperature (8°C).
Figure 110. Structural 
analogy of investigated 
substrate 133d with pyrroli-
dine-type heterocyclic ald-
oximes.
[104]
Since also this reaction stops at about 50 % conversion, it remains unclear if 
there is an inhibition by one of the stereoisomers or if one or more 
stereoisomers are again inert substrates. This issue will certainly be adressed in 
future experiments but could not be clarified in the present study. Since 
tetrahydrofuran is known to undergo conformational changes even at room 
temperature (signals with higher order in NMR spectra) this could also indicate 
that the product racemizes by ring-inversion after a possible enantioselective 
dehydration. 
The target molecules, bearing a pyrrolidine ring system, would of course have 
similar properties. An alternative methodology would be the use of acylated 
pyrrolidine derivatives of type 141 (see Figure 112, page 104) to increase the 
barrier for conformational changes and also enhance the enantiospecific 
discrimination by the aldoxime dehydratase.
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Figure 111. Biotransfor-
mation of racemic E/Z-133d
by OxdB at low temperature 
(8°C).
Figure 112. Alteration of 
pyrrolidine-type substrates 
in view of facilitated 
derivatization and enhanced 
discrimination by Oxds.
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E/Z-3-PHENYLBUTYRALDOXIME (133E)
The only β-chiral substrate investigated in the present study, 
namely 3-phenylbutyraldoxime (133e), should elucidate two more informations 
on the applicability of aldoxime dehydratases. On the one hand, β-chiral nitriles 
are not prone to epimerization and could therefore give indications on a 
potential enzyme-induced epimerization of the products after the dehydration. 
On the other hand, the selectivity of the dehydration could be enhanced by a 
chain-elongation, with the substituents being closer orientated to the protein 
backbone and therefore presumably bound with stronger stereospecific 
discrimination.
Also with this substrate, the aldoxime dehydratase first produces the 
corresponding nitrile with a high enantiomeric excess (60 % ee at 30 % 
conversion, see Figure 113) which decreases steadily and in relation with the 
conversion until yielding a racemic product at full conversion. This indicates an
enantioselectivity for one enantiomer but also the lack of an unreactive isomer, 
thus leading to a racemate in the end. It is yet promising that there is also a 
kinetically preferred enantiomer of this β-chiral compound and it should be 
worthy to manipulate the biocatalyst to further reduce or completely eliminate 
the activity for the enantiomer with the lower reaction rate. Notably, the 
β-chiral aldoxime was the only substrate which did not include an inert isomer.
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Figure 113. Biotransfor-
mation of racemic E/Z-131e
by OxdB at low temperature 
(8°C).
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3.6 INVESTIGATION OF A DYNAMIC KINETIC RESOLUTION PROCESS
The successful synthesis of enantiomerically pure (S)-2-phenylpropionitrile by 
the use of an aldoxime dehydratase was an encouraging result. This process is 
somehow limited by the need for isomerically pure E-aldoxime and reaching 
only 50 % conversion for the desired nitrile. While the specific synthesis of
E-aldoximes remained unresolved during the present study, the racemization 
of the remaining E-(R)-aldoxime was examined. The most common way to 
epimerize α-chiral carbonyl compounds in aqueous media is by changing the 
pH towards an either more acidic or more basic value and thus initiating an 
enolization process. With regard of maintaining enzymatic activity throughout 
the epimerization, the reaction was reproduced at elevated pH values of 8, 9 
and 10 (see Table 22). The reaction rates slowed down with increasing pH. 
Nevertheless, the reaction yielded around 50% of unreacted E-(R)-133a. 
Entry Buffer (50mM) pH
Conversion
[%]
ee
[%]
1 NaOAc 5.0 <0.5a n.d.
2 KPB 7.0 27.7b 98.1c
3 KPB 8.0 37.2b 97.9c
4 Ethanolamine 9.0 8.9 n.d.
5 Ethanolamine 10.0 7.3a n.d.
This inability to epimerize can be rationalized by the lower pKa of the aldoxime 
proton in contrast to the α-proton. The deprotonated species 142 seems to be 
stable towards epimerization and also towards biotransformation, therefore 
slowing down the reaction rate (see Figure 114).
Table 22. pH-Dependence 
of the biocatalytic 
dehydration of E-rac-133a
in aqueous reaction media.
(a) Significant hydrolysis of the
substrate (b) No hydrolysis, only 
product-related conversion (c) 
HPLC analysis of the remaining 
aldoxime shows no racemization 
(up to 24 hours).
Figure 114. pH-Dependent 
deprotonation of the free 
aldoxime, counteracting a 
pH-induced epimerization 
of the stereogenic center.
[107]
From these results it seemed favorable to extend the methodologies towards 
biphasic reaction media, containing an aqueous solution for the biocatalytic 
dehydration and an organic solution for the in situ racemization of inert
E-(R)-133a to E-(S)-133a. To get a general view on required reagents for the 
epimerization it was first determined which organic solvent can be combined 
with the enzymatic reaction. A number of typical water-immiscible solvents 
were examined in a biphasic biotransformation for their effect on the whole-
cell catalyst.
Entry Solvent
Conversion
[%]
ee (139a)
[%]
ee (Z-
131a)
[%]
ee (E-131a)
[%]
1 MTBE 33.8 29.3 (S) 85.8 (S) 27.7 (R)
2 EtOAc 20.0 17.2 (R) 79.3 (S) 6.8 (R)
3 n-Hexane 62.5 60.5 (S) - >99.8 (R)
4 DCMa 21.6 50.4 (R) 97.0 (S) 6.70 (R)
5 n-BuOAc 20.4 44.8 (S) 30.6 (R) 29.4 (R)
6 CHCl3a 7.40 56.3 (R) 5.50 (S) 0.50 (R)
7 THF 22.8 13.0 (S) 38.3 (S) 13.7 (R)
8 2-PrOH 33.3 39.6 (S) 0.20 (R) 37.2 (R)
The experiments clearly show an unchanged biotransformation for the binary 
mixture with n-hexane (Table 23, page 107, entry 3) with quantitative 
conversion of all active isomers. Other common solvents like MTBE, ethyl 
acetate and butyl acetate showed a decrease in conversion, with the product 
mixture showing enantiomerically enriched compounds (entries 1-2 and 5). 
Halogenated solvents like dichloromethane and chloroform led to a visible 
denaturation of the cells during the reaction (entries 4 and 6). Nevertheless, the 
biotransformation in the binary medium with dichloromethane showed almost 
equal conversion to ethyl acetate, suggesting denaturation of the whole-cells 
but not necessarily of the aldoxime dehydratase. THF and 2-propanol were also 
investigated, leading to a more or less homogenous reaction mixture (entries 7 
and 8). Of all tested solvents, n-hexane was chosen as the most promising for 
Table 23. Compatibility of 
organic solvents for the 
biocatalytic dehydration of 
E-rac-133a in binary 
reaction media.
(a) Strong denaturation visible, no 
further conversion detected
[108]
further development of a racemization process without influencing the whole-
cell catalysis.
SOLUBILITY AND DISTRIBUTION IN BINARY REACTION MEDIA WITH N-HEXANE
By introducing an organic and immiscible solvent, the substrate concentration 
in the aqueous phase is subjected to change. Therefore, the solubility of 133a
and the corresponding nitrile 139a had to be determined (see Figure 115).
Judging from the preceding experiments with increased substrate 
concentration it was favorable to reach around 5 – 10 mM for an unchanged 
biotransformation. Interestingly, by mixing an excess of substrate with the 
aqueous buffer medium of the reaction, a saturated substrate solution with a 
concentration of 20.8 ± 0.2 mM was obtained (see Table 24, entries 1-3). With 
this high solubility, the binary mixture had to be engineered not to exceed the 
limitation of 5 – 10 mM.
Entry Compound
Concentration
[mM]
Solubility
[g/L]
1 E/Z-133a 20.8 ± 0.1
3.1 ± 0.02 E/Z-133a 20.8 ± 0.3
3 E/Z-133a 20.8 ± 0.2
4 139a 13.7 ± 1.8 1.8 ± 0.2
Figure 115. General scheme 
for the distribution of 
reagents and products in a 
binary reaction mixture.
Table 24. Solubility of 
substrate of product in the 
buffered reaction medium 
without organic solvent.
[109]
Different concentrations of the substrate were prepared in pure n-hexane and 
mixed with an equal volume of the aqueous buffer. 
Entry
Organic phase concentration
E/Z-133a [mM]
Aqueous phase concentration
E/Z-133a [mM]
1 10 1.45
2 20 2.49
3 30 3.23
4 40 3.81
5 50 4.13
After reaching the distribution equilibrium, the substrate concentration in the 
aqueous phase was quantified by reversed-phase HPLC. Due to its low polarity 
the substrate was significantly enriched in the organic phase and did not 
exceed 5 mM concentration even when using a 50 mM solution of E/Z-133a in 
n-hexane (see Table 25, entry 5). This was also very promising for increasing 
the product concentration of the process from 1 g/L (aqueous mixture) to 
around 7.5 g/L (binary mixture). These results were the basis for the following 
trials of an in situ racemization for a dynamic kinetic resolution of 
(S)-2-phenylpropionitrile ((S)-139a).
Table 25. Distribution of the 
substrate in 1:1 v/v binary 
mixtures with n-hexane.
Table 26. Racemization 
tests of the product mixture 
of the biotransformation 
under Bronsted acid or 
Lewis base catalysis. 
(a) 1,8-Diazabicyclo[5.4.0]undec-7-
ene (DBU), 1,4-diazabicyclo[2.2.2]-
octane (DABCO), N,N-dimethyl-4-
aminopyridine (DMAP) (b) 
Hydrolysis to the corresponding 
aldehyde.
Entry Catalysta (eq.) Mode of action E/Z
E-(R)-133
[% ee]
(S)-139
[% ee]
132b
[%]
1 none - 99:1 >99 78 -
2 PhCOOH (1.0) Brønsted acid 71:29 >99 78 63
3 DBU (1.0) Lewis base 99:1 >99 64 0.0
4 DABCO (1.0) Lewis base 99:1 >99 n. d. 0.0
5 DMAP (0.3) Lewis base 99:1 >99 n. d. 0.0
[110]
The adjustment of pH in organic media was achieved by the addition of 
organic acids and bases and their effect on enantiomerically pure substrate and 
product was examined by chiral HPLC analysis (see Table 26, page 109). 
Addition of a Brønsted acid, e.g. benzoic acid, the remaining enantiomerically 
pure E-(R)-aldoxime isomerized to its Z-diastereomer and also hydrolyzed to 
the corresponding aldehyde in about 63% conversion, presumably with 
residual water from either the crude product of the biotransformation or the 
reagent itself (entry 2). Notably, neither the enantiomeric excess of the 
remaining aldoxime nor of the present nitrile product changed in this acidic 
medium. In contrast to that, commonly used nitrogen-containing Lewis base 
catalysts like 1,4-diazabicyclo[2.2.2]-octane (DABCO) and N,N-
dimethylaminopyridine (DMAP) did not exhibit any effect on the product 
mixture (entries 4 and 5). As opposed to this, 1,8-diazabicyclo[5.4.0]-undec-7-
ene (DBU) did affect the enantiomeric excess of the mixture, unfortunately, only 
regarding the enantiomeric excess of the nitrile (entry 3). While the remaining 
aldoxime remained untouched, the nitrile continuously epimerized towards its 
racemate. The reason for this behavior was not further investigated, but was 
supposedly related to the pKa of the respective structures, as described for the 
pH-dependent racemization (see Figure 114, page 106). Since the problem 
seemed to be based on the free aldoxime, an additional step was considered 
for masking the free aldoxime in situ, racemizing this intermediate and unmask 
the free aldoxime again for the biotransformation.
3.7 EXPLORATION OF A LIPASE-COUPLED DYNAMIC KINETIC RESOLUTION 
PROCESS
GOTOR and MENENDEZ first achieved the oximolysis of different acetates by 
using lipases from Pseudomonas sp., Candida cylindracea, Aspergillus niger, 
Humicola lanuginosa and a porcine pancreatic lipase, showing different 
activities sufficient for preparative application (see Figure 116).73
Figure 116. Lipase-
catalyzed acylation of 
various ketoximes and 
benzaldoxime with vinyl 
carboxylates by GOTOR and
MENENDEZ.73
[111]
Additionally, SALUNKHE and NAIR successfully acetylated different ketoximes of 
type 144 and also benzaldoxime with a lipase from Pseudomonas cepacia, 
immobilized on diatomite (Amano PS-D), and vinyl acetate (145) as highly 
active and irreversible acetyl donor (see Figure 117).74
These acetyl oximes of type 146 would mask the more acidic proton of the 
aldoxime, allowing the epimerization of the chiral aldoxime under base-
catalysis. Masking of functional groups in situ is not trivial as the addition and 
the removal of the masking group should be coupled in an equilibrium to 
ensure reversibility (see Figure 118). In addition, the presence of an aqueous 
phase is complicating the procedure by the possibility of hydrolytic 
side-reactions.
First of all, the right masking group had to be found. Since it should be able to 
withstand a binary mixture with water, chemical reactions were excluded. A 
second enzymatic reaction should be capable of working in a binary mixture 
and also have the necessary chemoselectivity to specifically react with free 
aldoxime. For this reason, the lipase-coupled acylation of the remaining 
aldoxime was investigated. 
Figure 118. Proposed 
scheme of a reversible 
masking of free aldoximes 
and epimerization of their 
derivatives for a dynamic 
kinetic resolution.
Figure 117. Lipase-
catalyzed acetylation of 
various ketoximes and 
benzaldoxime with vinyl 
acetate by SALUNKHE and 
NAIR.74
[112]
3.7.1 LIPASE-CATALYZED SYNTHESIS OF ALDOXIME ESTERS
In the present study, two of the chiral substrates were examined for this 
reaction, using the same lipase from Pseudomonas cepacia (Amano PS-D, 
immobilized on diatomite) or lipase B from Candida antarctica (CAL-B, 
immobilized on acrylic resin) and vinyl acylates (see Table 27). 
Entry 133 R3 Lipase
Time 
[h]
148a-c
[%]
139a,b
[%]
E/Z 148a-c
[%]
1 a Me PS-D 12 85.1 14.3 81:19
2 b Me PS-D 18 10.6 34.4 88:12
3 b Me PS-D 72 26.7 31.1 92:8
4 b Me CAL-B 72 55.2 43.2 88:12
5 b Ph PS-D 72 n.d.b n.d.b n.d.b
6 b Ph CAL-B 72 n.d.b n.d.b n.d.b
The preliminary results were quite positive, with the aldoximes 133a and 133b
being acetylated with high conversions in n-hexane, the benchmark solvent for 
the intended racemization process. All substrates and biocatalysts showed the 
necessary high activity for this oximolysis reaction. 
In regard of an enantioselective reaction, which would facilitate the aldoxime 
dehydration by acylating only the inert substrate enantiomer, the products 
Table 27. Lipase-catalyzed
acylation of chiral aldoximes 
with vinyl carboxylates in 
organic medium.  
(a) Hydrolysis to the correspond-
ding aldehyde (b) not detected.
Figure 119. E2-elimination 
leading to a mixture of 
E-aldoxime esters and 
corresponding nitriles of the 
substrates 133a and 133b.
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were also analyzed by chiral HPLC for an enantiomeric excess of the acyl 
aldoximes. Racemic reference compounds were synthesized by standard 
procedures in form of a SCHOTTEN-BAUMANN reaction with the corresponding 
acyl chlorides and triethylamine (data not shown). It was during this reference 
synthesis that an isomeric enrichment was observed. By analyzing the NMR 
spectra of the crude product after removing the solvent, not only acyl aldoxime 
of type 148 was present but also the corresponding nitrile 139 obtained by 
carboxylic acid elimination. Noteworthy, this predominantly occurred with the 
Z-aldoxime esters of type Z-rac-148 following an E2-elimination mechanism 
(see Figure 119, page 112).
3.7.2 HYDROLASE-CATALYZED DEACYLATION OF ISOMERICALLY ENRICHED 
ALDOXIME ESTERS
With the prospect of synthesizing E-aldoxime esters from E/Z-aldoxime 
mixtures, it was further examined, if the cleavage of said acyl groups would 
then produce free E-aldoximes in high isomeric purity. While the experiments 
with the substrate E-rac-148b have to be regarded as preliminary results and 
will be subjected to optimzation in future studies, it was not possible to 
produce isomerically pure E-aldoximes from pure E-aldoxime esters by means 
of a biocatalytic hydrolysis at room temperature. This could be related to 
enzymatic isomerization or thermodynamically-induced isomerization at room 
temperature.
Entry Hydrolasea (amount)
Time
[h]
Conversion
[%]
E/Za
1 CAE (1.5 mL) 7.5 >95.0 72:28
2 Amano PS-D (50 mg) 19.5 >95.0 82:18
Nevertheless, the results indicated a controllable isomerization by either 
temperature or biocatalyst amount. This would also be adressed during the 
establishment of an in situ racemization process, since the racemic Z-aldoxime 
would also decrease the enantiomeric excess of the desired nitrile.
Table 28. Hydrolase-cata-
lyzed deacetylation of 
racemic aldoxime acetates 
148b in aqueous medium.  
(a) Cephalosporin acetylesterase 
(CAE), Lipase from Pseudomonas 
cepacia, immobilized on diatomite 
(PS-D).
[114]
3.8 PURIFICATION OF ENANTIOMERICALLY PURE NITRILES FROM 
BIOTRANSFORMATIONS IN AQUEOUS MEDIUM
With a selective E-aldoxime synthesis and a dynamic kinetic resolution, the 
product mixture would certainly be of high purity for the desired nitrile. 
Nevertheless, the current process yielded a mixture of around 50% 
enantiomerically enriched nitrile and 50% remaining aldoxime. These 
compounds could easily be separated by column chromatography. However, 
chromatography should always be the last choice for purification, especially if 
the by-product could be reused. The enantiomerically pure remaining E-
aldoxime does not epimerize, but is prone to isomerization and hydrolysis. So 
in general, it should be feasible to hydrolyze the aldoxime to its corresponding 
aldehyde, which is then again epimerized (see Figure 120). This racemate 
could then be used again as starting material or eliminated from the product 
mixture.
3.8.1 HYDROLYSIS OF REMAINING ALDOXIME FROM PRODUCT MIXTURES 
AFTER BIOTRANSFORMATION
The effect of acidic media on the enantiomerically pure nitrile was already 
determined during the initial racemization tests in chapter 3.6 (see Table 26, 
page 109). A product mixture of the biotransformation containing 
enantiomerically enriched nitrile (S)-139a (78% ee) and enantiomerically pure 
E-(R)-131a (>99% ee) was subjected to pH change by addition of concentrated 
hydrochloric acid. The respective acid concentration was calculated and the 
mixture was stirred for 60 minutes at room temperature or 80 °C. The 
hydrolysis was determined for up to 0.2 M acid concentration and showed 
significant conversion of aldoxime to the corresponding aldehyde 
(see Figure 121, page 115).
Figure 120. pH-Induced 
hydrolysis of the remaining 
aldoxime to the epimeriz-
able aldehyde.
[115]
During the hydrolysis, the enantiomeric excess of the product remained stable, 
while the formed (R)-aldehyde immediately racemized in acidic aqueous 
solution. Notably, the hydrolysis was only negligibly accelerated at 80 °C. By 
raising the acid concentration to about 1.0 M, the reaction should be complete 
within 60 minutes, which is promising for this first step of the intended 
extractive purification method.
3.8.2 EXTRACTIVE SEPARATION OF RACEMIC ALDEHYDE FROM 
ENANTIOMERICALLY PURE NITRILE
The extractive separation of racemic aldehyde was subsequently tested by 
bisulfite addition. Since bisulfite adducts of aldehydes are hardly soluble, 
sometimes even in aqueous media, this methodology would only allow the 
nitrile to be extracted. The relative content of aldehyde was analyzed by chiral 
HPLC from an extraction with MTBE. The solvent was chosen for its 
compatibility with the chiral stationary phase. The applicability for product 
mixtures was tested by adding enantiomerically pure nitrile as an internal 
reference. The mixture was subjected to aqueous solutions of sodium bisulfite 
with varying concentrations (see Figure 122, page 116). 
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Figure 121. pH-Induced 
hydrolysis of the remaining 
aldoxime at different HCl 
concentrations and tem-
peratures.
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Each solution was stirred for 30 minutes at room temperature to reach an 
addition equilibrium prior to extraction. After complete extraction of the 
enantiomerically enriched nitrile 139a (78% ee), the aqueous phase now 
consists of the pure bisulfite adduct. By raising the pH value to basicity, the 
remaining hydroxylamine from the hydrolytic reaction again condensed with 
the free aldehyde, yielding racemic E/Z-mixtures of aldoxime 133a.
To investigate the cleavage of bisulfite adducts, a solution of bisulfite adduct 
was subjected to potassium carbonate addition. The current concentration was 
calculated related to the aqueous volume and the relative content of aldehyde 
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Figure 122. Bisulfite 
addition and associated 
elimination of aldehyde 
from nitrile extraction with 
MTBE.
Figure 123. Cleavage of 
bisulfite adducts by 
basification with neat 
potassium carbonate and 
extraction of pure aldehyde 
with MTBE.
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was again determined via extraction with MTBE and chiral HPLC analysis 
(see Figure 123, page 116). The mixtures were again stirred for 30 minutes at 
room temperature prior to extraction. The aldehyde was quantitatively 
recovered at carbonate concentrations above 80 mM. By these few extractive 
steps, the chiral nitrile was obtained in high purity and the remaining inert 
substrate was hydrolyzed and also extracted as highly pure starting material.
3.9 CONCLUSION AND OUTLOOK
The present work started from basically no literature regarding an 
enantioselectivity of aldoxime dehydratases (Oxds). Even more, the only 
comments about chiral aldoximes which were actually converted by Oxds 
stated the racemic composition of the products. By reducing the activity of the 
biocatalyst, i.e. an aldoxime dehydratase from Bacillus sp. OxB-1 overexpressed 
in recombinant E. coli HB101 / pOxD-9OF, and the free energy of the system 
with lowering the reaction temperature, an unidentified enantioselectivity for 
the chiral E-aldoxime of 2-phenylpropionaldehyde (E-133a) was observed for 
the first time. The kinetic progress of the enzymatic reaction was analyzed from 
a mixture of two diastereomers of E- and Z-aldoxime consisting of a racemate. 
By identifying an inert substrate, namely E-(R)-133a, as well as the absolute 
configuration of the enantiomerically enriched nitrile (S)-139a, the 
enantioselectivity for this substrate could be clarified. 
Furthermore, by separating E- and Z-aldoximes from their mixture, essentially 
pure (S)-139a was synthesized in a kinetic resolution starting from racemic 
E-133a (>99% isomeric purity), with 50% conversion and an excellent 
Figure 124. Synthesis of 
enantiomerically pure (S)-2-
phenylpropionitrile by an 
enzymatic dehydration of a 
racemic aldoxime by means 
of a kinetic resolution.
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enantioselectivity of 98% ee (see Figure 124, page 117). This unusual 
enantiopreference for E-aldoximes was also observed for four other chiral 
substrates which were not investigated in more detail. The inert substrate and 
only by-product E-(R)-133a was also investigated for an in situ racemization 
process in view of a dynamic kinetic resolution. The inability to epimerize free 
aldoximes was to be circumvented by a lipase-coupled esterification in a binary 
mixture with n-hexane. This binary mixture revealed itself to be of even greater 
advance than initially planned. The biotransformation with a resting cell 
suspension of the aldoxime dehydratase was not altered by the presence of an 
equal volume of n-hexane. In addition, the low substrate concentration of 
5 mM for the purely aqueous reaction mixture could be increased to at least 
50 mM in a binary reaction mixture on the basis of a determined distribution 
coefficient for the chiral substrate. 
Finally, a purification procedure for non-quantitative conversion to the 
enantiomerically pure nitrile was established which was solely done by pH 
adjustment and salt addition to obtain highly pure nitrile and also racemic 
aldehyde from the remaining impurities, which could be recycled for a 
following reaction batch.
Further studies on the enantiopreference of aldoxime dehydratases for other 
chiral aldoximes are in progress. Currently, efforts are made to crystallize the 
investigated aldoxime dehydratase and clarify the binding of substrates in the 
active center, with in silico studies confirming the experimental results and 
predict the necessary alterations to enhance the enantiopreference for the 
Z-aldoxime diastereomer. Pharmaceutically relevant target molecules will also 
be subject to experiments in the near future.
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4 BIOCATALYTIC REDUCTION OF BETA-OXO CARBONYL COMPOUNDS 
IN THE CHEMOENZYMATIC SYNTHESIS OF ENANTIO- AND 
DIASTEREOMERICALLY PURE PHARMACEUTICAL BUILDING BLOCKS
The following project consisted of two different target molecules, i.e. β-amino 
alcohols 150 and β-lactones 152, with α,β-disubstitution patterns for the 
synthesis of diastereomers (see Figure 125). The β-amino alcohol project was 
first investigated within the own diploma thesis. While the general synthetic 
pathway was successfully established with remarkable observations, the search 
for active enzymes was challenging. The following chapters will investigate 
different approaches to circumvent biocatalytic bottlenecks of the used alcohol 
dehydrogenases.
The second target molecule, i.e. the β-lactone of type 152, was part of a lab 
course project based on the literature-known and already observed activity and 
selectivity for the enantio- and diastereoselective reduction of 
α,β-disubstituted β-oxo esters. The respective chapters will give a brief 
overview of identified selectivities and the use of the corresponding β-hydroxy 
esters for the chemoenzymatic synthesis of β-lactones.
Figure 125. General project 
overview for the retro-
synthetic approach to 
β-amino alcohols and 
β-lactones from racemic 
β-oxo carbonyl compounds.
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4.1 COMBINATION OF ENZYMES IN THE SYNTHESIS OF ENANTIOMERICALLY 
PURE BUILDING BLOCKS
There are countless examples of successful biotransformations for simple 
substrate to product conversion in industrial syntheses.75 They are also readily 
integrated in multi-step synthesis of high value.76 Nevertheless, a real challenge 
still remains to combine multiple enzymatic steps, either with different enzymes 
or even one enzyme capable of multiple reaction types. The complexity of 
finding optimal conditions for more than one enzymatic step in the same 
system or having specific chemoselectivities is a demanding task. Most of the 
literature-known processes combining different enzymes in one pot are related 
to cofactor regeneration. The most common examples employ oxidoreductase 
enzymes, e.g. alcohol dehydrogenases or keto reductases, with nicotinamide 
adenine dinucleotide phosphate (NAD(P)+) as hydride transfer reagent. For 
example, the use of a glucose dehydrogenase and the cheap stoichiometric 
“hydride donor” D-glucose is implemented in many NAD(P)H-dependent redox 
reactions.77 This methodology of generating or regenerating reagents was also 
achieved by utilizing a glucose oxidase (GOX) for the in situ preparation of 
hydrogen peroxide (H2O2) from again cheap glucose (153) and molecular 
oxygen by KUMAR et al. (see Figure 126).78 The combination of this process 
with a chloroperoxidase (CPO)-catalyzed oxidation was successfully used in the 
synthesis of benzoxazones and benzothiazones of type 159 starting from 
aldehydes of type 157. This is also a good example of controlling the amount 
of highly reactive reagents in situ. Hydrogen peroxide would denaturate the 
biocatalyst in higher concentrations, thus limiting the direct addition of 
commercially available H2O2 solutions.79 By using glucose as a stoichiometric 
reagent, the total amount of reagent can easily be controlled, since both the 
Figure 126. Bienzymatic 
synthesis of benzoxazones 
and benzothiazones by
oxidative coupling of 
aromatic aldehydes with 
o-aminophenol and 
o-aminothiophenol by 
KUMAR et al..78
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oxidative process by molecular oxygen and the subsequent hydrolysis of 
gluconolactone (154) to gluconate (155) are irreversible. This method was also 
established with a D-amino acid oxidase (DAO) for an enantioselective 
sulfoxidation by OKRASA et al..80 They prepared chiral aryl-methylsulfoxides of 
type 161 with good to excellent enantioselectivities of up to 97% ee 
(see Figure 127). 
This concept was later extended to heteroaromatic sulfoxides by the same 
research group.81 Although in situ generation of reagents is of high interest in 
this field, also intermediary compounds from within a multi-step synthesis can 
be formed by the combination of enzymes. 
ZHANG et al. successfully established a monooxygenase-catalyzed hydroxylation 
of cyclic methylene compounds 162 with an alcohol dehydrogenase-catalyzed 
oxidation to the corresponding ketones of type 163 (see Figure 128, page 
122).82 The low oxidative activity of an alcohol dehydrogenase from 
Lactobacillus kefir for the formation of the cyclic ketone was enhanced by the 
Figure 127. Bienzymatic 
enantioselective synthesis of 
chiral aryl methylsulfoxides 
with molecular oxygen as 
environmentally benign oxi-
dation reagent by OKRASA ET 
AL..80
Figure 128. Bienzymatic 
tandem process for the 
synthesis of cyclic ketones 
from cyclic methylene 
groups by ZHANG ET AL..82
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addition of acetone as more active substrate towards reduction, thus pushing 
the equilibrium in the desired direction. By this tandem reaction they were able 
to oxidize the compounds 162a-c to their corresponding ketones 163a-c with 
yields of around 88% and with perfect regioselectivity. A bienzymatic process, 
consisting of a combination of a monooxygenase and an alcohol 
dehydrogenase as isolated enzymes, was recently also successfully established 
for the oxidation of cycloalkanes of type 164 (see Figure 129). STAUDT et al. 
prepared the corresponding cycloalkanones 165 with a P450 monooxygenase 
from Bacillus megaterium.83 These cyclic ketones are used for the production of 
lactams, e.g. -caprolactam, which is one of the starting materials for nylon 6-6.
Apart from the previously discussed functional group conversions, there are 
also some cases of multienzymatic processes for the kinetic resolution of 
racemates. For example, WU et al. prepared enantiomerically pure 
(S)-β-phenylalanine and related β-amino acids of type (S)-166 by combining a 
phenylalanine aminomutase and a phenylalanine ammonia lyase 
(see Figure 130).84 At first, the aminomutase converts the undesired 
(R)-β-phenylalanine enantiomer (R)-166 into its (S)-α-phenylalanine analogue 
of type (S)-167. Subsequently, a phenylalanine ammonia lyase from 
Rhodosporidium toruloides converts the intermediate to its cinnamic acid 
deriva-tive 168, therefore driving the equilibrium of the aminomutase reaction 
to completion. The enantiomerically pure (S)-β-phenylalanine was obtained 
after ion exchange chromatography. 
Figure 129. Bienzymatic 
tandem process for the 
synthesis of cycloalkanones 
by STAUDT ET AL..83
Figure 130. Bienzymatic 
kinetic resolution of 
(S)-β-phenylalanine deriva-
tives by WU ET AL..84
Abbreviations: phenylalanine ami-
nomutase (PAM), phenylalanine 
ammonia lyase (PAL).
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Also, some meta- and para-substituted β-phenylalanine derivatives 166 were 
obtained in about 50% conversion and with excellent enantioselectivities of 
97-99% ee. This process could certainly be even more valuable with an 
equilibrium preferably producing the racemic β-amino acid 166 from the 
cinnamic acid 168, turning it into a deracemization process.
4.2 SYNTHESIS OF BETA-AMINO ALCOHOL DERIVATIVES FOR THE 
PRODUCTION OF HIV-I PROTEASE INHIBITORS
The fight against the human immunodeficiency virus (HIV) is still ongoing. In 
the past decades, numerous drugs were developed to inhibit its activitiy 
through different strategies. The inhibition of the HIV-I protease, an aspartate 
protease responsible for cleaving viral polypeptides into pharmacologically 
active proteins, is one target. The protease has a specific substrate binding 
pattern to recognize the crucial peptide bonds. This peptide bond is for 
example the carboxylate of L-phenylalanine (see Figure 131). Potent inhibitors 
mimic the tetrahedral intermediate 170 prior to bond cleavage. The inhibitors
contain usually tetrahedral structures not prone to bond breaking, such as 
geminal silandiols 172 or quarterny carbinols 173 (see Figure 132). This 
structure is also embedded into peptide-like structures to enhance substrate 
binding and decrease substitution by the original polypeptide substrate. 
Figure 131. HIV-I protease-
catalyzed cleavage of 
phenylalanine residues in 
viral peptide synthesis.
Figure 132. Phenylalanine 
derivatives mimicking the 
tetrahedral intermediate ac-
ting as active-site inhibitors. 
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A prominent example is Atazanavir (174), the active pharmaceutical ingredient 
of Reyataz®, manufactured by Bristol-Myers Squibb (see Figure 133).85
The enzyme-substrate complex is imitated by the chiral secondary carbinol 175
related to the phenylalanine carboxylate after aspartate addition. Since this 
carbinol will not eliminate under the given conditions, the substrate is blocking 
the active site of the protease and the formation of viral proteins is 
prevented.86
4.2.1 RETROSYNTHETIC STRATEGIES
The main building block, the β-amino alcohol of type 175, could be 
synthesized according to Figure 134. The functional-group interconversion of 
an aliphatic, primary amide of type 176 to its corresponding amine 175 can be 
accomplished via CURTIUS or HOFMANN degradation. The latter was already 
investigated during the own diploma thesis and was proven to be 
straightforward, with retention of the absolute configuration. 
Figure 133. Main pharma-
cologically active structure 
in HIV-1 protease inhibitor 
Atazanavir and identification 
of the necessary building 
block.
Figure 134. Retrosynthetic 
approach to enantio- and 
diastereomerically pure 
β-amino alcohols starting 
from racemic β-oxocarbonyl 
compounds.
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This carboxylic amide 176 can either be synthesized through ammonolysis of 
the corresponding carboxylic ester or by hydration of the respective 
carbonitrile. Due to the ultimate goal of implementing biocatalysis in as many 
reaction steps as possible, these conversions were also partially examined for 
an enzymatic alternative. The enantio- and diastereoselectivity of the chiral 
secondary carbinol of type 176 is introduced by a stereoselective ketone 
reduction via alcohol dehydrogenases. The benefit of using 1,3-dicarbonyl 
compounds like 177 or 178 lies in their tendency to racemize in aqueous 
media without additional catalyst, thus enabling a dynamic kinetic resolution 
process for the biocatalytic reduction.
4.2.2 PRELIMINARY RESULTS FOR THE REDUCTION OF α-SUBSTITUTED 
β-OXO AMIDES
The enantio- and diastereoselective reduction of β-oxo amides of type 177 for 
the synthesis of β-hydroxy amides like 176 as precursors for β-amino alcohols 
is an already known concept. However, most of the enzymatic literature 
examples have a very limited substrate scope. For instance, QUIRÓS et al. 
successfully reduced β-substituted β-oxo amides 179 with an alcohol 
dehydrogenase from Mortierella isabellina (see Figure 135).87
The respective β-hydroxy amides 180a and 180b were obtained in high yields 
of 82-83% and with excellent enantioselectivities of 92% and >99% ee, 
respectively. While these biotransformations were restricted to α-unsubstituted 
β-oxo amides, ROZZELL and coworkers from BioCatalytics Inc. patented a closely 
related enzymatic reduction, however, with α,β-disubstituted short-chain 
aliphatic or β-aryl β-oxo amides.88 Remarkably, the used alcohol 
dehydrogenase from Geotrichum candidum could also reduce cyclic β-oxo 
amides in a fermentation process and obtain the products in excellent 
enantioselectivities of >99% ee. They also applied commercially available 
baker’s yeast from Sigma-Aldrich for the enantio- and diastereoselective 
Figure 135. Enantioselective 
enzymatic reduction of 
β-substituted β-oxo amides to 
their β-hydroxy amides by 
QUIRÓS et al.87
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production of short-chain aliphatic β-hydroxy amides. Noteworthy, also β-oxo 
hydrazides, obtained from reacting the corresponding β-oxo esters with 
hydrazine, could be reduced to one diastereomer of the β-hydroxy hydrazides 
by fermentation with Colletotrichum gloeosporioides. However, no optical 
purities or even conversions are disclosed. QUIRÓS et al. also published the 
enantio- and diastereoselective reduction of cyclic β-oxo amides of type 181
(see Figure 136).89
Surprisingly, the diastereoselectivity for this reduction changed completely by 
using either unsubstituted amides (anti-selective for 182) or n-allyl and n-
benzyl amides (syn-selective for 182). In addition, the enantiomeric excess for 
the α-chiral center tremendously improved from around 50% ee to almost 
perfect 99% ee by using n-monosubstituted β-oxo amides.
In the preceding diploma study, β-oxo amides related to the phenylalanine-
type β-amino alcohol 185a and also a norephedrine-type structure 185b were 
prepared according to literature-known procedures from commercially 
available ethyl acetoacetate (183a) and ethyl benzoylacetate (183b) 
(see Figure 137).90 After ammonolysis of the racemic β-oxo esters 184 in 
aqueous ammonia solution, the crystalline β-oxo amides 185 were 
preparatively screened with a number of alcohol dehydrogenases provided by 
collaboration partners. 
Figure 136. Enantio- and 
diastereoselective reduction 
of cyclic β-oxo amides to 
their β-hydroxy amides by 
QUIRÓS et al..89
Figure 137. Substrate syn-
thesis of racemic β-oxo 
amides during the diploma 
thesis.90
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A preliminary photometric screening suggested sufficient activities of the 
investigated alcohol dehydrogenases for the reduction of the prepared β-oxo 
amides. Unfortunately, these photometric activities, related to the decrease in 
absorption of the cofactor NAD(P)H at 340 nm, could not be reproduced in 
preparative scale. In fact, none of the tested alcohol dehydrogenases showed 
activity for the reduction of 185a or 185b (see Table 29).
Entry 185 ADH (selectivity)
Conversiona
[%]
ee 
[%]
de 
[%]
1 a Rhodococcus sp. (S) n. d. - -
2 a evocatal 1.1.200 (R) n. d. - -
3 a Lactobacillus sp. (R) n. d. - -
4 a Thermoanaerobacter sp. (S) n. d. - -
5 b Rhodococcus sp. (S) n. d. - -
6 b evocatal 1.1.200 (R) n. d. - -
7 b Lactobacillus sp. (R) n. d. - -
These were somehow surprising results, since the corresponding racemic β-oxo 
esters of type 184 (see Figure 137, page 127) were readily converted by the 
same biocatalysts. Therefore, an explanation for the missing activity was 
focused on the difference between an ethyl ester and a primary amide. An 
initial idea of lower solubilities for the β-oxo amides was investigated by a
quantitative 1H-NMR analysis of saturated substrate solutions in D2O and 
showed, on the contrary, higher aqueous concentrations. Another possible 
reason was assumed in the polarity of the active center, more specifically the 
amino acid side chains in the proximity of the carboxyl moiety. 
Table 29. Preparative scree-
ning of various alcohol 
dehydrogenases for the 
enantio- and diastereo-
selective reduction of
α,β-disubstituted β-oxo 
amides.
(a) n.d. = not detected
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4.2.3 REDUCTION OF α-CYANOKETONES
The disappointing results from the biocatalytic reduction of β-oxo amides for 
the syntheses of pharmaceutically relevant β-amino alcohols were the reason 
for reconsidering the synthetic route in this work. With the target compounds 
still being the β-hydroxy amides, the amide moeity was to be introduced after 
the enantio- and diastereoselective reduction with alcohol dehydrogenases. 
Thus, a secondary strategy was tested, with a “masked” carboxylic amide in 
form of its corresponding nitrile (see Figure 138). The use of nitriles instead of 
other amide derivatives like N-alkyl or even N,N-dialkyl amides is beneficial for 
the subsequent preparation of the unsubstituted primary amide. 
This synthetic route starting from racemic β-oxo nitriles is in parts already 
literature-known for cyclic α-cyanoketones. DEHLI and GOTOR successfully 
reduced 2-cyanocycloalkanones of type 190 with alcohol dehydrogenases from 
different microorganisms in a highly enantio- and diastereoselective manner, 
with the best results obtained after fermentation with Saccharomyces montanus
(see Figure 139).91
The obtained 2-cyanocycloalkanols 191 were further derivatized to their 
corresponding β- and γ-amino alcohol derivatives 192 and 193 by chemical 
methods.
Figure 138. General con-
cept for the biocatalytic 
reduction of β-oxo nitriles 
and subsequent formation 
of β-hydroxy amides.
Figure 139. Dynamic kinetic 
resolution of α-cyano cyclo-
alkanones and chemical 
derivatization to cyclic 
β-amino alcohols by DEHLI
and GOTOR.91
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This approach to cyclic amino alcohols has some important advantages in 
contrast to, for example, epoxidation of cycloalkenes and diastereoselective 
ammonolysis. First of all, this biocatalytic reduction can be tuned to yield, in 
principle, all four stereoisomers of 191 separately. In addition, the substrate 
synthesis is straightforward. Aliphatic medium-chain dinitriles, which are 
commercially available, undergo an intramolecular CLAISEN-type condensation 
by addition of strong bases like sodium hydride or potassium tert-butoxide. 
The intermediary α-cyano ketimine is stabilized by tautomerization to the 
enamine and has to be hydrolyzed in acidic aqueous media at elevated 
temperatures. While this reaction benefits from the intramolecular preference 
and high chemo- and regioselectivity of using aliphatic dinitriles without 
additional functional groups, the adaptation for this work needed a more 
sophisticated approach.
4.2.3.1 SUBSTRATE SYNTHESIS OF Β-OXO NITRILES RELATED TO THE TARGET 
BUILDING BLOCK OF ATAZANAVIR
Retrosynthetic analysis of the β-amino alcohol structure 194 revealed two lead 
structures 197 for a biocatalytic reduction with alcohol dehydrogenases 
(see Figure 140). The main difference, the halogenated methylene group, is 
not trivial to introduce. The preference of halogenation with bromine or
N-halosuccinimide (NXS) was in all cases the α-position, since it is activated by 
two electron-withdrawing groups (see Figure 141, page 131). Under weak 
basic reaction conditions, this chloride 201 was then also eliminated as 
hydrochloric acid under the formation of the cinnamonitrile derivative 202. 
Figure 140. Retrosynthetic 
approach to the main 
Atazanavir building block 
starting from racemic β-oxo 
nitriles.
[131]
Nevertheless, the difference between a methyl and chloromethyl moiety should 
be low for alcohol dehydrogenases. For this reason, the unhalogenated β-
oxonitrile 197a was synthesized, also as a direct reference compound for the β-
oxo amide 185a, which was not reduced in preceding experiments (see Table , 
page 128). 
While the acetyl-substrate 197a was synthesized rather facile by a crossed 
CLAISEN-type reaction (see Figure 140, page 130, pathway B) between 
3-phenylpropionitrile and ethyl acetate, the corresponding halogenated 
reagents degraded under the basic reaction conditions, leading to a crude 
product consisting mainly of starting material and unidentified impurities. In 
addition, the more chemo- and regioselective approach by an α-unsubstituted 
α-cyano-α’-haloacetone 198 could not be investigated due to the 
unavailability of the starting material (pathway A).   Due to these reasons, 
pathway B was modulated to gain excess to the α’-substituted compound 
197b (see Figure 142). 
Ethyl glycolate (206) was chosen as commercially available precursor. For the 
chemoselectivity of the alkoxide-catalyzed condensation reaction, the α-
hydroxy group was protected as tetrahydropyranyl (THP) acetal 205. THP was 
considered as the optimal protective group due to its base-stability and its 
facile introduction and removal under neutral conditions, with pyridinium p-
toluenesulfonate (PPTS) as catalyst (see Figure 143, page 132). 
Figure 141. Unsuccessful 
halogenation due to wrong 
regioselectivity of the 
reaction.
Figure 142. Modulation of 
the substrate synthesis for  
an enhanced chemo- and 
regioselectivity.
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The protection of 206 was achieved on a 10-gram-scale. Excess of starting 
material 3,4-dihydro-2H-pyran (207) was removed at 60 °C in high vacuum. 
The catalyst was removed by filtration over a short silica column. In addition, 
the subsequent crossed CLAISEN condensation was also successful to a brief 
extend, reaching a product-related conversion of 10% (see Figure 144). 
The low conversion in contrast to the reaction with ethyl acetate (208) could be 
related to the bulkiness of the THP group. The crude product rac-204 was 
partially purified via preparative HPLC to increase the product content from 
about 15% to 56%, with 3-phenylpropionitrile (200) as the main impurity. The 
crude product could nevertheless be used as substrate for the biocatalytic 
reduction since none of the impurities has a ketone moiety and under the 
premise of them not acting as inhibitors. 
4.2.3.2 ANALYTICAL METHODS FOR THE DETERMINATION OF THE CONVERSION 
AND ENANTIOSELECTIVITY
The β-hydroxy nitriles were analyzed by 1H-NMR spectroscopy and chiral 
normal-phase HPLC (see Figure 145). The main interest was of course the 
identification of the respective enantio- and diastereomers of 196a produced 
by different alcohol dehydrogenases. 
Figure 143. THP protection 
of ethyl glycolate under 
PPTS-catalysis.
Abbreviations: dichlormethane 
(DCM), pyridinium p-toluene-
sulfonate (PPTS).
Figure 144. Crossed CLAISEN
condensation for the syn-
thesis of α-benzyl-β-oxo  
nitriles.
Abbreviations: potassium tert-but-
oxide (KOtBu), tetrahydrofuran 
(THF).
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Since the β-hydroxy nitrile 196a is unknown to literature, the isomers had to be 
assigned by different assumptions. In general, the enantiospecificity of alcohol 
dehydrogenases is usually defined, especially with alkyl methylketones. Thus, 
an alcohol dehydrogenase from Rhodococcus sp., which is (S)-selective, was 
used to assign two of the diastereomers in the HPLC chromatogram at 34.1 
min and 42.2 min according to their carbinol configuration (see Figure 145, 
page 133). The respective diastereomer was determined using the HPLC peak 
ratio of 3:2 and comparison with the 1H-NMR spectra (see Figure 146, page 
133). In these spectra, the diastereomers had also the ratio of 3:2, with the 
signals of the carbinol being sufficiently separated for integration. 
Nevertheless, the assignment of syn- and anti-diastereomers for acyclic organic 
molecules is not trivial. The preference of hydride addition during the reference 
synthesis with sodium borohydride produces anti-diastereomers. In addition, 
the corresponding β-hydroxy esters and amides were intensively studied 
during the own diploma thesis.90 By comparing the respective low-field shifts 
Figure 145. HPLC analysis 
of the racemic reference 
compound for the bio-
catalytic reduction of β-oxo
nitrile 197a.
Figure 146. 1H-NMR of 
diastereomers in accordance 
with the HPLC ratio of 3:2 
and assignment to the syn-
and anti-isomers.
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of the syn-diastereomers in relation to the anti-diastereomers, the HPLC 
isomers could be further assigned. However, it should be pointed out that only 
the derivatives of these β-hydroxy nitriles will give final proof of their absolute 
configuration.
4.3.3.3 BIOCATALYTIC REDUCTION OF β-OXO NITRILES RELATED TO THE 
BUILDING BLOCK OF ATAZANAVIR
The dehalogenated substrate 197a was preparatively screened for active and 
stereoselective alcohol dehydrogenases. As anticipated, the biocatalysts 
showed high activities for the conversion of the racemic β-oxo nitrile 
(see Table 30, page 134). The corresponding β-hydroxy nitrile 196a was 
synthesized with quantitative conversion and with excellent enantioselectivities 
for both (S)- and (R)-carbinols, corresponding to the enantioselectivity of the 
biocatalysts. In these initial preparative screenings with high enzyme amounts, 
the diastereomeric excess was also increased, confirming a dynamic kinetic 
resolution process. The absolute configuration of the products was determined 
in analogy to extensive NMR studies on the β-hydroxy amide shifts during the 
diploma thesis.90 The diastereomers obtained in enantiomerically pure form are 
expected to be syn-configured for the alcohol dehydrogenases from 
Rhodococcus sp. and the bacterial ADH evocatal 1.1.200 (entries 1-2) and anti-
configured for the alcohol dehydrogenase from Lactobacillus kefir (entry 3).
Entry ADH (selectivity)
Conversion 
[%]
eea
[%]
deb
[%]
1 Rhodococcus sp. (S) >95 >99 (3S) 82.4 (syn)
2 evocatal 1.1.200 (R) >95 >99 (3R) 65.7 (syn)
3 Lactobacillus kefir (R) >95 >99 (3R) 40.2 (anti)
Table 30. Preparative 
screening of various alcohol 
dehydrogenases for the 
enantio- and diastereo-
selective reduction of β-oxo 
nitriles.
(a) Determined by chiral HPLC 
analysis (b) Determined by 1H-
NMR and chiral HPLC analysis.
[135]
Thus, three of the four possible stereoisomers of 196a were successfully 
generated by these biocatalysts, at least in highly enantio- and 
diastereomerically enriched form.
4.4 HOFMANN DEGRADATION OF β-HYDROXY AMIDES
In parallel to the enzymatic reductions, the subsequent chemical derivatization 
of β-hydroxy amides of type 195 to the corresponding β-amino alcohols 194
was examined (see Figure 140, page 130). Due to the lack of active biocatalysts 
for the β-oxo amides (see Table 29, page 128), the following experiments were 
conducted with a diastereomerically enriched racemic mixture of β-hydroxy 
amides of type 195. The enrichment of diastereomers can be explained by the 
steric hindrance of the α-chiral substituent, thus preferring the hydride addition 
to form the anti-hydroxy amide. The HOFMANN rearrangement can be used for 
the functional-group interconversion (FGI) of these carboxylic, primary amides 
to their corresponding chain-shortened amines. This reaction occurs with 
halonium ions in basic media, usually by combining the haline with aqueous 
sodium hydroxide. In the present work, the β-hydroxy amide 195a was 
degraded with a commercially available sodium hypochlorite solution (15 w-%, 
see Figure 149, page 136). The basic reagent first deprotonates the primary 
amide 195 in an equilibrium with its corresponding base 216, which is in return 
chlorinated to 217 (see Figure 147). This additionally activated chloroamide is 
deprotonated to its anion 218 and undergoes spontaneous elimination of 
chloride under formation of a six-electron nitrene intermediate 219. This 
nitrene rearranges in a highly concerted manner to the isocyanate 220, 
concluding this HOFMANN degradation. For this reason, α-chiral amides can be 
converted under complete retention of the absolute configuration, without 
Figure 147. Proposed 
mechanism of the hypo-
chlorite-induced HOFMANN
rearrangement of diastereo-
meric β-hydroxy amides.
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epimerization. The isocyanate 220 is highly reactive towards nucleophiles and 
can therefore be used for the synthesis of different carbamate derivatives. 
Usually, the high excess of water present in the hypochlorite solution leads to 
the formation of a carbamic acid of type 223, which decarboxylates to the free 
amine of type 194 or its hydrochloride (see Figure 148).
Since the β-hydroxy amides in this work are all diastereomers, an unreported 
epimerization would be observable by chiral HPLC analysis but also in 1H-NMR 
spectra. Interestingly, the HOFMANN rearrangement yielded predominantly the 
intramolecular addition product of type 221.
This oxazolidinone 221 was analyzed with 1H-NOESY spectra to identify the 
NMR shifts of its syn- and anti-diastereomers. Based on this data and the 
premiss of a complete retention of the absolute configuration, the syn- and
anti-diastereomers of the β-hydroxy amide were also assigned. The 
diastereomeric excess was therefore determined by 1H-NMR integration of the 
crude products. Even for the mainly racemic reference compounds, the 
diastereomeric excess of 30% de for the intermediate anti-β-hydroxy amide 
195a was unchanged in the oxazolidinone 221a, which was obtained in 
Figure 148. Nucleophilic 
addition derivatizing the 
isocyanate 220 by an 
inter- or intramolecular re-
action to obtain the 
corresponding β-amino 
alcohol.
Figure 149. Borohydride 
reduction of racemic β-oxo 
amide and subsequent 
Hofmann rearrangement 
under retention of the 
diastereomeric excess.
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quantitative conversion and again with a diastereomeric excess of 30% de for 
its anti-diastereomer (see Figure 149). This is in accordance with the 
theoretical course of the HOFMANN degradation to proceed with complete 
retention of the absolute configuration.
4.5 SYNTHESIS OF β-LACTONE DERIVATIVES FOR THE PRODUCTION OF 
NOVEL INHIBITORS OF BACTERIAL VIRULENCE FACTORS
Another pharmacologically relevant structure is a β-lactone for the inhibition of 
bacterial virulence factors.9293 These β-lactones function essentially like β-
lactams, inhibiting proteins by irreversible acylation. However, antibiotics based 
on β-lactams are no universal remedies and the number of pathogens being 
immune to them is increasing rapidly. These bacteria are widely known a Multi-
Drug-Resistant Organisms (MDROs) and are usually classified by their ability to 
counter certain antibiotics, e.g. penicillin and vancomycin, like the methicillin-
resistant Staphylococcus aureus (MRSA). This rise in resistance is the driving 
force behind new drug motifs, like β-lactones of type 152 (see Figure 150). 
Initial studies from the SIEBER group determined a series of β-lactone structures 
which were potent inhibitors for bacterial virulence factors like the caseinolytic 
protease ClpP (see Figure 151).92 A proof of concept for the chemoenzymatic 
synthesis of related structures, containing an enantio- and diastereoselective 
Figure 150. Retrosynthetic
approach for the production 
of enantio- and diastereo-
merically pure β-lactones 
from racemic β-oxo esters.
Figure 151. Lead structures 
of antibiotic β-lactones 
determined by the SIEBER
group.92
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reduction with alcohol dehydrogenases, was investigated in the present work 
(see Figure 150).
4.5.1 STATE OF THE SCIENTIFIC KNOWLEDGE ON β-LACTONE SYNTHESES
The lead structures of antibacterial β-lactones were determined by BÖTTCHER
and SIEBER, who synthesized the inhibitors by a condensation reaction of 
thioesters 226 with aldehydes of type 228 (see Figure 152). 94,95
The aldolate 229 substitutes the thioester intramolecularly under formation of 
the β-lactone 231 in low to moderate isolated yields of 14-37%. Notably, only 
racemic mixtures of anti-lactones could be prepared by this method. CHANDRA
et al. on the other hand successfully synthesized syn-β-lactones from achiral 
precursors by utilizing chiral alkaloids of type 232 and 235 in optically pure 
Figure 152. Synthetic ap-
proach for racemic anti-β-
lactones by aldol addition 
and thioester substitution 
by BÖTTCHER and SIEBER.95
Abbreviations: Lithium N,N-diiso-
propylamide (LDA).
Figure 153. Synthesis of 
3-methylated β-lactones as 
chiral precursors in the 
synthesis of Erythronolide B 
by CHANDRA et al..96
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form (see Figure 153).96 The β-lactones 233 and 236 were used as activated 
precursors in a multi-step synthesis of Erythronolide B and were obtained in 
high yields of >95% and excellent diastereoselectivities of >95% de.
Another catalytic synthesis of chiral syn-β-lactones of type 239 was achieved 
by KRAMER et al. with insertion of carbon monoxide (CO) into anti-configured 
epoxides 237 using a chromium(III) tetracarbonylcobaltate complex salt 238
(see Figure 154).97 Remarkably, this reaction takes place at already 1 bar of CO 
and room temperature, with excellent conversions and under full inversion of 
the sterically less hindered stereogenic center.
For the production of pharmaceutically relevant trans-β-lactones, KULL and 
PETERS also applied a metal catalyst 242 for an intramolecular aldolate 
esterification of aldehydes 241 with carboxylic acid bromides 240 (see 
Figure 155).98
Despite using only short-chained alkyl substituents, the β-lactones 243 were 
prepared in moderate to high yields of 62-96%, with very good 
enantioselectivies of 87-95% ee and also excellent diastereoselectivities of up 
to 96% de. Although all of the described methods are highly versatile 
regarding the substitution pattern and commercially available starting 
Figure 154. Diastereoselec-
tive syn-β-lactone synthesis 
through carbon monoxide 
insertion into chiral epox-
ides by KRAMER et al.97
Figure 155. Enantio- and 
diastereoselective synthesis 
of trans-β-lactones via 
metal-catalyzed conden-
sation of carboxylic acid 
bromides and aldehydes by 
KULL and PETERS.98
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materials, high enantio- and diastereoselectivities were only achieved with 
complex catalysts or enantiomerically pure precursors. Thus, a biocatalytic 
alternative by enantio- and diastereoselective reductions of racemic β-oxo 
esters yielding all four possible isomers separately would be an attractive goal.
4.5.2 SUBSTRATE SYNTHESIS AND REFERENCE COMPOUNDS
Apart from the commercially available ethyl 2-benzyl-3-oxobutanoate (184a, 
see Figure 156), various β-oxo esters of type 184 were synthesized by 
alkylation (Route A) or in a two-step process combining a KNOEVENAGEL
condensation with a C=C reduction (Route B). The lead compounds were 
chosen in regard of a general applicability of the process. In view of a practical 
synthesis, aromatic and heteroaromatic aldehydes of type 244 were condensed 
with α-unsubstituted β-oxo esters of type 183. These reactions were catalyzed 
by a Bronsted acid/base pair of piperidine/acetic acid or 
pyrrolidine/trifluoroacetic acid. Subsequently, the α-acetyl β-arylacrylates 245
were reduced by different strategies. For instance, the chloroacetyl derivative 
245e dehalogenated during hydrogenation with palladium on charcoal and 
was therefore reduced with a stoichiometric amount of a HANTZSCH ester based 
on altered literature procedures from OUELLET et al..99 The compounds 184
obtained on Route A by monoalkylation of α-unsubstituted β-oxo esters of 
Figure 156. Synthetic stra-
tegies for the synthesis of  
racemic α,β-disubstituted 
β-oxo esters.
[141]
type 183 were already successfully prepared during the author’s diploma 
thesis90 and were used after purification via column chromatography (see 
Table 31). This was mandatory as the main impurities were the α,α-dialkyl β-
oxo esters, which are unable to racemize and could not be used for a dynamic 
kinetic resolution. In addition, the products would lose their α-chirality.
Entry R1 R2 X
Conv.a
[%]
Isol. Yieldb
[g(%)]
1 Me Bn Br >95 1.63 (79.0)
2 Ph Me I >95 0.75 (34.0)
The substrate spectrum was extended to heteroatom-containing aromatic 
moieties, since these could be beneficial for substrate binding in the active side 
by interactions with protic peptide residues. Hence, two heteroaromatic 
compounds, i.e. the 2-thienyl and 3-pyridyl derivatives of substrate 184a, were 
synthesized from the corresponding commercially available aldehydes and 
ethyl acetoacetate (see Table 32, page 142, entries 3 and 4). Furthermore, the 
already established phenyl group was extended to its 4-hydroxy derivative 
184e analogous to a phenylalanine – tyrosine comparison (entry 5). This 
synthesis was of particular success since the product precipitated in 
spectroscopically pure form from the reaction mixture when utilizing tert-butyl 
methyl ether (MTBE) as solvent, reducing the work-up to simple filtration and 
washing with MTBE. Finally, considering the implementation of β-lactones into 
larger molecular structures, the methyl substituent of 244a was altered to its 
corresponding chloromethyl derivative (entries 2 and 6). The initial synthesis 
was conducted without solvent and in the presence of an ionic liquid, i.e. 3-
methoxypropylamine acetate, which was reported by WANG et al. as catalyst for 
HENRY and KNOEVENAGEL reactions (entries 1 and 2).100 Although the reaction 
proceeded with quantitative conversions and moderate isolated yields, the 
procedure was again changed to a different catalyst. This was due to the 
compatibility of the pyrrolidine/trifluoroacetic acid catalyst with both 
KNOEVENAGEL condensation and HANTZSCH reduction. Thus, this protocol was 
favored in view of a sequential one-pot process for this γ-halogenated β-oxo 
Table 31. Synthesis of α,β-
disubstituted β-oxo esters
via monoalkylation.
(a) The crude product contained 
mono- and dialkylated com-
pounds in varying ratios (b) 
Determined after column chro-
mategraphy on silica.
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ester. A tandem-reaction seems also possible but was not examined in the 
present work.
The KNOEVENAGEL products 244 were either purified or used as crude material 
for the subsequent C=C reduction to the actual substrates of type 184 (see 
Table 33). While most of the acrylates of type 244 were reduced by 
hydrogenation with palladium on charcoal at atmospheric pressure and room 
temperature (see Table 33, page 143, entries 1, 4 and 6), the 3-pyridyl 
derivative 244c exhibited a lower reactivity and a non-quantitative conversion 
of 47.2% after 18 hours (entry 5). As mentioned before, the chloromethyl 
compound 244e was dehalogenated under the same conditions, leading to the 
respective substrate 184a.
In contrast to that, the hydride reduction with a HANTZSCH ester was successful 
with a product-related conversion of 91.3% (entry 3). Unfortunately, the E-
acrylate 245e and the corresponding racemic β-oxo ester 184f showed similar 
retention times on TLC analysis, aggravating the establishment of a purification 
method. Additionally, also preparative HPLC yielded always mixtures with 
residual E-245e. Hence, the biocatalytic experiments were conducted with 
mixtures.
Table 32. Synthesis of α-
acyl-β-arylacrylic esters by 
Knoevenagel condensation 
of aromatic aldehydes with 
β-oxo esters.
(a) The crude product contained 
unreacted residual aldehyde and 
excess ethyl acetoacetate (b) 
Determined after purification by 
column chromatography, recrys-
tallization or distillation, re-
spectively.
Entry
183
[mmol]
R1 R3 Acid/base Solvent
Conv.a
[%]
Isol. Yieldb
[g(%)]
1 100 Me Ph MPA/AcOH none >95 12.2 (56.1)
2 50 Cl-Me Ph MPA/AcOH none >95 3.89 (51.3)
3 100 Me 2-Thienyl Piperidine/AcOH MTBE >95 20.6 (n.d.)a
4 50 Me 3-Pyridyl Piperidine/AcOH MTBE >95 6.45 (58.8)b
5 100 Me 4-OH-Ph Piperidine/AcOH MTBE >95 22.9 (97.9)c
6 100 Cl-Me Ph Pyrrolidine/TFA EtOAc >95 19.8 (n.d.)a
[143]
4.5.3 ANALYTICAL METHODS FOR THE DETERMINATION OF THE ENANTIO-
AND DIASTEREOSELECTIVITY
The reference compounds of racemic β-hydroxy esters of type 225 were 
prepared from crude mixtures of hydrogenated KNOEVENAEGEL products by 
sodium borohydride reduction in tetrahydrofuran (THF) at 0-4°C. This solvent 
and temperature were mandatory as β-oxo esters can be further reduced to 
their corresponding 1,3-diols, in contrast to the expected chemoselectivity of 
sodium borohydride to reduce solely the ketone moiety. This was already 
observed during the own diploma thesis90 but is also known in literature by the 
work of KIM et al., who investigated the borohydride reduction comparing 
methanol and THF as solvents.101 Since both β-oxo esters and activated C=C 
bonds can be reduced by hydrides, crude mixtures containing residual 
KNOEVENAGEL products 245 did not need to be purified to obtain 
spectroscopically pure racemic β-oxo esters of type 225. 
ETHYL (2RS,3RS)-2-BENZYL-3-HYDROXYBUTANOATE
This compound was chosen as a reference for the biocatalytic reduction with 
alcohol dehydrogenases (ADH) since it was already successfully used during 
Table 33. Synthesis of 
racemic β-oxo esters by ene 
reduction of KNOEVENAGEL
products.
(a) Determined by 1H-NMR 
spectroscopy (b) Determined after 
purification.
Entry R1 R3 [red] Solvent
Conv.a
[%]
Isol. Yieldb
[g(%)]
1 Cl-Me Ph Pd/C, H2 none >95 n.d.a
2 Cl-Me Ph HANTZSCH ester EtOAc 91.3 n.d.
3 Me 2-Thienyl Pd/C, H2 MTBE >95 0.91 (91.3)
4 Me 3-Pyridyl Pd/C, H2 MTBE 47.2 n.d.
5 Me 4-OH-Ph Pd/C, H2 MTBE >95 0.95 (94.8)
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the own diploma thesis.90 However, new analytical methods for its conversion 
needed to be established as a base for the novel substrates 184c-f, which are 
literature-known in organic synthesis but have never been used with an ADH 
before. While the conversion could be determined via 1H-NMR by integration 
of the benzylic protons due to the shifting after carbonyl reduction, the 
enantiomeric excess was calculated by integration of the enantiomeric peaks 
on chiral normal-phase HPLC (see Figure 157). 
Although the four diastereomers could not be separated completely, the 
enantiomeric excess of the syn-β-hydroxy esters of 225a was determined. Also, 
the diastereomeric excess was quantified by integration of syn- and anti-
diastereomers on chiral HPLC and confirmed by 1H-NMR integration. In 
contrast to enantiomers, diastereomers have altered magnetic environments 
and can be differentiated by NMR spectroscopy.For exemplary purposes, the 
HPLC analysis of the product of a biocatalytic reduction with an alcohol 
dehydrogenase from Rhodococcus sp., is presented (see Figure 158). This ADH 
is predominantly (S)-selective for the carbonyl reduction. Hence, the 
enantiomerically enriched peak of the syn-enantiomers was assigned with the 
(2R,3S)-configured β-hydroxy ester 225a. Based on the integration, the 
enantioselectivity for the syn-product (2R,3S)-225a was higher than 99.8% ee. 
In addition, the diastereoselectivity for the syn-product was 68.9% de.
Figure 157. HPLC chroma-
togram of racemic 225a for 
the determination of the 
enantio- and diastereomeric 
excess.
[145]
The values obtained for the other alcohol dehydrogenases were determined 
analogously. Nevertheless, a separation method for the anti-β-hydroxy esters 
would be essential for analyzing anti-selective biocatalysts in future 
experiments.
ETHYL (2RS,3RS)-2-(4-HYDROXYPHENYLMETHYL)-3-HYDROXYBUTANOATE
The p-hydroxyphenylmethyl substrate 184e was synthesized in high purity due 
to its crystallization after KNOEVENAGEL condensation and high reactivity for the 
palladium/charcoal-catalyzed hydrogenation. Spectroscopically pure reference 
compounds were obtained after borohydride reduction, facilitating the 
establishment of analytical methods (see Figure 159). In contrast to the 
heteroaromatic substrates, the 4-hydroxyphenylmethyl compound 225d was 
separated on chiral HPLC, at least for highly enantioselective biocatalysts. To 
emphasize this, the biocatalytic reduction of 184e with an alcohol 
dehydrogenase from Rhodococcus sp. is shown (see Figure 160). As stated 
before, this ADH is (S)-selective for the carbonyl reduction and showed syn-
selectivity for the standard substrate 184a.
Figure 158. HPLC chroma-
togram of the biocatalytic 
reduction of 184a with an 
alcohol dehydrogenase 
from Rhodococcus sp..
[146]
It was therefore used to assign the absolute configuration of all diastereomers 
of 225d. Although an integral for the corresponding (R)-carbinol can be 
observed, some impurities were produced during the biocatalytic reduction. 
Figure 159. HPLC chroma-
togram of racemic 225d for 
the determination of the 
enantio- and diastereomeric 
excess.
Figure 160. HPLC chroma-
togram of the biocatalytic 
reduction of 184e with an 
alcohol dehydrogenase 
from Rhodococcus sp.
[147]
The corresponding absorption spectrum was also different. A possible 
explanation would be the pH of the aqueous reaction mixture. The enzymatic 
reaction was done at a pH of 8.0, which would certainly convert some of the 
free p-hydroxyphenyl products into their corresponding sodium phenolates. 
The slight yellow coloration during the reaction also confirmed this hypothesis 
due to its disappearance after extraction with tert-butyl methyl ether (MTBE). 
Nevertheless, even without purification the enantiomeric excess of the syn-(3S)-
product 225d can be calculated to >99.9% ee.
The other b-hydroxy esters 225b-c and 225f were analyzed in the same way.
4.5.4 ENOATE REDUCTASE-CATALYZED SYNTHESIS OF RACEMIC β-OXO 
ESTERS
From a conceptional point of view, the C=C reduction of α-acyl-β-arylacrylates 
of type 244 could also be achieved by a biocatalytic reduction, more 
specifically with an ene reductase. Therefore, the synthesized KNOEVENAGEL
products 244 were investigated in a one-pot reaction with an ene reductase 
from Gluconobacter oxydans (Gox-ER) in combination with an alcohol 
Entry R1 R3
Substrate
E/Z-245
Product
E/Z-245
Conv. to 184 Conv. to 225 Conv. to 246
1 Cl-Me Ph 62:38 59:41 n.d.b n.d.b 6.3
2 Me 2-Thienyl 76:24 5:95 82.0 n.d.b n.d.b
3 Me 3-Pyridyl 77:23 39:61 22.4 n.d.b n.d.b
4 Me 4-OH-Ph 74:26 54:46 19.1 obsc. n.d.b
Table 34. Preparative 
screening for different 
activities of oxidoreductases 
on mixtures of unsaturated 
and saturated β-oxo esters.
(a) Determined by 1H-NMR 
spectroscopy (b) Determined by 
chiral HPLC analysis.
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dehydrogenase from Lactobacillus kefir (LK-ADH, see Table 34, page 147). 
This ADH was primarily implemented for an in situ cofactor regeneration with 
2-propanol as cosolvent and cosubstrate. Due to the necessity of the cofactor 
NADPH for the ene reductase, alcohol dehydrogenases preferring NADH could 
not be used. In addition, previous experiments with the substrate 184a
indicated a very low activity of LK-ADH for β-oxo esters of this substitution 
pattern, minimizing the risk of undesired side-reactions. Thus, the C=C 
reduction to the racemic β-oxo ester should have been predominant and 
observable by chiral HPLC. Remarkably, the reaction of the chlorinated acrylate 
244e resulted in the carbonyl reduction to the β-hydroxycinnamic ester 
(see Table 34, page 147, entry 1). No ene reduction was observed, whether to 
the racemic β-oxo ester 184f or the double-reduced β-hydroxy ester 225e. 
Judging from the comparison with the other experiments, the chloromethyl 
substituent seems to enhance the activity of this substrate, at least for the 
biocatalytic reduction with LK-ADH. On the contrary, the heteroaromatic 
derivatives showed moderate to high activities for the ene reductase from 
Gluconobacter oxydans and no ADH-related carbonyl reduction. The 2-thienyl 
substrate 244b was reduced with 82.0% conversion to the racemic β-oxo ester 
184c (entry 2). Also the 3-pyridyl derivative 244c was reduced, however, with a 
lower activity, reaching a conversion of 22.4% under equal reaction conditions 
(entry 3). Also surprising was the formation of enantio- and diastereomerically 
enriched β-hydroxy ester of the 4-hydroxyphenyl substrate 244d (entry 4), 
suggesting also enhanced reactivity for LK-ADH. Both enzymes showed activity 
for C=C or C=O reduction, respectively. Unfortunately, the experiment was 
done with a crude mixture of 244d and contained an impurity overlaying two 
of the diastereomer peaks on the chiral HPLC. Nevertheless, the lack of one
anti-enantiomer indicated a highly enantioselective carbonyl reduction to the 
(3R)-hydroxy ester 225d. These initial experiments showed promising 
tendencies for the subsequent preparative screenings of alcohol 
dehydrogenases.
4.5.5 ENANTIO- AND DIASTEREOSELECTIVE SYNTHESIS OF Β-HYDROXY 
ESTERS VIA ALCOHOL DEHYDROGENASES
Based on the established analytical methods for the β-oxo ester reduction, the 
substrates were preparatively screened with available alcohol dehydrogenases. 
The investigated biocatalysts were already discussed in chapters 4.2.2 (page 
121) and 4.3.3.2 (page 133) for the reduction of β-oxo amides and β-oxo 
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nitriles, respectively. The separation of standard substrates obtained by 
monoalkylation and the compounds obtained by KNOEVENAGEL reaction is 
related to the purity of the substrates (see Table 35). In accordance with the 
experimental results from the reduction of β-oxo nitriles (chapter 4.3.3.2, page 
133), the α-benzylated β-oxo ester 184a was converted with all of the 
investigated biocatalysts. Especially the alcohol dehydrogenase from 
Rhodococcus sp. was highly active with quantitative conversion and with an 
excellent enantioselectivity of >99% ee for the (3S)-enantiomer (see Table 35, 
page 149, entry 1). In addition, the diastereopreference for the syn-product was 
also very good, with a diastereomeric excess of up to 80% de. In contrast to 
this high activity, the 3-phenyl derivative 184b was not converted at all, 
undermining the occasional limitation of alcohol dehydrogenases not to 
convert ketones with two bulky substituents.
Entry R1 R2
ADH
(selectivity)
Conv.a
[%]
eeb
[%]
deb
[%]
1 Me Bn Rhodococcus sp. (S) >95 >99 (3S) 80 (syn)
2 Me Bn evocatal 1.1.200 (R) 68 >99 (3R) 95 (syn)
3 Me Bn Lactobacillus sp. (R) 24 >99 (3R) 33 (anti)
4 Ph Me Rhodococcus sp. (S) - - -
5 Ph Me evocatal 1.1.200 (R) - - -
6 Ph Me Lactobacillus sp. (R) - - -
The preparative screening with other 2-arylmethyl substrates was confined to 
the 2-thienylmethyl (184c) and the 4-hydroxyphenyl (184e) derivative. For 
these cases, the crude products were analyzed for enantio- and 
diastereopreference of the enzymes. Unfortunately, an unidentified impurity 
overlaid the integrated diastereomers in the reactions with the bacterial ADH 
evocatal 1.1.200. 
Table 35. Preparative 
screening of monoalkylated 
β-oxo esters with alcohol 
dehydrogenases
(a) Determined by 1H-NMR 
spectroscopy (b) Determined by 
chiral HPLC analysis.
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Therefore, only the enantiomeric excess of the syn-products  were successfully 
determined. The biocatalysts showed the expected excellent 
enantioselectivities of >99% ee for the corresponding (R)- or (S)-carbinol. The 
diastereomeric excess was moderate with 30.4% de for the 2-thienylmethyl β-
oxo ester 184c and 36.5% for the p-hydroxyphenylmethyl ester 184e, 
respectively. This is nevertheless promising since the low diastereomeric excess 
is based on a controllable competition between the pH-induced racemization 
and the biocatalytic conversion. The high enzyme amount used in these initial 
experiments led to a faster overall conversion. By reducing the catalyst amount, 
the racemization could induce a more effective dynamic kinetic resolution. 
4.5.6 BIOCATALYTIC HYDROLYSIS OF BETA-HYDROXY ESTERS AND 
COMBINATION WITH AN ENZYMATIC REDUCTION
The hydrolysis of enantio- and diastereomerically enriched β-hydroxy esters 
225 to their corresponding β-hydroxy carboxylic acids 224 was achieved by 
rather simple hydrolysis with an ethanolic sodium hydroxide solution (1.25 M) 
and stirring at 60 °C. Notably, in contrast to the β-oxo esters, the β-hydroxy 
esters did not epimerize during hydrolysis in basic aqueous medium. 
Entry 184 R1 R2
ADH
(selectivity)
Conv.a
[%]
eeb
[%]
deb
[%]
1c a Me Ph Rhodococcus sp. (S) >95 >99 (3S) 79.8 (syn)
2c a Me Ph evocatal 1.1.200 (R) 68 >99 (3R) 94.4 (syn)
3 c Me 2-Thienyl Rhodococcus sp. (S) >95 >99 (3S) 30.4 (syn)
4 c Me 2-Thienyl evocatal 1.1.200 (R) >95 >99 (3R) n.d.d
5 e Me 4-OH-Ph Rhodococcus sp. (S) >95 >99 (3S) 36.5 (syn)
6 e Me 4-OH-Ph evocatal 1.1.200 (R) >95 >99 (3R) n.d.d
Table 36. Preparative 
screening of heteroatom-
containing α-arylmethyl 
β-oxo esters with alcohol 
dehydrogenases
(a) Determined by 1H-NMR 
spectroscopy (b) Determined by 
chiral HPLC analysis (c) Reference 
entries for comparison with 
standard substrate (d) Peaks 
overlaid by unidentified impurity.
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Nevertheless, during storage at 4-8 °C for several hours, diastereomerically 
enriched crystals of 224a were formed in the crude product. Recrystallization of 
the product in MTBE yielded spectroscopically pure 224a with an altered 
diastereomeric excess of 70% de. The racemic β-hydroxy ester 225a was also 
hydrolyzed for establishing chiral HPLC methods (see Figure 161). 
The racemic mixture was almost completely separated. In addition, the 
absolute configurations of the corresponding peaks were assigned by 
comparison with the product of a biocatalytic hydrolysis with porcine liver 
esterase (PLE). This enzyme was used after a photometric screening assay 
identified potent hydrolases for the saponification of the racemic β-
hydroxyester 225a (see Figure 162). In view of a bienzymatic tandem process 
with alcohol dehydrogenases, the racemic β-oxo ester 184a was also screened. 
Unfortunately, all active hydrolases showed even higher activity for the 
hydrolysis of the starting material. Figure X shows the results of the 
photometric screening with the acid-base indicator bromothymol blue. Due to 
the formation of a carboxylic acid, the pH of the reaction mixture decreases, 
leading to a yellow absorption for the protonated indicator species. This 
coloration is measured at 432 nm or 615 nm, respectively. The latter was used 
in this example. The highest activity, observed with the strongest coloration to 
yellow, was measured for the porcine liver esterase (PLE, row E). However, the 
b-oxo ester 184a was more active and led to the formation of an unstable b-
oxo carboxylic acid which decarboxylates to the achiral ketone 250. In the 
presence of alcohol dehydrogenases this ketone would certainly be reduced to 
the corresponding carbinol, which itself would remain as impurity. To get a 
deeper insight in the respective reactivities of the b-oxo ester 184a and the b-
Figure 161. HPLC chroma-
togram of racemic 224a for 
the determination of the 
enantio- and diastereomeric 
excess.
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hydroxy ester 225a, both substrates were tested in a preparative screening with 
PLE and in comparison with a parallel alcohol dehydrogenase-catalyzed 
reduction.
184a 184a 225a 225a BL 184a 184a 225a 225a BL
A 0.83 0.83 0.94 0.91 0.90 I 0.83 0.84 0.95 0.96 0.92
B 1.60 1.23 1.29 1.48 1.37 J 0.93 0.89 1.01 1.02 1.05
C 0.88 0.91 1.00 1.03 1.00 K 0.71 0.72 0.86 0.85 0.85
D 0.89 0.94 1.06 1.01 0.99 L 0.97 0.97 1.08 1.13 0.99
E 0.44 0.45 0.60 0.60 0.88 M 0.87 0.89 1.05 1.02 0.94
F 0.90 0.93 1.03 1.03 0.95 N 0.89 0.92 1.02 0.94 0.91
G 0.83 0.74 1.01 0.94 0.91 O 0.87 0.90 1.04 1.03 0.98
H 1.39 1.30 1.49 1.07 1.58 P 0.93 0.94 1.04 1.08 0.99
A Protease from Rhizopus sp. I Pronase from Streptomyces griseus
B Alcalase ® CLEA J Protease from Aspergillus saitoi
C Protease from Aspergillus sp. (ABCR) K Protease from bovine pancreas
D Amano Acylase (Aspergillus melleus) L Protease S, Pyrococcus furiosus
E Porcine liver esterase (PLE, crude) M Amano Lipase M, Mucor javanicus
F Protease from Bacillus amilolyquefaciens N Protease from Bacillus sp. (Sigma)
G α-Chymotrypsin (Biozym CHY-03) O Protease from Bacillus licheniformis
H Amano Lipase PS (Pseudomonas cepacia) P Protease from Aspergillus oryzae
Remarkably, the biocatalytic hydrolysis of rac-225a with porcine liver esterase 
stopped at about 47% conversion. Also the one-pot process with racemic β-
oxo ester 184a in the presence of an alcohol dehydrogenase from Rhodococcus
sp. stopped at this state. A possible product inhibition was subsequently ruled 
out with the addition of further substrate (see Figure 163, page 153, green 
line) and the observation of the same reaction behavior. Due to the formation 
of a carboxylic acid, the reaction was continuously titrated with diluted sodium 
hydroxide (1.0M) and the consumption was recorded).
Figure 162. Photometric 
screening assay for the 
identification of potent 
hydrolases for the 
saponification of β-oxo and 
β-hydroxy esters.
[153]
The tremendous difference in activity can be explained by the parallel 
hydrolysis of racemic β-oxo ester 184a to its carboxylic acid and subsequent 
decarboxylation, a side-reaction which was also predominant in the 
photometric screening assay.
Analysis of the crude product on chiral HPLC revealed an enantioselectivity of 
porcine liver esterase for the (3S)-diastereomers (see Figure 164, page 153). 
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Figure 163. Titer consump-
tion of the biocatalytic 
hydrolysis with porcine liver 
esterase (PLE) in a two-step 
(blue) or one-pot process 
(red) for the synthesis of 
enantio- and diastereo-
merically enriched β-hydro-
xy carboxylic acids. After 16 
hours and reaching a 
stationary progress, more 
substrate 184a was added 
to the one-pot process 
(green line).
Figure 164. HPLC chroma-
togram of the biocatalytic 
hydrolysis of racemic 225a
by porcine liver esterase 
(PLE).
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This (S)-selectivity for β-hydroxy esters was also observed in literature reports 
for the desymmetrization of dialkyl 3-hydroxyglutarates by SANTANIELLO et al..102
4.5.7 LACTONIZATION OF ENANTIO- AND DIASTEREOMERICALLY ENRICHED 
β-HYDROXY CARBOXYLIC ACIDS
The final step of an intramolecular esterification for the synthesis of β-lactones 
of type 152 was done by a chemical reaction, since β-lactones are potent 
inhibitors of hydrolases and are thus not formed by an e.g. lipase-catalyzed 
transesterification. Common literature procedures for the synthesis of β-
lactones from β-hydroxy carboxylic acids use derivatizing reagents activating 
the carboxylic ester, so it can be substituted by the free carbinol. Mostly, the 
carboxylate is activated by the addition of benzenesulfonyl chloride103 or 
toluenesulfonyl chloride in the presence of pyridine104. This way the resulting 
acidic by-products are neutralized. In addition, the weak nucleophilic carboxylic 
acid is activated as carboxylate for predominant activation. 
Entry Base Solvent
Conv.
[%]
eeb
[%]
deb
[%]
1 Na2CO3 Cyclohexane >95 >99 (3S) 70 (syn)
2 Pyridine Pyridine >95 >99 (3S) 83 (syn)
Nevertheless, under these reaction conditions, a possible side-reaction could 
be the activation of the carbinol as leaving group and SN2 reaction by the 
carboxylate under complete inversion of the stereogenic center. Parallel 
activations would therefore result in lowered diastereoselectivities. Within this 
work, two reagent combinations were examined (see Table 37, page 154). 
Table 37. Chemical derivati-
zation of β-hydroxy carbo-
xylic acids to their corres-
ponding β-lactones.
(a) Determined by 1H-NMR 
spectroscopy (b) Determined by 
chiral HPLC analysis.
[155]
On the one hand, the lactonization with toluenesulfonyl chloride (TosCl) in the 
presence of anhydrous sodium carbonate proceeded smoothly without 
epimerization of the stereogenic centers. Nevertheless, a 6-fold excess of TosCl 
and a 12-fold excess of hardly soluble inorganic base seemed exaggerating. 
Therefore, another reaction was done by reacting 224a with two equivalents of 
TosCl in pyridine as solvent. 
Figure 165. HPLC chroma-
togram of racemic 152a for 
the determination of the 
enantio- and diastereomeric 
excess.
Figure 166. HPLC chroma-
togram of enantio- and 
diastereomerically enriched 
β-lactones with base-
induced epimerization 
towards diastereomeric 
enrichment.
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After extractive work-up, the crude product showed quantitative conversion of 
the starting material, but also a change in the diastereomeric excess compared 
to the β-hydroxy carboxylic acid 224a (see Figure 166, page 155). This was 
presumably related to the high excess of pyridine epimerizing the α-
stereogenic center over a prolonged reaction time of 24 hours. Although the 
epimerization did arbitrarily enrich the desired diastereomer (3R,4S)-152a, the 
epimerization itself is counteracting the intended retention of the absolute 
configuration implemented by the biocatalytic reduction. Thus, additional 
experiments will be necessary to find a suitable lactonization reaction for β-
hydroxy carboxylic acids of type 224a.
4.6 CONCLUSION AND OUTLOOK
The enantio- and diastereoselective reduction of β-oxo carbonyl compounds 
was successfully achieved for α,β-disubstituted β-oxo nitriles of type 197a to 
circumvent the lack of activity for the corresponding β-oxo amides. Three 
alcohol dehydrogenases were tested for their reduction. All of them showed 
high activities with quantitative conversion of the substrate, excellent 
enantioselectivities for the carbonyl reduction and also high 
diastereoselectivities for the vicinal stereogenic center. By using racemizable β-
oxo nitriles 197a, a dynamic kinetic resolution process for the preparation of 
enantiomerically pure and diastereomerically enriched β-hydroxy nitriles 196a
was successfully established, with three of four possible diastereomers directly 
addressable (see Figure 167, page 156).
Although the subsequent hydration to the corresponding β-hydroxy amides 
was not investigated in the present work, the chemical degradation of 
diastereomerically enriched racemic β-hydroxy amides was successfully 
established under complete retention of the diastereomeric excess. The 
obtained 4,5-disubstituted oxazolidin-2-ones are excellent precursors for the 
Figure 167. Enantio- and 
diastereoselective synthesis 
of three of four possible 
diastereomers of β-hydroxy 
nitrile 196a by dynamic 
kinetic resolution of racemic 
β-oxonitrile 197a.
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synthesis of β-amino alcohols and the cyclic urethane structure represents an 
intramolecular protecting group for the regioselective monoalkylation of the 
corresponding amino alcohol.
Besides nitrogen-containing β-oxo carbonyl compounds, also β-oxo esters 184 
have been successfully reduced by the use of alcohol dehydrogenases 
(see Figure 168). The stereoselectivities were in good agreement with those 
obtained for the β-oxo nitriles 197. Furthermore, a two-step synthesis of 
β-arylmethyl substrates was realized by combination of a BRÖNSTED
acid/base-catalyzed KNOEVENAGEL condensation to obtain the intermediates of 
type 245 and a subsequent ene reduction with palladium charcoal or a hydride 
reduction with a Hantzsch ester. 
Additionally, a chloromethyl moiety was inserted in view of a subsequent 
insertion of the β-lactone moiety into larger molecular structures by, for 
example, a WITTIG reaction. Furthermore, an ene reductase from Gluconobacter 
oxydans showed high activities for the C=C reduction of heteroatom-
containing β-arylacrylates. This could be favorable in regard of a bienzymatic 
tandem reaction for the synthesis of enantio- and diastereomerically pure β-
hydroxy esters starting from α-unsubstituted β-oxo esters and aldehydes (see 
Figure 169).
The chemical saponification of the β-hydroxy esters was investigated for a 
biocatalytic alternative. A photometric screening assay identified porcine liver 
esterase as potent hydrolase. The enzymatic hydrolysis was successfully 
achieved in a sequential two-step process after ADH reduction or in a one-pot 
process starting from racemic β-oxo esters in the presence of an ADH. PLE 
revealed itself to be highly enantioselective for the hydrolysis of the (3S)-β-
hydroxyester, thereby further increasing the diastereomeric excess from the 
biocatalytic reduction with an alcohol dehydrogenase from Rhodococcus sp.
Figure 168. Synthesis of 
new racemic β-oxo ester 
substrates and biocatalytic 
reduction with alcohol 
dehydrogenases in a 
dynamic kinetic resolution 
process.
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Finally, a chemical lactonization protocol was achieved. By using different 
inorganic or organic bases, an epimerization of the α-stereogenic center was 
either minimized or draw towards enrichment of the predominant
syn-diastereomer.
As these results demonstrate the versatility of the described chemoenzymatic 
routes to β-amino alcohols and β-lactones, many reactions were still in the 
initial stage and could surely be optimized for an enhanced diastereoselectivity. 
Also, the biocatalytic hydration of β-hydroxy nitriles, as well as the enzymatic 
hydrolysis of β-hydroxy esters represent a challenge for future experiments.
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5 CHEMOENZYMATIC SYNTHESIS OF AN ETAMICASTAT PRECURSOR
BY ENOATE REDUCTASE-CATALYZED REDUCTION OF 3-
SUBSTITUTED 2H-CHROMENES
This project was based on a recent publication of a multi-kg scale process for 
Etamicastat, a dopamine β-hydroxylase inhibitor for the treatment of 
hypertension and heart failure, by BIAL Portela.105 The key building block of this 
compound, the enantiomerically pure 3-aminochroman 251, can be 
synthesized from the corresponding 3-substituted 2H-chromene by 
enantioselective C=C reduction and derivatization (see Figure 176). 
This methodology was based on the extensive work of M.SC. TINA RESS on the 
enantioselective reduction of α-methylated nitroalkenes of type 252.106 The 
author is grateful for her great experience and expertise in this field and for 
many fruitful discussions regarding ene reductases (ER).
Figure 176. Retrosynthe-
tic approach to Etamicastat 
by an enan-tioselective 
C=C reduction and 
derivatization to the chiral 
3-aminochroman.
Figure 177. Literature-
known a-methyl nitro-
alkene reduction and 
intended route to the chiral 
3-aminochroman building 
block of Etamicastat by an 
ene reductase (ER)-
catalyzed C=C reduction.
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5.1 ENE REDUCTASES FOR THE ENANTIOSELECTIVE SYNTHESIS OF CHIRAL 
CARBON-CARBON BONDS
The previous chapters comprised of the use of alcohol dehydrogenases for an 
enantio- or diastereoselective carbonyl reduction and the synthesis of 
corresponding chiral secondary carbinols. In addition to these C=O reductions, 
C=C reductions are also achievable with biocatalysis. Ene reductases have 
become of great interest in the last couple of years and their applicability for 
bulk and fine chemicals increases steadily.107 Belonging to the family of Old 
Yellow Enzymes (OYE) these proteins catalyze the trans-selective reduction of 
activated alkenes by means of a cofactor-dependent enantioselective hydride 
addition to the β-position and a trans-selective protonation. 
Recently, the industrial application of ene reductases was successfully 
demonstrated by DEBARGE and his coworkers from Pfizer during an evaluation 
of different synthetic routes to Pregabalin (Lyrica).108 The enzymatic route is 
based on the ene reductase-catalyzed reduction of the E-3-cyanoacrylic ester 
258 to the (S)-3-cyano ester 259 (see Figure 178). In addition, the biocatalytic 
reduction of the corresponding β-cyano carboxylic acid 261 is currently under 
investigation. Interestingly, by using E- or Z-alkenes, the substrate binding is 
also inverted, yielding the opposite enantiomer of the product. Nevertheless, 
the reduction of the pure E-acrylic ester yielded the desired product in 
excellent enantiomeric purities of >99% ee (S). Notably, the substitution 
pattern of the α- and β-position is strongly influencing the enantiopreference 
of the enzyme. YANTO et al. screened various activated alkenes of type 262 for 
an enantioselective reduction with ene reductases from Kluyveromyces lactis
(KYE-1) and Yersinia bercovieri (Yers-ER) (see Figure 178, page 167) .109 Two 
closely-related substrates, more specifically α- and β-methyl nitrostyrene, were 
Figure 178. Ene reduct-ase-
catalyzed route to Pregabalin 
(Lyrica) by DEBARGE and 
coworkers from Pfizer.108
[168]
reduced with either excellent or no selectivity, depending on the position of 
the methyl substituent. 
While the investigated biocatalysts were only selective for the β-methyl 
substrate, BURDA et al. applied an ene reductase from Gluconobacter oxydans
(Gox-ER) for the highly enantioselective reduction of α-methyl β-aryl 
nitroalkenes.110 During their studies, the substitution pattern of the aromatic 
moiety also affected the enantiomeric excess. Substrates with para-substituents 
were converted with significantly lower enantioselectivity than meta-
substituted α-methyl β-aryl nitroethylenes. Nevertheless, the conversions were 
predominantly very high and had excellent enantioselectivities of up to 95% ee.
However, it should also be pointed out that the planar substrates with ortho-
and meta-substituents can also have conformers, which could probably 
influence the binding orientation in the active site.
Figure 179. Substrate spec-
trum for ene reductases 
demonstrating the versatility 
of these biocatalysts (YANTO et 
al.).109
Figure 180. Enantioselective 
β-aryl α-methyl nitroalkene 
reduction with an ene 
reductase from Glucono-bacter 
oxydans by BURDA et al.110
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5.2 SYNTHESIS OF 3-SUBSTITUTED 2H-CHROMENES BY A ROBINSON 
ANNULATION TYPE CONDENSATION OF SALICYLIC ALDEHYDE WITH 
ACTIVATED ETHYLENES
From a conceptional point of view the chiral 3-aminochroman building block 
251 of Etamicastat could be produced from various amine precursors like 
nitroalkanes (266a), carboxylic acids 266b and amides 266c, nitriles (266d) and 
aldehydes (266e) (see Figure 181).
These precursors have an α-chiral carbon atom with alkyl substituents and can 
therefore be synthesized asymmetrically by a C=C reduction of the 
corresponding α,β-unsaturated compounds, leading to 3-substituted 
2H-chromene structures of type 266. These chromenes, especially the 
3-nitrochromene 266a, have a very similar structure compared to the 
previously discussed α-methyl β-aryl nitroalkenes 264, which have been 
successfully reduced before. Furthermore, only one aromatic conformation is 
possible, oppressed by the annulated dihydro-2H-pyran heterocycle. The 
synthesis of these 3-substituted 2H-chromenes was also extensively studied by 
Merck as organic compounds for new liquid crystal media.111 Interestingly, one 
of the industrial pathways to Etamicastat also incorporated this methodology 
of a Robinson annulation-type ring condensation of the corresponding salicyl 
aldehyde with acrylonitrile, leading to the unsaturated analogue of the 3-
cyanochroman 266d.112 Based on these syntheses, four 3-substituted 2H-
chromenes were prepared in the present study. At first, commercially available 
2,4-difluorophenol (270) is ortho-formylated via DUFF reaction with 
Figure 181. Retrosynthetic 
approach to chiral amine
precursors based on an 
electron-withdrawing group 
(blue).
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hexamethylenetetramine (267) under strongly acidic conditions 
(see Figure 182).
The protonation of urotropine (267) leads to the formation of an iminium 269, 
which undergoes an electrophilic aromatic substitution reaction (SE,Ar) with the 
phenol 270. After rearomatization of the MEISENHEIMER complex 271, the 
aminomethyl compound 272 is fairly stable. 
Hydrolysis with sulfuric acid (24%) induces a second iminium formation and 
proton transfer to the stable aromatic benzimine derivative 275. Addition of 
Figure 182. Proposed mech-
anism for the DUFF formyl-
ation of 2,4-difluorophenol.
Figure 183. DUFF formylation 
of 2,4-difluorophenol in 
trifluoroacetic acid (TFA).
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water leads to the metastable aminal 276, which eliminates the amine 278
under formation of the desired salicylic aldehyde 277. Under these aqueous 
acidic conditions, the byproduct 278 is completely  degraded to ammonia and 
formic acid derivatives. Due to the low solubility of the product 277 in aqueous 
medium, the purification is achieved by simple filtration (see Figure 183, page 
170). The moderate yield of 54.2% is presumably due to the high volume of the 
aqueous acidic medium (300 mL). The mother liquor was not evaporated but 
showed further crystallization while standing at room temperature.
The subsequent ROBINSON annulation-type condensation starts with the 
MICHAEL addition of the phenolate 279 to the β-position of the activated 
ethylene reagent 280 (see Figure 184). This enolate 281 further reacts 
intramolecular with the aldehyde to the aldol derivative 282. Given the basicity 
of the reaction and the stabilization by the electron-withdrawing group, this 
adduct eliminates hydroxide in an E1cb mechanism to yield the desired 3-
substituted 2H-chromene 252. As straightforward as this reaction may seem, 
the product-related conversion was in most cases only moderate (15-40%, see 
Table 38, page 172) and the synthesis with acrylamide yielded no product at 
all. Invariably, the salicylic aldehyde 277 was recycled by extraction from the 
acidified reaction mixture and did not show degradation to its corresponding 
salicylic acid. Thus, the reason for the low conversion was found in the 
polymerization of the activated ethylene reagent 280. Among the examined 
reagents, acrylamide had the highest tendency to polymerize under the basic 
reaction conditions, solidifying the mixture to a hardly soluble sponge. 
Alteration of the experimental procedure was made by the addition of p-
methoxyphenol as stabilizer, however, with only minor effect on the 
experimental results. 
Figure 184. Proposed mech-
anism for the ROBINSON
annulation-type condensation 
to 3-substituted 2H-chro-
menes.
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Entry 252 EWGa Baseb Solvent
Isol. Yieldc
[g (%)]
1 a CHO K2CO3 Dioxane 0.15 (15.5)
2 b CONH2 Bu2NH Toluene 0.38 (39.3)
3 c CN DABCO - 0.87 (40.9)
4 d NO2 Bu2NH Toluene n.d. ( - )
A special case was the preparation of the 3-nitro-2H-chromene 252a. The 
necessary nitroethylene (280a) is hardly available as a commercial reagent. 
Therefore, the reagent was freshly prepared by elimination reaction from 
2-nitroethanol (284, see Figure 185, page 173). Although this compound is 
manufactured commercially, the compound can also be produced from the 
bulk chemicals nitromethane and paraformaldehyde via HENRY reaction. A 
literature procedure for the preparation of nitroethylene from 2-nitroethanol 
(284) was examined. The starting material 284 was mixed with phthalic acid 
anhydride and heated to melting temperature. The product 280a was directly 
distilled from the reaction mixture and condensed to solidification. Residual 
water was separated via extraction with dichloromethane. Nevertheless, 
another impurity, i.e. nitromethane, resulted from a retro-HENRY reaction and 
was also distilled into the product. Keeping the polymerization in mind, a 
second strategy was also pursued, activating the free carbinol to a better 
leaving group and alkylation of the salicylate. This O-nitroethyl derivative could 
then be basified to undergo the intramolecular cyclization without 
polymerization. 
Table 38. Substrate syn-thesis 
of various 3-substituted 
2H-chromenes.
(a) carbaldehyde (CHO), carbox-
amide (CONH2), carbonitrile (CN) 
nitro (NO2) (b) 1,4-Diazabi-
cyclo[2.2.2]octane (c) Determined 
after purification by column 
chromatography on silica.
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While the preparation of the corresponding 2-bromo-1-nitroethane 285 was 
successfully achieved by mixing 2-nitroethanol with phosphorous tribromide, 
the subsequent alkylation predominantly yielded the elimination product 280a
(see Figure 185). Therefore, another literature procedure was tested, again 
with phthalic acid anhydride, but now in the presence of the salicylic aldehyde 
to immediately condensate the nitroethylene (280a) to the desired chromene 
252a. This way, the concentration of ethylene reagent is minimized related to 
the other reagents, preventing polymerization. This one-pot procedure, which 
was later also found in literature113, yielded around 40% of analytically pure 
3-nitro-2H-chromene 252a after silica filtration of the reaction mixture without 
additional work-up. Notably, phthalic acid anhydride was identified to be 
irrelevant for product-related conversion. The same reaction yielded again 
around 40% of pure product without addition of anhydride, demonstrating the 
tendency of 2-nitroethanol to form nitroethylene under basic conditions at 
elevated temperatures.
5.3 REFERENCE COMPOUNDS AND ANALYTICAL METHODS FOR THE 
DETERMINATION OF PRODUCT-RELATED CONVERSION AND A POSSIBLE 
ENANTIOSELECTIVITY
The successful synthesis of 6,8-difluoro-3-nitro-2H-chromene 252a also 
focused the subsequent analysis on this compound. The racemic 
3-nitrochroman 251 was synthesized by reduction with sodium borohydride 
and was also separated by chiral HPLC analysis (see Figure 186). Since these 
nitro-compounds are unknown to literature, no reference data was available. 
Figure 185. Synthetic routes 
to the heterocyclic nitroalkene.
Abbreviations: dichloromethane 
(DCM).
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The absolute configuration of the two enantiomers could therefore not be 
assigned.
However, judging from the photodiode array (PDA) spectrum of the substrate 
measurement (200-300 nm), the compound had multiple absorption maxima,
also in the visible spectrum region (see Figure 187). This becomes relevant 
when analyzing enzyme kinetics for substrates. For NAD(P)H-dependent 
oxidoreductases, the literature assay for measuring the enzymatic activity is 
based on the absorption maximum of the reduced cofactor at  = 340 nm. By 
consumption of cofactor for the biocatalytic reduction, the absorbance 
decreases in proportion to the amount of reduced substrate. With an extinction 
coefficient of 6.2 x 103 L/mol*cm, this decrease can be used to determine the 
volumetric activity of the biocatalyst for the given substrate in units (U) 
corresponding to umol of substrate converted per minute. With a substrate 
and/or product having an own absorption at 340 nm, the calculation would be 
flawed. For this reason, a new photometric assay for the conversion of  6,8-
difluoro-3-nitro-2H-chro-mene 252a was established.
5.4 ESTABLISHMENT OF A PHOTOMETRIC ASSAY FOR THE REDUCTION OF 
2H-CHROMENES TO THEIR CORRESPONDING CHROMANS
The use of NAD(P)H absorption for the kinetic measurement is based on its 
high extinction coefficient of 6.2 x 10³ L/mol*cm at 340 nm. In addition, most 
substrates bearing an aromatic moiety have no absorption above 300 nm and 
Figure 186. HPLC chromato-
gram of racemic 3-nitro-
chroman as analytical refer-
ence.
Figure 187. HPLC absorption 
spectra of the nitrochromene 
252a suggesting absorption 
bands in the visible light 
region.
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would therefore not distort the measurement. The PDA spectrum of the 
substrate 252a however, indicated significant absorption above 300 nm. 
Therefore, the reaction components and the reaction mixture of the ene 
reductase-catalyzed reduction of 3-nitro-2H-chromene to its 3-nitrochroman 
were analyzed photometrically (see Figure 188).
It is clearly shown that the substrate 252a has a significantly higher fraction of 
the overall absorption at 340 nm. Even the product has a slight absorption in 
this region. Measuring the kinetics at this wavelength would comprise of the 
decrease of cofactor, decrease of substrate and an increase of product. Hence, 
the spectrum was examined for a wavelength specifically related to the 
decrease of only one component, e.g. the substrate itself. At 400 nm and 
above, only the substrate is responsible for the absorption of the reaction 
mixture. Neither the cofactor nor the product would interfere at this 
wavelength. The molar extinction coefficient of 6,8-difluoro-3-nitro-2H-
chromene was determined by measuring the absorbance of four different 
weigh-ins of substrate, each diluted to three different concentrations. By this, a 
total of 12 concentrations were recorded and the molar extinction coefficient 
was calculated according to LAMBERT-BEER’s law (see Table 39).
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Figure 188. Absorption 
spectra of reaction compo-
nents and the reaction mixture 
of the nitrochromene reduc-
tion.
Abbreviations: Nicotinamide adenine 
dinucleotide phosphate (NAD(P)H).
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Conc. 252a
[mol/L]
E
[a.u.]
l
[mm]

[L/(mol*cm)]
4.69E-05 0.168 10 3,57E+03
3.98E-05 0.133 10 3,34E+03
6.64E-05 0.170 10 2,56E+03
3.15E-05 0.097 10 3,09E+03
9.38E-05 0.324 10 3,46E+03
7.96E-05 0.251 10 3,16E+03
1.33E-04 0.397 10 2,99E+03
6.31E-05 0.194 10 3,08E+03
1.88E-04 0.643 10 3,43E+03
1.59E-04 0.526 10 3,31E+03
2.66E-04 0.818 10 3,08E+03
1.26E-04 0.418 10 3,32E+03
Average  3,20E+03
Std dev. 2,57E+02
Rel. dev. 8,05%
With a molar extinction coefficient of ε = 3.2 ± 0.3 * 10³ L/(mol*cm), the 
biocatalytic reduction of 252a was measured directly for substrate-related 
conversion. This is also important for the determination of kinetics under actual 
reaction conditions. Without using the cofactor absorption, an in situ cofactor 
regeneration can be implemented and the effect of additives can be measured 
directly by photometric analysis.
5.5 BIOCATALYTIC REDUCTION WITH AN ENE REDUCTASE FROM 
GLUCONOBACTER OXYDANS (GOX-ER)
In parallel to the establishment of analytical methods, the synthesized 
substrates of type 252 were preparatively screened with an enzyme-coupled 
Table 39. Determination of the 
molar extinction coefficient of 
substrate 252a at 400 nm.
Abbreviations: Standard deviation
(Std dev.), relative deviation (Rel. dev.)
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cofactor regeneration. As described before, the ene reductase from 
Gluconobacter oxydans uses NADPH as cofactor. Thus, an alcohol 
dehydrogenase from Lactobacillus kefir was used for cofactor regeneration 
under consumption of stoichiometric amounts of 2-propanol. With an alcohol 
content of 25% v/v, this was also beneficial for a more homogenous reaction 
mixture. The low solubilities of nitroalkenes were already extensively studied in 
the work of M.SC. TINA RESS.114
Entry 252 / 266 EWGa
Conversion 
[%]
Yield 
[mg (%)]
ee 
[%]
1 e CHO >95.0b n.d. n.d.
2 d CN <1.0 - -
3 a NO2 >95.0 n.d. < 1.0 (6.7)c
The biocatalytic reduction was successfully achieved with the 3-carbaldehyde 
derivative 252e and the 3-nitrochromene 252a (see Table 40). The 
corresponding carbonitrile 252d was inert as substrate (entry 2). Unfortunately, 
the otherwise low activity observed for the alcohol dehydrogenase from 
Lactobacillus kefir during this study was enhanced for the substrate 252e and 
led to significant amounts of side-products by carbonyl reduction, i.e. the allylic 
alcohol and the hydroxymethylchroman.. The crude product was not further 
analyzed. In contrast to that, the nitrochromene 252a was converted 
chemoselectively, without observation of literature-known side-activities like a 
biocatalytic Nef reaction.115 Unfortunately, the formed nitrochroman showed 
only a slight enantiomeric excess of 6.7% ee after 6 hours reaction time, 
continuously decreasing to reach a racemic mixture after 24 hours. Due to the 
lack of additional enzymes, this project was not further investigated.
Table 40. Preparative 
screening of 3-substituted 2H-
chromenes 252 for the 
biocatalytic reduction with an 
ene reductase from 
Gluconobacter oxydans.
(a) carbaldehyde (CHO),carbonitrile 
(CN) nitro (NO2) (b) LK-ADH-
catalyzed reduction of carb-aldehyde; 
2H-chromene-3-carbinol and 
3-hydroxymethylchroman as 
by-products (c) racemic product after 
24 hours, however, 6.7% ee after 6 
hours reaction time.
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5.6 DISCUSSION AND OUTLOOK
A facile synthesis of 3-substituted 2H-chromenes was successfully adapted for 
the preparation of a literature-unknown 3-nitro-2H-chromene as prochiral 
precursor of Etamicastat (see Figure 189). Unfortunately, the investigated 
biocatalyst, an ene reductase from Gluconobacter oxydans, showed only minor 
enantioselectivity for the reduction, even leading to a racemic product after 
prolonged reaction times, indicating a slow racemization process. Nevertheless, 
during the search for chiral HPLC methods, a new photometric assay was 
established, specifically related to the actual product formation and not the 
error-prone cofactor consumption. By this alternative photometric assay, in situ
kinetics can be measured in the presence of a cofactor regeneration, thus 
giving a more detailed insight into the actual reaction progress. This can also 
be useful for examination of additive effects on the activity or stability of ene 
reductases. Although the product was obtained as a racemate, this project 
clearly substantiated the potential of biocatalysis for pharmaceutical syntheses. 
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6 ABSTRACT
The present work on chemoenzymatic syntheses of pharmaceutically relevant 
building blocks consists of four separate studies. One of two main projects was 
the establishment of a biocatalytic desymmetrization route within a multi-step 
synthesis of the blockbuster drug Rosuvastatin, which had an annual world 
market sale of 6.253 billion US dollars in 2012. An initial route was adjusted 
several times to circumvent chemical as well as biocatalyst limitations. After 
extensive analysis of the reaction parameters and subsequent optimization of 
the biocatalytic process, the final route to the enantiomerically enriched key 
intermediate, the chiral phosphoranylidene 93b, was successfully realized with 
high yields, excellent enantioselectivities and only one necessary product 
isolation within nine consecutive reaction steps. The most notable fact is that a 
bienzymatic process for the production of ethyl (3R)-hydroxyglutarate (60) was 
realized to circumvent a low enantioselectivity of the biocatalyst for the starting 
material (see Figure 190). By this method, the enantioselectivity of the 
hydrolase α-chymotrypsin was increased from moderate 60% ee to excellent 
>97% ee. In addition, the reaction proceeded smoothly even at a substrate 
concentration of 4.0 mol/L of 22a, leading to a binary mixture of aqueous 
reaction buffer and organic substrate phase of around 1:1 volumetric ratio. By 
combining the highly enantioselective desymmetrization with a subsequent 
chemoselective deacetylation by the hydrolase cephalosporin C acetylesterase 
(CAE), the enantiomerically enriched ethyl (3R)-hydroxyglutarate (60) was 
produced in more than 350 g/L, which is remarkable for a biocatalytic process.
The subsequent derivatization to the enantiomerically enriched ylide (3R)-93b 
(see Figure 191, page 181), was established using literature-known 
protective-group chemistry and activated carboxylic acid derivatives. Although 
the desired ylide 93b could not be isolated in pure crystalline form, the content 
and enantiomeric excess were determined by the conversion of aldehyde in the 
following WITTIG reaction and chiral HPLC analysis of a preparative TLC 
Figure 190. Bienzymatic pro-
cess for the production of the 
enantiomerically enriched 
monoester (3R)-60 at high 
substrate concentrations.
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purification of the crude product, respectively. With respect to the already 
established WITTIG reaction with the commercial ylide and the need for 
1.1 equivalents of reagent, the conversion of aldehyde revealed an ylide 
content of 78-87%. The enantiomeric excess was determined to be 98% ee, an 
optical purity which was considered to be sufficient for an industrial scale-up. A 
patent application for this chemoenzymatic multi-step synthesis is currently 
pending.
The other main project, the biocatalytic synthesis of chiral nitriles, started from 
basically no literature regarding an enantioselectivity of aldoxime dehydratases
(Oxds), a recently discovered and characterized enzyme belonging to the class 
of lyases. Within this work, the first scientific evidence for an enantioselective 
dehydration of racemic aldoximes was produced. By reducing the activity of the 
biocatalyst, i.e. an aldoxime dehydratase from Bacillus sp. OxB-1 (OxdB) 
overexpressed in recombinant E. coli HB101 / pOxD-9OF, and the free energy
of the system by lowering the reaction temperature, a kinetic resolution of the 
racemic E-aldoxime of 2-phenylpropionaldehyde (E-133a) was observed for the 
first time (see Figure 192). 
The progress of the enzymatic reaction was analyzed from a mixture of two 
diastereomers of E- and Z-aldoxime consisting of a racemate. By identifying an 
inert substrate, namely E-(R)-133a, as well as assigning the absolute 
configuration of the enantiomerically enriched nitrile (S)-139a, the 
Figure 192. Synthesis of 
enantiomerically pure 
(S)-2-phenylpropionitrile by 
an enzymatic dehydration of 
the racemic E-aldoxime 
133a by means of a kinetic 
resolution.
Figure 191. Chemical deriva-
tization of enantiomerically 
pure monoester (3R)-60 to 
the desired phosphorous 
ylide (3R)-93b in the chemo-
enzymatic synthesis of 
Rosuvastatin.
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enantiospecificity of OxdB for this substrate was clarified. The key to this 
enantioselective nitrile synthesis was found by separating E- and Z-aldoximes 
from their mixture. Essentially pure (S)-139a was synthesized in a kinetic 
resolution starting from racemic E-133a (>99% isomeric purity), with 50% 
conversion and an excellent enantioselectivity of 98% ee (see Figure 192, page 
181), while the corresponding Z-aldoxime resulted in a racemic product. This 
unusual enantiopreference for E-aldoximes was also observed for four other 
chiral substrates bearing aliphatic, cyclic, bicyclic and heterocyclic substituents, 
demonstrating the high value of this methodology.
The third project consisted of two target structures, namely β-amino alcohols 
related to HIV-1 protease inhibitors and β-lactones as potent antibiotic drugs. 
Both compound classes were synthesized by a dynamic kinetic resolution 
starting from racemic α,β-disubstituted β-oxo carbonyl compounds. In all 
cases, the applied biocatalysts were oxidoreductases, more precisely alcohol 
dehydrogenases from Rhodococcus sp., Lactobacillus sp., a commercial ADH, 
evocatal 1.1.200, and an ene reductase from Gluconobacter oxydans. The latter 
was primarily used for substrate synthesis by C=C reduction of the 
corresponding α-acyl -aryl acrylates. The enantio- and diastereoselective 
reduction of β-oxo carbonyl compounds was successfully achieved for 
α,β-disubstituted β-oxo nitriles of type 197a to circumvent a lack of activity 
observed for the corresponding β-oxo amides. Three alcohol dehydrogenases 
were tested for their reduction. All of them showed high activities with 
quantitative conversion of the substrate, excellent enantioselectivities for the 
carbonyl reduction and also high diastereoselectivities for the vicinal 
stereogenic center (see Figure 193). 
By using the racemizable β-oxo nitrile 197a, a dynamic kinetic resolution 
process for the preparation of enantiomerically pure and diastereomerically 
enriched β-hydroxy nitrile 196a was successfully established, with three of four 
possible diastereomers directly addressable.
Figure 193. Enantio- and 
diastereoselective synthesis 
of three of four possible 
diastereomers of β-hydroxy 
nitrile 196a by dynamic 
kinetic resolution of racemic 
β-oxonitrile 197a.
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Although the subsequent hydration to the corresponding β-hydroxy amides 
was not investigated in this work, the chemical degradation of 
diastereomerically enriched racemic β-hydroxy amides were successfully 
established by means of a HOFMANN rearrangement under complete retention 
of the diastereomeric excess (see Figure 194). The obtained 4,5-disubstituted 
oxazolidin-2-ones are excellent precursors for the synthesis of β-amino 
alcohols and the cyclic urethane structure represents an intramolecular 
protecting group for the regioselective monoalkylation of the corresponding 
amino alcohol.
Besides nitrogen-containing β-oxo carbonyl compounds, also β-oxo esters 184 
were successfully reduced by the use of alcohol dehydrogenases 
(see Figure 195). The stereoselectivities were in good agreement with those 
obtained for the β-oxo nitriles 197. Furthermore, a two-step synthesis of 
β-arylmethyl substrates was realized by combination of a BRÖNSTED
acid/base-catalyzed KNOEVENAGEL condensation to obtain the intermediates of 
type 245 and a subsequent ene reduction with palladium charcoal or a hydride 
reduction with a HANTZSCH ester. Additionally, a chloromethyl moiety was 
Figure 195. Synthesis of 
new racemic β-oxo ester 
substrates and biocatalytic 
reduction with alcohol 
dehydrogenases in a 
dynamic kinetic resolution 
process.
Figure 194. Synthesis of 
enantio- and diastereo-
merically pure 4,5-disub-
stituted oxazolidin-2-ones 
from racemic β-oxo nitriles.
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inserted in view of a subsequent insertion of the β-lactone moiety into larger 
molecular structures by, for example, a WITTIG reaction. The chemical 
saponification of the β-hydroxy esters was investigated for a biocatalytic 
alternative. A photometric screening assay identified porcine liver esterase as 
potent hydrolase. The enzymatic hydrolysis was successfully achieved in a 
sequential two-step process after ADH reduction or in a one-pot process 
starting from racemic β-oxo esters in the presence of an ADH. PLE revealed 
itself to be highly enantioselective for the hydrolysis of the (3S)-β-hydroxy
ester, thereby further increasing the diastereomeric excess from the biocatalytic 
reduction with an alcohol dehydrogenase from Rhodococcus sp.. In addition, a 
chemical lactonization protocol was achieved (see Figure 196). By using 
different inorganic or organic bases, an epimerization of the α-stereogenic 
center was either minimized or drawn towards enrichment of the predominant
syn-diastereomer. 
Last but not least, a facile synthesis of 3-substituted 2H-chromenes was 
successfully adapted for the preparation of a literature-unknown 3-nitro-2H-
chromene as prochiral precursor of the dopamine β-hydroxylase inhibitor 
Etamicastat. Despite the fact that the investigated biocatalyst, an ene reductase 
from Gluconobacter oxydans, showed only low enantioselectivity for the desired 
reduction, a new photometric assay was established, specifically related to the 
actual product formation and not the error-prone cofactor consumption, which 
is often used for oxidoreductase activity measurements. By this alternative
photometric assay, in situ kinetics can be measured in the presence of a 
cofactor regeneration, thus giving a more detailed insight into the actual 
reaction progress. This will be useful as a general assay for examination of 
additive effects on the activity or stability of ene reductases. 
The investigated processes clearly demonstrate the impact of biocatalytic 
alternative syntheses in organic chemistry, especially by their combination in 
chemoenzymatic synthesis of pharmaceutically relevant, enantiomerically pure 
building blocks.
Figure 196. Synthesis of 
enantio- and diastereo-
merically pure 3,4-disub-
stituted β-lactones from 
racemic β-oxo esters.
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7 ZUSAMMENFASSUNG
Die hier vorgestellte Arbeit im Bereich der chemoenzymatischen Synthese von 
pharmazeutisch relevanten Synthesebaustainen besteht aus vier Einzelstudien. 
Eines der zwei Hauptprojekte war die Etablierung einer biokatalytischen 
Desymmetrisierung in Verbindung mit einer Mehrstufensynthese des 
Blockbuster-Wirkstoffs Rosuvastatin, der im Jahr 2012 mit einem 
Weltmarktanteil von 6.253 Milliarden US-Dollar zu Buche schlug. Die geplante 
Syntheseroute musste aufgrund von chemischen als auch biokatalytischen
Einschränkungen mehrmals verändert werden. Nach intensiver Analyse der 
Reaktionsbedingungen und anschließender Optimierung des biokatalytischen 
Prozesses konnte die enantiomerenreine Schlüsselverbindung, das chirale 
Phosphor-Ylid 93 in hohen Ausbeuten, exzellenten Enantioselektivitäten und 
ausschließlich einer einzigen Aufreinigung über sechs aufeinanderfolgende 
Stufen synthetisiert werden. Am bemerkenswertesten war hierbei die 
Realisierung eines bienzymatischen Prozesses für die Darstellung des 
enantiomerenreinen (3R)-Hydroxyglutarsäuremonoethylesters (60) mit 
Umgehung einer niedrigen Enantioselektivität des Biokatalysators. (siehe 
Abbildung 1). Hierdurch konnte die Enantioselektivität der Hydrolase 
α-Chymotrypsin von mäßigen 60% ee auf hervorragende >97% ee gesteigert 
warden. Hinzu kommt, dass die Reaktion selbst bei einer Substratkonzentration 
von 4.0 mol/L bezüglich 22a noch problemlos lief und dabei einer binären 
1:1-Mischung aus wäßriger Pufferlösung und organischer Substratphase 
entsprach. Durch die Kombination der hochenantioselektiven 
Desymmetrisierung mit einer nachfolgenden, chemoselektiven Deacetylierung 
unter Verwendung der Hydrolase Cephalosporin C Acetylesterase (CAE) konnte 
enantiomerenangereicherter Monoester 60 mit einer Produktkonzentration 
von mehr als 350 g/L synthetisiert werden. Eine solche hohe 
Produktkonzentration ist herausragend für biokatalytische Prozesse. Die 
anschließende Derivatisierung zum enantiomerenangereicherten Phosphor-Ylid 
Abbildung 1. Bienzymati-
scher Prozess für die 
Darsellung von enantiome-
renangereichertem Mono-
ester 60 bei hohen Substrat-
konzentrationen. 
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93b wurde mit Hilfe von literaturbekannten Schutzgruppen und Aktivestern 
etabliert. (siehe Abbildung 2), Obwohl das angestrebte Ylid nicht in kristalliner 
Reinform gewonnen werden konnte, wurde sein Gehalt in Rohprodukten und 
sein Enantiomerenüberschuss bestimmt. Ersteres erfolgte über die 
anschließende Wittigsynthese mit dem hetereoaromatischen Aldehyd von 
Rosuvastatin, letzteres mit Hilfe einer chiralen HPLC-Analyse nach teilweiser 
Aufreinigung über eine präparative DC. Unter Berücksichtigung der gängigen 
Wittigsynthese mit dem kommerziell erhältlichen Ylid und dem Bedarf von 1.1 
Äquivalenten, die Umsetzung des Aldehyds bestätigte einen Gehalt im Bereich 
von 78-87% im Rohprodukt der Ylidsynthese. Der Enantiomerenüberschuss 
wurde auf 98% ee bestimmt, gleichbedeutend mit einer optischen Reinheit, die 
für eine industrielle Anwendung ausreichend waren. Eine diesbezügliche 
Patentanmeldung ist im Gange. 
Das zweite Hauptorjekt, die enantioselective Synthese von chiralen Nitrilen, 
hatte nahezu keine Literaturgrundlage bezüglich einer Enantioselektivität von 
Aldoximdehydratasen (Oxds), einem kürzlich entdeckten und charakterisierten 
Enzym, das zur Klasse der Lyasen gehört. Innerhalb der hier vorgestellten Arbeit 
wurde erstmals eine enantioselective Dehydratation von racemischen 
Aldoximen wissenschaftlich belegt. Durch Reduzierung der Enzymaktivität des 
Biokatalysators, d.h. der Aldoximdehydratase aus Bacillus sp. OxB-1 (OxdB), die 
in recombinanten E. coli HB101 / pOxD-9OF überexprimiert wurde, und der 
Absenkung der freien Energie des Systems durch Abkühlung auf 8 °C wurde 
eine kinetische Racematspaltung des chiral E-Aldoximes von 
2-Phenylpropionaldehyd erstmals beobachtet.
Abbildung 3. Synthese von 
enantiomerenreinem 
(S)-2-Phenylpropionitril 139a
durch enzymatische Dehydra-
tation des racemischen 
E-Aldoxims 133a im Sinne 
einer kinetischen Racemat-
spaltung.
Abbildung 2. Chemische De-
rivatisierung von enantio-
merenreinem Monoester 60
zum angestrebten Phosphor-
Ylid 93b für die Synthese von 
Rosuvastatin.
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Der Verlauf der Enzymreaktion wurde mit einer Diastereomerenmischung des 
E- und Z-Aldoxims analysiert, die aus Racematen bestand. Durch Identifizierung 
eines inerten Substrats, genauergesagt E-(R)-133a, und der Zuordnung der 
absoluten Konfiguration des enantiomerenangereicherten Nitrils 139a, konnte 
die Enantiospezifität des Enzyms für dieses Substrat abschließend geklärt
werden. Der Schlüssel für diese enantioselektive Nitrilsynthese lag in der 
Separierung von E- und Z-Aldoximes aus ihrer Mischung. Nahezu optisch 
reines (S)-139a wurde ausgehend von racemischem E-133a (>99% 
Isomerenreinheit) durch eine kinetische Racematspaltung gewonnen, mit 50% 
Umsatz und einem hervorragenden Enantiomerenüberschuss von 98% ee 
(siehe Abbildung 3, Seite 186). Die Synthese basierend auf dem 
entsprechendem Z-Aldoxim führte zu einem racemischen Produkt. Diese 
ungewöhnliche Enantiopreferenz für E-Aldoxime wurde ebenfalls bei vier 
weiteren, chiralen Substraten, beobachtet. Diese beinhalten aliphatische, 
zyklische, bizyklische und heterozyklische Strukturen und verdeutlichen den 
hohen Wert dieser Synthesemethode. 
Das dritte Projekt war auf zwei Leitstrukturen ausgerichtet, genauergesagt 
β-Aminoalkoholen, die strukturverwandt mit HIV-1 Proteaseinhibitoren sind, 
und β-Lactonen als mögliche Antibiotika. Beide Strukturklassen wurden über 
eine dynamisch-kinetische Racematspaltung ausgehend von racemischen 
β-Oxocarbonylverbindungen hergestellt. In jedem Fall waren die verwendeten 
Biokatalysatoren Oxidoreduktasen, genauergesagt Alkoholdehydrogenasen 
(ADH) aus Rhodococcus sp., Lactobacillus sp., einer kommerziellen ADH, 
evocatal 1.1.200, und einer En-Reduktase aus Gluconobacter oxydans. 
Letztgenannte wurde primär für die Substratsynthese genutzt, über eine C=C-
Reduktion der entsprechenden α-Acyl--arylacrylsäureester. Die enantio- und 
diastereoselektive Reduktion von β-Oxocarbonylverbindungen wurde 
erfolgreich für α,β-disubstituted β-Oxonitrile wie 197a durchgeführt, um die 
fehlende Aktivität der ADHs gegenüber den entsprechenden 
β-Oxocarbonsäureamiden zu kompensieren. Drei Alkoholdehydrogenasen 
wurden im Zuge dessen getestet.
Abbildung 4. Enantio- und 
diastereoselektive Synthese 
der drei von vier möglichen 
Diastereomeren des β-hydro-
xynitrils 196a mittels dyna-
misch-kinetischer Racemat-
spaltung.
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Alle zeigten hohe Aktivitäten mit quantitativen Umsätzen, ausgezeichneten 
Enantioselektivitäten für die Carbonylreduktion und ebenfalls hohe 
Diastereoselektivitäten für das benachbarte Stereozentrum. Bei der 
Verwendung von racemisierbarem 197a konnte eine dynamisch-kinetische 
Racematspaltung (DKR) für die Darstellung von enantiomerenreinem und 
diastereomerenangereichertem β-Hydroxynitril 196a erfolgreich etabliert 
werden. Drei von vier möglichen Diastereomeren waren durch geeignete Wahl 
des Biokatalysators direkt synthetisierbar (siehe Abbildung 4, Seite 187).
Der später durchgeführte Hofmann-Carbonsäureabbau verlief unter 
vollständiger Retention der absoluten Konfiguration. Die dadurch zugänglichen  
4,5-disubstituierten Oxazolidin-2-one sind hervorragende Vorstufen bei der 
Synthese von  β-Aminoalkoholen und das zyklische Urethan enspricht einer 
intramolekularen Schutzgruppe für die regioselektive Monoalkylierung des 
jeweiligen Aminoalkohols. 
Neben stickstoffhaltigen β-Oxocarbonylverbindungen wurden auch 
β-Oxocarbonsäureester 184 erfolgreich mit ADHs umgesetzt.
(siehe Abbildung 6). Die Stereoselektivitäten waren dabei in guter 
Übereinstimmung mit den Versuchen zu β-Oxonitrilen 197. Ebenfalls realisiert 
Abbildung 5. Synthese von 
enantio- und diastereo-
merenreinen 4,5-disubsti-
tuierten Oxazolidin-2-onen 
basierend auf racemischen 
β-Oxonitrilen.
Abbildung 6. Synthese von 
neuen racemischen β-Oxo-
ester-Substraten und deren 
biokatalytische Reduktion in 
einer DKR.
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wurde eine zweistufige Synthese von β-Arylmethylsubstraten durch 
Kombination einer BRÖNSTED säure-/basenkatalysierten KNOEVENAGEL
Kondensation zu den Verbindungen des Typs 245 und einer darauffolgenden 
Alkenreduktion mit Palladium/Aktivkohle bzw. einer HANTZSCH-Ester-Reduktion. 
Zusätzlich wurde eine Chlormethylgruppe eingeführt, um das β-Lacton 152a
z.B. über eine WITTIG-Reaktion in größere Molekülstrukturen einzubinden. 
Desweiteren wurde eine chemische Lactonisierung erzielt (siehe Abbildung 7). 
Durch die Verwendung von verschiedenen anorganischen und organischen 
Basen wurde eine Epimerisierung entweder vermindert oder in Richtung einer 
weiteren Diastereomerenanreicherung des syn-Diastereomers gedrängt. 
Zu guter Letzt wurde eine simple Synthese von 3-substituierten 2H-Chromenen 
erfolgreich auf die Darstellung eines literaturunbekannten 3-Nitro-2H-
chromens übertragen. Dieses stellt eine prochirale Vorstufe des Dopamin-β-
hydroxylaseinhibitors Etamicastat dar. Abgesehen davon, dass der untersuchte 
Biokatalysator, die En-Reduktase aus Gluconobacter oxydans, nur eine sehr 
niedrige Enantioselektivität bezüglich des Nitrosubstrats aufweist, wurde ein 
neuartiger Photometertest etabliert. Dieser misst nun spezifisch die 
Produktbildung der En-Reduktase-katalysierten Reaktion anstatt die 
fehlerbehaftete Cofaktorabnahme, die Gang und Gäbe bei photometrischen 
Aktivitätsbestimmungen von Oxidoreduktasen ist. Durch diesen alternativen 
Photometertest lässt sich die Reaktionskinetik in der Gegenwart einer Cofaktor-
Regenerierung bestimmen. Dies dürfte sich als nützlich erweisen, wenn es 
darum geht, den Einfluss von Additiven auf die Aktivität und Stabilität von 
En-Reduktasen zu untersuchen. 
Die untersuchten Prozesse zeigen deutlich den Einfluss von biokatalytischen 
Alternativsynthesen in der organischen Synthesechemie, vor allem in Bezug auf 
deren Kombination in chemoenzymatischen Synthesen von pharmazeutisch 
relevanten, enantiomerenreinen Synthesebausteinen. 
Abbildung 7. Synthese von 
enantio- und diastereo-
merenreinen 3,4-disubsti-
tuierten β-Lactonen basie-
rend auf racemischen β-Oxo-
nitrilen.
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8 EXPERIMENTAL PROCEDURES - ROSUVASTATIN
8.0 MATERIALS AND METHODS
Solvents and reagents
Unless stated otherwise all chemicals and solvents (reagent and HPLC grades) 
were purchased from commercial manufacturers (Sigma-Aldrich, ABCR, Alfa 
Aesar, Tokyo Chemical Industry Co., Ltd., Carl Roth GmbH & Co. KG) and used 
without further purification. Methyl (3R)-(tert-butyldimethylsilyl)-oxy-5-oxo-6-
(triphenylphosphor-anylidenyl)-hexanoate, n-(4-(4-fluorophenyl)-5-formyl-6-
isopropylpyrimidin-2-yl)-N-methylmethane-sulfonamide, Rosuvastatin methyl 
ester and Rosuvastatin calcium salt were provided by Sandoz GmbH, Kundl, 
Austria.
Enzymes
Samples of α-chymotrypsin or mixtures with trypsin were purchased from BBI 
enzymes, Biozym, Biocon and Sigma-Aldrich. Cephalosporin C acetylesterase 
was provided by Sandoz GmbH, Kundl, Austria. Lipases Amano AYS, Amano PS 
SD, Amano P were provided from Amano Enzymes Inc, Nagoya, Japan. 
Dehydroabietylamine was purified according to chapter 8.0.3. Deuterated 
solvents chloroform-d (>99.9%, stabilized with silver foil, 0.03% v/v TMS) and 
dimethylsulfoxid-d6 (>99.8%) were purchased from Acros Organics, New 
Jersey, USA and Alfa Aeser, Lancashire, UK, respectively.
Photometric measurements
Photometric assays for active hydrolases were measured on 96-well plates 
(Thermo Scientific Nunc*) in a Multiskan GO microplate spectrophotometer 
from Thermo Fisher Scientific Inc., Waltham, MA, USA. The absorbance at 
wavelengths of 433 nm and 618 nm, respectively, were plotted against
reference solutions for relative changes. Absorbance spectra of compounds, 
molar extinction coefficients and time courses of reactions were measured on a 
V-630 spectrophotometer, equipped with a PSC-763 air-cooled automatic 6-
position Peltier cell-changer, from JASCO Inc., Easton, MD, USA. The data was 
analyzed with Spectra Manager 2 (Vers. 2.08.04).
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Incubators
The microplates containing hydrolase screening solutions were incubated in a 
Heidolph Titramax 1000 microplate shaker combined with a Heidolph 
Inkubator 1000. The 96-well plates were shaken for 2-24 hours at 25-60 °C.
High-Performance Liquid Chromatography (HPLC)
The conversion and composition of aqueous reaction phases was measured on 
a LC-2000 HPLC system equipped with PU2080 Plus pumps, a DG2080-53 
degasser, a MD-2010 Plus multiwavelength detector, a CO-2060 Plus column 
thermostat, an AS-2059-SF Plus autosampler and a RI-2031 Plus refractive 
index detector from JASCO Inc., Easton, MD, USA. The samples were separated 
on reversed-phase HPLC columns Nucleosil 100-5 C18 from Macherey-Nagel 
GmbH & Co. KG, Düren, Germany, or SunFire C18 from Waters GmbH, 
Eschborn, Germany, respectively. Mixtures of water and acetonitrile, methanol 
or aqueous buffers at various pH ranges were used as eluents. The composition 
and optical purity of extracted samples were determined on another LC-2000 
HPLC system with identical equipment (excl. RI detector) and additional 
modules for the use of supercritical carbon dioxide as apolar mobile phase, i.e. 
a F250 cryostat from Julabo GmbH, Seelbach, Germany, and a BP-2080 Plus 
back pressure generator from JASCO Inc., Easton, MD, USA, respectively. The 
samples were separated on normal-phase chiral HPLC columns, i.e  Chiralpak 
AD-H, Chiralcel OD-H, Chiralcel OJ-H, Chiralcel OB-H and Chiralpak IC, 
respectively, from Chiral Technologies Europe SAS, Illkirch, France, with 
mixtures of 2-propanol in n-hexane and/or SC-CO2 as mobile phase. The data 
was analyzed with the chromatography software Galaxie (Vers. 1.10.0.5590) 
from Agilent / Varian, Inc., Walnut Creek, CA, USA.
Gas chromatography (GC)
The enantiomeric excess of (2RS)-phenylpropanol was measured on a GC-2010
equipped with an AOC-20i autoinjector from Shimadzu Corp., Kyoto, Japan, 
and a chiral GC column Rt-bDEXmTM from Restek Corp., Bellefonte, PA, USA, or 
a GC-2010 Plus equipped with an AOC-20i autoinjector, an AOC-20s 
autosampler, and a chiral GC column Rxi®-5ms from the same manufacturers. 
The compounds were detected by a flame ionization detector (FID) and the 
data was analyzed with LabSolutions / GCsolution (Vers. 2.41.00).
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Nuclear Magnetic Resonance (NMR)
All 1H-, 13C-, COSY-, NOESY- and HMQC-NMR spectra were measured on either 
a DRX 500 MHz NMR or AV 300 MHz NMR from Bruker Corp., Billerica, MA, 
USA. All 19F- and 31P-NMR spectra were measured on an AV 500 MHz NMR 
from the same manufacturer with capillaries containing CFCl3 (δ = 0.0 ppm) 
and Me3PO4 (δ = 4.0 ppm), dissolved in acetone-d6, as internal standards. The 
measurements were processed with MestReNova (Vers. 7.0.2-8636) from 
Mestrelab Research S.L., Santiago de Compostela, Spain. The shifts were 
measured in chloroform-d, acetone-d6 and dimethylsulfoxide-d6, respectively, 
and will be given in relation to tetramethylsilane (TMS, δ = 0.0 ppm) or a 
residual solvent peak according to literature values116. The frequencies used for 
1H- and 13C- measurements were 500 MHz and 126 MHz (DRX500), 300 MHz 
and 75 MHz (AV300), respectively. The frequencies for 19F- and 31P-
measurements were 470 MHz and 202 MHz (AV500), respectively. Unless 
stated otherwise all samples were measured at room temperature.
Mass spectrometry (GC-MS, ESI-MS)
For GC-MS analysis the sample was separated in a GC-17A (Version 3)/MS QP 
5050A from Shimadzu Corp., Kyoto, Japan, equipped with an AOC-20i 
autoinjector and a capillary column HP-5ms from Agilent Technologies, Inc., 
Loveland, Colorado. The spectra were recorded with helium carrier gas (0.95 
bar) and an ionization energy of 70 eV. Integrals were not corrected. The data
was analyzed with LabSolutions GC/MS solution (Version 1.02) from Shimadzu 
Corp., Kyoto, Japan.
Polarimetry
For the identification of enantiomers their specific optical rotary power was
measured on a Model 341 polarimeter from Perkin Elmer Instruments, 
Waltham, MA, USA. All values were measured at least five times in a 10-mm cell 
at 589.3 nm (Sodium D-Line). The direction of polarization was given as “+” 
(dextrorotary) or “-“ (levorotary), respectively.
Infrared spectroscopy
Infrared spectra were recorded with a NICOLET 380 FT-IR spectrometer from 
Thermo Electron Corp., now Thermo Fisher Scientific, Inc., Waltham, MA, USA, 
and analyzed with the OMNIC (Vers. 7.3) software.
pH Stat
For maintaining the pH during hydrolysis of carboxylic esters in aqueous 
reaction media, a titrino apparatus, i.e. Titroline alpha plus from SI analytics 
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(Schott AG), Mainz, Germany, and Titrino 702 SM from METROHM GmbH & Co. 
KG, Filderstadt, Germany, was used. The data was recorded and analyzed with 
the software TitriSoft (Vers. 2.73) and/or tiamo (Vers. 1.2.1) from the same 
manufacturers, respectively.
Melting points
The melting points of solid compounds were measured at least three times on 
a B-540 melting point analyzer from BUCHI Labortechnik AG, Flavil, 
Switzerland.
Mixing and centrifugation
Samples in 1.5-mL-, 15-mL- and 50-mL-vials were mixed on a Vortex Genie 2 
from Scientific Industries, Inc., Bohemia, NY, USA. Heterogeneous mixtures 
were separated by centrifugation in a himac CT15RE (T15A61-1929 rotor) from 
Hitachi Koki Co., Ltd., Tokyo, Japan, or a HERAEUS Multifuge 3S-R from Thermo 
Fisher Scientific, Inc., Waltham, MA, USA, respectively.
8.0.1 N-BENZYL BENZOATE
A mixture of benzoic acid (1.22 g, 10.0 mmol) and triethylamine (2.09 mL, 
15.0 mmol) was dissolved in ethyl acetate (10 mL). After the addition of 
benzylamine (1.09 mL, 10.0 mmol) and tris-n-propylphosphonic anhydride 
(T3P, 50 w% in EtOAc, 5.90 mL, 10.0 mmol) the resulting solution was stirred for
five hours at room temperature. The reaction was quenched by the addition of 
hydrochloric acid (1M, 10 mL). The phases were separated and the organic 
phase was washed with saturated sodium bicarbonate solution (10 mL) and 
brine (10 mL). After drying over MgSO4 all volatile compounds were removed 
in vacuo. The crude product was recrystallized from ethanol/n-hexane and 
dried in high vacuum to obtain colorless needles.
Isolated yield: 1.04 g (4.94 mmol, 49.4%).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 7.79 (d, J = 6.9 Hz, o-Bz-H), 7.53 – 7.48 (t,
J = 7.4 Hz, 1H, p-Bz-H), 7.46 – 7.41 (t, J = 7.5 Hz, 2H, m-Bz-H), 7.36 (m, 4H, Ar-
H), 7.33 – 7.28 (m, 1H, Ar-H), 4.65 (d, J = 5.6 Hz, 2H, CH2).
13C-NMR (126 MHz, CDCl3): δ [ppm] = 167.43, 138.26, 134.39, 131.53, 128.76, 
128.57, 127.89, 127.57, 127.01, 44.10.
Mp: 104-106 °C (Lit. 107–108 °C (EtOH))117.
The data corresponds to literature values.117
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8.0.2 DETERMINATION OF THE REACTIVE CONCENTRATION OF COMMERCIAL
N-BUTYLLITHIUM SOLUTIONS
The following titration was conducted based on a literature procedure from
BURCHAT et al..118 A solution of n-benzyl benzoate (212 mg, 1.00 mmol) in abs. 
THF (10 mL) was cooled to -78 °C (acetone/dry ice). The corresponding n-
butyllithium solution (1.6 M in n-hexane) was added dropwise via syringe 
(1.0 mL max.). The volume for stoichiometric deprotonation of the starting 
material, thus corresponding to 1.0 mmol active n-butyllithium, was 
determined by an intense blue coloration of the solution, resulting from the 
dianionic species of n-benzyl benzoate. 
Consumed volume: 0.85 mLi
Titer concentration: 1.18 M (based on result).
8.0.3 PURIFICATION OF (+)-DEHYDROABIETYLAMINE
8.0.3.1 (+)-DEHYDROABIETYLAMINE ACETATE
Commercially available dehydroabietylamineii (100 g, 350 mmol max.) was 
diluted with toluene (150 mL). A solution of glacial acetic acid (20.0 mL, 350 
mmol) in toluene (50 mL) was added dropwise and the mixture was stirred at 
room temperature. On congelation of the mixture, toluene (100 mL) was added 
and the suspension was heated to reflux (120 °C) until homogenization. The 
solution was slowly cooled to room temperature until precipitation occurs. The 
precipitate was filtered off and washed with cold toluene (50 mL). The residue
was recrystallized in toluene to obtain the product as colorless solid.
Isolated yield: 42.8 g (123.87 mmol, 64.2 %).
Mp: 139-141 °C (Lit: 140-143 °C119).
Specific rotation: a = +28.5° (c = 5, MeOH, 28 °C) (Lit: +30.2° (c = 5, MeOH, 
25 °C))
i This volume was necessary under the given conditions (considering dryness of solvent, dryness 
of inert gas and contact to humidity during transfer via syringe). The resulting concentration
does not correspond to the actual concentration of the commercial solution. The titration can be 
used to determine the necessary amount of base for complete deprotonation prior to each 
experiment.
ii Commercial purity of 55%.
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8.0.3.2 (+)-DEHYDROABIETYLAMINE
(+)-Dehydroabiethylamine acetate (10.0 g, 28.9 mmol) was suspended in dist. 
H2O (40 mL) and heated until homogenization. Subsequently, an aqueous 
solution of sodium hydroxide (10 w%, 15 mL, 37.5 mmol) was added and the 
solution was slowly cooled to room temperature. After extraction with MTBE 
(3x 50 mL) the combined organic phase was washed with dist. H2O (50 mL) and 
dried over anhydrous potassium carbonate. All volatile compounds were 
removed in vacuo to obtain the product as colorless oil which crystallizes under 
storage at 4 °C.
Isolated yield: 8.10 g (28.4 mmol, 98.3%).
Mp: 39 - 41 °C (Lit: 43-45 °C119).
8.1 STANDARD OPERATING PROCEDURE 1 (SOP1): SUBSTRATE SYNTHESIS 
FOR THE HYDROLASE-COUPLED DESYMMETRIZATION OF O-PROTECTED 
DIETHYL 3-HYDROXYGLUTARATES
The following syntheses were based on literature-known procedures from 
various authors. The corresponding reference will be given in parenthesis for 
each substrate.
If not stated otherwise, a solution of catalyst (0.1 - 10 mol-%) and the 
corresponding protective group reagent (1.05 eq.) was mixed with diethyl 
3-hydroxyglutarate (4.00 mmol) and stirred for 2 - 48 hours at 20 - 60 °C. The 
reaction was quenched by addition of saturated sodium bicarbonate solution 
(5 mL/mmol) and stirred for additional 30 minutes at room temperature. The 
mixture was extracted with ethyl acetate (3 x 20 mL) and the combined organic 
phases were dried over MgSO4. All volatile compounds were removed in vacuo
and the crude product was further dried in high vacuum before being analyzed 
by NMR spectroscopy. If necessary, the crude product was purified by column 
chromatography or distillation, respectively. 
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Table 41. Substrate synthesis of O-protected diethyl 3-hydroxyglutarates
Entry R X Cat. (mol%)
Time 
[h]
Temp. 
[ °C]
Conv.
[%]a
Yield
[g (%)]
1 Ac OAc
Zn(ClO4)2
(0.1)
2 20 >95.0
0.84 
(85.3)
2 Boc OBoc
Zn(OAc)2
(10.0)
6 60 >95.0
1.11 
(91.2)
3 TFA OTFA
Zn(ClO4)2
(1.0)
2 20 >95.0
1.07 
(89.1)
4 PhAc Cl - 16 0-20 >95.0
5.30 
(82.2)
5 MeOAc Cl
Pyridine 
(110)
24 0-20 92.1
3.54 
(64.0)
6 TBS Cl 1H-imidazole 24 20 >95.0
0.58 
(36.4)
7 THP - PPTS 21 20 >95.0
1.68 
(58.3)
(a) Determined by integration of 1H-NMR signals for 3-DHG and products.
8.1.1 DIETHYL 3-(ACETYL)-OXYGLUTARATE
The synthesis was conducted according to BARTOLI et al..120 A mixture of zinc 
perchlorate hexahydrate (1.5 mg, 0.004 mmol, 0.1 mol%) and acetic anhydride 
(397 μL, 4.2 mmol, 1.05 eq.) was mixed with diethyl 3-hydroxyglutarate (741 μL, 
4.0 mmol) and stirred for two hours at room temperature. The work-up was 
done as described in SOP1. The crude product was obtained as colorless oil 
and used without further purification.
Isolated yield: 0.84 g (3.41 mmol, 85.3 %).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 5.51 (m, 1H, CH-O), 4.13 (dq, J = 7.2 Hz, 
4H, O-CH2-CH3), 2.69 (d, J = 6.3 Hz, 4H, CH2-CH-CH2), 2.02 (s, 3H, C(=O)-CH3), 
1.24 (t, J = 7.2 Hz, 6H, CH2-CH3).
13C-NMR (125 MHz, CDCl3): δ [ppm] = 170.06 (1C, (O=)C-CH3), 170.00 (2C, 
CO2Et), 67.06 (1C, CH-OAc), 60.93 (2C, O-CH2-CH3), 38.60 (2C, CH2-CH-CH2), 
21.07 (1C, (O=)C-CH3) 14.28 (2C, CH2-CH3). 
The data corresponds to literature-known values.121
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Table 42. Scale-up for the synthesis of diethyl 3-(acetyl)-oxyglutarate
Entry
Amount DHG
[mmol]
Conversion
[%]
Isolated yield
[g (%)]
1 4.00 >95.0 0.84 (85.0)
2 20.0 >95.0 4.70 (95.4)
3 200 >95.0 43.4 (88.1)
4 500 >95.0 111 (90.5)
8.1.2 DIETHYL 3-(TERT-BUTYLOXYCARBONYL)-OXYGLUTARATE
The synthesis was conducted according to BARTOLI et al..120 Diethyl 3-hydroxy-
glutarate (741 μL, 4.00 mmol) and boc anhydride (916.7 mg, 4.2 mmol, 1.05 eq.)
were mixed. After addition of zinc acetate dihydrate (87.8 mg, 0.4 mmol, 0.10 
eq.) the mixture was stirred for six hours at 60 °C. The work-up was conducted 
as described in SOP1. The crude product was obtained as colorless oil and used 
without further purification.
Isolated yield: 1.11 g (3.65 mmol, 91.2 %).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 5.36 (m, 1H, CH-O), 4.19 – 4.09 (m, 4H, 
O-CH2-CH3), 2.71 – 2.70 (m, 4H, CH2-CH-CH2), 1.47 (s, 9H, C-(CH3)3), 1.25 (t, 
J = 7.2 Hz, 6H, CH2-CH3).
13C-NMR (125 MHz, CDCl3): δ [ppm] = 169.89, 152.56, 82.70, 69.77, 60.95, 
38.76, 27.86, 14.26.
The compound is unknown to literature.
8.1.3 DIETHYL 3-(TRIFLUORACETYL)-OXYGLUTARATE
The synthesis was conducted according to BARTOLI et al120. Diethyl 3-
hydroxyglutarate (741 μL, 4.0 mmol) and trifluoroacetic anhydride (584 μL, 4.2 
mmol, 1.05 eq.) were mixed. After the addition of zinc perchlorate hexahydrate 
(14.9 mg, 0.04 mmol, 0.01 eq.) the mixture was stirred for two hours at room 
temperature. The work-up was done as described in SOP1. The crude product
was obtained as colorless oil and used without further purification.
Isolated yield: 1.07 g (3.56 mmol, 89.1%).
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1H-NMR (500 MHz, CDCl3): δ [ppm] = 5.75 (m, 1H, CH-O), 4.20 – 4.14 (m, 4H, 
O-CH2-CH3), 2.80 (d, J = 6.6 Hz, 4H, CH2-CH-CH2), 1.25 (t, J = 7.3 Hz, 6H, CH2-
CH3).
13C-NMR (125 MHz, CDCl3): δ [ppm] = 169.10, 156.54, 114.50, 71.05, 61.50, 
38.23, 14.25.
The compound is unknown to literature.
8.1.4 DIETHYL 3-(PHENYLACETYL)-OXYGLUTARATE
The synthesis was conducted according to BARTOLI et al120. Diethyl 3-
hydroxyglutarate (741 μL, 4.0 mmol) and phenylacetyl chloride (555 μL, 4.2 
mmol, 1.05 eq.) were mixed at 0-4 °C. The mixture was stirred for 16 hours 
while thawing up to room temperature. The work-up was done as described in 
SOP1. The crude product was obtained as a colorless oil and used without 
further purification.
Isolated yield: 5.30 g (16.4 mmol, 82.2%).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 7.32-7.24 (m, 5H, Ar-H), 5.53 (m, 1H, CH-
O), 4.10-4.07 (m, 4H, O-CH2-CH3), 3.59 (s, 2H, CH2-Ph), 2.69 (d, 4H, J = 6.3 Hz, 
CH2-CH-CH2), 1.20 (t, 6H, J = 7.1 Hz, CH2-CH3).
The compound is unknown to literature.
8.1.5 DIETHYL 3-(METHOXYACETYL)-OXYGLUTARATE
The synthesis was conducted according to a procedure of ÖHRLEIN and 
BAISCH122. Diethyl 3-hydroxyglutarate (3.70 ml, 20.0 mmol) was diluted with 
dichloromethane (1 mL) and cooled to 0-4 °C. Pyridine (1.78 ml, 22.0 mmol, 1.1 
eq.) and methoxyacetyl chloride (2.00 ml, 22.0 mmol, 1.1 eq.) were added
dropwise. The mixture was brought to room temperature and further stirred for 
12 hours. The reaction was quenched by the addition of ethyl acetate (20 mL) 
and saturated sodium bicarbonate solution. The phases were separated and 
the organic phase was washed once with each hydrochloric acid (1N), saturated 
bicarbonate solution and brine. After drying over MgSO4 the solvent and all 
volatile compounds were removed in vacuo. The crude product was purified by 
distillation (0.15 mbar, 126-128 °C) to obtain the product as colorless oil.
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Isolated yield: 3.54 g (12.8 mmol, 64.0%).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 5.63 (m, 1H, CH-O), 4.15 (q, 4H, J = 7.2 
Hz, O-CH2-CH3), 4.00 (s, 2H, CH2-O-CH3), 3.43 (s, 3H, CH2-O-CH3), 2.73 (d, 4H,
J = 6.3 Hz, CH2-CH-CH2), 1.26 (t, 6H, J = 7.2 Hz, CH2-CH3).
13C-NMR (125 MHz, CDCl3): δ [ppm] = 169.65, 169.33, 69.64, 67.41, 60.90, 
59.36, 38.45, 14.15.
The data corresponds to literature-known values.123
8.1.6 DIETHYL 3-(TERT-BUTYLDIMETHYLSILYL)-OXYGLUTARATE
The synthesis was conducted based on a procedure of HEATHCOCK et al.124
Diethyl 3-hydroxyglutarate (974 μL, 5.0 mmol) and 1H-imidazole (0.51 g, 7.5 
mmol, 1.5 eq.) were dissolved in THF (15 mL). After addition of
tert-butyldimethylchlorosilane (0.83 g, 5.5 mmol, 1.1 eq.) the suspension was 
stirred for 24 hours at room temperature. The work-up was conducted 
according to SOP1. The crude product was analyzed by NMR spectroscopy and 
shows quantitative conversion. The crude product was purified by column 
chromatography on silica (15% v/v ethyl acetate in cyclohexane) to obtain a 
colorless oil.
Isolated yieldi: 0.58 g (1.82 mmol, 36.4%).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 4.55 (m, 1H, CH-O), 4.16-4.11 (m, 4H, O-
CH2-CH3), 2.54 (dd, 4H, J = 6.1 Hz, CH2-CH-CH2), 1.26 (t, 6H, J = 7.2 Hz, CH2-
CH3), 0.85 (s, 9H, C-(CH3)3), 0.07 (s, 6H, Si-CH3).
13C-NMR (125 MHz, CDCl3): δ [ppm] = 171.10, 66.39, 60.49, 42.65, 25.67, 17.91, 
14.19, -4.89.
The data corresponds to literature-known values.124
8.1.7 DIETHYL 3-(TETRAHYDROPYRAN-2-YL)-OXYGLUTARATE
Pyridinium p-toluenesulfonate (0.25 g, 1.00 mmol, 0.1 eq.) was added to a 
solution of diethyl 3-hydroxyglutarate (2.04 g, 10.0 mmol) and dihydropyrane 
i Following fractions were contaminated with different contents of silanol and therefore 
discarded.
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(1.26 g, 15.0 mmol, 1.5 eq.) in dichloromethane (70 mL). The mixture was stirred 
for 21 hours at room temperature. The reaction was quenched with addition of 
a saturated sodium bicarbonate solution (50 mL). The phases were separated 
and the aqueous phase was extracted with dichloromethane (3x 50 mL). The 
combined organic phase was dried over MgSO4 and all volatile compounds
were removed in vacuo. The crude extract was purified by column 
chromatography (10% v/v ethyl acetate in cyclohexane) to obtain the product 
as colorless oil.
Isolated yield: 1.68 g (5.83 mmol, 58.3%).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 4.48 (m, 1H, CH-O), 4.13 (m, 5H, O-CH2-
CH3, O-CH-O), 3.38-3.88 (m, 2H, H2C-CH2-O), 2.54-2.82 (m, 4H, CH2-CH-CH2), 
1.51-186 (m, 6H, CH2-CH2-CH2), 1.26 (dt, J = 7.1 Hz, 6H, CH2-CH3).
The data corresponds to literature-known values.125
8.2 STANDARD OPERATING PROCEDURE 2 (SOP2): COLORIMETRIC 
SCREENING ASSAY OF HYDROLASES FOR THE DESYMMETRIZATION OF 
O-PROTECTED DIETHYL 3-HYDROXYGLUTARATES
The colorimetric assay was based on an already published acid-base-assay 
from BAUMANN126. A solution of a hydrolase (180 μL, 1 mg/mL) in KPB (pH 7.3, 
50 mM) was pipetted into a 96-well-plate. The corresponding substrate (20 μL,
20 mM in DMSO containing 0.75 M bromothymol blue) was added and the 
resulting color changes observed by time-dependent measurement in a plate 
reader at 418 nm and 626 nm, respectively. The obtained values were 
compared with hydrolase solutions (180 μL, 1 mg/mL) without substrate 
containing bromothymol blue (20 μL, 0.75 M in DMSO) and with substrate 
solutions in the absence of biocatalyst.
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Table 43. Photometric assay for potential hydrolases in the 
desymmetrisation of TBS-DHG
Hydrolase
Activity (Abs) Rel. activity
DHG TBS-DHG DHG TBS-DHG
α-Chymotrypsin 
(Biozym CHY-03)
0.106 0.131 100% 100%
Alcalase CLEA 0.101 0.067 95% 51%
Protease from Rhizopus sp. 0.097 0.080 92% 61%
Protease from Aspergillus sp. 0.082 0.074 77% 56%
Amano Acylase 0.079 0.094 75% 72%
Protease from Aspergillus saitoi 0.023 0.031 22% 24%
α-Chymotrypsin 
(AppliChem Grade I)
0.028 0.048 26% 37%
Protease S from 
Pyrococcus furiosus
0.051 0.089 48% 68%
Protease from Aspergilus oryzae 0.053 0.053 50% 40%
Protease from
Bacillus licheniformis
0.016 0.018 15% 14%
α-Chymotrypsin 
(AppliChem Grade II)
0.034 0.053 32% 40%
Protease from bovine pancreas 0.075 0.166 71% 127%
α-Chymotrypsin (Amresco) 0.016 0.021 15% 16%
Pronase 0.062 0.042 58% 32%
Protease from Bacillus sp. 0.024 0.014 23% 11%
Protease from 
B. amyloliquefaciens
0.087 0.171 82% 131%
8.3 STANDARD OPERATING PROCEDURE 3 (SOP3): PREPARATIVE 
DESYMMETRIZATION OF DHG AND ITS O-PROTECTED DERIVATIVES BY 
THE USE OF HYDROLASES
An adequate amount of hydrolase (1.6 – 18 kU/mmol) was dissolved in KPB (pH 
8.0, 50mM) to reach the desired substrate concentration (0.05 – 6.00 M) and 
titrated with aqueous sodium hydroxide solution (2.0 N) to pH 8.0. After 
addition of the corresponding amount of DHG or its O-protected derivatives 
the resulting emulsion was stirred vigorously at room temperature. The 
progress of the reaction was monitored by the volume of titer (aq. sodium 
hydroxide) consumed to neutralize the free carboxylic acid and maintaining pH 
8.0. After reaching the end of the reaction the solution was acidified (pH 1-2) 
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with hydrochloric acid (12 N) and extracted with ethyl acetate (3x 1:1 v/v). The 
combined organic phases were dried over MgSO4 and all volatile compounds
were removed in vacuo. The conversion was determined witH-NMR 
spectroscopy. Unless otherwise stated the crude extract was further used 
without purification.
8.3.1 (3R)- 5-ETHOXY-3-HYDROXY-5-OXOPENTANOIC ACID
The synthesis was conducted according to SOP3. A solution of α-chymotrypsin 
(2.50 g, Biozym CHY-03) in KPB (50.0 mL, 50mM, pH 8.0) was titrated with 
aqueous sodium hydroxide solution (1.0M) to pH 8.0. After addition of diethyl 
3-hydroxyglutarate (9.26 mL, 50.0 mmol) to reach a substrate concentration of 
1.0 M the resulting emulsion was vigorously stirred for 48 hours at room 
temperature. The progress of the reaction was monitored by the volume of 
titer (1.0 M sodium hydroxide) consumed to neutralize the free carboxylic acid 
and maintaining pH 8.0. The work-up was conducted as described in SOP3. 
Yield: 6.65 g (37.7 mmol, 75.4 %).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 4.47 (m, 1H, CH-OH), 4.18 (q, 2H, J = 7.2 
Hz, O-CH2-CH3), 2.62 – 2.54 (m, 4H, CH2-CH-CH2), 1.28 (t, 3H, J = 7.1 Hz, CH2-
CH3).
The data corresponds to literature-known values.127
Table 44. Scale-up for the synthesis of (3R)-5-ethoxy-3-hydroxy-5-oxo-
pentanoic acid
Entry
Substrate
[mmol]
Biocatalyst
[mg]
Sub. 
conc.
[M]
Conversion
[%]
Yield
[g (%)]
1 50.0 2500 1.00 >95 6.65 (75.4)
2 100 7500 2.00 >95 8.73 (49.5)
3 100 7500 2.00 >95 9.65 (54.8)
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8.3.2 (3R)-5-ETHOXY-3-(ACETYL)-OXY-5-OXOPENTANOIC ACID
The synthesis was conducted according to SOP3. A solution of α-chymotrypsin 
(300 mg, Biozym CHY-03) in KPB (10.0 mL, 50 mM, pH 8.0) was titrated with 
aqueous sodium hydroxide solution (4.0 M) to pH 8.0. After addition of diethyl 
3-(acetyl)-oxyglutarate (9.85 g, 40.0 mmol) to reach a substrate concentration 
of 4.0 M the resulting emulsion was vigorously stirred for 6-24 hours at room 
temperature. The progress of the reaction was monitored by the volume of 
titer (4.0 M sodium hydroxide) consumed to neutralize the free carboxylic acid 
and maintaining pH 8.0. The work-up was done as described in SOP3.
Yield: 9.12 g (91% product contenti, 38.2 mmol, 95.4 %).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 5.50 (m, 1H, CH-O), 4.16 (q, 2H, J = 7.2 
Hz, O-CH2-CH3), 2.79 (dd, 2H, J = 6.0 Hz, CH2-COOH), 2.72 (d, 2H, J = 6.3 Hz, 
CH2-COOEt), 2.05 (s, 1H, (O=)C-CH3), 1.26 (t, 6H, J = 7.1 Hz, CH2-CH3).
13C-NMR (126 MHz, CDCl3): δ [ppm] = 175.13, 170.08, 169.84, 66.56, 60.93, 
38.29, 37.93, 20.95, 14.15.
The data corresponds to literature-known values.121
Table 45. Scale-up for the synthesis of (3R)-(acetyl)-oxy-5-ethoxy-5-oxo-
pentanoic acid
Entry
Substrate
[mmol]
Biocatalyst
[mg]
Sub. 
conc.
[M]
Conversion
[%]
Yield
[g(%)]
1 15.0 49.3 1.00 >95 3.37 (97.2)
2 40.0 300 4.00 >95 9.12 (95.5)
3 50 2500 5.00 >95 8.58 (78.6)
4 60 2500 6.00 >95 9.91 (75.7) 
5 100 7500 2.00 >95 21.8 (95.4)
i Determined by quantitative NMR integration against internal standard (see chapter 2.4.3, page 
16).
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8.3.3 (3R)-5-ETHOXY-3-(METHOXYACETYL)-OXY-5-OXOPENTANOIC ACID
The synthesis was conducted according to SOP3. A solution of α-chymotrypsin 
(100 mg, Biozym CHY-03) in KPB (10.0 mL, 50mM, pH 8.0) was titrated with 
aqueous sodium hydroxide solution (1.0M) to pH 8.0. After addition of diethyl 
3-(methoxyacetyl)-oxyglutarate (2.76 g, 10.0 mmol) to reach a substrate 
concentration of 1.0 M the resulting emulsion was vigorously stirred for 6-24 
hours at room temperature. The progress of the reaction was monitored by the 
volume of titer (1.0 M sodium hydroxide) consumed to neutralize the free
carboxylic acid and maintaining pH 8.0. The work-up was done as described in 
SOP3. NMR analysis shows a conversion of >95% (74% product-related, 21% 
hydrolysis of methoxyacetyl ester).
Yield: 2.09 g (74% product contenti, 6.23 mmol, 62.3%).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 5.64 (m, 1H, CH-O), 4.17 (q, 2H, J = 7.1 Hz, 
O-CH2-CH3), 4.04 (s, 2H, CH2-O-CH3), 3.45 (s, 3H, O-CH3), 2.84 (d, 2H, J = 6.3 Hz, 
CH2-COOH), 2.77 (d, 2H, J = 6.3 Hz, CH2-COOEt), 1.28 (t, 3H, J = 7.2 Hz, CH2-
CH3).
The data corresponds to literature-known values.128
8.3.4 (3S)-5-ETHOXY-3-HYDROXY-5-OXOPENTANOIC ACID
The synthesis was conducted according to SOP3. Candida antarctica lipase B 
(350 mg, immobilized on acrylic resin) was suspended in KPB (15.0 mL, 50 mM, 
pH 8.0) and titrated with aqueous sodium hydroxide solution (1.0 M) to pH 8.0. 
After addition of diethyl 3-hydroxyglutarate (2.04 g, 10.0 mmol) to reach a
substrate concentration of 0.7 M the resulting heterogeneous mixture was 
vigorously stirred for two hours at room temperature. The progress of the 
reaction was monitored by the volume of titer (1.0 M sodium hydroxide) 
consumed to neutralize the free carboxylic acid and maintaining pH 8.0. The 
work-up was conducted as described in SOP3. NMR analysis shows 
quantitative conversion. The product was used without further purification.
Isolated yield: 643 mg (3.65 mmol, 36.5%).
i Determined by quantitative NMR integration after identification of all impurities.
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1H-NMR (500 MHz, CDCl3): δ [ppm] = 4.47 (m, 1H, CH-OH), 4.18 (q, 2H, J = 7.2 
Hz, O-CH2-CH3), 2.62 – 2.54 (m, 4H, CH2-CH-CH2), 1.28 (t, 3H, J = 7.1 Hz, CH2-
CH3).
The data corresponds to literature-known values.129
8.4 (3S)-5-ETHOXY-3-(ACETYL)-OXY-5-OXOPENTANOIC ACID
Acetic anhydride (3.96 mL, 42.0 mmol, 2.1 eq.) and zinc perchlorate 
hexahydrate (14.9 mg, 0.04 mmol, 0.002 eq.) were mixed and stirred for 
10 minutes at room temperature. After the addition of (3S)-5-ethoxy-3-
hydroxy-5-oxopentanoic acid (3.52 g, 20.0 mmol) the solution was vigorously 
stirred for four hours at room temperature. A saturated sodium bicarbonate 
solution (50 mL) was added to hydrolyze the excess of anhydride. The solution
was stirred for another 30 minutes and extracted with ethyl acetate (3x 50 mL). 
The organic layer was dried over MgSO4 and all volatile compounds were 
removed in vacuo to obtain the product as colorless oil.
Isolated yield: 3.46 g (15.9 mmol, 79.3 %).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 5.50 (m, 1H, CH-O), 4.16 (q, 2H, J = 7.2 
Hz, O-CH2-CH3), 2.79 (dd, 2H, J = 6.0 Hz, CH2-COOH), 2.72 (d, 2H, J = 6.3 Hz, 
CH2-COOEt), 2.05 (s, 1H, (O=)C-CH3), 1.26 (t, 6H, J = 7.1 Hz, CH2-CH3).
13C-NMR (126 MHz, CDCl3): δ [ppm] = 175.13, 170.08, 169.84, 66.56, 60.93, 
38.29, 37.93, 20.95, 14.15.
The data corresponds to literature-known values.121
8.5 STANDARD OPERATING PROCEDURE 4 (SOP4): PREPARATIVE 
DESYMMETRIZATION BY LIPASE-CATALYZED AMINOLYSIS OF DIETHYL 
3-HYDROXYGLUTARATE
The synthesis was conducted based on a procedure by SÁNCHEZ et al..130
Candida antarctica lipase B (immobilized on acrylic resin) was suspended in an 
adequate solvent (10 mL) or the corresponding amine itself. Diethyl 3-
hydroxyglutarate (2.00 – 10.0 mmol) and the primary or secondary amine 
(1.00 – 50.0 eq.) were added and the suspension was stirred for 24 hours at 20-
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60 °C. The biocatalyst was filtered off and washed with the same solvent or 
dichloromethane (2x 10 mL). The filtrate was concentrated in vacuo and the 
crude product was purified by column chromatography or recrystallization, 
respectively. 
Table 46. Lipase-catalyzed aminolysis of DHG with various primary and 
secondary amines
Entry R1 R2
DHG
[mmol]
CAL-B
[mg]
Temp.
[ °C]
Solvent
Conv.
[%]
Yield
[g (%)]
1 H Bn 2.00 180 20 Dioxane >95
0.52
(98.9)
2 H Bn 2.00 180 20 THF >95
0.47
(89.3)
3 H Bn 2.00 180 20 MTBE >95
0.49
(93.1)
4 H Bn 2.00 180 20 Toluene 84.0 n.d.
5 H Bn 10.0 907 20 MTBE >95
2.20 
(83.1)
6 Me Bn 10.0 900 reflux MTBE 7.2
0.16 
(5.6)
6 Et Et 2.00 180 reflux MTBE 0 -
7 morpholine 10.0 900 reflux MTBE n.d.
0.86
(35.0)
8 pyrrolidine 5.00 110 20 MTBE 55.9 n.d.
9 piperidine 5.00 113 reflux MTBE 32.0 n.d.
8.5.1 ETHYL (3S)-5-(N-BENZYLAMINO)-3-HYDROXY-5-OXOPENTANOATE
The synthesis was conducted according to SOP4. To a suspension of Candida 
antarctica lipase B (907 mg, immobilized on acrylic resin) in MTBE (30 mL) were 
added benzylamine (1.10 mL, 10.0 mmol, 1.00 eq.) and diethyl 3-
hydroxyglutarate (1.86 mL, 10.0 mmol) in the given order. The mixture was 
stirred for 17 hours at room temperature. The biocatalyst was filtered off and 
washed with MTBE (3 x 30 mL). The filtrate was concentrated in vacuo and the 
crude product recrystallized in MTBE to obtain a colorless solid. The 
enantiomeric excess could not be determined yet.
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Isolated yield: 2.20 g (8.31 mmol, 83.1 %).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 7.33-7.25 (m, 5H, Ar-H), 6.67 (s, 1H, n-H), 
4.43-4.37 (m, 3H, CH-O, CH2-Ph), 4.14 (q, 2H, J = 7.1 Hz, O-CH2-CH3), 2.55-2.38 
(m, 4H, CH2-CH-CH2), 1.26 (t, 3H, J = 7.1 Hz, CH2-CH3).
13C-NMR (125 MHz, CDCl3): δ [ppm] = 172.12, 171.23, 138.07, 128.71, 127.69, 
127.51, 65.31, 60.85, 34.44, 42.02, 40.85, 14.15
.
The data corresponds to literature-known values.131
8.5.2 ETHYL (3S)-5-(N-BENZYL-N-METHYLAMINO)-3-HYDROXY-5-OXO-
PENTANOATE
The synthesis was conducted according to SOP4. To a suspension of Candida 
antarctica lipase B (900 mg, immobilized on acrylic resin) in MTBE (10 mL) were 
added n-benzylmethylamine (1.30 mL, 10.0 mmol, 1.00 eq.) and 
diethyl 3-hydroxy-glutarate (1.86 mL, 10.0 mmol) in the given order. The 
mixture was stirred for 17 hours at 60 °C. The biocatalyst was filtered off and 
washed with MTBE (3x 30 mL). The filtrate was concentrated in vacuo and the 
crude product was purified via column chromatography (50-100% v/v ethyl 
acetate in cyclohexane) to obtain a 3:2 E/Z-mixture as yellow oil. The 
enantiomeric excess could not be determined.
Isolated yield: 157 mg (0.56 mmol, 5.6%).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 7.45 – 7.13 (m, 10H, Ar-H), 4.68 – 4.58 (d,
J = 3.2 Hz, 2H, n-CH2-Ph), 4.57 – 4.48 (m, 2H, CH-OH), 4.46 – 4.43 (dd, J = 5.9, 
3.4 Hz, 2H, n-CH2-Ph), 4.22 – 4.17 (q, J = 7.1 Hz, 2H, O-CH2-CH3), 4.17 – 4.12 (q,
J = 7.2 Hz, 2H, O-CH2-CH3), 3.03 – 2.96 (s, 3H, n-CH3), 2.96 – 2.89 (s, 3H, n-CH3), 
2.76 – 2.46 (m, 8H, CH2-CH-CH2), 1.32 – 1.28 (t, J = 7.2 Hz, 3H, CH2-CH3), 1.28 –
1.23 (t, J = 7.1 Hz, 3H, CH2-CH3).
13C NMR (125 MHz, CDCl3): δ [ppm] = 172.31, 171.98, 171.61, 171.53, 136.81, 
135.95, 129.04, 128.73, 128.69, 127.96, 127.80, 127.71, 127.52, 126.26, 65.29, 
65.28, 65.18, 60.87, 60.63, 60.60, 53.19, 50.66, 43.48, 41.99, 40.97, 40.71, 38.84, 
38.42, 34.74, 33.77, 14.20, 14.16.
The compound is unknown to literature.
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8.5.3 ETHYL (3S)-HYDROXY-5-(N-MORPHOLINO)-5-OXOPENTANOATE
The synthesis was conducted according to SOP4. To a suspension of Candida 
antarctica lipase B (900 mg, immobilized on acrylic resin) in MTBE (10 mL) were 
added morpholine (0.87 mL, 10.0 mmol, 1.00 eq.) and diethyl 3-
hydroxyglutarate (1.86 mL, 10.0 mmol) in the given order. The mixture was 
stirred for 17 hours at reflux temperature. The biocatalyst was filtered off and 
washed with MTBE (3x 10 mL). The filtrate was concentrated in vacuo and the 
crude product was purified by column chromatography on alkaline aluminum 
oxide (50-100 % v/v ethyl acetate in cyclohexane) to obtain a colorless solid. 
The enantiomeric excess could not be determined.
Isolated yield: 0.860 g (3.50 mmol, 35.0%).
1H-NMR (CDCl3, 500 MHz): δ [ppm] = 4.52 – 4.41 (m, 1H, CH-O), 4.18 – 4.12 
(m, 2H, O-CH2-CH3), 3.72 – 3.46 (m, 8H, CH2-CH-CH2, n-CH2-CH2), 2.66 – 2.36 
(m, 4H, N-CH2-CH2), 1.28 (t, 3H, J = 7.2 Hz, CH2-CH3).
13C-NMR (CDCl3, 125 MHz): δ [ppm] = 171.6, 170.3, 66.8, 66.5, 65.0, 60.6, 45.9, 
41.7, 41.0, 38.5, 14.2. 
The data corresponds to literature-known values.131
8.5.4 ETHYL (3S)-HYDROXY-5-(N-PYRROLIDINO)-5-OXOPENTANOATE
The synthesis was conducted according to SOP4. To a suspension of Candida 
antarctica lipase B (110 mg, immobilized on acrylic resin) in MTBE (10 mL) were 
added pyrrolidine (418 μL, 5.0 mmol, 1.00 eq.) and diethyl 3-hydroxyglutarate 
(1.0 mL, 5.0 mmol) in the given order. The mixture was stirred for 12 hours at 
room temperature. The biocatalyst was filtered off and washed with MTBE (3 x 
10 mL). The filtrate was concentrated in vacuo and the crude product was 
analyzed by NMR spectroscopy. The crude product was partially purified by a 
silica filtration (MTBE) and analyzed by chiral HPLC (Daicel ChiralPak AD-H, 91:9 
SC-CO2/IPA, 0.7 mL/min, 216 nm, 10 MPa back pressure) to determine an 
enantiomeric excess of 59.1% ee.
Conversion: 55.9 %.
1H-NMR (300 MHz, CDCl3): δ [ppm] = 4.51 – 4.40 (m, 1H, CH-OH), 4.15 (q,
J = 7.1 Hz, 2H, O-CH2-CH3), 3.51 – 3.35 (m, 4H, CH2-N-CH2), 2.69 – 2.35 (m, 4H, 
CH2-CH-CH2), 2.03 – 1.80 (m, 4H, CH2-CH2), 1.31 – 1.22 (m, 3H, CH2-CH3). 
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13C-NMR (75 MHz, CDCl3): δ [ppm] = 170.75, 169.61, 64.43, 59.69, 45.98, 44.83, 
40.57, 39.37, 25.23, 23.65, 13.50.
The data corresponds to literature-known values.131
8.5.5 ETHYL (3S)-HYDROXY-5-(N-PIPERIDINO)-5-OXOPENTANOATE
The synthesis was conducted according to SOP1. To a suspension of Candida 
antarctica lipase B (113 mg, immobilized on acrylic resin) in MTBE (10 mL) was 
added piperidine (495 μL, 5.0 mmol, 1.00 eq.) and diethyl 3-hydroxyglutarate 
(1.0 mL, 5.0 mmol) in the given order. The mixture was stirred for four hours at 
reflux temperature. The biocatalyst was filtered off and washed with MTBE (3x 
10 mL). The filtrate was concentrated in vacuo and the crude product analyzed 
by NMR spectroscopy. The enantiomeric excess could not be determined yet.
Conversion: 32.0%
1H-NMR (300 MHz, CDCl3): δ [ppm] = 4.45 (m, 1H, CH-OH), 4.15 (q, J = 7.2, 2H, 
O-CH2-CH3), 3.62 – 3.47 (m, 2H, n-CH2), 3.40 – 3.33 (m, 2H, n-CH2), 2.54 (m, 4H, 
CH2-CH-CH2), 1.64 – 1.49 (m, 6H, CH2-CH2-CH2), 1.26 (t, J=7.1, 3H, CH2-CH3). 
13C-NMR (75 MHz, CDCl3): δ [ppm] = 171.2, 169.5, 64.8, 60.2, 46.1, 42.1, 40.7, 
38.1, 26.0, 25.2, 24.0, 13.8.
The data corresponds to literature-known values.131
8.6 STANDARD OPERATING PROCEDURE 5 (SOP5): DETERMINATION OF 
AN ENANTIOMERIC EXCESS OF CHIRAL CARBOXYLIC ACIDS BY 
COUPLING WITH ENANTIOPURE (R)- AND (S)-1-PHENYLETHYLAMINE
The desymmetrized monoester (2.00 mmol) and triethylamine (4.00 mmol, 2.0
eq.) were dissolved in ethyl acetate (10 mL) and cooled to 0-4 °C. Subsequently, 
enantiopure (R)- or (S)-1-phenylethylamine (2.00 mmol, 1.00 eq.) and 
tris-n-propylphosphonic anhydride (T3P, 2.30 mmol, 1.15 eq.) were added
dropwise and in the given order. The mixture was stirred at 0-20 °C and the 
progress of reaction was monitored via TLC. The reaction was quenched with 
addition of saturated sodium bicarbonate solution and stirring for additional 
10 minutes at room temperature. After separation of the phases the aqueous 
phase was extracted with ethyl acetate (2x 10 mL) and the combined organic 
phase was washed once with hydrochloric acid (0.5 M, 30 mL), saturated 
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sodium bicarbonate solution (30 mL) and brine (30 mL). After drying over 
MgSO4 all volatile compounds were removed in vacuo. The crude product was 
used without further purification and analyzed by NMR and chiral HPLC. The 
enantiomeric excess of the previous desymmetrization was determined by the 
diastereomeric excess of the corresponding 1-phenylethylamide.
Table 47. Determination of the enantiomeric excess by derivatization to a 
diastereomeric amide
Entry Description / additive
Conv.
[%]
de
[%]
STDEV 
de [+- %]
1 Benchmark DHG >95 60.7 0.4
2 Benchmark 3-acetyl-DHG (1.0M) >95 97.6 0.6
3 1.2M sodium acetate >95 97.6 1.0
4 1.2M sodium chloride >95 98.1 0.4
5 2.4M sodium acetate >95 96.8 0.2
6 0.1 mol% zinc perchlorate >95 97.0 0.1
7 3-Acetyl-DHG (2.0M) >95 97.1 0.5
8 1.0M ammonium sulfate >95 97.3 0.0
9 Reaction medium: dest. H2O >95 96.0 0.9
10 Purified α-chymotrypsin (fraction 1) >95 97.0 n.d.
11 Purified α-chymotrypsin (fraction 2) >95 97.2 n.d.
12 Purified α-chymotrypsin (fraction 3) >95 97.5 n.d.
13 3-Acetyl-DHG (3.0M) >95 96.8 n.d.
14 3-Acetyl-DHG (4.0M) >95 96.7 n.d.
15 Chymotrypsin / Trypsin 1:1 >95 96.8 n.d.
8.6.1 (3R,1’R)-ETHYL 5-(N-(1-PHENYLETHYL)AMINO)-3-(ACETYL)-OXY-5-
OXOPENTANOATE
The synthesis was conducted according to SOP5. A solution of 
(3R)-5-ethoxy-3-(acetyl)-oxy-5-oxopentanoic acid  (436 mg, 2.00 mmol) and 
triethylamine (558 μL, 4.00 mmol, 2.0 eq.) in ethyl acetate (10 mL) was cooled 
HPLC method:
Column: Daicel ChiralPak OJ-H
Eluent: SC-CO2/2-PrOH 95:5 v/v
Back pressure: 10 MPa
Flowrate: 0.8 mL/min
Detection wavelength: 208 nm
Column temperature: 20 °C
Sample concentration: 2 mg/mL
Injection volume: 10 μL
Rt: 14.0 min (3R,7R), 15.5 min (3S,7R)
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to 0-4 °C. Subsequently, (R)-1-phenylethylamine (318 μL, 2.00 mmol, 1.00 eq.) 
and tris-n-propylphosphonic anhydride (T3P, 50 wt-% in EtOAc, 1.45 mL, 2.30 
mmol, 1.15 eq.) were added dropwise and in the given order. The mixture was 
stirred at 0-20 °C and the progress of reaction was monitored via TLC. The 
work-up was done as described in SOP5. The crude product was analyzed by 
chiral HPLC and showed an enantiomeric excess of 98.1+- 0.4% ee. The 
product was purified by a short column chromatography on silica (MTBE) to 
obtain a colorless solid.
Isolated yield: 592 mg (1.84 mmol, 92.1%).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 7.38 – 7.22 (m, 5H, Ar-H), 6.02 (d, 1H,
J = 8.0 Hz, n-H), 5.45 (m, 1H, CH-O), 5.12 (m, 1H, CH-NH), 4.13 (qd, J = 7.2, 6.1 
Hz, 2H, O-CH2-CH3), 2.78 (dd, J = 15.9, 5.4 Hz, 1H, HN-CO-CH2a), 2.64 (dd,
J = 15.9, 6.8 Hz, 1H, HN-CO-CH2b), 2.58 (d, J = 6.3 Hz, 2H, O-CO-CH2), 1.98 (s, 
3H, CO-CH3), 1.49 (d, J = 6.9 Hz, 3H, CH-CH3), 1.25 (t, J = 7.1 Hz, 3H, CH2-CH3).
The data corresponds to literature-known values.132
8.6.2 (3R,1’S)-ETHYL 5-(N-(1-PHENYLETHYL)AMINO)-3-(ACETYL)-OXY-5-
OXOPENTANOATE
The synthesis was conducted according to SOP5. A solution of 
(3R)-5-ethoxy-(acetyl)-oxy-5-oxopentanoic acid  (436 mg, 2.00 mmol) and 
triethylamine (558 μL, 4.00 mmol, 2.0 eq.) in ethyl acetate (10 mL) was cooled 
to 0-4 °C. Subsequently, (R)-1-phenylethylamine (318 μL, 2.00 mmol, 1.0 eq.) 
and tris-n-propylphosphonic anhydride (T3P, 50w% in EtOAc, 1.45 mL, 2.30 
mmol, 1.15 eq.) were added dropwise and in the given order. The mixture was 
stirred at 0-20 °C and the progress of reaction was monitored via TLC. The 
work-up was done as described in SOP5. The crude product was analyzed by 
chiral HPLC and showed an enantiomeric excess of 97.6+- 0.6% ee. The 
product was purified by recrystallization (n-hexane/2-propanol 1:1 v/v) to 
obtain a colorless solid.
Isolated yield: 487 mg (1.52 mmol, 75.8%).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 7.38 – 7.22 (m, 5H, Ar-H), 6.02 (d,
J = 8.0 Hz, 1H, NH), 5.45 (m, 1H, CH-O), 5.12 (m, 1H, CH-NH), 4.13 (qd, J = 7.2, 
6.1 Hz, 2H, O-CH2-CH3), 2.78 (dd, J = 15.9, 5.4 Hz, 1H, HN-CO-CH2a), 2.64 (dd,
J = 15.9, 6.8 Hz, 1H, HN-CO-CH2b), 2.58 (d, J = 6.3 Hz, 2H, O-CO-CH2), 1.98 (s, 
3H, CO-CH3), 1.49 (d, J = 6.9 Hz, 3H, CH-CH3), 1.25 (t, J = 7.1 Hz, 3H, CH2-CH3).
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The data corresponds to literature-known values.132
8.7 STANDARD OPERATING PROCEDURE 6 (SOP6): BIOCATALYTIC 
REMOVAL OF O-ACETYL GROUP BY THE USE OF HYDROLASES
The crude or isolated product from the previous desymmetrization with 
chymotrypsin (10.0 – 50.0 mmol) was dissolved in KPB (50mM, pH 8.0) or an 
organic solvent to reach a certain substrate concentration (1.0 – 4.0M) and, in 
the case of aqueous medium, titrated to pH 8.0 with aqueous sodium 
hydroxide solution (1.0 - 4.0M). An adequate amount of hydrolase was added 
and the resulting mixture was stirred at room temperature. The progress of the 
reaction was monitored by the volume of titer (1.0 – 4.0M sodium hydroxide) 
consumed to neutralize the free carboxylic acid and maintaining pH 8.0. After 
reaching the end of the reaction the solution was acidified (pH 1-2) with 
hydrochloric acid (12M) and extracted with ethyl acetate (3x 1:1 v/v). The 
combined organic phases were dried over MgSO4 and all volatile compounds
were removed in vacuo. The conversion was determined by NMR spectroscopy. 
Unless otherwise stated the crude extract was further used without purification.
Table 48. Removal of O-acetyl protective group by the use of hydrolases
Entry
Amount 
substrate
[mmol]
Biocatalyst
(g)
Additive 
(eq.)
Conc. 
substrate
[M]
Conversion
[% (h)]
Yield
[g(%)]
1 10.0
CAL-B 
(1.00)
EtOH 
(2.00)
1.43 22.0 (15.5) n.d.
2 10.0
CAL-B 
(1.00)
EtOH 
(10.0)
1.43 30.1 (76.5) n.d.
3 1.25
Amano PS 
SD (0.05)
- 0.05 4.76 (24.0) n.d.
4 1.25
Amano AK 
(0.05)
- 0.05 7.41 (24.0) n.d.
5 1.25
Amano 
AYS (0.05)
- 0.05 4.76 (24.0) n.d.
6 5.00
CAL-B 
(0.50)
EtOH 
(17.1)
0.50 5.66 (24.0) n.d.
7 5.00
CAL-B 
(0.50)
EtOH 
(34.2)
0.50
<1.00 
(24.0)
n.d.
8 4.58 CAL-B MeOH 0.76 <1.00 n.d.
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(0.20) (5.38) (24.0)
9 5.00
CCAH 
(0.05)
- 1.00 12.3a (18.5) n.d.
10 10.0
CCAH 
(0.05)
- 1.00 89.5 (5.5)
1.47 
(74.8)
11 40.0
CCAH 
(0.50)
- 0.80 >95.0 (4.5)
5.43 
(77.0)
12 48.5
CCAH 
(0.50)
- 4.00 >95.0 (8.0)
4.28 
(50.1)
(a) pH decreased to 3-4 which could have deactivated the enzyme
8.7.1 (3R)-5-ETHOXY-3-HYDROXY-5-OXOPENTANOIC ACID
The synthesis was conducted according to SOP6. A solution of 
(3R)-5-ethoxy-3-acetoxy-5-oxopentanoic acid (10.6 g, 48.5 mmol) in KPB 
(12.5 mL, 50mM, pH 8.0) was titrated to pH 8.0 with aqueous sodium hydroxide 
solution (4.0 M). Cephalosporin C acetylesterase (CAE, immobilized, 500 mg)
was added and the resulting suspension was stirred at room temperature. The 
progress of the reaction was monitored by the volume of titer (1.0 – 4.0 M 
sodium hydroxide) consumed to neutralize the free carboxylic acid and 
maintaining pH 8.0. The biocatalyst was filtered off and the work-up was done 
as described in SOP6. The conversion and the product content were 
determined by NMR spectroscopy.
Yield: 6.09 g (70.2% product contenti, 24.3 mmol, 50.1 %).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 4.47 (m, 1H, CH-OH), 4.18 (q, 2H, J = 7.2 
Hz, O-CH2-CH3), 2.62 – 2.54 (m, 4H, CH2-CH-CH2), 1.28 (t, 3H, J = 7.1 Hz, CH2-
CH3).
The data corresponds to literature-known values.127
8.8 STANDARD OPERATING PROCEDURE 7 (SOP7): PROTECTION OF 
ΒETA-HYDROXY CARBONACIDS AS TERT-BUTYLDIMETHYLSILYLETHERS
The synthesis was based on a procedure from SCHOENHERR et al..129 A solution 
of 5-ethoxy-3-hydroxy-5-oxopentanoic acid (5.00 – 117 mmol) and 1H-
imidazole (2.0-6.0 eq.) in an adequate solvent was stirred at room temperature. 
After the addition of tert-butyldimethylchlorosilane (1.1-2.2 eq.) the mixture
i Determined by quantitative NMR integration against internal standard (see chapter 2.4.3, page 
16).
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was stirred for 6-72 hours at 20-80 °C. The progress of the reaction was 
monitored via TLC. The reaction was quenched by addition of methanol (50 % 
v/v) and a solution of potassium carbonate (0.5 eq.) in dist. H2O (1:2 v/v). The 
progress was again monitored via TLC. Brine (1:2 v/v) was added to enhance 
phase separation The aqueous phase was separated and extracted with MTBE 
(2 x 1:1 v/v). The combined organic phase was washed once with brine (2:3 v/v), 
dried over MgSO4 and all volatile compounds were removed in vacuo. The 
main impurity was tert-butyldimethylsilanol which can be removed by 
evaporation of its hydrate or silica filtration (10 % v/v ethyl acetate in 
cyclohexane).
Table 49. TBS-protection of β-hydroxy carboxylic acids
Entry
Educt
[mmol]
TBS-Cl
(eq.)
1H-
imidazole 
(eq.)
Solvent 
( °C)
Conversion
[% (h)]
Yield
[g (%)]
1 5.00 2.20 6.00 THF (20)
>95.0 
(17.0)
2.26 
(75.4)
2 10.0 1.10 3.00
MTBE 
(20)
43.2 (26.0) n.d.
3 5.00 1.50 2.50
MTBE 
(reflux)
59.2 (12.0) n.d.
4 5.00 2.00 3.00
MTBE 
(reflux)
89.3 (20.0)
1.82 
(51.9)
5 30.8 2.20 2.20
MTBE 
(reflux)
87.0 (6.0)
10.5 
(50.5)
6 40.0 2.20 2.20
2-Me-
THF (80)
31.8 (18.0) n.d.
7 100 2.00 2.00 THF (20)
>95.0 
(21.0)
9.80 
(23.6)
8 117 2.00 2.00
EtOAc 
(20)
78.1 (19.5) n.d.
9 100 2.00 2.00 THF (20)
>95.0 
(16.5)
16.8 
(57.8)
8.8.1 (3R)-5-ETHOXY-3-(TERT-BUTYLDIMETHYLSILYL-)OXY-5-OXO-
PENTANOIC ACID
The synthesis was conducted according to SOP7. To a solution of
(3R)-5-ethoxy-3-hydroxy-5-oxopentanoic acid (17.6 g, 0.10 mol) in dry THF 
[217]
(100 mL) was added 1H-imidazole (30.1 g, 0.20 mol, 2.0 eq.). tert-
Butyldimethyl-chlorosilane (13.6 g, 0.2 mol, 2.0 eq.) was dissolved in dry THF 
(50 mL) and added in one portion. The slurry was vigorously stirred at room 
temperature until TLC shows complete conversioni. The reaction was diluted 
with methanol (75 mL) and subsequently mixed with a potassium carbonate 
solution (6.91 g, 0.05 mol, 0.5 eq.) in dist. H2O (75 mL). The resulting emulsion 
was stirred until TLC shows complete hydrolysis of the side-productii. The work-
up was done as described in SOP7. The crude product was contaminated by 
excess silanol (20-60 %) which was completely removed by silica filtration (10 % 
v/v ethyl acetate in cyclohexane) to obtain the product as colorless oil. 
Isolated yield: 16.8 g (57.8 mmol, 57.8 %).
1H-NMR (300 MHz, CDCl3): δ [ppm] = 4.63 – 4.47 (m, 1H, CH-O), 4.21 – 4.07 
(dd, J = 7.2, 1.4 Hz, 2H, O-CH2-CH3), 2.84 – 2.40 (m, 4H, CH2-CH-CH2), 1.38 –
1.12 (t, J = 7.2 Hz, 3H, CH2-CH3), 0.92 – 0.76 (s, 9H, C-(CH3)3), 0.13 – 0.04 (d,
J = 1.8 Hz, 6H, Si-CH3).
The spectroscopic data corresponds to literature-known values.129
8.9 STANDARD OPERATING PROCEDURE 8 (SOP8): PROTECTION OF 
ΒETA-HYDROXYAMIDES AS TERT-BUTYLDIMETHYLSILYL ETHERS
The corresponding amide (2.00 mmol) and 1H-imidazole (3.0 eq.) were 
dissolved in the given organic solvent and tert-butyldimethylchlorosilane (1.1 –
2.0 eq.) was added in portions at room temperature. The suspension was 
stirred for 2-6 hours at 20-60 °C. The mixture was diluted with ethyl acetate 
(10 – 50 mL) and washed with dist. H2O (1:2 v/v), saturated sodium bicarbonate 
solution (1:2 v/v) and brine (1:2 v/v). The organic phase was dried over MgSO4
and all volatile compounds were removed in vacuo. The crude product was 
purified by column chromatography on silica (33% v/v ethyl acetate in 
cyclohexane).The product is analyzed via NMR spectroscopy.
i The reaction is monitored by TLC (cyclohexane/ethyl acetate 1:1) on silica with bromocresol green as acid/base 
indicator and terminated after disappearance of the educt.
ii The hydrolysis of the TBDMS-ester is monitored with phosphomolybdic acid solution as plunge reagent and 
terminated after complete disappearance of the side-product.
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Table 50. TBS-protection of β-hydroxy amides
Entr
y
R1 R2
TBS-Cl 
(eq.)
1H-Imidazole
(eq.)
Conv. 
[%]
Isol. yield
[g(%)]
1 H Bn 1.1 3.0 >95.0 0.49 (64.5)
2 Me Bn 2.0 3.0 >95.0 0.20 (66.0)
3 Morpholine 2.0 3.0 >95.0 0.12 (83.4)
8.9.1 ETHYL (3S)-5-(N-BENZYLAMINO)-3-((TERT-BUTYLDIMETHYLSILYL)-
OXY-5-OXOPENTANOATE
The following synthesis was conducted according to SOP8. To a solution of 
ethyl (3S)-5-(N-benzylamino)-3-hydroxy-5-oxopentanoate (0.53 g, 2.00 mmol) 
and 1H-imidazole (0.41 g, 6.00 mmol, 3.0 eq.) in THF (6 mL) was added
tert-butyldimethylchlorosilane (0.33 g, 2.20 mmol, 1.1 eq.). The resulting 
suspension was stirred for two hours at room temperature. The work-up was 
done as described in SOP8. The crude product was purified by column 
chromatography on silica (33 % v/v ethyl acetate in cyclohexane) to obtain a 
colorless oil.
Isolated yield: 0.49 g (1.29 mmol, 64.5 %).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 7.70 (s, 1H, n-H), 7.27-7.34 (m, 5H, Ar-H), 
4.47-4.53 (m, 2H, CH2-Ph), 4.38 (q, 2H, J = 7.1 Hz, O-CH2-CH3), 4.12 (m, 1H, CH-
O), 2.53-2.57 (m, 2H, CH2-CONH), 2.43-2.47 (m, 2H, CH2-COOEt), 1.26 (t, 3H,
J = 7.1 Hz, CH2-CH3), 0.84 (s, 9H, C-(CH3)3), 0.07 (s, 6H, Si-CH3).
13C-NMR (125 MHz, CDCl3): δ [ppm] = 171.05, 138.10, 128.70, 127.95, 127.51,
66.73, 60.61, 43.90, 43.63, 41.72, 25.67, 17.80, 14.17, -5.04.
The compound is unknown to literature.
[219]
8.9.2 ETHYL (3S)-5-(N-BENZYL-N-METHYL)-AMINO)-3-((TERT-BUTYLDI-
METHYLSILYL)-OXY-5-OXOPENTANOATE
The following synthesis was conducted according to SOP8. To a solution of 
ethyl (3S)-5-(N-benzyl-N-methyl)-amino)-3-hydroxy-5-oxopentanoate (216 
mg, 0.77 mmol) and 1H-imidazole (162 mg, 2.32 mmol, 3.0 eq.) in MTBE (5 mL) 
was added tert-butyldimethylchlorosilane (247 mg, 1.55 mmol, 2.0 eq.). The 
resulting suspension was stirred for six hours at reflux temperature. The work-
up was done as described in SOP8. The crude product was purified by column 
chromatography on silica (33 % v/v ethyl acetate in cyclohexane) to obtain a 
colorless oil with an E/Z-ratio of 3:2.
Isolated yield: 0.20 g (0.51 mmol, 66.0 %).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 7.39-7.14 (m, 5H, Ar-H), 4.61-4.41 (m, 
3H, CH2-Ph, CH-O), 4.19-4.10 (q, J = 7.1 Hz, 2H, O-CH2-CH3), 2.96, 2.91 (s, 3H,
n-CH3), 2.70-2.45 (m, 4H, CH2-CH-CH2), 1.28, 1.23 (t, 3H, J = 7.1 Hz, CH2-CH3), 
0.85 (s, 9H, C-(CH3)3), 0.08, 0.05 (2s, 6H, Si-CH3).
The compound is unknown to literature.
8.9.3 ETHYL (3S)-5-N-MORPHOLINO-3-((TERT-BUTYLDIMETHYLSILYL)-
OXY-5-OXOPENTANOATE
The following synthesis was conducted according to SOP8. To a solution of 
ethyl (3S)-hydroxy-5-N-morpholino-5-oxopentanoate (102 mg, 0.40 mmol) and 
1H-imidazole (81.7 mg, 1.20 mmol, 3.0 eq.) in MTBE (5 mL) was added
tert-butyldimethylchlorosilane (121 mg, 1.55 mmol, 2.0 eq.). The resulting 
suspension was stirred for six hours at reflux temperature. The work-up was 
done as described in SOP8. The crude product was purified by column 
chromatography on silica (33 % v/v ethyl acetate in cyclohexane) to obtain a 
colorless oil.
Isolated yield: 0.12 g (0.33 mmol, 83.4 %).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 4.62 (m, 1H, CH-O), 4.12 (m, 2H, O-CH2-
CH3), 3.72-3.46 (m, 8H, CH2-CH3), 2.69-2.45 (m, 4H, CH2-CH-CH2), 1.26 (t, 3H,
J = 7.1 Hz, CH2-CH3), 0.85 (s, 9H, C-(CH3)3), 0.08, 0.05 (2s, 6H, Si-CH3).
13C-NMR (125 MHz, CDCl3): δ [ppm] = 171.19, 169.34, 66.94, 66.86, 66.69, 
60.42, 46.72, 42.53, 41.90, 39.99, 25.73, 17.92, 14.20, -4.67, -5.03. 
The compound is unknown to literature.
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8.10 STANDARD OPERATING PROCEDURE 9 (SOP9): ACTIVATION OF 
O-PROTECTED ΒETA-HYDROXYCARBONACIDS
The following syntheses were based on literature procedures from different 
sources. The corresponding references were given in parenthesis. In general, 
the free O-protected carboxylic acid (1.60 – 15.0 mmol) was dissolved in an 
organic solvent (5 – 30 mL) and deprotonated with a non-nucleophilic base, 
e.g. triethylamine. The carboxylate was then converted into active esters or an 
acid chloride by the use of different reagents. The reaction was quenched with 
the addition of aqueous saturated sodium bicarbonate solution (1:1 v/v), the 
phases were separated and the aqueous phase was extracted with additional 
organic solvent (2 x 1:1 v/v). In the case of water-miscible solvents, the mixture
was brought to saturation with neat sodium chloride. The combined organic 
phase was dried over MgSO4 and all volatile compounds were removed in 
vacuo. The crude product was analyzed by NMR spectroscopy and directly used 
without further purification, if not stated otherwise.
Table 51. Synthesis of activated carbonacid derivatives
Entr
y
R
(mmol
)
Reagent 
(eq.)
Additive 
(eq.)
Solvent 
(T [ °C])
Conv. 
(t)
[% (h)]
Yield
[g (%)]
1
Ac 
(1.60)
ClCOOMe 
(1.25)
TEA 
(1.50)
Toluene 
(-40)
86.3 
(0.5)
0.29 
(60.6)
2
Ac 
(5.00)
ClCOOMe 
(1.25)
TEA 
(1.50)
MTBE 
(-40)
>95.0 
(0.5)
0.94 
(68.1)
3
Ac 
(4.00)
C2O2Cl2
(1.30)
DMF 
(0.01)
DCM 
(0-20)
>95.0 
(4.0)
n.d.
4
TBS 
(3.77)
(H3C)3CCOCl
(1.03)
TEA
(1.03)
THF 
(0)
0.0 (3.0) -
5
TBS 
(3.44)
TosCl
(1.10)
TEA 
(1.10)
MTBE 
(20)
0.0 
(24.0)
-
6
TBS
(2.00)
ClCOOMe
(1.65)
TEA 
(1.25)
MTBE 
(-60)
>95.0 
(1.0)
0.28 
(33.8)
7
TBS 
(15.0)
ClCOOMe 
(1.50)
TEA 
(2.00)
MTBE 
(-70)
78.7 
(2.0)
5.64 
(n.d.)
8
TBS 
(12.6)
ClCOOMe 
(1.50)
TEA 
(2.00)
MTBE 
(-70)
91.7 
(2.0)
3.17 
(66.1)
9
TBS 
(5.00)
ClCOOMe 
(1.50)
TEA 
(2.00)
MTBE 
(-70)
91.0 
(16.5)
1.16 
(66.8)
[221]
8.10.1 METHYL (3S)-5-ETHOXY-3-(ACETYL)-OXY-5-OXOPENTANOYL-
CARBONATE 
The synthesis was based on a patent procedure from Teva Pharmaceuticals.133
A mixture of (3R)-5-ethoxy-3-(acetyl)-oxy-5-oxopentanoic acid (1.09 g, 5.0 
mmol) and triethylamine (1.04 mL, 7.50 mmol, 1.5 eq.) in MTBE (30 mL) was 
cooled to -40 °C (ethanol/dry ice) under argon atmosphere. A solution of 
methyl chloroformate (484 μL, 6.25 mmol, 1.25 eq.) in MTBE (5 mL) was added 
dropwise and the mixture was stirred for 20 minutes while thawing up to 0 °C. 
The reaction was quenched with addition of dist. H2O (20 mL) and the phases
were separated immediately. The organic phase was washed with dist H2O 
(20 mL), saturated sodium bicarbonate solution (2 x 10 mL) and brine (10 mL).  
After drying over MgSO4 all volatile compounds were removed in vacuo and 
the crude product was analyzed by NMR spectroscopy. No impurities were 
observed.
Isolated yield: 940 mg (3.40 mmol, 68.1 %).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 5.51 (m, 1H, CH-O), 4.16 (q, 2H, J = 7.2 
Hz, O-CH2-CH3), 3.91 (s, 3H, O-CH3), 2.97-2.85 (m, 2H, CH2-COOMoc), 2.78-2.69 
(m, 2H, CH2-COOEt), 2.05 (s, 1H, (O=)C-CH3), 1.26 (t, 6H, J = 7.1 Hz, CH2-CH3).
13C-NMR (125 MHz, CDCl3): δ [ppm] = 169.90, 169.55, 164.31, 149.15, 66.00, 
60.99, 56.09, 38.11, 37.96, 20.85, 14.14.
The compound is unknown to literature.
8.10.2 (3S)-5-ETHOXY-3-(ACETYL)-OXY-5-OXOPENTANOYL CHLORIDE
The synthesis was conducted according to a patent procedure from OEHRLEIN et 
al..122 A solution of (3R)-5-ethoxy-3-(acetyl)-oxy-5-oxopentanoic acid (0.87 g, 
4.00 mmol) and a catalytic amount of DMF (2 μL) in dry dichlormethane (5 mL)
was cooled to 0-4 °C. Oxalyl dichloride (440 μL, 5.20 mmol, 1.3 eq.) was added 
dropwise and the mixture was stirred for 30 minutes at 0 °C and additional 3.5 
hours at room temperature. The reaction was quenched with addition of 
saturated sodium bicarbonate solution (5 mL) and the phases were separated 
immediately. The aqueous phase was extracted with DCM (2 x 10 mL) and the 
combined organic phase was washed with brine (10 mL).  After drying over 
MgSO4 all volatile compounds were removed in vacuo and the crude product
[222]
was analyzed by NMR spectroscopy. The 13C-NMR shows complete conversion 
to the corresponding acid chloride.
Isolated yield: 619 mg (2.62 mmol, 65.4%).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 5.50 (m, 1H, CH-O), 4.16 (q, 2H, J = 7.2 
Hz, O-CH2-CH3), 2.79 (dd, 2H, J= 6.0 Hz, CH2-COCl), 2.72 (d, 2H, J = 6.3 Hz, CH2-
COOEt), 2.05 (s, 1H, (O=)C-CH3), 1.26 (t, 6H, J = 7.1 Hz, CH2-CH3).
13C-NMR (125 MHz, CDCl3): δ [ppm] = 175.36, 170.08, 169.84, 66.56, 60.93, 
38.29, 37.93, 20.95, 14.15.
The data corresponds to literature-known values.133
8.10.3 METHYL (3S)-5-ETHOXY-3-(TERT-BUTYLDIMETHYLSILYL)-OXY-5-
OXOPENTANOYLCARBONATE
Triethylamine (1.40 mL, 10.0 mmol, 2.00 eq.) was added to a solution of 
(3R)-5-ethoxy-3-(tert-butyldimethylsilyl)-oxy-5-oxopentanoic acid (1.46 g, 
5.00 mmol) in MTBE (30 mL) and the mixture was cooled to -70 °C (acetone/dry 
ice). Methyl chloroformate (580 μL, 7.5 mmol, 1.50 eq.) was dissolved in MTBE 
(20 mL) and added dropwise. After stirring for two hours at -70 °C the reaction
was warmed up to 0 °C and filtrated. All volatile compounds were removed in 
vacuo. NMR analysis of the crude product shows a conversion of 91.0% with 
9 % starting material as the sole impurity. 
Yield: 1.28 g (91.0% product content, 3.34 mmol, 66.8 %).
1H-NMR (300 MHz, CDCl3): δ [ppm] = 4.63 – 4.47 (m, 1H, CH-O), 4.21 – 4.07 
(dd, J = 7.2, 1.4 Hz, 2H, O-CH2-CH3), 3.91 (s, 3H, O-CH3), 2.84 – 2.40 (m, 4H, 
CH2-CH-CH2), 1.38 – 1.12 (t, J = 7.2 Hz, 3H, CH2-CH3), 0.92 – 0.76 (s, 9H, C-
(CH3)3), 0.13 – 0.04 (d, J = 1.8 Hz, 6H, Si-CH3).
The compound is unknown to literature.
[223]
8.11 STANDARD OPERATING PROCEDURE 10 (SOP10): SYNTHESIS OF 
STABILIZED PHOSPHOR YLIDES AS WITTIG AND HORNER-
WADSWORTH-EMMONS REAGENTS
The following syntheses were based on literature procedures from different 
sources. The corresponding references will be given in parenthesis. In general, 
a methylated triphenylphosphine or dimethyl methylphosphonate, respectively,
was dissolved in abs. THF and deprotonated by dropwise addition of n-
butyllithium at -50 to -78 °C (ethanol or acetone/dry ice). This methylene 
solution was stirred for 1-3 hours while thawing up to room temperature. An 
activated carbonacid derivative was dissolved in MTBE and added dropwise to 
the again cooled methylene solution. The mixture was stirred for two hours 
while thawing up to room temperature. The reaction was quenched with the 
addition of aqueous saturated sodium bicarbonate solution (1:1 v/v), the 
phases were separated and the aqueous phase was extracted with additional 
organic solvent (2 x 1:1 v/v). In the case of water-miscible solvents, the mixture
was brought to saturation with neat sodium chloride. The combined organic 
phase was dried over MgSO4 and all volatile compounds were removed in 
vacuo. The crude product was analyzed by NMR spectroscopy and directly used 
without further purification, if not stated otherwise.
Table 52. Synthesis of phosphor ylides as Wittig and HWZ reagents
Entry
Reagent 
(eq)
R1 
(mmol)
X
Solvent 
(T[ °C])
Conv. 
(t)
[% (h)]
Yield
[g(%)]
1
Ph3PCH3Br 
(2.0)
H 
(3.60)
BnNHa
THF/toluene 
(-55)
n.d.b -
2
Ph3PCH3Br 
(2.0)
2-THP 
(2.30)
BnNHa
THF 
(-55)
n.d.b -
3
Ph3PCH3Br 
(2.0)
Ac 
(2.50)
Cl
THF 
(-55)
n.d.c -
4
Ph3PCH3Br 
(2.0)
Ac 
(2.30)
MeOC
O 
THF 
(-55)
n.d.c -
5
Ph3PCH3Br 
(2.0)
TBS 
(1.00)
EtO
THF 
(-15)
27.0d
(3.0)
n.d.
6
(MeO)2POCH
3
(4.0)
TBS 
(2.00)
EtO
THF 
(-78)
74.0e
(2.5)
0.32 
(n.d.)
7 Ph3PCH3Br TBS MeOC THF/toluene 61-69f 0.34 
[224]
(2.0) (0.80) O (-70) (3.0) (n.d.)
8
Ph3PCH3Br 
(2.5)
TBS 
(3.67)
MeOC
O
THF 
(-78)
n.d.g -
9
Ph3PCH3Br 
(2.5)
TBS 
(9.00)
MeOC
O
THF 
(-78)
n.d.g -
a(S)-enantiomer through lipase-catalyzed aminolysis bnot determined; the lower pKa of protic 
moieties (NH < OH < methylene) led to various side-products which could neither be isolated 
nor identified cnot determined; the strongly basic methylene compound led to major elimination 
of acetic acid with the loss of chirality dreactivity of ethyl ester too low  equantitative conversion 
of the starting material, mixture of at least four products incl. elimination products with loss of 
chirality, 26% product-related conversion fconversion was determined by the conversion of 
aldehyde in the subsequent Wittig reaction, incl. correction of 1.1 eq. aldehyde and 97% 
conversion of the reference reaction g not determined, isolation methods were tested but 
unsuccessful
8.11.1 ETHYL RAC-3-(TERT-BUTYLDIMETHYLSILYL)-OXY-5-OXO-6-
(TRIPHENYL-PHOSPHORANYLIDENYL)-HEXANOATEi
Methyltriphenylphoshonium bromide (714 mg, 2.0 mmol) was suspended in 
abs. THF (5.0 mL) and cooled to -50 °C (ethanol/dry ice). After addition of n-
butyllithium (1.25 mL, 1.6 M in hexanes, 2.0 mmol) the mixture was stirred for 
60 minutes while thawing up to room temperature. The solution was again 
cooled to -40 °C and diethyl 3-(tert-butyldimethylsilyl)-oxyglutarate (318 mg, 
1.0 mmol), dissolved in abs. THF (5.0 mL), was added dropwise via syringe. The 
work-up was done as described in SOP9. Analysis of the crude product by NMR 
spectroscopy showed a product-related conversion of 27%. The product was 
not further purified.
1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.53 – 7.41 (m, 15H, Ar-H), 4.61 – 4.51
(m, 1H, CH-O), 4.21 – 4.07 (q, J = 7.4 Hz, 2H, O-CH2-CH3), 3.69 (d, J = 15.9 Hz, 
1H, P=CH), 2.76 – 2.42 (m, 4H, CH2-CH-CH2), 1.25 (t, J = 7.3 Hz, 3H, CH2-CH3), 
0.84 (s, 9H, C-(CH3)3), 0.08, 0.06 (2s, 6H, Si-CH3).
ESI-MS: m/z [fragment] = 549.74 [M+H]+.
The compound was known in literature. However, no NMR data was available.
i This experiment gave a good insight into the reactivity of the ethyl ester moiety under the 
given reaction conditions, a side reaction which could lead to the opposite enantiomer of the 
desired synthetic route.
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8.11.2 ETHYL RAC-3-((TERT-BUTYLDIMETHYLSILYL)-OXY-6-(DIMETHOXY-
PHOSPHORYL)-5-OXOHEXANOATE
Dimethyl methylphosphonate (1.03 mL, 9.6 mmol) was dissolved in abs. THF 
(10 mL) and cooled to -50 °C (ethanol/dry ice). After the dropwise addition of
n-butyllithium (5.25 mL, 1.6M in hexanes, 8.4 mmol) the solution was stirred for 
60 minutes at -50 °C. A solution of diethyl 3-(tert-butyldimethylsilyl)-
oxyglutarate (720 mg, 2.0 mmol) in abs. THF (10 mL) was added dropwise and 
the resulting mixture was stirred for additional two hours at -50 °C. The work-
up was done as described in SOP9. Analysis of the crude product by NMR 
spectroscopy showed a product-related conversion of 26 %. The product was 
not further purified.i
1H-NMR (300 MHz, CDCl3): δ [ppm] = 4.58 (m, 1H, CH-O), 4.23 – 4.15 (m, 2H, 
O-CH2-CH3), 3.79, 3.78 (2q, J = 11.0 Hz, 6H, P-O-CH3), 3.11 (d, J = 23.6 Hz, 2H, 
P-CH2-CO), 2.88 (d, J = 6.0 Hz, 2H, CH2), 2.56 (dd, J = 15.0, 5.8 Hz, 1H, CHa2), 
2.46 (dd, J = 15.0, 6.4 Hz, CHb2), 1.27 (t, J = 7.3 Hz, 3H, CH2-CH3), 0.84 (s, 9H, C-
(CH3)3), 0.07 (s, 3H, Si-CH3), 0.06 (s, 3H, Si-CH3).
The data corresponds to literature values (methyl ester).124
8.11.3 ETHYL (3R)-(TERT-BUTYLDIMETHYLSILYL)-OXY-5-OXO-6-(TRIPHENYL-
PHOSPHORANYLIDENYL)-HEXANOATE
Methyltriphenylphosphonium bromide (572 mg, 1.6 mmol) was suspended in 
abs. THF (20 mL) and cooled to -70 °C (acetone/dry ice). After dropwise 
addition of n-butyllithium (1.10 mL, 1.5 M in hexanes, 1.6 mmol) the mixture
was stirred for 60 minutes while thawing up to room temperature. The solution
was cooled to -50 °C and a solution of methyl (3S)-5-ethoxy-3-(tert-
butyldimethyl-silyl)-oxy-5-oxopentanoylcarbonate (279 mg, 0.8 mmol) in dry 
toluene (5 mL) was added dropwise. The mixture was stirred for additional two 
hours at -50 °C to room temperature. The work-up was done as described in 
SOP9. The product-related conversion of 61-69% was determined by the 
subsequent Wittig reaction and the conversion of the heteroaromatic aldehyde 
with respect to its excess of 1.1 eq. and the conversion of 97% of the reference 
i Comparison with the triphenylphosphorylide shows an enhanced reactivity but also enhanced 
side-product formation; the starting material is converted in 74% to at least three side-products, 
two of them identified as the corresponding acrylates after silanol elimination
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reaction with the commercial methylester ylide. The enantiomeric excess was 
calculated to be 98.1% ee. (see Figure 46, page 43).
1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.53 – 7.41 (m, 15H, Ar-H), 4.61 – 4.51
(m, 1H, CH-O), 4.21 – 4.07 (q, J = 7.4 Hz, 2H, O-CH2-CH3), 3.69 (d, J = 15.9 Hz, 
1H, P=CH), 2.76 – 2.42 (m, 4H, CH2-CH-CH2), 1.25 (t, J = 7.3 Hz, 3H, CH2-CH3), 
0.84 (s, 9H, C-(CH3)3), 0.08, 0.06 (2s, 6H, Si-CH3).
The compound was known in literature. However, no NMR data was available.
8.12 STANDARD OPERATING PROCEDURE 11 (SOP11): WITTIG REACTION 
OF DIFFERENT PHOSPHOR YLIDES WITH THE HETEROAROMATIC CORE 
OF ROSUVASTATIN
The following synthesis was based on a literature procedure from WATANABE et 
al..134 The corresponding O-protected triphenylphosphoranylide (1.15 eq.) and
N-(4-(4-fluorophenyl)-5-formyl-6-isopropylpyrimidin-2-yl)-N-methylmethane-
sulfonamide (0.49 - 29.0 mmol) were dissolved in various organic and aqueous 
media and stirred for 6-24 hours at 90 °C or the corresponding reflux 
temperature. After cooling to room temperature the mixture was diluted with 
dist. H2O (3:1 v/v) and extracted with an appropriate organic solvent (3 x 1:1 
v/v). The combined organic phase was dried over MgSO4 and all volatile 
compounds were removed in vacuo. If not stated otherwise the product was 
purified by column chromatography on silica (10 % v/v ethyl acetate in 
cyclohexane).
Table 53. Wittig reaction with phosphoranylidenes and heteroaromatic 
aldehyde
Entry R
Ald
[mmol]
Solvent
Conv. (time) 
[%(h)]
Isolated yielda
[g (%)]
1 Me 0.90 MeCN 69.2 (12) n.d.
2 Me 0.90 H2O 68.5 (12) n.d.
3 Me 0.90 KPB/iPA 97.2 (12) 0.43 (78.6)
4 Me 2.85 iPA 97.4 (8.5) 1.43 (82.6)
5 Et 0.49 iPA 62.8 (6.0) n.d.
6 Me 28.9 MTBE 98.0 (18.0) n.d.
(a) n.d. = not determined
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8.12.1 METHYL E-(3R)-((TERT-BUTYLDIMETHYLSILYL)-OXY-7-(4-(4-FLU-
OROPHENYL)-6-ISOPROPYL-2-(N-METHYLMETHYLSULFONAMIDO)-
PYRIMIDIN-5-YL)-5-OXOHEPT-6-ENOATE
The synthesis was conducted according to SOP11. Methyl (3R)-(tert-butyl-
dimethylsilyl)-oxy-5-oxo-6-(triphenylphosphoranylidenyl)-hexanoate (1.80 g, 
3.28 mmol, 1.15 eq.) and N-(4-(4-fluorophenyl)-5-formyl-6-isopropylpyrimi-
din-2-yl)-N-methylmethane-sulfonamide (1.00 g, 2.85 mmol) were dissolved in 
2-propanol (10 mL) and stirred for 8.5 hours at 90 °C. The work-up was done as 
described in SOP11. The crude product was purified by column 
chromatography on silica (10 % v/v ethyl acetate in cyclohexane).
Isolated yield: 1.43 g (2.35 mmol, 82.6 %).
1H-NMR (400 MHz, CDCl3): δ [ppm] = 7.70-7.60 (m, 3H, Ar-CH=C, m-Ar-H), 
7.12 (t, J = 8.6 Hz, 2H, o-Ar-H), 6.16 (d, J = 16.4 Hz, 1H, C=CH-CO), 4.60 (m, 1H, 
CH-O), 3.66 (s, 3H, O-CH3), 3.59 (s, 3H, S-CH3), 3.51 (s, 3H, n-CH3), 3.36 (m, 1H, 
H3C-CH-CH3), 2.75 (dd, J = 5.7 Hz, 2H, (O=)C-CH2), 2.49 (dd, J = 5.7 Hz, 2H,
CH2-COOMe), 1.29 (d, J = 6.6 Hz, 6H, H3C-CH-CH3), 0.81 (s, 9H, C-(CH3)3), 0.06, 
0.01 (2s, 6H, Si-CH3).
The data corresponds to literature-known values.
8.12.2 ETHYL E-(3R)-((TERT-BUTYLDIMETHYLSILYL)-OXY-7-(4-(4-FLUORO-
PHENYL)-6-ISOPROPYL-2-(N-METHYLMETHYLSULFONAMIDO)-
PYRIMI-DIN-5-YL)-5-OXOHEPT-6-ENOATE
The synthesis was conducted according to SOP11. Ethyl 
(3R)-(tert-butyldimethylsilyl)-oxy-5-oxo-6-(triphenylphosphoranylidenyl)-
hexanoate (309 mg, 0.56 mmol, 1.15 eq.) and N-(4-(4-fluorophenyl)-5-formyl-
6-isopropyl-pyrimidin-2-yl)-N-methyl-methanesulfonamide (172 mg, 0.49 
mmol) were dissolved in 2-propanol (2 mL) and stirred for 6.0 hours at 90 °C. 
The work-up was done as described in SOP11. NMR analysis of the crude 
product showed 87% conversion of the aldehyde. It was not further purified.
1H-NMR (400 MHz, CDCl3): δ [ppm] = 7.70-7.60 (m, 3H, Ar-CH=C, m-Ar-H), 
7.12 (t, 2H, J = 8.6 Hz, o-Ar-H), 6.16 (d, 1H, J = 16.4 Hz, C=CH-CO), 4.60 (m, 1H, 
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CH-O), 4.21 – 4.07 (q, J = 7.4 Hz, 2H, O-CH2-CH3), 3.59 (s, 3H, S-CH3), 3.51 (s, 
3H, n-CH3), 3.36 (m, 1H, H3C-CH-CH3), 2.75 (dd, 2H, J = 5.7 Hz, (O=)C-CH2), 2.49 
(dd, 2H, J = 5.7 Hz, CH2-COOMe), 1.29 (d, 6H, J = 6.6 Hz, H3C-CH-CH3), 1.25 (t,
J = 7.3 Hz, 3H, CH2-CH3), 0.81 (s, 9H, C-(CH3)3), 0.06, 0.01 (2s, 6H, Si-CH3).
The data corresponds to literature-known values (methyl ester).
8.13 STANDARD OPERATING PROCEDURE 12 (SOP12): REMOVAL OF
TERT-BUTYLDIMETHYLSILYL PROTECTIVE GROUP
The following syntheses were conducted according to literature procedures. 
The corresponding references will be given in parenthesis. In general, the O-
TBS protected enone (0.69 - 2.30 mmol) was dissolved in an appropriate 
organic solvent (18 - 20 mL) and a protonating or fluorinating reagent was 
added. The reaction was quenched by the addition of saturated aqueous salt 
solution. The aqueous phase was extracted with MTBE or ethyl acetate (3 x 1:1 
v/v) and the combined organic phase was washed with brine (1:2 v/v). After 
drying over MgSO4 all volatile compounds were removed in vacuo. Unless 
stated otherwise the product was used without further purification.
Table 54. TBS-deprotection of Wittig reaction products
Entry
Enone 
[mmol]
Reagent Solvent
Conversion
[%]
Yield
[g(%)]
1 0.69 TBAF THF >95.0 n.d.
2 2.30 HCl EtOH >95.0 1.00 (88.1)
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8.13.1 METHYL E-(3R)-7-(4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-(N-
METHYL-METHANESULFONAMIDO)-PYRIMIDIN-5-YL)-3-HYDROXY-5-
OXOHEPT-6-ENOATE BY TBAF DEPROTECTION
The synthesis was conducted according to a literature procedure from TOUATI
et al..135 Tetra-n-butylammonium fluoride (0.75 mL, 1.0 M in THF, 0.75 mmol)
was added dropwise to a solution of ethyl E-(3R)-((tert-butyldimethyl-
silyl)-oxy-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethyl-sulfonamido)-
pyri-midin-5-yl)-5-oxo-hept-6-enoate (377 mg, 0.69 mmol) in THF (20 mL). The 
mixture was stirred for 14 hours at room temperature. The reaction was 
quenched by the addition of saturated ammonium chloride solution (10 mL) 
and the aqueous solution was extracted with ethyl acetate (3 x 20 mL). The 
combined organic phase was dried over MgSO4 and all volatile compounds
were removed in vacuo. The conversion of >95.0 % was determined by analysis 
with 1H-NMR spectroscopy. Due to the toxicity of hydrofluoric acid and 
therefore strict avoidance of acidic conditions, this methodology was 
considered inferior to the acidic hydrolysis.i The crude product was not further 
purified.
1H-NMR (400 MHz, CDCl3): δ [ppm] = 7.70-7.60 (m, 3H, Ar-CH=C, m-Ar-H), 
7.12 (t, 2H, J = 8.6 Hz, o-Ar-H), 6.16 (d, 1H, J = 16.4 Hz, C=CH-CO), 4.56 (m, 1H, 
CH-O), 3.66 (s, 3H, O-CH3), 3.59 (s, 3H, S-CH3), 3.51 (s, 3H, n-CH3), 3.36 (m, 1H, 
H3C-CH-CH3), 2.75 (dd, 2H, J = 5.7 Hz, (O=)C-CH2), 2.49 (dd, 2H, J = 5.7 Hz, 
CH2-COOMe), 1.29 (d, 6H, J = 6.6 Hz, H3C-CH-CH3).
The data corresponds to literature-known values.
8.13.2 METHYL E-(3R)-7-(4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-(N-
METHYL-METHANESULFONAMIDO)-PYRIMIDIN-5-YL)-3-HYDROXY-5-
OXOHEPT-6-ENOATE BY ACIDIC HYDROLYSIS
The synthesis was conducted according to a patent procedure from Teva 
Pharmaceuticals.136 To a solution of ethyl E-(3R)-((tert-butyldimethylsilyl)-oxy-
7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonami-do)-pyrimidin-
5-yl)-5-oxohept-6-enoate (1.14 g, 2.30 mmol) in EtOH (18 mL) was added 
dropwise hydrochloric acid (2.0 mL, 2 M). The mixture was stirred for six hours 
i However, TBS fluoride should be easier to remove by distillation as the corresponding silanol or its hydrate.
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at room temperature. The work-up was conducted with saturated sodium 
bicarbonate solution and MTBE as described in SOP12. Analysis with 1H-NMR 
spectroscopy revealed quantitative conversion. The crude product was purified 
by column chromatography on silica (10 % v/v ethyl acetate in cyclohexane) to 
obtain a pale yellow oil.
Isolated yield: 1.00 g (2.02 mmol, 88.1 %).
1H-NMR (400 MHz, CDCl3): δ [ppm] = 7.70-7.60 (m, 3H, Ar-CH=C, m-Ar-H), 
7.12 (t, 2H, J = 8.6 Hz, o-Ar-H), 6.16 (d, 1H, J = 16.4 Hz, C=CH-CO), 4.56 (m, 1H, 
CH-O), 3.66 (s, 3H, O-CH3), 3.59 (s, 3H, S-CH3), 3.51 (s, 3H, n-CH3), 3.36 (m, 1H, 
H3C-CH-CH3), 2.75 (dd, 2H, J = 5.7 Hz, (O=)C-CH2), 2.49 (dd, 2H, J = 5.7 Hz, 
CH2-COOMe), 1.29 (d, 6H, J = 6.6 Hz, H3C-CH-CH3).
The data corresponds to literature-known values (methyl ester).
8.14 STANDARD OPERATING PROCEDURE 13 (SOP13):
DIASTEREOSELECTIVE REDUCTION OF ΒETA-CHIRAL ENONES BY 
SODIUM BOROHYDRIDE
Sodium borohydride (1.3 – 2.0 eq.) was dissolved in an appropriate dry organic 
solvent (20 mL) and cooled to the given temperature. After the addition of any 
additives, e.g. diethyl methoxyborane (0.5 – 1.0 eq.), a solution of β-chiral 
enone (0.06 – 2.30 mmol) in a mixture of methanol and THF (2:7 v/v) was 
added dropwise while maintaining low temperature. The resulting mixture was 
stirred at cold temperature until TLC control shows quantitative conversion. 
Subsequently, the cold solution was poured onto a mixture of aqueous sodium 
bicarbonate solution (1.0 wt-%, 1:3 v/v) and ethyl acetate (2:3 v/v). The phases
were separated and the aqueous phase was extracted with ethyl acetate (2 x 
1:2 v/v). The combined organic phase was washed with brine (1:3 v/v) and 
concentrated in vacuo. In the case of added borane the organic phase was 
concentrated to 2/3 of the extraction volume and heated to 50 °C before 
hydrogen peroxide (35 % in H2O, 3 eq.) was added dropwise. The mixture was 
stirred for 90 minutes at 45 °C. The phases were separated and the organic 
phase was washed with brine (1:1 v/v) before all volatile compounds were 
removed in vacuo. The crude product was analyzed by 1H-NMR spectroscopy. 
Unless stated otherwise the product was used without further purification.
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Table 55. Diastereoselective reduction of -chiral enone with NaBH4
Entry
R1
[mmol]
Additive 
(eq.)
Solvent 
( °C)
Conv. 
(time)
[%(h)]
d.r.
(syn/anti)
Yield
[g(%)]
1
TBS 
(0.06)
-
THF 
(0)
>95.0 (1.0) 80:20 n.d.
2
H 
(2.30)
Et2BOMe 
(0.5)
THF 
(-15)
>95.0 (1.0) 66:34
1.20 
(n.d.)
3
H 
(2.00)
Et2BOMe 
(0.5)
THF 
(-70)
>95.0 (2.0) 65:35
0.92 
(n.d.)
4
H 
(1.00)
Et2BOMe 
(1.0)
THF 
(-15)
>95.0 (1.0) 80:20 n.d. (-)
5
H 
(1.00)
Et2BOMe 
(1.0)
THF 
(-70)
>95.0 (1.0) >98:2 n.d. (-)
8.14.1 METHYL E-(3R,5S)-3-((TERT-BUTYLDIMETHYLSILYL)-OXY-7-(4-(4-
FLUOROPHENYL)-6-ISOPROPYL-2-(N-METHYLMETHYLSULFONAMI-
DO)-PYRIMIDIN-5-YL)-5-HYDROXYHEPT-6-ENOATE
The synthesis was based on a literature procedure from KIM et al.137 A solution 
of ethyl E-(3R)-((tert-butyldimethylsilyl)-oxy-7-(4-(4-fluorophenyl)-6-isopropyl-
2-(N-methylmethylsulfonamido)-pyrimidin-5-yl)-5-oxohept-6-enoate (38.0 mg, 
0.06 mmol) in THF (2.0 mL) was cooled to 0-4 °C. Sodium borohydride (4.4 mg, 
0.12 mmol, 2.0 eq.) was added and the mixture was stirred for 60 minutes at 0-
4 °C. The work-up was conducted as described in SOP13. NMR analysis showed 
quantitative conversion of the starting material and a diastereomeric ratio of 
80:20 for the major-diastereomer. Due to its low amount the product was not 
further purified.
1H-NMR (500 MHz, CDCl3): δ [ppm] = 7.66-7.63 (m, 2H, m-Ar-H), 7.09 (t, 2H,
J = 8.8 Hz, o-Ar-H), 6.64 (d, 1H, J = 16.0 Hz, Ar-CH=C), 5.45 (dd, 1H, J = 5.3, 
16.0 Hz, C=CH-C), 4.46 (m, 1H, H2C-CH-OH), 4.21 (m, 1H, CH-CH-OH), 3.74 (s, 
3H, O-CH3), 3.68 (s, 1H, OH), 3.57 (s, 3H, S-CH3), 3.52 (s, 3H, n-CH3), 3.51 (s, 1H, 
OH), 3.36 (m, 1H, H3C-CH-CH3), 2.49-2.47 (m, 2H, CH2-COOMe), 1.59-1.45 (m, 
2H, CH-CH2-CH), 1.27 (d, 6H, J = 6.6 Hz, H3C-CH-CH3), 0.81 (s, 9H, C-(CH3)3), 
0.06, 0.01 (2s, 6H, Si-CH3).
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8.14.2 METHYL E-(3R,5S)-7-(4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-(N-
ME-THYLMETHANESULFON-AMIDO)-PYRIMIDIN-5-YL)-3,5-
DIHYDROXYHEPT-6-ENOATE (ROSUVASTATIN METHYL ESTER)
The synthesis was conducted according to SOP13. Sodium borohydride (115 
mg, 3.0 mmol, 1.3 eq.) was suspended in dry THF (15 mL) and cooled to -70 °C
(acetone/dry ice). Diethyl methoxyborane (2.3 mL, 1.0 M in THF, 2.3 mmol, 1.0 
eq.) was added dropwise and the resulting solution was degased with argon. 
Subsequently, a solution of methyl E-(3R)-7-(4-(4-fluorophenyl)-6-isopropyl-2-
(N-methylmethylsulfon-amido)-pyrimidin-5-yl)-3-hydroxy-5-oxohept-6-enoate 
(1.17 g, 2.3 mmol) in a mixture of methanol and THF (2:7 v/v, 23 mL) was added 
dropwise while maintaining -70 °C. The reaction progress was observed via TLC 
control (silica, 50% ethyl acetate in n-heptane). The reaction was stirred for 
60 minutes until TLC shows quantitative conversion of starting material. The 
work-up was done as described in SOP13. Analysis with 1H-NMR spectroscopy 
confirms quantitative conversion and shows a diastereomeric ratio of >98:2 for 
the major diastereomer. Comparison with the reference data identified the 
major diastereomer as the desired syn-1,3-diol. The product was not further 
purified.
1H-NMR (500 MHz, CDCl3): δ [ppm] = 7.66-7.63 (m, 2H, m-Ar-H), 7.09 (t,
J = 8.8 Hz, 2H, o-Ar-H), 6.64 (d, J = 16.0 Hz, 1H, Ar-CH=C), 5.45 (dd, J = 5.3, 
16.0 Hz, 1H, C=CH-C), 4.46 (m, 1H, H2C-CH-OH), 4.21 (m, 1H, CH-CH-OH), 3.74
(s, 3H, O-CH3), 3.68 (s, 1H, OH), 3.57 (s, 3H, S-CH3), 3.52 (s, 3H, n-CH3), 3.51 (s, 
1H, OH), 3.36 (m, 1H, H3C-CH-CH3), 2.49-2.47 (m, 2H, CH2-COOMe), 1.59-1.45
(m, 2H, CH-CH2-CH), 1.27 (d, J = 6.6 Hz, 6H, H3C-CH-CH3).
The data corresponds to the commercial reference compound.
8.15 PROCESS DEVELOPMENT A: PURIFICATION OF INTERMEDIATES 
AVOIDING COLUMN CHROMATOGRAPHY
Since most of the compounds have a high boiling point of above 200 °C, 
distillation was not investigated. Most of the intermediates were carboxylic 
acids and were therefore tested for crystallization as free acid, sodium salt and 
ammonium salt. The first two forms were investigated for crystallization from 
the crude product. None of the experiments were successful. However, with 
some primary and secondary amines, crystallization can be easily achieved.
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8.15.1 DICYCLOHEXYLAMINE (3R)-5-ETHOXY-3-(ACETYL)-OXY-5-OXO-
PENTANOATE
A mixture of (3R)-5-ethoxy-3-(acetyl)-oxy-5-oxopentanoic acid (1.00 g crude 
product, 4.58 mmol max.) and dicyclohexylamine (916 μL, 4.60 mmol) was 
dissolved in MTBE (4.0 mL) and stirred at reflux temperature. n-Hexane (2.0 mL)
was added dropwise and the turbid solution was cooled slowly to room 
temperature with stirring and to -20 °C while resting. The precipitate was 
filtered off, washed with cold n-hexane (8.0 mL) and dried in high vacuum to 
obtain spectroscopically pure product as colorless, amorphous solid.
Isolated yield: 697 mg (1.75 mmol, 38.1%).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 5.57 – 5.47 (m, 1H, CH-O), 4.20 – 4.04 
(dq, J = 7.1 Hz, 2H, O-CH2-CH3), 3.01 – 2.89 (m, 2H, CH-N-CH), 2.86 – 2.77 (dd,
J = 15.5 Hz, 1H, CHa2), 2.68 – 2.54 (m, 2H, CH2), 2.50 – 2.38 (dd, J = 15.3 Hz, 1H, 
CHb2), 2.08 – 1.91 (m, 7H, CH2, (O=)C-CH3), 1.86 – 1.72 (m, 4H, CH2), 1.69 – 1.58 
(m, 1H, CH2), 1.49 – 1.34 (m, 5H, CH2), 1.32 – 1.09 (m, 9H, CH2, CH2-CH3).
The compound is unknown to literature.
8.15.2 DICYCLOHEXYLAMINE (3R)-5-ETHOXY-3-HYDROXY-5-OXOPENTAN-
OATE
A mixture of (3R)-5-ethoxy-3-hydroxy-5-oxopentanoic acid (810 mg crude 
product, 4.60 mmol max.) and dicyclohexylamine (916 μL, 4.60 mmol) was 
dissolved in MTBE (4.0 mL) and stirred at reflux temperature. n-Hexane (2.0 mL)
was added dropwise and the turbid solution was cooled slowly to room 
temperature with stirring and to -20 °C while resting. The precipitate was 
filtered off, washed with cold n-hexane (8.0 mL) and dried in high vacuum to 
obtain spectroscopically pure product as colorless, amorphous solid.
Isolated yield: 952 mg (2.66 mmol, 57.9%).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 4.47 (m, 1H, CH-O), 4.20 – 4.04 (dq,
J = 7.1 Hz, 2H, O-CH2-CH3), 3.01 – 2.89 (m, 2H, CH-N-CH), 2.86 – 2.77 (dd,
J = 15.5 Hz, 1H, CHa2), 2.68 – 2.54 (m, 2H, CH2), 2.50 – 2.38 (dd, J = 15.3 Hz, 1H, 
CHb2), 2.08 – 1.91 (m, 4H, CH2), 1.86 – 1.72 (m, 4H, CH2), 1.69 – 1.58 (m, 1H, 
CH2), 1.49 – 1.34 (m, 5H, CH2), 1.32 – 1.09 (m, 9H, CH2, CH2-CH3).
[234]
The compound is unknown to literature.
8.15.3 DICYCLOHEXYLAMINE (3R)-5-ETHOXY-3-(TERT-BUTYLDIMETHYL-
SILYL)-OXY-5-OXOPENTANOATE
A mixture of (3R)-5-ethoxy-3-(tert-butyldimethylsilyl)-oxy-5-oxopentanoic acid 
(1.34 g crude product, 4.60 mmol max.) and dicyclohexylamine (916 μL, 4.60 
mmol) was dissolved in MTBE (8.0 mL) and stirred at reflux temperature. n-
Hexane (4.0 mL) was added dropwise and the turbid solution was cooled slowly 
to -20 °C while stirring. The precipitate was filtered off and dried in high 
vacuum to obtain spectroscopically pure product as colorless, amorphous solid.
Isolated yield: 1.15 g (2.44 mmol, 53.0%).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 4.57 – 4.50 (m, 1H, CH-O), 4.16 – 4.05
(m, 2H, O-CH2-CH3), 2.88 – 2.82 (m, 2H, CH-N-CH), 2.75 – 2.71 (dd, J = 3.5, 14.8
Hz, 1H, CHa2), 2.52 – 2.41 (m, 2H, CH2), 2.37 – 2.32 (dd, J = 8.5, 15.1 Hz, 1H, 
CHb2), 2.01 – 1.94 (m, 4H, CH2), 1.80 – 1.74 (m, 4H, CH2), 1.66 – 1.60 (m, 1H, 
CH2), 1.39 – 1.12 (m, 14H, CH2, CH2-CH3), 0.85 (s, 9H, C-(CH3)3), 0.08, 0.06 (2s, 
6H, Si-CH3).
The compound is unknown to literature.
8.15.4 (+)-DEHYDROABIETYLAMINE (3R)-5-ETHOXY-3-HYDROXY-5-OXO-
PENTANOATE
A mixture of (3R)-5-ethoxy-3-hydroxy-5-oxopentanoic acid (1.00 g crude 
product, 5.67 mmol max.) and (+)-dehydroabietylamine (1.62 g, 5.70 mmol)
was dissolved in MeOH (12.5 mL) and stirred at reflux temperature. Dist. H2O 
(10 mL) was added dropwise and the turbid solution was cooled slowly to room 
temperature with stirring and to 0-4 °C while resting. The precipitate was 
filtered off, washed with cold dist. H2O (10 mL) and dried in high vacuum to 
obtain spectroscopically pure product as colorless, amorphous solid.
Isolated yield: 1.89 g (4.10 mmol, 71.3%).
1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.20 (d, J = 8.1 Hz, 1H, 6-Ar-H), 7.05 –
6.98 (m, 1H, 5-Ar-H), 6.94 – 6.89 (m, 1H, 3-Ar-H), 4.47 (m, 1H, CH-OH), 4.18 (q, 
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2H, J = 7.2 Hz, O-CH2-CH3), 2.97 – 2.78 (m, 3H, CH2-Ar, CH-(CH3)2), 2.64 – 2.54 
(m, 5H, CH2-CH-CH2, H3N-CH2a), 2.45 (d, J = 13.2 Hz, 1H, H3N-CH2b), 2.38 – 2.25 
(m, 1H, CH2a), 1.86 – 1.27 (m, 13H, CH2b, CH2), 1.28 – 1.22 (m, 12H, Ar-C-CH3, 
CH-(CH3)2, CH2-CH3), 0.92 (s, 3H, CH3).
The compound is unknown to literature. The spectroscopical data corresponds to 
the respective separate components.
8.16 PROCESS DEVELOPMENT B: COMBINATION OF REACTION STEPS TO 
REDUCE ISOLATION PROCEDURES
The following procedures are combinations of already described procedures
with the purpose of shortening the synthetic route to a minimum of isolation 
steps. The solvents of various reactions were also exchanged to reduce the 
work-up steps.
8.16.1 COMBINATION OF ACETYLATION, BIOCATALYTIC DESYMMETRIZATION 
AND DEACETYLATION
Zinc perchlorate hexahydrate (37.2 mg, 0.10 mmol, 0.01 eq.) was dissolved in 
acetic anhydride (990 μL, 10.5 mmol, 1.05 eq.) at room temperature. After the 
addition of diethyl 3-hydroxyglutarate (2.04 g, 10.0 mmol) the reaction was 
stirred for two hours at room temperature.i Aqueous potassium phosphate 
buffer (KPB, 10.0 mL, 50 mM, pH 8.0) was added and the resulting emulsion
was neutralized by the addition of neat sodium carbonate (583 mg, 5.50 mmol, 
0.55 eq.) in portions. After the addition of α-chymotrypsin (100 mg, Biozym 
CHY-03) the reaction was stirred for 24 hours at room temperature while 
maintaining the pH of 8.0 by titration with sodium hydroxide (4.0M). The 
biocatalyst was removed via μLtrafiltration (Merck Millipore, PLGC, 10,000 
NMWCii, regenerated cellulose) and a suspension of Cephalosporin C 
i Due to the absence of solvent the reaction progress can be directly monitored by NMR 
spectroscopy.
ii NMWC = nominal molecular weight cut-off
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acetylesterase (CAE, immobilized, 500 mg) in KPB (7.5 mL, 50 mM, pH 8.0) was 
added. The reaction was stirred for 5.5 hours while maintaining the pH of 8.0 
by titration with sodium hydroxide (4.0 M). The immobilized biocatalyst was 
removed by filtration (glass frit Por4, 10-16 μm) and the filtrate was brought to 
pH 1 with hydrochloric acid (12 M). After saturation with neat sodium chloride 
the aqueous phase was extracted with ethyl acetate (2 x 25 mL). The combined 
organic phase was washed with brine (25 mL) and dried over MgSO4. The 
product was isolated from remaining enzyme debris by filtration over a short 
silica column. All volatile compounds were removed in vacuo to obtain 
spectroscopically pure product (1.68 g, 9.52 mmol, 95.2 % over 3 steps) as 
colorless oil.
The spectroscopical data is identical with chapter 8.3.1.
8.16.2 COMBINATION OF WITTIG REACTION AND TBS DEPROTECTION
A suspension of methyl (3R)-(tert-butyldimethylsilyl)-oxy-5-oxo-6-
(triphenylphos-phoranylidenyl)-hexanoate (19.9 g, 32.8 mmol, 1.15 eq.) and n-
(4-(4-fluorophenyl)-5-formyl-6-isopropylpyrimidin-2-yl)-N-methylmethane-
sulfonamide (10.0 g, 28.5 mmol) in 2-propanol (10 mL) was stirred for six hours 
at 90 °C. The solvent was removed in vacuo and the residue taken up in MTBE 
(30 mL) and cooled to -20 °C for 12 hours. Precipitated TPPO was filtered off 
and washed with MTBE (-20 °C, 20 mL) before the filtrate was concentrated in 
vacuo. The residue was taken up in ethanol (174 mL) and hydrochloric acid (2M, 
26.0 mL) was added dropwise. After complete addition the mixture was stirred 
for additional six hours at room temperature, until TLCi shows complete 
deprotection. Ethyl acetate (500 mL) and aqueous sodium bicarbonate solution 
(2%, 350 mL) was added under vigorous stirring. The phases were separated 
and the aqueous phase was again extracted with ethyl acetate (100 mL). The 
organic phase was dried over MgSO4 and concentrated in vacuo. The crude 
product was used without further purification.
The spectroscopical data is in accordance with chapter 8.13.2.
i Silica, 50% v/v ethyl acetate in n-heptane, UV detection
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8.16.3 ELIMINATION OF ALL ISOLATION STEPS BETWEEN BIOCATALYTIC 
DESYMMETRIZATION AND WITTIG REACTION
To a solution of α-chymotrypsin (300 mg, Biozym CHY-03) in KPB (10.0 mL, 
50 mM, pH 8.0) was added diethyl 3-(acetyl)-oxyglutarate (9.85 g, 40.0 mmol) 
to a substrate concentration of 4.0 M. The pH was adjusted to 8.0 by titration 
with sodium hydroxide (4.0 M). The emulsion was stirred for 24 hours at room 
temperature.i The homogenously dissolved biocatalyst was removed via
ultrafiltration (Merck Millipore, PLGC, 10,000 NMWC, regenerated cellulose). A 
suspension of Cephalosporin C acetylesterase (CAE, immobilized, 500 mg) in 
KPB (5.0 mL, 50 mM, pH 8.0) was added to the filtrate and the resulting mixture
was stirred for 7.6 hours at room temperature.i The immobilized biocatalyst was 
subsequently removed via filtration over a glass frit (Por4, 10-16 μm) and the 
filtrate was brought to pH 1 by the addition of hydrochloric acid (12 M) and 
saturated with neat sodium chloride. The solution was extracted with ethyl 
acetate (2 x 50 mL) and the combined organic phase was dried over MgSO4. All 
volatile compounds were removed in vacuo. Quantitative 1H-NMR analysis with 
p-chlorobenzyl alcohol as internal standard revealed a product content of 6.84 
g (38.8 mmol, 97.0%). The major part of this product (5.90 g, 33.5 mmol) was 
used for the following reaction.ii The intermediate was taken up in ethyl acetate 
(85 ml) before 1H-imidazole (16.1 g, 73.8 mmol, 2.2 eq.) was added in portions. 
To the turbid mixture was added a solution of tert-butyldimethylchlorosilane 
(11.1 g, 73.8 mmol, 2.2 eq.) in ethyl acetate (50 mL) and the resulting 
suspension was stirred for 72 hoursiii at room temperature. The solvent and 
part of the main impurity tert-butyldimethylsilanol were removed in vacuo. The 
residue was taken up in THF (20 mL) and methanol (10 mL). A solution of 
potassium carbonate (2.31 g, 16.75 mmol, 0.5 eq.) in dist. H2O (10 mL) was 
added and the turbid mixture was stirred for two hours at room temperature. 
The reaction was quenched by the addition of hydrochloric acid (0.5 M, 
60.0 mL, pH 3-4) and saturated with neat sodium chloride. The organic phase
was separated and the aqueous phase was extracted with ethyl acetate (2 x 
i The reaction progress is monitored by the consumption of titer (4.0M sodium hydroxide) to 
neutralize the product or byproduct and maintaining pH 8.0 during the conversion of diester.
ii The remaining product was used for purification procedures and the determination of optical 
purity (in this case 97.2% ee, see Table 8, page 21)
iii The reaction progress could not be controlled before 72 hours, however, other experiments 
with TLC control indicate quantitative conversion within the first 10 hours.
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60 mL). The combined organic phase was dried over MgSO4 and all volatile 
compounds were removed in vacuo to obtain the crude product (13.2 g). 
Quantitative 1H-NMR analysis shows a product content of 7.85 g (27.0 mmol, 
80.7%). The residue was taken up in MTBE (70 mL) and mixed with 
triethylamine (7.48 mL, 54.0 mmol, 2.0 eq.). The mixture was cooled to -70 °C
(acetone/dry ice) and a solution of methyl chloroformate (3.13 mL, 40.5 mmol, 
1.5 eq.) in MTBE (30 mL) was added dropwise while maintaining -70 °C. The 
reaction was stirred for 120 minutes at -70 °C and subsequently warmed up to 
0 °C. Dist. H2O (50 mL) was added and the phases were immediately separated. 
The organic phase was washed with saturated sodium bicarbonate solution 
(50 mL) and dried over MgSO4 before all volatile compounds were removed in 
vacuo. The crude product (12.1 g) was quantified by 1H-NMR spectroscopy with 
p-chlorobenzyl alcohol as internal standard to contain the mixed anhydride 
(9.03 g, 25.9 mmol, 96.0%) in a mixture with tert-butyldimethylsilanol as main 
impurity. The residue was taken up in MTBE (30 mL) and used without 
purification for the next step. Methyltriphenylphosphonium bromide (23.2 g, 
65.0 mmol, 2.5 eq.) was suspended in abs. THF (150 mL) and cooled to -50 °C
(acetone/dry ice) before n-butyllithium (1.5 M in hexanes, 43.3 mL, 65.0 mmol, 
2.5 eq.) was added dropwise. The mixture was stirred for two hours while 
thawing up to room temperature. The resulting ylide solution was again cooled 
to -50 °C and the mixed anhydride solution was added dropwise. The mixture
was stirred for three hours while thawing up to room temperature. The reaction
was quenched by the addition of dist. H2O (50 mL) and MTBE (50 mL) and was 
further stirred for 30 minutes at room temperature. The phases were separated 
and the aqueous phase was extracted with MTBE (2 x 50 mL). The combined 
organic phase was washed with saturated sodium bicarbonate solution (2x 
50 mL) and brine (50 mL) before drying over MgSO4. All volatile compounds
were removed in vacuo and the crude product (18.4 g) was used without 
purification for the following Wittig reaction. N-(4-(4-fluorophenyl)-5-for-myl-
6-isopropylpyrimidin-2-yl)-N-methylmethane-sulfonamide (8.27 g, 23.5 mmol)
was added and the mixture was taken up in 2-propanol (50 mL). The resulting 
suspension was stirred for 19 hours at 90 °C. The solvent was removed in vacuo
before the residue was dissolved in MTBE (50 mL) and cooled to -20 °C. 
Precipitated triphenylphosphine oxide (TPPO) was removed via filtration and 
the filtrate was concentrated in vacuo. Analysis via 1H-NMR spectroscopy 
revealed a product-related conversion of 78%, corresponding to an overall 
yield of 12.2 g (19.6 mmol, 58.6% over 6 steps). Due to the remaining 
impurities the product could not be purified by crystallization.
The spectroscopical data is in accordance with chapter 8.12.2.
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8.16.4 ELIMINATION OF ALL ISOLATION STEPS BETWEEN PHOSPHOR YLIDE 
AND ROSUVASTATIN METHYL ESTER
A suspension of methyl (3R)-(tert-butyldimethylsilyl)-oxy-5-oxo-6-
(triphenylphos-phoranylidenyl)-hexanoate (8.53 g, 16.0 mmol, 1.10 eq.) and N-
(4-(4-fluorophenyl)-5-formyl-6-isopropylpyrimidin-2-yl)-N-
methylmethanesulfonamide (5.10 g, 14.5 mmol) in MTBE/EtOH (20 mL, 1:1 v/v)
was stirred for 19 hours at 80 °C.i The mixture was diluted with ethanol 
(100 mL) and hydrochloric acid (2.0 M, 13.0 mL) was added dropwise.ii After 
stirring for six hours at room temperature the solution was diluted with MTBE 
(100 mL) and subsequently washed with saturated sodium bicarbonate solution 
(100 mL) and brine (100 mL). The organic phase was dried over MgSO4 and all 
volatile compounds were removed in vacuo. The residue was taken up in 
MTBE/EtOH (50 mL, 1:1 v/v) and cooled to -70 °C (acetone/dry ice). Diethyl 
methoxyborane (1.0M in THF, 14.5 mL, 14.5 mmol, 1.0 eq.) was added dropwise 
to the stirring solution. Sodium borohydride (0.71 g, 18.9 mmol, 1.3 eq.) was 
added in portions and the mixture was stirred for additional three hours at -
70 °C.iii An aqueous sodium bicarbonate solution (2.0 M, 25 mL) was added and 
the phases were separated. The aqueous phase was extracted with MTBE 
(50 mL) and the combined organic phase was washed with brine (50 mL). The 
organic phase was separated and hydrogen peroxide (33 % in H2O, 15 mL) was 
added dropwise at 50 °C. The mixture was stirred for additional 90 minutes at 
50 °C and subsequently diluted with brine (30 mL). After additional 40 minutes
stirring while cooling down to room temperature, the phases were separated 
and the organic phase was washed with brine (75 mL). The solution was dried 
over MgSO4 and all volatile compounds were removed in vacuo. The crude 
product was analyzed by 1H-NMR spectroscopy. Comparison with an internal 
standardiv revealed a product content of 5.03 g (10.2 mmol, 70.3 % overall 
yield) for Rosuvastatin methyl ester.
The spectroscopical data is in accordance with chapter 8.14.2.
i 1H-NMR analysis shows a product-related conversion of 97% for the aldehyde.
ii The solution decolorizes from orange to light yellow during TBS deprotection. TLC control is 
done on silica (50 % v/v ethyl acetate in n-heptane)
iii The reaction progress is monitored via TLC control (silica, 50 % ethyl acetate in n-heptane)
iv p-Chlorbenzyl alcohol
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8.17 PROCESS DEVELOPMENT C: RECYCLING OF BIOCATALYSTS
8.17.1 RECYCLING PROCEDURE FOR ΑLPHA-CHYMOTRYPSIN FROM 
HOMOGENOUS REACTION
A solution of α-chymotrypsin (500 mg, CHY-03) in KPB (12.5 mL, 50 mM, pH 
8.0) was stirred at room temperature. Diethyl 3-(acetyl)-oxyglutarate (12.3 g, 
50.0 mmol) was added to a substrate concentration of 4.0 M. The resulting 
emulsion was stirred vigorously at room temperature while maintaining pH 8.0 
by titration with sodium hydroxide (4.0 M). After the complete conversion of 
starting material the clear reddish-colored solution was transferred to 
an ultrafiltration stirring cell (100 mL) equipped with an ultrafiltration 
membrane (Merck Millipore, PLGC, 10,000 NMWC, regenerated cellulose)) via
pipette. The cell was pressurized with argon (2.0 bar) while stirring at 500 rpm. 
The clear filtrate was collected and directly used for the following step. After 
depressurizing the cell the remaining enzyme slurry was taken up in KPB 
(12.5 mL, 50 mM, pH 8.0) and transferred to the titration vessel for the second 
reaction cycle. Diethyl 3-(acetyl)-oxyglutarate (12.3 g, 50.0 mmol) was added 
and the reaction was stirred at room temperature while maintaining pH 8.0 by 
titration with sodium hydroxide (4.0 M). This procedure was continued until five 
reaction cycles were complete. The productivity was calculated with the 
reaction time necessary to reach quantitative conversion for each reaction 
batch, i.e. the consumption of the minimum theoretical amount of sodium 
hydroxide (12.5 mL, 4.0 M), and interpolation to 1.0 g of intermediate within 24 
hours (see Table 56, page 241).
8.17.2 RECYCLING PROCEDURE FOR CEPHALOSPORIN C ACETYLESTERASE 
(CAE) FROM HETEROGENOUS REACTION
The filtrate of the first batch of the desymmetrization described in chapter
8.16.1, i.e. KPB (25 mL, 25 mM, pH 8.0) containing sodium (3R)-5-ethoxy-
3-(ace-tyl)-oxy-5-oxopentanoate (12.0 g, 50.0 mmol), was collected in a 
titration vessel and stirred at room temperature. Cephalosporin C 
acetylesterase (CAE, immobilized, 500 mg) was added and the resulting 
suspension was stirred at room temperature while maintaining pH 8.0 by 
titration with sodium hydroxide (4.0 M). After the complete conversion of 
intermediate the suspension was filtered over a glass frit (Por4, 10-16 μm). The 
filtrate was collected for extraction and the biocatalyst was transferred to the 
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titration vessel with a scoop. It was taken up with the filtrate of the second 
cycle from the desymmetrization reaction and again stirred at room 
temperature while maintaining pH 8.0 by titration with sodium hydroxide 
(4.0 M). This procedure was continued until five reaction cycles were complete. 
The productivity was calculated with the reaction time necessary to reach 
quantitative conversion for each reaction batch, i.e. the consumption of the 
minimum theoretical amount of sodium hydroxide (12.5 mL, 4.0M), and 
interpolation to 1.0 g of intermediate within 24 hours (see Table 56, page 241).
After saturation with neat sodium chloride the work-up of the filtrates was 
conducted as described in SOP6. 
Table 56. Recycling of homogenous and heterogenous biocatalysts
Cycle Conversion I Conversion II
α-Chymotrypsin 
I
CAEa II
[%] [%] [mg/(gPr*d)] [mg/(gPr*d)]
1 >95.0 >95.0 31.51 44.35
2 >95.0 >95.0 32.12 44.64
3 >95.0 >95.0 38.27 49.36
4 >95.0 >95.0 68.34 49.65
5 >95.0 >95.0 124.43 49.91
(a) Cephalosporin C acetyl hydrolase (CAE), immobilized
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8.18 PROCESS DEVELOPMENT D: OPTIMIZATION OF EXTRACTION YIELDS BY 
PHYSICOCHEMICAL AND TECHNICAL MEANS
8.18.1 CONTINUOUS LIQUID – LIQUID EXTRACTION BY PERFORATION IN A 
KUTSCHER - STEUDEL APPARATUS
The following procedure was used for the extraction of aqueous reaction 
phases of the biocatalytic desymmetrization with α-chymotrypsin (chapter 8.3) 
and the biocatalytic deacetylation with Cephalosporin C acetylesterase (chapter 
8.7.1), respectively. Both biocatalysts were present in the solution, leading to 
significant emulsification during usual work-up in a separation funnel.
In general, the acidified aqueous phase of a biocatalytic reaction was placed in 
a KUTSCHER – STEUDEL apparatus for the continuous extraction with organic 
solvents that have a lower density as the buffered reaction mixture, e.g. ethyl 
acetatei and tert-butyl methylether (MTBE). The aqueous solution was diluted 
to 50 vol-% of the extraction tube and overlayed by 50 vol-% of the 
corresponding organic solvent. A down-pipe was immersed and the receiver 
was filled with 100 vol-% of the same organic solvent. The receiver solution was 
stirred for 4-12 hours at reflux temperature. The boiling solvent was distilled 
into a DIMROTH cooler above the down-pipe and was directly flowing to the 
bottom of the extraction tube, bubbling through the aqueous phase and 
continuously extracting organic compounds. The surface of the organic solvent 
rises until it streams back into the receiver. With this methodology the product 
was continuously enriched in the receiver without additional solvent. Due to 
the low perturbation of the aqueous phase, emulsification was also significantly 
reduced.
Table 57. Continous liquid-liquid extraction of aqueous reaction media
Entry R (mmol) Solvent Perforation [h] Yield [g (%)]
1 Ac (40.0) AcOEt 4 8.45 (96.8)
2 Ac (40.0) MTBE 4 7.94 (90.9)
3 H (40.0) MTBE 12 6.63 (94.1)
i Ethyl acetate showed better extraction yields than MTBE. However, there were also significant 
boiling delays which do not occur in MTBE.
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8.18.2 DETERMINATION OF THE DISTRIBUTION COEFFICIENTS IN BINARY 
PHASES FOR MINIMIZING THE AMOUNT OF ORGANIC SOLVENTS IN 
EXTRACTIVE WORK-UPS
The continuous liquid-liquid extraction depends on the availability of technical 
equipment, in this case, a perforator. As it was not an option for the industrial 
process, the distribution coefficient for (3R)-5-ethoxy-3-hydroxy-5-
oxopentanoic acid in various binary extraction mixtures was determined 
empirically.
In general, a crude product of β-oxycarboxylic acid was weight into a vial and 
dissolved in hydrochloric acid (5 mL, 2.0 M), mimicking the acidified aqueous 
reaction mixture prior to extraction. The solution was overlaid with the same 
volume of an immiscible organic solvent (see Table 58, page 243) and was 
vigorously shaken for 30 seconds. The mixture was resting for ten minutes
while the phases separated. Three aliquots of each 1.0 mL of the organic phase 
were transferred to flasks and all volatile compounds were removed in vacuo. 
The residue was weighed out and analyzed by 1H-NMR spectroscopy. By 
comparison with an internal standard, p-chlorobenzyl alcohol, the product 
content was determined and extrapolated to the total volume of organic 
solvent. As it was common practice to salt out water-soluble organic 
compounds with a partition coefficient of P < 10, the experiments were also 
done with a solution of hydrochloric acid in brine (2.0 M) as aqueous phase.
Table 58. Determination of the distribution coefficients (D) of 
(3R)-5-ethoxy-3-hydroxy-5-oxopentanoic acid in various 
extraction mixtures
Ethyl acetate
Weigh-out D
Content 
(NMR)
D 
(NMR)
[mg]
Sample 1 477,10 3,78 69,5% 1,22
Sample 2 474,45 3,68 71,0% 1,26
Sample 3 469,60 3,51 71,8% 1,27
Weigh-in [mg] 888,51 Average D 3,66 1,25
Content (NMR) [mg] 603,30 STDEV D 0,11 0,02
Ethyl acetate with NaCl 
saturation
Weigh-out D
Content 
(NMR)
D 
(NMR)
[mg]
Sample 1 550,90 5,99 93,4% 4,01
Sample 2 560,55 6,81 87,6% 3,24
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Sample 3 564,00 7,16 94,1% 4,74
Weigh-in [mg] 890,31 Average D 6,66 3,99
Content (NMR) [mg] 642,80 STDEV D 0,49 0,61
tert-Butyl methylether
Weigh-out D
Content 
(NMR)
D 
(NMR)
[mg]
Sample 1 325,15 1,19 63,4% 0,52
Sample 2 320,30 1,15 65,2% 0,54
Sample 3 321,65 1,16 64,1% 0,52
Weigh-in [mg] 882,37 Average D 1,16 0,53
Content (NMR) [mg] 599,13 STDEV D 0,02 0,005
tert-Butyl methylether with 
NaCl saturation
Weigh-
out
D
Content 
(NMR)
D 
(NMR)
[mg]
Sample 1 430,55 2,08 88,7% 1,49
Sample 2 443,35 2,28 89,9% 1,67
Sample 3 425,45 2,01 94,5% 1,71
Weigh-in [mg] 882,87
Average 
D
2,12 1,62
Content (NMR) [mg] 637,43 STDEV D 0,12 0,09
Isopropyl acetate
Weigh-
out
D
Content 
(NMR)
D 
(NMR)
[mg]
Sample 1 249,50 0,64 91,2% 0,55
Sample 2 255,10 0,66 87,8% 0,54
Sample 3 246,60 0,63 86,4% 0,50
Weigh-in [mg] 886,92
Average 
D
0,64 0,53
Content (NMR) [mg] 640,36 STDEV D 0,01 0,02
Isopropyl acetate with NaCl 
saturation
Weigh-
out
D
Content 
(NMR)
D 
(NMR)
[mg]
Sample 1 462,75 2,57 95,7% 2,22
Sample 2 457,35 2,47 95,8% 2,14
Sample 3 453,55 2,40 95,2% 2,05
Weigh-in [mg] 889,89
Average 
D
2,48 2,14
Content (NMR) [mg] 642,50 STDEV D 0,07 0,07
Methyl-THF
Weigh-
out
D
Content 
(NMR)
D 
(NMR)
[mg]
Sample 1 483,40 2,56 90,8% 1,88
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Sample 2 484,25 2,57 91,1% 1,91
Sample 3 506,40 3,05 91,0% 2,18
Weigh-in [mg] 885,95
Average 
D
2,73 1,99
Content (NMR) [mg] 672,44 STDEV D 0,23 0,13
Methyl-THF with NaCl 
saturation
Weigh-
out
D
Content 
(NMR)
D 
(NMR)
[mg]
Sample 1 641,90
24,2
2
86,2% 4,81
Sample 2 639,25
21,9
3
86,3% 4,73
Sample 3 611,10
10,6
7
95,6% 6,94
Weigh-in [mg] 880,63
Average 
D
18,9
4
5,49
Content (NMR) [mg] 668,40 STDEV D 5,93 1,02
Table 59. Calculations of the number of necessary extractions for 
quantitative extraction of (3R)-5-ethoxy-3-hydroxy-5-
oxopentanoic acid from aqueous reaction media
Extr. # >95% 1M conc.
Organic solvent D
STDEV 
(+-)
1 2 3 4 5 6
Ethyl acetate 1,25 0,02 55,6% 80,2% 96,1% 99,8% 100,0% 100,0%
Ethyl acetate + NaCl 3,99 0,61 80,0% 96,0% 99,8% 100,0% 100,0% 100,0%
Isopropyl acetate 0,53 0,02 34,6% 57,3% 81,8% 96,7% 99,9% 100,0%
Isopropyl acetate + NaCl 1,62 0,07 61,8% 85,4% 97,9% 100,0% 100,0% 100,0%
Methyl-THF 1,99 0,13 66,6% 88,8% 98,7% 100,0% 100,0% 100,0%
Methyl-THF + NaCl 5,49 1,02 84,6% 97,6% 99,9% 100,0% 100,0% 100,0%
tert-Butyl methylether 0,53 0,005 34,6% 57,3% 81,8% 96,7% 99,9% 100,0%
tert-Butyl methylether + NaCl 2,14 0,09 68,2% 89,9% 99,0% 100,0% 100,0% 100,0%
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9 EXPERIMENTAL PROCEDURES – ALDOXIME DEHYDRATASES
9.0 MATERIALS AND METHODS
Chemicals
Unless stated otherwise all chemicals and solvents (reagent and HPLC grades) 
were purchased from commercial manufacturers (Sigma-Aldrich, Nacalai 
Tesque, Tokyo Chemical Industry Co., Ltd., Wako Pure Chemical Industries, Ltd., 
Kanto Chemical Co. Inc.) and used without further purification. 
Phenylacetaldehyde, 2-phenyl-propionaldehyde, cyclohex-3-ene-1-
carboxaldehyde, bicyclo[2.2.1]hept-5-ene-2-carboxaldehyde, tetrahydrofuran-
3-carboxaldehyde (50 w% in H2O) and 3-phenylbutyraldehyde were purchased 
from Tokyo Chemical Industry Co., Ltd., Tokyo, Japan. Tetrahydrofuran-3-
carboxaldehyde was purified by extraction with ethyl acetate and subsequent 
Kugelrohr distillation. Hydroxylammonium chloride (Wako 1st grade) was 
purchased from Wako Pure Chemical Industries, Ltd., Osaka, Japan. Bacto Yeast 
Extract, Bacto Tryptone and agar powder were purchased from Wako Pure 
Chemical Industries, Ltd., Osaka, Japan and Nacalai Tesque, Shiga, Japan, 
respectively. Deuterated solvents chloroform-d (>99.9%, stabilized with silver 
foil, 0.03% v/v TMS) and dimethylsulfoxide-d6 (>99.8%) were purchased from 
Acros Organics, New Jersey, USA and Alfa Aeser, Lancashire, UK, respectively.
Photometric measurements
The protein content of purification fractions was determined by staining with 
“Bio-Rad Protein Assay Dye Reagent Concentrate” from Bio-Rad Laboratories 
GmbH, Munich, Germany, in a 1:5 dilution. The absorbance at 595 nm was 
measured on 96-well plates (Thermo Scientific Nunc*) in a TECAN infinite®
M200 Pro and plotted against a linear standard curve of bovine serum albumin 
(BSA, Cohn Fraction V, pH 7.0) purchased from Wako Pure Chemical Industries, 
Ltd., Osaka, Japan. The cell growth (OD) of cultivation experiments was 
measured at 610 nm in 10mm cuvettes in a JASCO V-630Bio 
spectrophotometer against the corresponding pure growth medium.
Incubators
The 0.5 mL-scaled screening experiments were conducted in a TAITEC 
BioShaker M-BR-024 at 15 °C and 30 °C, respectively. The biotransformations at 
8 °C were reciprocally shaken in a TAITEC PersonalLt-10F equipped with a 
freezing unit (5 - 200 mL scale) or a constant temperature bath with magnetic 
stirrer EYELA PSL-2000 (100 - 500 mL scale), respectively. The cell cultures 
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(250 - 1000 mL) were incubated in a New Brunswick Scientific innova® 44, 
Eppendorf, Enfield, USA.
Centrifugation
Removal of whole-cells for work-up and HPLC analysis was done in a 
Eppendorf Centrifuge 5415R or HITACHI CT15RE (15,000 rpm, 4 °C, 5 min, 
1.5 mL microtubes), a HITACHI CR22GIII (12,000 rpm, 4 °C, 5 min, 5 - 50 mL 
falcon tubes) and a HITACHI CR 21G (6,000 rpm, 4 °C, 10 min, 500 mL PPCO 
bottles), respectively. The latter was also used for the work-up and 
concentration of cell cultures. Pooled purification fractions of OxdB were 
concentrated in Millipore Centriprep centrifuge filtration units equipped 
with ULtracel® 10K membranes (10,000 Da MWC) at 3,000 x g and 4 °C.
Nutrient media and agar plates
Overexpression of Oxd in recombinant E. coli was carried out in LB medium 
(1.0 % Bacto Tryptone, 0.5 % Bacto Yeast Extract, 1.0 % sodium chloride, pH 
7.0) or MMI medium (1.25 % Bacto Tryptone, 2.5 % Bacto Yeast Extract, 0.85 % 
sodium chloride, 20 mM Tris-HCl [pH 7.5], 0.4 % glycerol), respectively, 
containing 100 mg/mL ampicillin. Induction of lac expression was initiated with 
the addition of 1 mM isopropyl-β-thiogalactopyranoside (IPTG) either from the 
beginning or after reaching the exponential cell growth (A610 = 0.5 - 1.0). For 
the cultivation of already expressed vectors 2 μL of a glycerol stock solution 
(1:1 v/v) of HB101/pOxD-9OF and BL21 Star (DE3)/pOxD-S17, respectively, were 
spread over LB agar plates containing 100 μg/mL ampicillin. The plates were 
incubated at 37 °C for 12-16 hours.
High-Performance Liquid Chromatography (HPLC)
The conversion and composition of the aqueous reaction phase was measured 
on a Shimadzu LC20-AD equipped with a SPD-20A UV/Vis detector, a CTO-
20AC column oven (40 °C), a SIL-20AC autosampler and a reversed-phase HPLC 
column COSMOSIL 5C18-MS-II (4.6 ID x 150 mm) with isocratic mixtures of 
acetonitrile in DIW (10-30 %) as mobile phase. The enantiomeric excess of 2-
phenylpropionitrile, bicycle[2.2.1]-hept-5-ene-2-carbonitrile and 3-
phenylbutyronitrile was measured on a Shimadzu LC-10AT equipped with a 
FLOM Co. Ltd. GASTORR degasser unit, a WatersTM 486 UV/Vis detector, a 
Waters 717 plus autosampler, a Sugai U-620 V50 column heater and a 
Shimadzu C-R6A Chromatopac printer. The enantiomers were separated on 
normal-phase Daical Chiralcel OJ-H, OD-H and Chiralpak AD-H columns, 
respectively, with isocratic mixtures of 2-propanol in n-hexane (1-5 % v/v) as 
mobile phase.
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Gas chromatography (GC)
The enantiomeric excess of cyclohex-3-ene-1-carbonitrile and tetrahydro-
furan-3-carbonitrile were measured on a Shimadzu GC-14B equipped with an 
AOC-20i autoinjector, an AOC-20s autosampler, a C-R8A Chromatopac printer 
and a flame ionization detector (FID). The enantiomers were separated on a 
chiral GC column BGB-174 (0.25 ID x 30 m, 0.25 μm film) from BGB Analytik AG, 
Switzerland, at isocratic column temperatures of 120 °C or 150 °C.
Nuclear Magnetic Resonance (NMR)
All 1H-, 13C-, COSY-, NOESY- and HMQC-NMR spectra were measured on a 
Bruker AVANCE III ULtrashield 400 Plus and processed with the software 
TopSpin (Version 3.2). The shifts were measured in chloroform-d and 
dimethylsulfoxide-d6, respectively, and given in relation to tetramethylsilane 
(TMS, δ = 0.0 ppm). The frequencies used for 1H- and 13C- measurements were 
400 MHz and 100 MHz, respectively. Unless otherwise stated all measurements 
were done at room temperature.
Polarimeter
For the identification of enantiomers the specific optical rotary power of 
2-phenylpropionitrile and E-2-phenylpropionaldoxime were measured on an 
ATAGO AP-300 automatic polarimeter. All values were measured at least ten 
times in a 10.01-mm cell at 589.3 nm (sodium D-Line). The direction of 
polarization is given as “+” (dextrorotary) or “-“ (levorotary).
9.1 STANDARD OPERATING PROCEDURE 14 (SOP14): SYNTHESIS OF 
RACEMIC ALDOXIMES THROUGH CONDENSATION OF CHIRAL 
ALDEHYDES WITH HYDROXYLAMINE SALTS
Hydroxylamine salt (e.g. hydroxylamine hydrochloride, hydroxylamine 
phosphate, 1.0 - 1.5 eq.) and a soluble base (e.g. sodium acetate, potassium 
carbonate, pyridine, 1.3 - 2.0 eq.) were mixed and suspended in deion. H2O
(DIW) or ethanol (0.10 - 0.45 M) and vigorously stirred for five minutes at 0 °C 
to room temperature.i After the addition of racemic aldehyde (45.0 - 120.0 
mmol) the mixture was vigorously stirred for at least two hours at room 
i The salts are completely dissolved (hydroxylamine hydrochloride) or suspended (hydroxylamine 
phosphate), respectively. Regardless of isomerism at elevated temperatures there was nearly no 
effect of low temperature (even -20 °C in ethanol) on the isomeric ratio of E/Z-aldoxime.
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temperature, until TLC shows complete conversion.i The mixture was extracted 
three times with ethyl acetate (1:1 v/v), the organic phases were combined and 
dried over anhydrous MgSO4. After filtration the solvent was removed in vacuo
and the crude product was purified by column chromatography on silica or 
Kugelrohr distillation, respectively. The conformation and E/Z-ratio were 
determined via 1H-NMR spectroscopy and the enantiomeric excess was 
determined via chiral HPLC or GC, respectively. 
Table 60. Substrate synthesis of racemic aldoximes by condensation of chiral 
aldehydes with hydroxylamine
Entry R1 R2
Conv. (time)
[% (h)]
Isol. Yield
[g (%)]
1 Ph Me >95.0 (2.0) 8.46 (94.5)
2 1-Cyclohex-3-ene >95.0 (2.0) 3.63 (96.8)
3 2-Norborn-5-ene >95.0 (2.0) 2.40 (44.1)
4 3-Tetrahydrofuran >95.0 (2.0) 3.93 (75.9)
5 2-Ph-Pr H >95.0 (2.0) 3.03 (82.5)
9.1.1 RAC-E/Z-2-PHENYLPROPIONALDEHYDE OXIME
The synthesis was conducted according to SOP14. Hydroxylamine 
hydrochloride (6.25 g, 90.0 mmol, 1.5 eq.) and sodium carbonate (9.54 g, 90.0 
mmol, 1.5 eq.) were suspended in DIW (100 mL). After the addition of rac-
2-phenylpropionaldehyde (8.05 g, 60.0 mmol) the mixture was vigorously 
stirred at room temperature for at least two hours until TLC shows complete 
conversion. The work-up was done as described in SOP 14 to obtain the 
product as colorless oil (E/Z = 72:28). An aliquot of 0.20 g was separated into 
the corresponding E- and Z-isomer by column chromatography on silica (10% 
v/v ethyl acetate in n-hexane, Ø = 1.5 cm, h = 40 cm, 60-200 μm, pH 6-8) to 
yield 0.12 g rac-E-2-phenylpropionaldehyde oxime (98 % isomeric purity), 0.02 
g of an E/Z-mixture (1:1) and 0.06 g rac-Z-2-phenylpropionaldehyde oxime 
(92 % isomeric purity).
i The conversion is determined by TLC with different n-hexane/ethyl acetate eluents and 
phosphomolybdic acid (5 % in ethanol, heating to 300 °C).
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Reversed-phase HPLC: Nacalai Tesque COSMOSIL C18-MS-II, 30 % v/v
acetonitrile in water, 1.0 mL/min, 40 °C, 254 nm, Rt1 = 11.0 min (E), Rt2 = 12.4 
min (Z).
Normal-phase chiral HPLC: Daicel Chiralcel OJ-H, 5 % v/v 2-propanol in n-
hexane, 0.7 mL/min, 20 °C, 210 nm, Rt1 = 20.4 min (Z-2S), Rt1 = 26.7 min (E-2S), 
Rt1 = 30.0 min (Z-2R), Rt1 = 31.5 min (E-2R).
Isolated yield: 8.46 g (56.7 mmol, 94.5 %).
E-rac-2-Phenylpropionaldehyde oxime:
1H-NMR (400 MHz, CDCl3): δ [ppm] = 7.52 (d, J = 6.1 Hz, 1H, HC=NOH), 7.38 –
7.19 (m, 5H, Ar-H), 3.67 (m, J = 6.8 Hz, 1H, CH-CH=NOH), 1.46 (d, J = 7.0 Hz, 
3H, CH3).
13C NMR (100 MHz, CDCl3): δ [ppm] =155.09, 142.11, 128.74, 127.39, 126.95, 
40.37, 18.75.
Z-rac-2-Phenylpropionaldehyde oxime:
1H-NMR (400 MHz, CDCl3): δ [ppm] = 7.38 – 7.19 (m, 5H, Ar-H), 6.80 (d, J = 7.3 
Hz, 1H, HC=NOH), 4.45 (m, 1H, CH-CH=NOH), 1.42 (d, J = 7.0 Hz, 3H, CH3).
13C NMR (100 MHz, CDCl3): δ [ppm] =154.62, 141.78, 128.69, 127.19, 126.82, 
34.99, 18.28.
The data corresponds to literature-known values.138
9.1.2 RAC-E/Z-CYCLOHEX-3-ENECARBALDEHYDE OXIME
The following synthesis was performed according to SOP 14. Hydroxylamine
hydrochloride (3.13 g, 45.0 mmol) and sodium carbonate (4.77 g, 45.0 mmol) 
were suspended in dist. H2O (50 mL) and vigorously stirred at room 
temperature. After the addition of 3-cyclohexene-1-carboxaldehyde (3.30 g, 
30.0 mmol) the mixture was vigorously stirred for at least two hours until TLC 
shows complete conversion. The work-up was done as described in SOP14. 
After filtration the solvent was removed in vacuo and the crude product was 
purified via column chromatography on silica (h = 15 cm, Ø = 6 cm, 9 % v/v
ethyl acetate in n-hexane) to obtain the product as colorless oil in several 
isomeric mixtures (E/Z = 9:1, 4:1, 2:1).
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The chiral GC analysis for the corresponding nitrile shows the aldoxime at 
Rt1 = 18.9 min (Z) and Rt2 = 19.2 min (E), regardless of configuration.
Isolated yield: 3.63 g (29.0 mmol, 96.8 %).
E-rac-3-Cyclohexene-1-carbaldehyde oxime:
1H-NMR (400 MHz, CDCl3): δ [ppm] = 7.42 (d, J = 6.0 Hz, 1H, HC=NOH), 5.69 
(m, 2H, HC=CH), 2.60 – 2.45 (m, 1H, CH-CH=NOH), 2.32 – 1.78 (m, 5H, CH2), 
1.65 – 1.46 (m, 1H, CH2-CH2-CH).
13C-NMR (100 MHz, CDCl3): δ [ppm] = 155.33, 126.99, 125.10, 34.45, 28.50, 
26.10, 24.11.
Z-rac-3-Cyclohexene-1-carbaldehyde oxime:
1H-NMR (400 MHz, CDCl3): δ [ppm] = 6.65 (d, J = 7.3 Hz, 1H, HC=NOH), 5.69 
(m, 2H, HC=CH), 3.33 – 3.18 (m, 1H, CH-CH=NOH), 2.32 – 1.78 (m, 5H, CH2), 
1.65 – 1.46 (m, 1H, CH2-CH2-CH).
13C-NMR (100 MHz, CDCl3): δ [ppm] = 156.11, 127.06, 125.10, 29.76, 27.87, 
25.16, 23.75.
The data corresponds to literature-known values.139
9.1.3 RAC-E/Z-5-NORBORNENE-2-CARBALDEHYDE OXIME
The following synthesis was performed according to SOP 14. Hydroxylamine 
hydrochloride (4.17 g, 60.0 mmol) and sodium carbonate (6.36 g, 60.0 mmol) 
were suspended in DIW (40 mL) and vigorously stirred at room temperature. 
After the addition of 5-norbornene-2-carboxaldehyde (5.0 mL, 39.7 mmol) the 
mixture was vigorously stirred for at least two hours until TLC shows complete 
conversion. The work-up was done according to SOP 14. The crude product
was purified by column chromatography on silica (h = 12 cm, Ø = 6 cm, 15% 
v/v ethyl acetate in n-hexane) to obtain a diastereomeric mixture of the 
product as colorless oil (E-(R)/E-(S)/Z-(R)/Z-(S) = 0.47 : 0.08 : 0.35 : 0.10).
Isolated yield: 2.40 g (17.5 mmol, 44.1 %).
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E-(1S,2S,4S)-Bicyclo[2.2.1]hept-5-ene-2-carbaldoxime:
1H-NMR (400 MHz, CDCl3) δ 7.45 (d, J = 7.4 Hz, 1H, HC=NOH), 6.12 (m, 2H, 5 and 
6), 2.92 (m, 1H, 4), 2.82 (m, 1H, 1), 2.23 (m, 1H, 2), 1.62 (m, 1H, 3a), 1.45 (m, 1H, 
7a), 1.38 (m, 1H, 3b), 1.35 (m, 1H, 7b).
13C-NMR (100 MHz, CDCl3): δ [ppm] = 156.02, 137.42, 135.57, 49.50, 46.27, 
41.78, 38.72, 30.45.
E-(1S,2R,4S)-Bicyclo[2.2.1]hept-5-ene-2-carbaldoxime:
1H-NMR (400 MHz, CDCl3) δ 7.05 (d, J = 8.0 Hz, 1H, HC=NOH), 6.21 (m, 1H, 5),
5.98 (m, 1H, 6), 2.98 (m, 1H, 1), 2.90 (m, 1H, 2), 2.89 (m, 1H, 4), 1.99 (m, 1H, 3a), 
1.46 (m, 1H, 7a), 1.30 (m, 1H, 7b), 1.05 (m, 1H, 3b).
13C-NMR (100 MHz, CDCl3): δ [ppm] = 156.47, 138.04, 132.26, 49.40, 46.69, 
42.55, 38.91, 30.74.
Z-(1S,2S,4S)-Bicyclo[2.2.1]hept-5-ene-2-carbaldoxime:
1H-NMR (400 MHz, CDCl3) δ 6.72 (d, J = 8.0 Hz, 1H, HC=NOH), 6.12 (m, 2H, 5
and 6), 2.93 (m, 1H, 4), 2.85 (m, 1H, 1), 2.77 (m, 1H, 2), 1.50 (m, 1H, 3a), 1.45 (m, 
1H, 7a), 1.41 (m, 1H, 3b), 1.35 (m, 1H, 7b).
13C-NMR (100 MHz, CDCl3): δ [ppm] = 157.00, 137.67, 135.71, 49.50, 46.21, 
42.09, 33.84, 31.88.
Z-(1S,2R,4S)-Bicyclo[2.2.1]hept-5-ene-2-carbaldoxime:
1H-NMR (400 MHz, CDCl3) 6.37 (d, J = 7.4 Hz, 1H, HC=NOH), 6.21 (m, 1H, 5),
6.03 (m, 1H, 6), 3.46 (m, 1H, 2), 3.08 (m, 1H, 1), 2.92 (m, 1H, 4), 2.11 (m, 1H, 
3a1.46 (m, 1H, 7a), 1.30 (m, 1H, 7b), 0.91 (m, 1H, 3b).
13C-NMR (100 MHz, CDCl3): δ [ppm] = 156.96, 138.14, 132.67, 49.40, 45.47, 
42.55, 34.18, 32.12.
The compound is literature-known. However, no NMR data is available. The 
isomers were distinguished by 1H-COSY analysis of the diastereomers.
9.1.4 RAC-E/Z-TETRAHYDROFURAN-2-CARBALDEHYDE OXIME
The following synthesis was conducted according to SOP14. Hydroxylamine 
phosphate (2.96 g, 15.0 mmol) and sodium acetate (4.92 g, 60.0 mmol) were 
suspended in dist. H2O (40 mL) and vigorously stirred at room temperature. 
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After the addition of tetrahydrofuran-3-carboxaldehyde (4.10 mL, 45.0 mmol) 
the mixture was vigorously stirred for at least two hours until TLC shows 
complete conversion. The work-up was dome as described in SOP14. After 
filtration the solvent was removed in vacuo and the crude product was purified 
via Kugelrohr distillation (0.5 mbar, 110 °C to give the product as colorless oil 
(E/Z 50:50). 
The chiral GC analysis for the corresponding nitrile shows the aldoxime at 
Rt = 9.7 min, regardless of conformation or configuration.
Isolated yield: 3.93 g, (34.1 mmol, 75.9 %).
E-rac-Tetrahydrofuran-3-carbaldoxime:
1H-NMR (400 MHz, CDCl3): δ [ppm] = 7.32 (d, J = 6.7 Hz, 1H, HC=NOH), 3.95
(m, 1H, O-CH2-CH), 3.82 (m, 2H, O-CH2-CH2), 3.69 (m, 1H, O-CH2-CH), 3.08 (m, 
1H, CH2-CH-CH2), 2.18 (m, 1H, CH-CH2-CH2), 1.90 (m, 1H, CH-CH2-CH2).
13C-NMR (100 MHz, CDCl3): δ [ppm] = 152.02, 70.61, 68.03, 39.45, 30.58.
Z- rac-Tetrahydrofuran-3-carbaldoxime:
1H-NMR (400 MHz, CDCl3): δ [ppm] = 6.63 (d, J = 5.4 Hz, 1H, HC=NOH), 4.02
(m, 1H, O-CH2-CH), 3.92 (m, 2H, O-CH2-CH2), 3.65 (m, 1H, O-CH2-CH), 3.64 (m, 
1H, CH2-CH-CH2), 2.25 (m, 1H, CH-CH2-CH2), 1.82 (m, 1H, CH-CH2-CH2).
13C-NMR (100 MHz, CDCl3): δ [ppm] = 153.27, 70.86, 67.94, 35.05, 30.66.
The compound is literature-known. However, no NMR data is available.
9.1.5 RAC-E/Z-3-PHENYLBUTYRALDEHYDE OXIME
The following synthesis was conducted according to SOP14. Hydroxylamine 
phosphate (1.48 g, 7.5 mmol) and sodium acetate (2.46 g, 30.0 mmol) were 
suspended in dist. H2O (40 mL) and vigorously stirred at room temperature. 
After the addition of rac-3-phenylbutyraldehyde (3.35 mL, 22.5 mmol) the 
mixture was vigorously stirred for at least two hours until TLC shows complete 
conversion. The work-up was done as described in SOP14. After filtration the 
solvent was removed in vacuo and the crude product was purified by column 
chromatography on silica (Ø = 6cm, h = 8cm, 20% v/v ethyl acetate in 
cyclohexane) to obtain the product as colorless oil (E/Z = 50:50).
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Reversed-phase HPLC: Nacalai Tesque COSMOSIL C18-MS-II, 30 % v/v
acetonitrile in water, 1.0 mL/min, 40 °C, 254 nm, Rt1 = 14.9 min (E), Rt2 = 17.2 
min (Z).
Normal-phase chiral HPLC: Daicel Chiralcel OJ-H, 2 % v/v 2-propanol in n-
hexane, 0.7 mL/min, 20 °C, 210 nm, Rt1 = 33.2 min (Z-2S), Rt1 = 34.8 min (E-2S), 
Rt1 = 42.0 min (Z-2R), Rt1 = 45.6 min (E-2R).
Isolated yield: 3.03 g (18.6 mmol, 82.5 %).
E-rac-3-Phenylbutyraldoxime:
1H-NMR (400 MHz, CDCl3): δ [ppm] = 7.40 (d, J = 7.3 Hz, 1H, HC=NOH), 7.32 –
7.18 (m, 5H, Ar-H), 2.94 (m, 1H, Ph-CH-CH3), 2.53 – 2.41 (m, 2H, CH2), 1.31 (d,
J = 6.4 Hz, 3H, CH3).
13C-NMR (100 MHz, CDCl3): δ [ppm] = 151.02, 145.61, 128.61, 126.87, 126.46, 
38.00, 37.74, 22.22.
Z-rac-3-Phenylbutyraldoxime:
1H-NMR (400 MHz, CDCl3): δ [ppm] = 7.32 – 7.18 (m, 5H, Ar-H), 6.75 (d, J = 5.8
Hz, 1H, HC=NOH), 3.00 (m, 1H, Ph-CH-CH3), 2.77 – 2.58 (m, 2H, CH2), 1.29 (d,
J = 6.4 Hz, 3H, CH3).
13C-NMR (100 MHz, CDCl3): δ [ppm] = 151.26, 145.75, 128.61, 126.87, 126.46, 
37.20, 33.10, 21.67.
The compound is literature-known. However, no NMR data is available.
9.2 SYNTHESIS OF ISOMERICALLY ENRICHED E-2-PHENYLPROPION-
ALDOXIME
The following procedures were conducted according to literature procedures 
leading specifically to E- or Z-aldoximes. However, none of the tested methods 
could be adapted for aliphatic aldoximes. The crude products were not further 
purified.
[255]
Table 61. Stereoselective condensation with hydroxylamine for E- or Z-
aldoximes
Entry Catalyst Solvent Temp. Conv. ie (E/Z)
1 none H2O 20 >95% 60.3 (E)
2 none H2O 60 >95% 31.2 (E)
3 none EtOH -20 >95% 60.1 (E)
4 Mol. Sieves 3A none 20 n.d.a n.d.a
5 Pyridine EtOH 20 >95% 42.4 (E)
6 Cu(OAc)2 EtOH -40 >95% 23.2 (E)
(a) Decomposition of reagents, thus discarded.
9.3 STANDARD OPERATING PROCEDURE 15 (SOP15): SYNTHESIS OF 
RACEMIC NITRILES BY TPPO-CATALYZED OXIDATION OF ALDOXIMES
Oxalyl dichloride (1.5 eq.) and triphenylphosphine oxide (TPPO, 5 mol-%) were 
dissolved in dry dichloromethane (0.5 M) and stirred for 5 minutes at 0 °C. 
Racemic aldoxime (2.24 - 5.00 mmol) was dissolved in dry dichloromethane 
(10 mL) and added dropwise to the reaction solution. The reaction progress 
was monitored qualitatively by the emission of gaseous byproducts (CO2, CO, 
HCl). After two hours at 0 °C to room temperature the reaction was quenched 
by the addition of saturated aqueous sodium bicarbonate solution (20 mL). The 
aqueous phase was separated and extracted twice with dichloromethane (2 x 
50 mL). The organic phase was unified and washed once with brine (50 mL). 
The crude products were purified by column chromatography on silica (MTBE) 
or via Kugelrohr distillation, respectively, to remove remaining TPPO. The 
enantiomeric excess was determined by normal-phase chiral HPLC or GC. 
9.3.1 RAC-2-PHENYLPROPIONITRILE
Oxalyl dichloride (1.29 mL, 7.5 mmol) and triphenylphosphine oxide (69.6 mg, 
0.25 mmol) were dissolved in dry dichloromethane (10 mL) and stirred for 
5 minutes at 0 °C. rac-E/Z-2-phenylpropionaldehyde oxime (746 mg, 5.0 mmol) 
was dissolved in dry dichloromethane (10 mL) and added dropwise to the 
reaction solution. The work-up was done as described in SOP15. The crude 
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product was purified by filtration over a small silica column (MTBE) to obtain a 
colorless oil. 
Normal-phase chiral HPLC: Daicel Chiralcel OJ-H, 5 % v/v 2-propanol in n-
hexane, 0.7 mL/min, 210 nm, 20 °C, Rt1 = 13.8 min (R), Rt2= 14.3 min (S).
Isolated yield: 501 mg (3.82 mmol, 76.4%).
1H-NMR (400 MHz, CDCl3): δ [ppm] = 7.38 – 7.28 (m, 5H, Ar-H), 3.87 (q, J = 7.2 
Hz, 1H, CH-CN), 1.60 (d, J = 7.3 Hz, 3H, CH3).
13C-NMR (100 MHz, CDCl3): δ [ppm] = 137.17, 129.17, 128.06, 126.74, 121.66, 
31.22, 21.46.
The data corresponds to literature-known values.140
9.3.2 RAC-CYCLOHEX-3-ENECARBONITRILE
Oxalyl dichloride (0.29 mL, 3.36 mmol) and triphenylphosphine oxide (31.3 mg, 
0.11 mmol) were dissolved in dry dichloromethane (10 mL) and stirred for 
5 minutes at 0 °C. Cyclohex-3-enecarboxaldehyde oxime (281 mg, 2.24 mmol) 
was dissolved in dry dichloromethane (10 mL) and added dropwise to the 
reaction solution.  The work-up was conducted according to SOP15. The crude 
product was purified by Kugelrohr distillation (0.5 mbar, 100 °C). to obtain a
colorless oil.
Chiral GC (FID): BGB-174 (0.25 ID x 30 m, 0.25 μm film), 120 °C (isocratic), 
Rt1 = 22.5 min (major), Rt2 = 23.4 min (minor).
Isolated yield: 140 mg (1.31 mmol, 58.3 %).
1H-NMR (400 MHz, CDCl3): δ [ppm] = 5.79 – 5.73 (m, 1H, =CH-CH2-CH2), 5.67 –
5.62 (m, 1H, =CH-CH2-CH), 2.86 – 2.79 (m, 1H, CH-CN), 2.45 – 2.32 (m, 2H, 
=CH-CH2-CH), 2.31 – 2.04 (m, 2H, =CH-CH2-CH2), 2.03 – 1.84 (m, 2H, =CH-CH2-
CH2).
13C-NMR (100 MHz, CDCl3): δ [ppm] = 127.01, 123.28, 122.45, 28.19, 25.34, 
24.65, 22.92.
The compound is literature-known. However, no NMR data is available.
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9.3.3 RAC-5-NORBORNENE-2-CARBONITRILE
Oxalyl dichloride (0.47 mL, 5.48 mmol) and triphenylphosphine oxide (50.7 mg, 
0.18 mmol) were dissolved in dry dichloromethane (30 mL) and stirred for 
5 minutes at 0 °C. E/Z-5-norbornene-2-carbaldoxime (500 mg, 3.65 mmol) was 
dissolved in dry dichloromethane (10 mL) and added dropwise to the reaction 
solution.  The work-up was conducted according to SOP15. The crude product 
was purified via column chromatography on silica (MTBE) to obtain a colorless 
oil. 1H-NMR analysis shows a diastereomeric excess of 66.4 % de.
Normal-phase chiral HPLC: Daicel Chiralpak AD-H, 5 % v/v 2-propanol in
n-hexane, 0.7 mL/min, 210 nm, 20 °C, Rt1 = 7.8 min (S), Rt2= 8.6 min (R).
Isolated yield: 320 mg (2.69 mmol, 73.6 %).
(1S,2R,4S)-Bicyclo[2.2.1]-hept-5-ene-2-carbonitrile:
1H-NMR (400 MHz, CDCl3): δ [ppm] = 6.34 (dd, J = 5.7 Hz, 3.1 Hz, 1H, 5), 6.21
(dd, J = 5.7 Hz, 2.9 Hz, 1H, 6), 3.24 (m, 1H, 1), 3.04 (m, 1H, 4), 2.86 (dt, J = 9.4 
Hz, 3.8 Hz, 1H, 2), 2.13 (qd, J = 11.1 Hz, 3.5 Hz, 1H, 3a), 1.55 – 1.51 (m, 1H, 7b), 
1.37 – 1.32 (m, 1H, 3b), 1.23 – 1.19 (dm, 1H, 7a).
13C-NMR (100 MHz, CDCl3): δ [ppm] = 138.86, 132.77, 123.12, 48.55, 45.78, 
42.40, 32.50.
(1S,2S,4S)-Bicyclo[2.2.1]-hept-5-ene-2-carbonitrile:
1H-NMR (400 MHz, CDCl3): δ [ppm] = 6.17 (dd, J = 5.7 Hz, 2.9 Hz, 1H, 5), 6.05
(dd, J = 5.7 Hz, 3.1 Hz, 1H, 6), 3.24 (m, 1H, 4), 3.06 (m, 1H, 1), 2.20 (m, 1H, 3a), 
1.97 (dt, J = 12.3 Hz, 4.0 Hz, 1H, 2), 1.58 – 1.56 (m, 1H, 3b),  1.55 – 1.51 (m, 1H, 
7b), 1.23 – 1.19 (m, 1H, 7a).
13C-NMR (100 MHz, CDCl3): δ [ppm] = 138.16, 134.08, 123.64, 47.20, 45.78, 
41.85, 32.50.
The compound is literature-known. However, no 1H-NMR data is available.
9.3.4 RAC-TETRAHYDROFURAN-3-CARBONITRILE
Oxalyl dichloride (0.56 mL, 6.51 mmol) and triphenylphosphine oxide (60.4 mg, 
0.22 mmol) were dissolved in dry dichloromethane (30 mL) and stirred for 
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5 minutes at 0 °C. Tetrahydrofuran-3-carboxaldehyde oxime (500 mg, 4.34
mmol was dissolved in dry dichloromethane (10 mL) and added dropwise to 
the reaction solution.  The work-up was conducted according to SOP15. The 
crude product was purified via Kugelrohr distillation (0.5 mbar, 80 °C) to obtain
a colorless oil.
Chiral GC (FID): BGB-174 (0.25 ID x 30 m, 0.25 μm film), 120 °C (isocratic), 
Rt1 = 11.4 min (major), Rt2 = 12.3 min (minor). 
Isolated yield: 360 mg (3.71 mmol, 74.1 %).
1H-NMR (400 MHz, CDCl3): δ [ppm] = 4.05 – 3.84 (m, 4H, CH2-O-CH2), 3.09 (m, 
1H, CH-CN), 2.36 – 2.19 (m, 2H, CH2-CH2-O).
13C-NMR (100 MHz, CDCl3): δ [ppm] = 120.72, 70.53, 67.77, 30.87, 28.24.
The compound is literature-known. However, no NMR data is available.
9.3.5 RAC-3-PHENYLBUTYRONITRILE
Oxalyl dichloride (0.40 mL, 4.59 mmol) and triphenylphosphine oxide (44.8 mg, 
0.15 mmol) were dissolved in dry dichloromethane (30 mL) and stirred for 
5 minutes at 0 °C. rac-3-Phenylbutyraldehyde oxime (500 mg, 3.06 mmol), 
diluted with dry dichloromethane (5 mL) was added.  The work-up was 
conducted according to SOP15. The crude product was purified by column 
chromatography on silica (MTBE) to obtain a colorless oil.
Normal-phase chiral HPLC: Daicel Chiralcel OJ-H, 2 % v/v 2-propanol in n-
hexane, 0.7 mL/min, 210 nm, 20 °C, Rt1 = 23.3 min (major), Rt2= 24.6 min 
(minor).
Isolated yield: 420 mg (2.89 mmol, 94.5 %).
1H-NMR (400 MHz, CDCl3): δ [ppm] = 7.40 – 7.26 (m, 5H, Ar-H), 3.19 (m, 1H, 
Ph-CH-CH3), 2.61 (qd, J = 7.5 Hz, 6.5 Hz, 2H, CH2-CN), 1.48 (d, J = 7.0 Hz, 3H, 
CH3).
13C-NMR (100 MHz, CDCl3): δ [ppm] = 128.88, 127.34, 126.56, 118.58, 36.54, 
26.35, 20.68.
The data corresponds to literature-known values.141
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9.4 STANDARD OPERATING PROCEDURE 16 (SOP16): SYNTHESIS OF 
O-ACYLATED CHIRAL ALDOXIMES BY SCHOTTEN-BAUMANN REACTION
To a solution of aldoxime in an appropriate organic solvent (e.g. n-hexane, 
MTBE) was added triethylamine (2.0 eq.). The mixture was stirred for five 
minutes at room temperature. The desired acyl chloride (1.5 eq.) was added 
dropwise. The reaction was stirred for 2 – 6 hours at 0 °C to room temperature. 
Insoluble side products were filtered off and the filtrate was washed with 
saturated sodium bicarbonate solution (1:1 v/v). The aqueous phase was 
extracted with MTBE (2 x 1:1 v/v) and the combined organic phase was washed 
with brine (1:3 v/v). After drying over MgSO4 and evaporation of all volatile 
compounds the crude product was obtained as colored oil. It was purified by 
column chromatography on silica (MTBE). 
9.4.1 RAC-E-2-PHENYLPROPIONALDOXIME ACETATE
To a solution of E/Z-2-phenylpropionaldoxime (746 mg, 5.0 mmol) in n-hexane 
(50 mL) was added triethylamine (1.40 mL, 10.0 mmol). The mixture was stirred 
for five minutes at room temperature before acetyl chloride (533 μL, 7.5 mmol) 
was added dropwise. The reaction was stirred at room temperature for two 
hours. The work-up was done as described in SOP16. NMR analysis shows 
complete conversion of the free aldoxime to the E-oxime esteri and 19.9 % 
elimination to the corresponding nitrile. The compound was not further 
purified.
Yield: 910 mg.
1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.75 (d, J = 7.3 Hz, 1H, HC=N-O), 7.43 –
7.23 (m, 5H, Ar-H), 3.90 (m, 1H, Ph-CH-CH3), 2.16 (s, 3H, (O=)C-CH3), 1.55 (d,
J = 7.1 Hz, 3H, CH-CH3).
The compound is literature-unknown.
i The observed effect for E-conformational preference of the esterification is maximized in the 
chemical reaction. The reason for this behavior is yet to be identified.
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9.4.2 E-RAC-CYCLOHEX-3-ENE-1-CARBALDOXIME ACETATE
A solution of E/Z-cyclohex-3-ene-1-carbaldoxime (E/Z 72:28, 626 mg, 5.0 
mmol) and triethylamine (1.4 mL, 10.0 mmol, 2.0 eq.) in MTBE (25 mL) was 
cooled to 0-4°C. Acetyl chloride (533 uL, 7.5 mmol, 1.5 eq.) was added 
dropwise and the mixture was stirred for two hours at room temperature. The 
work-up was done as described in SOP16. The crude product was analyzed by 
1H-NMR spectroscopy and showed an E/Z ratio of 100:0 for the E-aldoxime 
acetate. The crude product was not purified.
9.4.3 E-RAC-CYCLOHEX-3-ENE-1-CARBALDOXIME BENZOATE
A solution of E/Z-cyclohex-3-ene-1-carbaldoxime (E/Z 72:28, 626 mg, 5.0 
mmol) and triethylamine (1.4 mL, 10.0 mmol, 2.0 eq.) in MTBE (25 mL) was 
cooled to 0-4°C. Benzoyl chloride (865 uL, 7.5 mmol, 1.5 eq.) was added 
dropwise and the mixture was stirred for two hours at room temperature. The 
work-up was done as described in SOP16. The crude product was analyzed by 
1H-NMR spectroscopy and showed an E/Z ratio of 6:1 for the aldoxime 
benzoate. 
9.5 STANDARD OPERATING PROCEDURE 17 (SOP17): SYNTHESIS OF
O-ACYLATED CHIRAL ALDOXIMES BY LIPASE-CATALYZED 
TRANSESTERIFICATION
The synthesis was conducted based on a literature procedure from SALUNKHE
and NAIR.142 A mixture of aldoxime (1.1 mmol) and the desired acyl ester (3.0 
eq.) in an appropriate solvent (e.g. n-hexane) was stirred for 10 minutes at 
room temperature.  After the addition of a lipase, the suspension was stirred 
for 12 hours at room temperature. The biocatalyst was removed via filtration 
and all volatile compounds were removed in vacuo. The crude products were 
analyzed by NMR spectroscopy and chiral HPLC, if an adequate method was 
found.
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9.5.1 (2RS)-E/Z-2-PHENYLPROPIONALDOXIME ACETATE
The following procedure is based on SOP17. A mixture of E/Z-2-phenyl-
propionaldoxime (3:2 E/Z, 164 mg, 1.1 mmol) and vinyl acetatei (277 μL, 3.0 
mmol) in n-hexane (10 mL) was stirred for 10 minutes at room temperature. 
After addition of lipase Amano PS-D (immobilized on diatomite, 50 mg) the 
suspension was stirred for 12 hours at room temperature. The work-up was 
done according to SOP17. The crude product was analyzed by NMR 
spectroscopy. It shows 70.6 % conversion to a mixture of E/Z-aldoxime ester 
(4:1) and remaining E/Z-aldoxime (2:1).ii The crude product was not further 
purified.
Yield: 220 mg
E-rac-O-Acetyl-2-phenylpropionaldoxime
1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.75 (d, J = 7.3 Hz, 1H, HC=N-O), 7.43 –
7.23 (m, 5H, Ar-H), 3.90 (m, 1H, Ph-CH-CH3), 2.16 (s, 3H, (O=)C-CH3), 1.55 (d,
J = 7.1 Hz, 3H, CH-CH3).
Z-rac-O-Acetyl-2-phenylpropionaldoxime
1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.20 (d, J = 7.6 Hz, 1H, HC=N-O), 7.43 –
7.23 (m, 5H, Ar-H), 4.40 (m, 1H, Ph-CH-CH3), 2.21 (s, 3H, (O=)C-CH3), 1.50 (d,
J = 7.3 Hz, 3H, CH-CH3).
The compound is unknown to literature.
9.5.2 (2RS)-E/Z-3-CYCLOHEXENE-1-CARBALDOXIME ACETATE
The following procedure is based on SOP17. A mixture of E/Z-cyclo-
hex-3-ene-1-carbaldoxime (3:2 E/Z, 164 mg, 1.1 mmol) and vinyl acetateiii (277 
μL, 3.0 mmol) in n-hexane (10 mL) was stirred for 10 minutes at room 
temperature. After addition of the corresponding lipase (immobilized) the 
suspension was stirred for 18 - 72 hours at room temperature. The work-up 
was done according to SOP17. The crude product was analyzed by NMR 
spectroscopy. It was not further purified.
i The same experiment with ethyl acetate as acyl donor led to <2 % conversion after 24 hours.
ii It is clearly shown that the E-isomer is being enriched during the reaction. This could be 
explained by thermodynamical effects preferring E-conformation.
iii The same experiment with ethyl acetate as acyl donor led to <2 % conversion after 24 hours.
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Table 62. Biocatalytic acetylation of racemic E/Z-cyclohex-3-ene-1-
carbaldoxime
Entry Lipase
Time
[h]
Conversiona
[%]
E/Zb
Nitrileb
[%]
1 Amano PS-D 18 45.0 88:12 34.4
2 Amano PS-D 72 57.8 92:8 31.1
3 CAL-B 72 98.4 88:12 43.2
(a) Conversion of starting material (b) Determined by 1H-NMR integration.
9.6 STANDARD OPERATING PROCEDURE 18 (SOP18): BIOCATALYTIC 
DEACETYLATION OF ALDOXIME ACETATES BY HYDROLASE-CATALYZED 
HYDROLYSIS
The corresponding aldoxime acetate (1.0 mmol) and a hydrolase are added to 
KPB (8.0, 50 mM, 10 mL) in a Titrino apparatus. The formed acetic acid is 
neutralized by the addition of aqueous sodium hydroxide solution (1.0M) to 
maintain the weak basic pH of 8.0. The reaction is stopped after the 
consumption of the theoretical amount of base and the biocatalyst is filtered 
off. The aqueous filtrate is extracted with MTBE (3x 25 mL) and the combined 
organic phase is washed with brine (25 mL). After drying over MgSO4 all 
volatile compounds are removed in vacuo (4°C). The crude product is analyzed 
with 1H-NMR spectroscopy. The initial experiments were not further purified.
Table 63. Biocatalytic hydrolysis of E-cyclohex-3-ene-1-carbaldoxime acetate
Entry Hydrolase (amount)
Time
[h]
Conversion
[%]
E/Za
1
Cephalosporin C acetylesterase (1.5 
mL)
7.5 >95.0 72:28
2 Amano PS-D (50 mg) 19.5 >95.0 82:18
(a) Determined by 1H-NMR integration
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9.7 RAC-2-PHENYLPROPANOL VIA NABH4 REDUCTION
A solution of DL-2-phenylpropionaldehyde (1.34 mL, 10.0 mmol) in THF 
(20 mL) was cooled to 0-4 °C. Sodium borohydride (378 mg, 10.0 mmol) was 
added in portions over five minutes. The mixture was stirred for additional two 
hours at 0-20 °C. The reaction was quenched by the addition of saturated 
sodium bicarbonate solution.  The mixture was extracted with MTBE (3x 25 mL) 
and the combined organic phase was washed once with brine. After filtration 
over a short silica column and drying over MgSO4 all volatile compounds were 
removed in vacuo. The product was obtained as colorless oil.
Normal-phase chiral HPLC: Chiralpak AD-H, 80:18:2 v/v SC-CO2/n-hexane/
2-propanol, 0.8 mL/min, 10 MPa back pressure, 216 nm): Rt1 = 25.0 min (S), 
Rt2 = 30.9 min (R).
Isolated yield: 1.26 g (9.25 mmol, 92.5 %).
1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.40 – 7.23 (m, 5H, Ar-H), 3.71 (d, J = 6.6 
Hz, 2H, CH2), 2.97 (h, J = 6.9 Hz, 1H, CH), 1.31 (d, J = 7.0 Hz, 3H, CH3).
The data corresponds to literature-known values.143
9.8 STANDARD OPERATING PROCEDURE 19 (SOP19): ENANTIOSELECTIVE 
REDUCTION OF RAC-2-PHENYLPROPIONALDEHYDE BY ALCOHOL 
DEHYDROGENASES
NAD(P)+ (2 mol %) was dissolved in KPB (50 mM, pH 8.0, 3:1 v/v) and an 
adequate amount of alcohol dehydrogenase was added. DL-2-
Phenylpropionaldehyde (10.0 mmol) was dissolved in 2-propanol (1:3 v/v) and 
added in one portion. The resulting emulsion was stirred for 24 hours at room 
temperature. The mixture was extracted with MTBE (3x 2:1 v/v) and the 
combined organic phase was washed once with brine (1:4 v/v). After drying 
over MgSO4 all volatile compounds were removed in vacuo. The crude product 
was analyzed by NMR spectroscopy and showed quantitative conversion in all 
cases. The enantiomeric excess was determined on a chiral HPLC column 
(Chiralpak AD-H, 80:18:2 v/v SC-CO2/n-hexane/2-PrOH, 0.8 mL/min, 10 MPa 
back pressure, 216 nm): Rt1 = 25.0 min (S), Rt2 = 30.9 min (R).
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Table 64. Biocatalytic reduction of DL-2-phenylpropionaldehyde by different 
ADH
Entry
ADH
(Batch-No.)
Sub
[mmol]
AD
H
[U]
Conv.
[%]
Yield
[g(%)]
ee
[%(RS)]
1 Rsp (327) 10.0 150 >95.0
1.34 
(98.4)
15.5 (S)
2
evo-1.1.200 
(365)
10.0 200 >95.0
1.31 
(96.2)
56.1 (R)
9.8.1 (2S)-PHENYLPROPANOL
The following synthesis was conducted according to SOP16. NAD+ (136.3 mg, 
0.2 mmol, 2.0 mol-%) was dissolved in KPB (150 mL, 50 mM, pH 8.0) and an 
alcohol dehydrogenase from Rhodococcus sp. (2.0 mL, 1:1 v/v in glycerin, 75 
U/mL) was added. DL-2-Phenylpropionaldehyde (1.34 mL, 10.0 mmol) was 
dissolved in 2-propanol (50mL) and added in one portion. The resulting 
emulsion was stirred for 24 hours at room temperature. The work-up was done 
as described in SOP16 to obtain the product as colorless oil with an 
enantiomeric excess of 15.5% ee (S).i
Isolated yield: 1.34 g (0.98 mmol, 98.4 %).
1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.40 – 7.23 (m, 5H, Ar-H), 3.71 (d, J = 6.6 
Hz, 2H, CH2), 2.97 (m, J = 6.9 Hz, 1H, CH), 1.31 (d, J = 7.0 Hz, 3H, CH3).
The data corresponds to literature-known values.143
9.8.2 (2R)-PHENYLPROPANOL
The following synthesis was conducted according to SOP16. NAD+ (136.3 mg, 
0.2 mmol, 2.0 mol-%) was dissolved in KPB (150 mL, 50 mM, pH 8.0) and the 
alcohol dehydrogenase evo-1.1.200 (evocatal, 100 mg, 2.0 U/mg) was added. 
DL-2-Phenylpropionaldehyde (1.34 mL, 10.0 mmol) was dissolved in 2-
propanol (50mL) and added in one portion. The resulting emulsion was stirred 
for 24 hours at room temperature. The work-up was done as described in 
i This was most likely due to the high enzyme amount. The experiment will be reproduced with 
10% of the biocatalyst amount.
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SOP16 to obtain the product as colorless oil with an enantiomeric excess of 
56.1% ee (R).i
Isolated yield: 1.31 g (0.96 mmol, 96.2 %).
1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.40 – 7.23 (m, 5H, Ar-H), 3.71 (d, J = 6.6 
Hz, 2H, CH2), 2.97 (m, J = 6.9 Hz, 1H, CH), 1.31 (d, J = 7.0 Hz, 3H, CH3).
The data corresponds to literature-known values.143
9.9 STANDARD OPERATING PROCEDURE 20 (SOP20): OVEREXPRESSION 
AND PURIFICATION OF VARIOUS ALDOXIME DEHYDRATASES (OXD) IN 
RECOMBINANT E. COLI
A single colony of recombinant E. coli HB101/pOxD-9OF or BL21 Star (DE3)/
pOxdS17, respectively, was transferred from a LB agar plate into a 20 mL test 
tube containing 5 mL of LB medium, 100 μg/mL ampicillin and 1 mM IPTG. The 
solution was incubated at 37 °C and reciprocally shaken for 18 hours. The 
preculture was transferred into a 500-mL Erlenmeyer flask with different 
volumes of media containing 100 μg/mL ampicillin and incubated with shaking 
at 200 rpm and 37 °C. After the cells reached the exponential growth rate 
(OD = A610 = 0.5-1.0), IPTG was added to a final concentration of 1 mMii. The 
suspension was shaken at 200 rpm and different temperatures. After 
centrifugation at 6,000 x g and 4 °C for 10 minutes, the supernatant was 
removed and the cells were washed and concentrated in 10 mM KPB 
containing 5 mM 2-mercaptoethanol and 1 mM dithiothreitol (DTT). The 
suspension was either disrupted by sonication to yield the cell-free extract of 
directly used for whole-cell biotransformations.
9.9.1 OVEREXPRESSION OF OXD FROM BACILLUS SP. (OXB-1) IN 
RECOMBINANT E. COLI HB101/POXD-9OF
The following procedure was conducted according to SOP17. The preculture 
was transferred into a 500-mL erlenmeyer flask with 245 mL LB mediumiii
i This was most likely due to the high enzyme amount. The experiment will be reproduced with 
10% of the biocatalyst amount.
ii Isopropyl β-thiogalactopyranoside (IPTG) initiates gene expression under the control of the 
lac operon or the T7 promoter.
iii The medium volume is based on literature procedures showing highest enzyme activity under 
these conditions.
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containing 100 μg/mL ampicillin and incubated for another 5.5 hoursi with 
shaking at 200 rpm and 37 °C. After the cells reached the exponential growth 
rate (OD = A610 = 0.5-1.0) IPTG was added to a final concentration of 1 mMii. 
The suspension was shaken for additional 9 hoursiii at 200 rpm and 30 °Civ. The 
work-up was done as described in SOP17.
Table 65. Time course of cell-growth of recombinant E. coli HB101 / pOxd90F
Entry
Time
[h]
OD (A610)
[a.u.]
Spec. Act.a
[U/Lcult]
1 2.0 0.04 n.d.
2 4.7 0.14 n.d.
3 5.0 0.25 n.d.
4 5.3 0.37 n.d.
5 8.5 1.30 402
6 12.5 1.70 700
7 14.0 1.82 705
(a) The specific activity was measured for E/Z-2-phenylpropionaldoxime as substrate
9.9.2 PURIFICATION OF ALDOXIME DEHYDRATASE (OXD) FROM 
RECOMBINANT E.COLI HB101/POXD-9OF
Unless stated otherwise 10 mM KPB (pH 7.0) containing 5 mM 2-
mercaptoethanol was used throughout the purification. The temperature was 
maintained at 4 °C for the entire process. The total protein content of the 
solutions was determined by photometric analysis with Coomassie Brilliant Blue 
G-250 staining (Bradford assay).
The cells of 2 L culture (17.11 g wet weight) were washed and concentrated 
with 10 mM KPB and disrupted in a KUBOTA Insonator 201M. After 
centrifugation at 12,000 x g and 4 °C for 10 minutes the cell-free extract (1.4 g 
total protein content) was brought to 40 % saturation by addition of solid 
ammonium sulfate. The formed protein pellet was removed by centrifugation 
(12,000 x g, 4 °C, 10 min) and the supernatant was saturated to 70 % 
ammonium sulfate. The active protein pellet was separated, dissolved in 10 mM 
i The lag phase of cell growth was previously measured in a time-dependent growth curve at 
610 nm.
ii Isopropyl β-thiogalactopyranoside (IPTG) binds to the lac repressor and initiates protein 
expression under lac operon control.
iii The activity of a 1-mL aliquot did not increase further; hence the cell growth reached the 
stationary phase.
iv The temperature is changed according to literature procedures indicating that the Oxd gene is 
higher expressed at the given temperature.
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KPB and dialyzed against the same buffer (2 x 5 L) for at least five hours. The 
solution was placed on a DEAE-Toyopearl column (24 mm x 150 mm, 
15 mg/mL) equilibrated with 10 mM KPB. After washing the column with 
10 mM KPB the enzyme was eluted with 320 mL of 100 mM KPB. The column 
was subsequently washed with 0.5 M sodium hydroxide solution, 2.0 M sodium 
chloride solution, deion. water, 20 % ethanol and was stored in 20 % ethanol 
for reuse. The active fractions were pooled and showed a total protein content 
of 244.0 mg. Ammonium sulfate was added to 30 % saturation and the solution 
was placed on a Butyl-Toyopearl column (25 mm x 110 mm, 15 mg/mL) 
equilibrated with 10 mM KPB at 30 % ammonium sulfate saturation. After 
washing the column with the same buffer the proteins were eluted with 10 mM 
KPB and a linear gradient of 30 - 0 % ammonium sulfate. The pooled active 
fractions showed a total protein content of 42.97 mg. The solution was dialyzed 
against 10 mM KPB (2 x 3 L) and concentrated to 2 mL in a centrifuge
ultrafiltration unit. The concentrate was injected on a Superdex 200 column 
(16/600) equilibrated with 50 mM KPB containing 100 mM sodium chloride and 
eluted with 150 mL of the same buffer. This procedure yielded 5.69 mg of 
purified Oxd with a specific activity of 8.47 U/mg, which was in good 
accordance to the literature value of 8.35 U/mg.144
Table 66. Purification of Oxd from recombinant E. coli HB101/pOxD-9OF
Entry Method
Total 
Protein 
(mg)
Specific 
activity 
(U/mg)
Total 
activity 
(U)
Recovery
(%)
Purification
(fold)
1
Cell-free 
extract
1357 0.21 279.2 100 1.0
2
40-70% 
(NH4)2SO4
958.8 0.23 220.5 79.0 1.1
3
DEAE-
Toyopearl
244.0 0.34 82.96 29.7 1.6
4
Butyl-
Toyopearl
42.97 1.80 77.35 27.7 8.6
5 Superdex 200 5.690 8.47 48.19 17.3 40
Figure 197. SDS-PAGE of OxdB
from recombinant E. coli HB101/ 
pOxD-9OF
(MP) marker proteins (1) cell-free extract 
(2) ammo-ium sulfate precipitation 
(40-70% saturation) (3) DEAE-Toyopearl 
(4) Butyl-Toyopearl (5) Superdex 200
[268]
9.9.3 OVEREXPRESSION OF OXD FROM RHODOCOCCUS GLOBERULUS
(OXDRG) IN RECOMBINANT E. COLI BL21 STAR (DE3) / POXDS17145
An Aliquot of 50 μl of the preculture was transferred into a 500-mL Erlenmeyer 
flask with 375 mL TB mediumi containing 100 μg/mL ampicillin and incubated 
for another 4.5 hoursii with shaking at 200 rpm and 37 °C. After the cells 
reached the exponential growth rate (OD = A610 = 0.5 - 1.0) IPTG was added to 
a final concentration of 1mMiii. The suspension was shaken for additional 12
hoursiv at 200 rpm and 25 °Cv. The work-up was done as described in SOP17. A 
cell-free extract was not prepared. All experiments were carried out with resting 
cells.
Table 67. Time course of cell-growth of recombinant E. coli BL21 Star (DE3)/ 
pOxdS17
Entry
Time
[h]
OD (A610)
[a.u.]
Spec. Act.a
[U/Lcult]
1 2.0 0.02 n.d.
2 3.0 0.06 n.d.
3 4.0 0.27 n.d.
4 4.5 0.50 n.d.
5 15.0 1.71 2590
6 16.5 1.74 2340
(a) The specific activity was measured for E/Z-2-phenylpropionaldoxime as substrate
9.10 STANDARD OPERATING PROCEDURE 21 (SOP21): GROWTH 
EXPERIMENTS WITH ADDITION OF CHIRAL SUBSTRATES
Agar plates containing 100 ug/mL ampicillin were prepared according to the 
previously described procedure, containing 5mM of different chiral aldoxime 
substrates. Resting cells of recombinant E. coli HB101 / pOxd90F were streaked 
over the plates and incubated for 12 hours at 37C. The growth was assessed 
qualitatively with the naked eye. One colony of each positive candidate was 
i The medium volume is based on literature procedures showing highest enzyme activity under 
these conditions.
ii The lag phase of cell growth was previously measured in a time-dependent growth curve at 
610 nm.
iii Isopropyl β-thiogalactopyranoside (IPTG) initiates protein expression under T7 promoter
control.
iv The activity of a 1-mL aliquot did not increase further; hence the cell growth reached the 
stationary phase.
v The temperature is changed according to literature procedures indicating that the Oxd gene is 
higher expressed at the given temperature.
Figure 198. Agar plate 
containning 5mM tetra-
hydrofuran-2-carbaldoxime 
with grown recombinant 
E. coli HB101/pOxD-9OF
after 12 hours at 37 °C.
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cultivated in 5 mL LB medium containing 100 ug/mL ampicillin and 1mM IPTG 
at 37C for 12 hours and measured for its specific activity towards E/Z-2-
phenylpropionaldoxime.
Table 68. Growth and specific activity of E. coli HB101/pOxD-9OF in the 
presence of chiral substrates
Entry Substrate additive (5 mM) Growth
Spec. act.
[U/Lcult]*
1 None +++ 572.7
2 E/Z-2-Phenylpropionaldoxime - n.d.
3 E/Z-3-Cyclohexene-1-carbaldoxime - n.d.
4 E/Z-5-Norbornene-2-carbaldoxime - n.d.
5 E/Z-Tetrahydrofuran-3-carbaldoxime +++ 457.5
6 E/Z-3-Phenylbutyraldoxime - n.d.
(a) Reaction temperature: 8 °C, reaction time: 10 min.
9.11 STANDARD OPERATING PROCEDURE 22 (SOP22): ASSAY PROCEDURE 
FOR THE DETERMINATION OF ENZYME ACTIVITY AND 
ENANTIOSELECTIVITY
The standard assay for the determination of Oxd activity was measured 
quantitatively for the product-related conversion of phenylacetaldoxime 
(PAOx) to phenylacetonitrile (PAN). 352.5 μL KPB (50 mM, pH 7.0), 125.0 μL 
flavin mononucleotide solution (FMN, 1 mM in DIW) and 10 μL of enzyme 
formulation (resting cell suspension or cell-free extract) were mixed in a 1.5 -
mL microtube and incubated at 30 °C for 5 minutes. The reaction was started 
by the addition of 12.5 μL PAOx solution (200mM in DMSO) to a final volume 
of 500 μL. After 60 seconds incubation at 30 °C and shaking at 200 rpm the 
reaction was quenched with hydrochloric acid (100 μL, 0.1 M). The solution was 
further diluted with 400 μL DIW and centrifuged at 15,000 rpm and 4 °C for 
five minutes. 800 μL of the supernatant were transferred to another microtube 
and again centrifuged under the same conditions. The supernatant (750 μL)
was transferred to a HPLC vial (1.5mL) and measured directly for product-
related conversion. The specific activity was calculated in units per liter of 
culture according to the following equation:
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Specific activity =
[PAN] ∗ Vexp
f ∗ t ∗ Vcat
[U L⁄ culture]
[PAN] concentration of phenylacetonitrile in [mmol/L] 
Vexp experiment volume in [L]
Vcat volume of enzyme solution in [L]
f dilution factor of concentrated enzyme solution
t reaction time in [min]
The specific activity for chiral substrates was measured in the same manner. In 
case of very low activity, specifically E/Z-3-cyclohexene-1-carbaldoxime and 
E/Z-tetrahydrofuran-3-carbaldoxime, the assay was changed to 100 μL enzyme 
solution and 262.5 μL KPB (50 mM, pH 7.0). For the determination of an 
enantiomeric excess of 2-phenylpropionitrile, 5-norbornene-2-carbonitrile and 
3-phenylbutyronitrile, the aqueous HPLC sample was further processed as 
follows. The solution was transferred into a 1.5-mL microtube and 750 μL MTBE 
was added. The extraction was done by using a vortexer at full speed for 15 
seconds. After centrifugation at 15,000 rpm and 4 °C for 30 seconds, the 
organic phase (500 μL) was transferred to a 1.2-mL HPLC vial and diluted with 
MTBE (500 μL). The samples (4.0 μL) were measured at 210 nm. Reference 
spectra can be seen in chapter 3.X.X. In case of products with low absorbance, 
specifically 3-cyclohexene-1-carbonitrile and tetrahydrofuran-3-carbonitrile, 
the enantiomeric excess was determined by chiral GC and FID analysis. The 
previously measured HPLC sample was transferred to a microtube and 
extracted with MTBE (300 μL) on a vortexer. After centrifugation at 15,000 rpm 
and 4 °C for 5 minutes, residual DMSO and H2O was removed by transferring
200 μL of the supernatant organic phase to another microtube and washing
with an equal volume (200 μL) of brine by vortexing. After a second 
centrifugation at 15,000 rpm and 4 °C for 5 minutes, 100 μL of the organic 
phase was transferred to a GC vial (150 μL) and analyzed by FID. The 
parameters are given in the corresponding experiments.
9.12 STANDARD OPERATING PROCEDURE 23 (SOP23): PREPARATION OF 
ACETONE-DRIED CELLS OF VARIOUS OXD IN RECOMBINANT E. COLI
AND COMPARISON OF FORMULATIONS
The following procedure was based on literature procedures by ASANO et 
al.146,147 The cultivation was conducted as described in chapters 9.8.1 and 9.8.3, 
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respectively. The washed cell suspension was poured into cold acetone (10:1
v/v, -20 °C) and immediately filtered under membrane vacuum. After washing 
with the same volume of cold acetone (-20 °C) the cells were dried in 
membrane vacuum and immediately stored at -20 °C until use.  The cells 
showed a stable activity even after four months in storage, while cell-free 
extracts and resting cell suspensions significantly lost their activities.
Table 69. Stability of enzyme activity according to enzyme formulation
Entry Oxd from Formulation
Storage 
time
[d]
Spec. 
Activitya
[U/Lcult (%)]
1
HB101 / pOxD-
9OF
resting cells 1 5625 (100)
2
HB101 / pOxD-
9OF
resting cells 20 3566 (63.4)
3
HB101 / pOxD-
9OF
acetone-dried 
cells
1 0.42b (100)
4
HB101 / pOxD-
9OF
acetone-dried 
cells
20 0.42b (99.5)
5
HB101 / pOxD-
9OF
acetone-dried 
cells
60 0.41b (96.2)
6
HB101 / pOxD-
9OF
acetone-dried 
cells
119 0.38 (89.6)
7
HB101 / pOxD-
9OF
cell-free extract 1 2016 (100)
8
HB101 / pOxD-
9OF
cell-free extract 10 1092 (54.2)
9
HB101 / pOxD-
9OF
cell-free extract 20 40 (1.98)
10
BL21 Star (DE3) / 
pOxdS17
acetone-dried 
cells
1 0.77b (100)
11
BL21 Star (DE3) / 
pOxdS17
acetone-dried 
cells
20 0.01b (1.3)
(a) Assay conditions: 500 μl-scale, 30 °C, 60 seconds incubation (b) Units per mg of dry cell 
weight.
9.13 STANDARD OPERATING PROCEDURE 24 (SOP24): ENANTIOSELECTIVE 
BIOTRANSFORMATION OF RACEMIC ALDOXIMES INTO 
ENANTIOMERICALLY ENRICHED NITRILES
A standard solution of aldoxime (200 mM in DMSO) was added to the aqueous 
reaction mixture consisting of flavin mononucleotide solution (FMN, 25 % v/v, 
1 mM in DIW), an Oxd formulation and KPB (pH 7.0, 50 mM) to a final volume 
of 5.0 – 500 mL (5 mM substrate conc.). The mixture was stirred at 8 °C for 24
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hours. After HPLC analysis for quantitative conversion the solution was 
centrifuged (12,000 rpm, 4 °C, 5 min) to remove the biocatalyst. The 
supernatant was extracted with ethyl acetate (3 x 1:1 v/v) and the organic 
phase was extracted twice with brine (2 x 1:4 v/v) to remove FMN and DMSO 
residues. After drying over MgSO4 the solvent was removed in vacuo. The 
crude product was purified via column chromatography on silica (5:1 v/v ethyl 
acetate in n-hexane) to separate the enantiomerically enriched product from 
remaining aldoxime. The products were analyzed by NMR, HPLC and 
polarimetry, respectively.
9.13.1 (2S)-PHENYLPROPIONITRILE FROM AN E/Z-MIXTURE OF 4:1
The following procedure was conducted according to SOP21. A standard 
solution of E/Z-2-phenylpropionaldoxime (E/Z ratio 4:1, 978 μL, 1.02 M in 
DMSO) was added to the aqueous reaction mixture consisting of 50 mL flavin 
mononucleotide solution (FMN, 1 mM in DIW), 4.0 mL of resting cell 
suspension (HB101/pOxD-9OF with a specific activity of 7 U/mL, KPB pH 7.0, 
50 mM) and KPB (pH 8.0, 50 mM) to a final volume of 200 mL (5 mM substrate 
concentration). The mixture was stirred at 8 °C for 24 hours. The work-up was 
done as described in SOP21. After purification via column chromatography the 
product and remaining aldoxime were obtained in spectroscopically pure form.
The enantiomeric excess was determined by chiral normal-phase HPLC (Daicel 
Chiralcel OJ-H, 5 % v/v 2-propanol in n-hexane, 0.7 mL/min, 210 nm, 20 °C, 
Rt1 = 13.8 min (R), Rt2= 14.3 min (S), Rt3 = 20.4 min (Z-2S), Rt4 = 26.7 min (E-2S), 
Rt5 = 30.0 min (Z-2R), Rt6 = 31.5 min (E-2R)).
Isolated yield ((2S)-phenylpropionitrile): 68.4 mg (0.52 mmol, 52.1 %).
Isolated yield (E-(2R)-phenylpropionaldehyde): 61.6 mg, (0.41 mmol, 
41.2 %).
(2S)-Phenylpropionitrile:
1H-NMR (400 MHz, CDCl3): δ [ppm] = 7.38 – 7.28 (m, 5H, Ar-H), 3.87 (q, J = 7.2 
Hz, 1H, CH-CN), 1.60 (d, J = 7.3 Hz, 3H, CH3).
13C-NMR (100 MHz, CDCl3): δ [ppm] = 137.17, 129.17, 128.06, 126.74, 121.66, 
31.22, 21.46.
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E-(2R)-Phenylpropionaldehyde oxime:
1H-NMR (400 MHz, CDCl3): δ [ppm] = 7.52 (d, J = 6.1 Hz, 1H, HC=NOH), 7.38 –
7.19 (m, 5H, Ar-H), 3.67 (m, J = 6.8 Hz, 1H, CH-CH=NOH), 1.46 (d, J = 7.0 Hz, 
3H, CH3).
13C NMR (100 MHz, CDCl3): δ [ppm] =155.09, 142.11, 128.74, 127.39, 126.95, 
40.37, 18.75.
Table 70. Selectivity of OxdB for E/Z-2-phenylpropionaldoxime (4:1)
Entry Product Configuration
ee
[%]
Isol. yield 
[mg(%)]
1 2-phenylpropionitrile (S)a 65.2
68.4 
(52.1)
2 E-2-phenylpropionaldoxime (R)b >99.8
61.6 
(41.2)
(a) identified by its specific optical rotation of [a]D24 = - 4.4 (c 2.25, CDCl3) (Lit. (R): [a]D20 = + 9.5 
(c 2.4, CHCl3) (b) identified by product configuration, specific optical rotation [a]D23 = - 7.57 (c 
1.32, CDCl3).
9.14 STANDARD OPERATING PROCEDURE 25 (SOP25): TIME COURSES FOR 
THE BIOTRANSFORMATION OF MIXTURES OR ISOMERICALLY ENRICHED 
E- AND Z-ALDOXIMES
The corresponding aldoxime (0.025 mmol, 200 mM in DMSO, 0.125 mL) was 
added to the aqueous reaction mixture consisting of flavin mononucleotide 
(FMN, 1 M in H2O, 1.25 mL), OxdB (resting cell suspension of recombinant E.coli 
HB101/pOxD-9OF, 7 U/mL, 0.10 mL) and KPB (50 mM, pH 7.0, 3.525 mL) at 
room temperature. The reaction was reciprocally shaken at 180 min-1 and 
8.0 °C. To measure the time course of the reaction, aliquots of 0.50 mL were 
transferred to a 1.5-mL-microtube and diluted with dist. H2O (0.50 mL). After 
centrifugation for five minutes at 15,000 rpm and 4 °C the supernatant 
(0.80 mL) was transferred to another microtube and centrifuged again (15,000 
rpm, 4 °C, 5 min). The resulting supernatant (0.75 mL) was transferred to a 
HPLC vial and directly measured (COSMOSIL C18-MS-II, 30% CH3CN in H2O, 
1.0 mL/min, 40 °C, 254 nm, Rt1 = 11.0 min (E-1), Rt2 = 12.4 min (Z-1), 
Rt3 = 18.1 min (2)) for conversion. Subsequently, the sample was again 
transferred to a 1.5-mL-microtube and overlaid with tert-butyl methylether 
(MTBE, 0.50 mL). After mixing on a vortexer the phases were separated by 
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centrifugation (15,000 rpm, 4 °C, 5 min) and the organic phase (0.40 mL) was 
transferred to another microtube. Brine was added (0.40 mL) and the mixture 
was again mixed by vortexer and centrifuged. The organic phase (0.30 mL) was 
transferred to a 1.0-mL-HPLC vial and diluted with additional MTBE (0.45 mL). 
The sample was measured on normal-phase chiral HPLC (Daicel Chiralpak OJ-
H, 5 % v/v 2-propanol in n-hexane, 0.7 mL/min, 20 °C, 210 nm, Rt1 = 13.8 min 
((R)-2), Rt2 = 14.4 min ((S)-2), Rt3 = 20.3 min (Z-(S)-1), Rt4 = 26.7 min (E-(S)-1), 
Rt5 = 30.0 min (Z-(R)-1), Rt6 = 31.5 min (E-(R)-1)) for the enantiomeric excess of 
both product and remaining substrate.
9.14.1 (2S)-PHENYLPROPIONITRILE FROM RACEMIC E-SUBSTRATE
The synthesis was conducted according to SOP22 with E-rac-2-phenylpropion-
aldoxime (3.73 mg, 0.025 mmol) at pH 7.0 and pH 8.0, respectively.
Table 71. Time course of Oxd dehydration for E-rac-2-phenylpropionaldoxime
Entry pH
Time
[min]
iea
[%]
[E]
in mM
[Z]
in mM
[CN]
in mM
ee
[%]
1 7.0 9 98.9 3.828 - 1.171 95.9 (S)
2 7.0 32 98.9 2.748 - 2.183 98.0 (S)
3 7.0 62 98.9 2.332 - 2.667 97.9 (S)
4 7.0 402 98.9 2.177 - 2.823 97.5 (S)
5 7.0 1382 98.9 2.192 - 2.809 96.2 (S)
6 8.0 38 98.9 (E) 3.421 - 1.579 96.8 (S)
7 8.0 226 98.9 (E) 2.274 - 2.728 97.9 (S)
8 8.0 1361 98.9 (E) 2.181 - 2.818 96.1 (S)
(a) Isomeric excess
9.14.2 (2R)-PHENYLPROPIONITRILE FROM RACEMIC Z-SUBSTRATE
The synthesis was conducted according to SOP22 with E-rac-2-phenylpropion-
aldoxime (6.15 mg, 0.025 mmol) at pH 7.0 and pH 8.0, respectively.
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Table 72. Time courses of aldoxime dehydration for Z-2-
phenylpropionaldoxime
Entry pH Time
Ie
[%]
[E]
in mM
[Z]
in mM
[CN]
in mM
ee
[%]
1 7.0 7 90.2 0.294 3.225 1.483
86.5
(R)
2 7.0 30 90.2 0.236 2.475 2.288
82.8
(R)
3 7.0 60 90.2 0.21 2.047 2.743
74.1
(R)
4 7.0 400 90.2 0.086 0.882 4.034
18.7
(R)
5 7.0 1380 90.2 0.035 - 4.966 -6.0 (R)
6 8.0 37
90.2 
(Z)
0.264 4.055 0.682
97.5 
(R)
7 8.0 225
90.2 
(Z)
0.215 2.168 2.615
85.9 
(R)
8 8.0 1360
90.2 
(Z)
0.089 1.134 3.777
36.4 
(R)
9.14.3 (RS)-3-CYCLOHEXENE-1-CARBONITRILE
The following procedure was conducted according to SOP22 with 
E/Z-3-cyclohexene-1-carbaldoxime (3.13 mg, 0.025 mmol) in DMSO (125 μL).
Table 73. Time courses of aldoxime dehydration of E/Z-3-
cyclohexene-1-carb-aldoxime
Entry Substrate
Time
[min]
iea
[%]
Conv.
[%]
eeb
[%]
1 E/Z-B 30 37.3 (E) 3.3 96.6
2 E/Z-B 60 37.3 (E) 13.6 83.1
3 E/Z-B 120 37.3 (E) 69.7 46.9
4 E/Z-B 240 37.3 (E) 75.9 17.2
(a) Isomeric excess (b) Determined by chiral HPLC (Daicel Chiralpak AD-H, 5% v/v 2-propanol in
n-hexane, 0.7 mL/min, 210 nm, 20 °C, Rt1 = 6.4 min, Rt2 = 7.5 min).
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9.14.4 (1R,2RS,3R)-5-NORBORNENE-2-CARBONITRILE
The following procedure was conducted according to SOP22 with
E/Z-5-norbornene-2-carbaldoxime (3.43 mg, 0.025 mmol) in DMSO (125 μL).
Table 74. Time courses of aldoxime dehydration of E/Z-5-norbornene-2-carb-
aldoxime
Entry Substrate
Time
[min]
iea
[%]
deb
[%]
rel. 
Conv. 
(R) [%]
rel. 
Conv. 
(S) [%]
eec
[%]
1 E/Z-C 30 19.8 (E)
41.5 
(R)
23.6 12.9
29.3 
(R)
2 E/Z-C 60 19.8 (E)
41.5 
(R)
46.0 28.3
23.8 
(R)
3 E/Z-C 120 19.8 (E)
41.5 
(R)
58.9 31.7
30.0 
(R)
4 E/Z-C 240 19.8 (E)
41.5 
(R)
64.9 35.1
29.8 
(R)
(a) Isomeric excess (b) Diastereomeric excess was determined by 1H-NMR integration (c) 
Determined by chiral HPLC (Daicel Chiralpak, 5 % v/v 2-propanol in n-hexane, 0.7 mL/min, 210 
nm, 20 °C, Rt1 = 7.8 min (S), Rt2= 8.6 min (R)).
9.14.5 (RS)-3-PHENYLBUTYRONITRILE
The following procedure was conducted according to SOP22 with E/Z-3-
phenyl-butyraldehyde oxime (4.08 mg, 0.025 mmol) in DMSO (125 μL).
Table 75. Time course of aldoxime dehydration of E/Z-3-phenylbutyraldoxime
Entry Substrate
Time
[min]
iea
[%]
Conv.
[%]
eeb
[%]
1 E/Z-E 30 0 29.0 60.6 (S)
2 E/Z-E 60 0 62.1 29.9 (S)
3 E/Z-E 120 0 97.3 2.3 (S)
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4 E/Z-E 240 0 >99.5 0.3 (S)
(a) Isomeric excess (b) Determined by chiral HPLC (Daicel Chiralcel OJ-H, 2 % v/v 2-propanol in 
n-hexane, 0.7 mL/min, 210 nm, 20 °C, Rt1 = 23.3 min (major), Rt2= 24.6 min (minor)).
9.15 STANDARD OPERATING PROCEDURE 26 (SOP26): SCALE-UP OF 
SUBSTRATE CONCENTRATION FOR THE BIOTRANSFORMATION OF 
E/Z-2 PHENYLPROPIONALDOXIME
A standard solution of E/Z-2-phenylpropionaldoxime in DMSO was added to 
the aqueous reaction mixture consisting of flavin mononucleotide (FMN, 1 M in 
H2O, 1.25 mL), OxdB (resting cell suspension of recombinant E. coli
HB101/pOxD-9OF, 7 U/mL, 0.10 mL) and KPB (50 mM, pH 7.0, 3.525 mL) at 
room temperature. The reaction was reciprocally shaken at 180 min-1 and 
different temperatures. Aliquots of 0.50 mL were transferred to a 1.5-mL-
microtube and diluted with dist. H2O (0.50 mL). After centrifugation for 
five minutes at 15,000 rpm and 4 °C the supernatant (0.80 mL) was transferred 
to another microtube and centrifuged again (15,000 rpm, 4 °C, 5 min). The 
resulting supernatant (0.75 mL) was transferred to a HPLC vial and directly 
measured (COSMOSIL C18-MS-II, 30% CH3CN in H2O, 1.0 mL/min, 40 °C, 254 
nm, Rt1 = 11.0 min (E-1), Rt2 = 12.4 min (Z-1), Rt3 = 18.1 min (2)) for conversion. 
Table 76. Scale up of substrate concentrations for the biotransformation of 
E/Z-2-phenylpropionaldoxime
Entry Substrate
Conc.
[mM]
Temp.
[C]
Time
[min]
Spec. act.
[U/Lculture]
Conv.
[%]
1 E/Z-A 5 30 1 1240 n.d.
2 E/Z-A 10 30 1 1850 n.d.
3 E/Z-A 10 30 30 886.3 n.d.
4 E/Z-A 25 30 30 1205.7 3.4
5 E/Z-A 50 30 30 404.0 2.4
6 E/Z-A 100 30 30 31.3 0.1
7 E/Z-A 10 8 30 115.0 56.6
8 E/Z-A 20 8 30 174.0 5.2
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9.16 (2R)-PHENYLPROPIONITRILE FROM INERT E-(2R)-PHENYLPROPION-
ALDEHYDE OXIME
A solution of E-(2R)-phenylpropionaldoxime (3.73 mg, 0.025 mmol) in DMSO 
(125 μL) was dissolved in a reaction mixture containing FMN (1.25 mL, 1 mM in 
dist. H2O), OxdB (resting cell suspension of recombinant E. coli HB101/pOxD-
9OF, 100 μL, 0.7 U) and KPB (50 mM, pH 7.0) to a final volume of 5.0 mL at 
5 mM substrate concentration. The resulting emulsion was mixed for three
hours with reciprocal shaking at 180 min-1 and 30 °C. The progress of the 
reaction was monitored according to the procedures described in SOP23.
Table 77. Temperature-induced conversion of inert E-(2R)-phenylpropion-
aldoxime by in situ-isomerization to active Z-(2R)-phenylpropion-
aldoxime
Entry Substrate Time ie [E] [Z] [CN] ee
1 E-(2R)-A 60
>99.4
(E)
4.740 0.260 - -
2 E-(2R)-A 173
>99.4
(E)
3.762 0.181 1.057
99.2
(R)
9.17 INVESTIGATION OF RACEMIZATION AND ISOMERIZATION IN AQUEOUS 
MEDIA
9.17.1 STANDARD OPERATING PROCEDURE 27 (SOP27): EFFECTS OF PH
CHANGE IN AQUEOUS MEDIUM
E-2-Phenylpropionaldoxime (125 μL, 200 mM in DMSO) was dissolved in 
different buffer systems at various pH values and mixed with FMN (1250 μL, 
1 mM in DIW). After addition of OxdB (resting cell suspension of recombinant 
E. coli HB101/pOxD-9OF, 100 μL, 0.7 U) to a final volume of 5 mL at 5 mM 
substrate concentration the emulsion was mixed with reciprocal shaking 
(160 min-1, 8 °C) for 240 minutes. The progress of the reaction was monitored 
according to the procedures described in SOP22.
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Table 78. Biotransformation of E-2-phenylpropionaldoxime at different pH 
values
Entry Buffera (50 mM) pH
Conversion
[%]
ee
[%]
1 NaOAc 5.0 <0.5b n.d.
2 KPB 7.0 27.7c 98.1d
3 KPB 8.0 37.2c 97.9d
4 Ethanolamine 9.0 8.9 n.d.
5 Ethanolamine 10.0 7.3b n.d.
(a) Sodium acetate (NaOAc), potassium phosphate buffer (KPB) (b) significant hydrolysis of the 
aldoxime (c) only product-related conversion, no hydrolysis observed (d) normal-phase HPLC 
showed no change in the content of E-(2R)-phenylpropionaldoxime even after 24 hours
9.17.2 STANDARD OPERATING PROCEDURE 28 (SOP28): RACEMIZATION 
AND ISOMERIZATION WITH ACID / BASE CATALYSTS IN N-HEXANE
The corresponding catalyst (0.0125 mmol, 50 mol-%), E-(2R)-phenyl-
propionaldoxime (>99.8 % ee, 3.73 mg, 0.025 mmol, 25 mM) and 
(2S)-phenylpropionitrile (77.6 % ee, 3.28 mg, 0.025 mmol, 25 mM) were 
dissolved in n-hexane (1 mL) and stirred at 8° C for three hours. An aliquot of 
100 μL was filtered over a small silica column (tert-butyl methylether, MTBE) 
and analyzed on a normal-phase chiral HPLC (Daicel Chiralpak OJ-H, 5 % 2-
propanol in n-hexane, 0.7 mL/min, 20 °C, 210 nm, Rt1 = 13.8 min ((R)-2), 
Rt2 = 14.4 min ((S)-2), Rt3 = 20.3 min (Z-(S)-1), Rt4 = 26.7 min (E-(S)-1), 
Rt5 = 30.0 min (Z-(R)-1), Rt6 = 31.5 min (E-(R)-1)) for racemization or 
isomerization effects. 
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Table 79. Racemization and Isomerization under acidic / basic catalysis in n-
hexane
Entry Catalysta E/Z (R-NOH)
ee (R-NOH)
[%]
ee (R-
CN) [%]
R-CHO
[%]
1 none 99:1 >99.8 77.6 0.0
2 BzOH 71:29 >99.8 77.6 63.0
3 DBU 99:1 >99.8 63.6 0.0
4 DABCO 99:1 >99.8 77.6 0.0
5 DMAP 99:1 >99.8 77.6 0.0
(a) Benzoic acid (BzOH), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 1,4-diazabicyclo[2.2.2]octane 
(DABCO), 4-(dimethylamino)-pyridine (DMAP)
9.18 IDENTIFICATION OF PREFERABLE REACTION CONDITIONS FOR OXD
BIOTRANSFORMATIONS IN A BINARY MEDIUM
9.18.1 STANDARD OPERATING PROCEDURE 29 (SOP29): EFFECT OF DMSO
REMOVAL ON OXDB BIOTRANSFORMATIONS
To prevent the binary reaction media from mixing, DMSO was removed from 
the standard KPB medium. E/Z-2-phenylpropionaldoxime (37.3 mg, 0.25 mmol) 
was either directly emulsified in KPB (pH 7.0, 50 mM) or previously dissolved in 
DMSO (1.25 mL). After the addition of OxdB (1 mL resting cell suspension of
recombinant E. coli HB101/pOxD-9OF) and FMN (12.5 mL, 1 mM in DIW), KPB
(50 mM, pH 7.0) was added to a final volume of 50 mL and mixed with 
reciprocal stirring (160 min-1, 8 °C) for 22 hours. Aliquots of 500 μL were taken 
at different reaction times to investigate a changing time course of the 
biotransformations.  The samples were analyzed as de
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Table 80. Biotransformation of E/Z-2-phenylpropionaldoxime in the presence 
or absence of DMSO as cosolvent
Entry Cosolvent
Time
[min]
2PPN
[mM]
Spec. Activity
[U/Lcult]b
1 DMSO 18 0.323 897.2
2 none 19 0.377 992.1
3 DMSO 69 0.511 -a
4 none 70 0.677 - a
5 DMSO 170 0.886 - a
6 none 171 1.086 - a
7 DMSO 285 1.230 - a
8 none 286 1.387 - a
9 DMSO 1296 2.464 - a
10 none 1297 2.030 - a
(a) The rapid decrease in activity due to partial product inhibition makes these values obsolete 
(b) Units per liter of cell culture
9.18.2 STANDARD OPERATING PROCEDURE 30 (SOP30): COMPATIBILITY OF
OXDB WITH BINARY REACTION MEDIA
The stability of OxdB in binary mixtures was tested according to the following 
procedure: E-2-phenylpropionaldoxime (98 μL, 255 mM in DMSO) was 
dissolved in KPB (2.55 mL, pH 7.0, 50 mM) and mixed with FMN (1.250 mL, 
1mM in DIW) and organic solvent (1.00 mL). After addition of OxdB (resting cell 
suspension of recombinant E. coli HB101/pOxD-9OF, 100 μL, 0.7 U) to a final 
volume of 5 mL at 5 mM substrate concentration the emulsion was mixed with 
reciprocal shaking (160 min-1, 8 °C) for 24 hours. After centrifugation at 
15,000 rpm and 4 °C for 10 minutes, an aliquot of 0.50 mL of the aqueous 
phase was transferred to a 1.5-mL-microtube and diluted with dist. H2O 
(0.50 mL). The solution was centrifuged (15,000 rpm, 4 °C, 5 min) again and the 
supernatant (0.80 mL) was transferred to another microtube before being 
centrifuged a third time (15,000 rpm, 4 °C, 5 min). The resulting supernatant 
(0.75 mL) was transferred to a HPLC vial and directly measured on a reversed-
phase column (COSMOSIL C18-MS-II, 30% CH3CN in H2O, 1.0 mL/min, 40 °C, 
254 nm, Rt1 = 11.0 min (E-1), Rt2 = 12.4 min (Z-1), Rt3 = 18.1 min (2)) for 
conversion. Subsequently, the sample was again transferred to a 1.5-mL-
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microtube and overlaid with tert-butyl methylether (MTBE, 0.50 mL). After 
mixing on a vortexer, the phases were separated by centrifugation (15,000 rpm, 
4 °C, 5 min) and the organic phase (0.40 mL) was transferred to another 
microtube. Brine was added (0.40 mL) and the mixture was again mixed by 
vortexing and centrifuged. The organic phase (0.30 mL) was transferred to a 
1.0-mL-HPLC vial and diluted with additional MTBE (0.45 mL). The sample was 
measured on normal-phase chiral HPLC (Daicel Chiralpak OJ-H, 5% 2-propanol 
in n-hexane, 0.7 mL/min, 20 °C, 210 nm, Rt1 = 13.8 min ((R)-2), Rt2 = 14.4 min 
((S)-2), Rt3 = 20.3 min (Z-(S)-1), Rt4 = 26.7 min (E-(S)-1), Rt5 = 30.0 min (Z-(R)-1), 
Rt6 = 31.5 min (E-(R)-1)) for the enantiomeric excess of both product and 
remaining substrate.
Table 81. Biotransformation of E/Z-2-phenylpropionaldoxime in binary 
reaction media
Entry Solvent Homogenity
Conv.
[%]
ee (2)
[%]
ee (Z-1)
[%]
ee (E-1)
[%]
1 MTBE biphasic 33.8 29.3 (S) 85.8 (S) 27.7 (R)
2 EtOAc biphasic 20.0 17.2 (R) 79.3 (S) 6.8 (R)
3 n-Hexane biphasic 62.5 60.5 (S) - >99.8 (R)
4 DCMa biphasic 21.6 50.4 (R) 97.0 (S) 6.70 (R)
5 n-BuOAc biphasic 20.4 44.8 (S) 30.6 (R) 29.4 (R)
6 CHCl3a biphasic 7.40 56.3 (R) 5.50 (S) 0.50 (R)
7 THF heterogenous 22.8 13.0 (S) 38.3 (S) 13.7 (R)
8 2-PrOH homogenous 33.3 39.6 (S) 0.20 (R) 37.2 (R)
(a) Cell denaturation was observed
9.18.3 STANDARD OPERATING PROCEDURE 31 (SOP31): SOLUBILITY OF 
E/Z-2-PHENYLPROPIONALDOXIME AND 2-PHENYLPROPIONITRILE IN 
AQUEOUS BUFFER
E/Z-rac-2-phenylpropionaldoxime (2-PPAOx, 200 mg) or rac-2-
phenylpropionitrile (2-PPN, 200 mg), respectively, were transferred to 1.5-mL 
microtubes and overlaid with 500 μL of KPB (50 mM, pH 8.0). The phases were 
mixed on a vortexer at full speed for 10 minutes and rested for additional two 
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hours. After centrifugation at 15,000 rpm and 4 °C for 10 minutes an aliquot of 
100 μL KPB was analyzed by reversed-phase HPLC (COSMOSIL C18-MS-II, 30% 
CH3CN in H2O, 1.0 mL/min, 40 °C, 254 nm, Rt1 = 11.0 min (E-2-PPAOx), 
Rt2 = 12.4 min (Z-2-PPAOx), Rt3 = 18.1 min (2-PPN)).
Table 82. Solubility of E/Z-2-phenylpropionaldoxime and 2-
phenylpropionitrile in aqueous buffer (pH 8.0)
Entry Compound
Concentration
[mM]a
Solubility
[g/L]
1 2-PPAOx 20.79 ± 0.13
3.10 ± 0.032 2-PPAOx 20.79 ± 0.32
3 2-PPAOx 20.78 ± 0.20
4 2-PPN 13.69 ± 1.84 1.80 ± 0.24
(a) interpolated from a standard curve (2.50 – 50.00 mM), each value is the average of three 
injections
9.18.4 STANDARD OPERATING PROCEDURE 32 (SOP32): DISTRIBUTION 
COEFFICIENTS FOR E/Z-2-PHENYLPROPIONALDOXIME IN BINARY 
REACTION MEDIA
The distribution coefficients were determined by quantitative measurement of 
remaining E/Z-2-phenylpropionaldoxime in the aqueous phase. 
E/Z-rac-2-phenyl-propionaldoxime (3.73 mg, 0.025 mmol) was overlaid with 
1.00 mL of KPB (50 mM, pH 7.0) and the desired volume of organic solvent. The 
phases were mixed on a vortexer at full speed for 10 minutes and rested for 
additional two hours. After centrifugation at 15,000 rpm and 4 °C for 
10 minutes an aliquot of 500 μL of the aqueous phase was analyzed by 
reversed-phase HPLC (COSMOSIL C18-MS-II, 30% CH3CN in H2O, 1.0 mL/min, 
40 °C, 254 nm, Rt1 = 11.0 min (E-2-PPAOx), Rt2 = 12.4 min (Z-2-PPAOx)) for 
remaining aldoxime concentration.
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Table 83. Distribution coefficients for various organic solvents at 5 mM 
substrate concentration
Entry Solvent
Vol. ratio
[vorg/vaq]
2-PPAOx 
(aq.)
[mM]
log D (pH 
7.0)
1 MTBE 1:5 < 0.05
n.d.
2 MTBE 2:5 < 0.05
3 DCM 1:5 < 0.05
n.d.
4 DCM 2:5 < 0.05
5 n-hexane 1:5 0.50
0.34 ±0.07
6 n-hexane 2:5 0.74
7 n-hexane 3:5 1.18
8 n-hexane 4:5 1.26
9 n-hexane 5:5 1.33
10 EtOAc 1:5 < 0.05
n.d.
11 EtOAc 2:5 < 0.05
9.18.5 STANDARD OPERATING PROCEDURE 33 (SOP33): ACTIVE AQUEOUS 
CONCENTRATIONS FOR E/Z-2-PHENYLPROPIONALDOXIME IN A 
BINARY REACTION MIXTURE OF KPB AND N-HEXANE
The active concentrations were determined by quantitative measurement of 
remaining E/Z-2-phenylpropionaldoxime in the aqueous phase. An appropriate 
amount of E/Z-rac-2-phenylpropionaldoxime was dissolved in n-hexane 
(2.50 mL) to set the desired concentration (10 – 50 mM). KPB (50 mM, pH 7.0, 
2.50 mL) was added and the phases were mixed on a vortex at full speed for 
10 minutes and rested for additional two hours. After centrifugation at 15,000 
rpm and 4 °C for 10 minutes, an aliquot of 500 μL of the aqueous phase was 
analyzed by reversed-phase HPLC (COSMOSIL C18-MS-II, 30% CH3CN in H2O, 
1.0 mL/min, 40 °C, 254 nm, Rt1 = 11.0 min (E-2-PPAOx), Rt2 = 12.4 min (Z-2-
PPAOx)) for the remaining aldoxime concentration.
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Table 84. Distribution of E/Z-2-phenylpropionaldoxime in n-hexane/KPB 
mixtures (1:1 v/v) at various starting concentrations
Entry
2-PPAOx (org.)
[mM]a
2-PPAOx (aq.)
[mM]b
1 10.0 1.45
2 20.0 2.49
3 30.0 3.23
4 40.0 3.81
5 50.0 4.13
(a) Determined by weigh-in (b) Determined via reversed-phase HPLC
9.19 PURIFICATION OF CHIRAL NITRILES FROM AQUEOUS PRODUCT 
MIXTURES
9.19.1 STANDARD OPERATING PROCEDURE 34 (SOP34): HYDROLYSIS OF 
REMAINING ALDOXIME IMPURITIES FROM CRUDE MIXTURES
A solution of E/Z-2-phenylpropionaldoxime (2.50 mM) and rac-2-
phenylpropio-nitrile (2.50 mM) in KPB (50 mM, pH 7.0, 10 mL), mimicking a 
50% conversion, was stirred at 20 °C or 80 °C and subsequently acidified by 
addition of aqueous hydrochloric acid. Aliquots of 500 μL were taken after 
60 minutes and analyzed by HPLC (COSMOSIL C18-MS-II, 30% CH3CN in H2O, 
1.0 mL/min, 40 °C, 254 nm, Rt1 = 11.0 min (E-2-PPAOx), Rt2 = 12.4 min (Z-2-
PPAOx), Rt3 = 18.1 min (2-PPN)).
Table 85. Acid-catalyzed hydrolysis of remaining aldoxime in non-quantitative 
conversions
Entry
2PPAOx
[mM]
2PPN
[mM]
HCl
[mM]
Temp.
[°C]
Conv.a
[%]
1 2.49 2.47 30 20 2.0
2 1.51 2.49 90 20 39.6
3 0.89 2.49 200 20 64.4
4 2.39 2.40b 30 80 4.4
5 1.10 2.39b 90 80 56.0
6 0.64 2.29b 200 80 74.4
(a) The conversion was calculated from the decrease of educt since the hydrolysis product was 
distributed between the free aldehyde and its hydrate (b) The whereabouts of decreasing nitrile
concentration remain unclear.
[286]
9.19.2 STANDARD OPERATING PROCEDURE 35 (SOP35): EXTRACTIVE 
SEPARATION OF ALDEHYDE IMPURITIES AS BISULFITE ADDUCTS
A mixture of 2-phenylpropionaldehyde (2PPA, 2.5 mM) and 2-
phenylpropionitrile (2PPN, 2.5 mM) was dissolved in KPB (10 mL, 50 mM, 
pH 7.0, containing 2.5 vol-% DMSO) and stirred at room temperature. Solid 
sodium bisulfite was added to the mixtures to obtain different bisulfite 
concentrations. The solutions were stirred for 30 minutes before aliquots of 
500 μL were overlaid with 500 μL MTBE and extracted using a vortex mixer at 
full speed for 20 seconds. After centrifugation at 15,000 rpm and 4 °C for 
5 minutes, 300 μL of the organic phase were transferred to an HPLC vial and 
diluted with 700 μL MTBE. The solution was filtrated over a short silica column 
to remove insoluble contaminants and analyzed by normal-phase chiral HPLC 
(Daicel Chiralpak OJ-H, 5% 2-propanol in n-hexane, 0.7 mL/min, 20 °C, 210 nm, 
Rt1 = 13.8 min ((R)-2), Rt2 = 14.4 min ((S)-2), Rt3 = 20.3 min (Z-(S)-1), 
Rt4 = 26.7 min (E-(S)-1), Rt5 = 30.0 min (Z-(R)-1), Rt6 = 31.5 min (E-(R)-1)).  
Table 86. Extractive separation of remaining aldehyde from product mixtures
Entry
HSO3-
[mM]
2PPN 
[rel. %]
2PPA
[rel. %]
1 0.00 100 100
2 5.04 98.9 82.7
3 54.7 99.1 21.6
4 81.0 99.5 5.80
5 99.9 98.1 1.10
9.20 RECYCLING OF WHOLE-CELL BIOCATALYSTS
9.20.1 STANDARD OPERATING PROCEDURE 36 (SOP36): SUBSEQUENT 
ADDITION OF NEW SUBSTRATE AFTER FIRST REACTION CYCLE
E/Z-2-Phenylpropionaldoxime (25.0 μmol, 200 mM in DMSO, 125 μL) was 
added to the aqueous reaction mixture consisting of flavin mononucleotide 
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(FMN, 1 M in H2O, 1.25 mL), OxdB (resting cell suspension of recombinant 
E. coli HB101/pOxD-9OF, 7 U/mL, 0.10 mL) and KPB (50 mM, pH 7.0, 3.525 mL) 
at room temperature. The reaction was reciprocally shaken for 24 hours at 180 
min-1 and 8.0 °C. Aliquots of 500 μL were analysed by reversed-phase HPLC
(COSMOSIL C18-MS-II, 30% CH3CN in H2O, 1.0 mL/min, 40 °C, 254 nm, 
Rt1 = 11.0 min (E-1), Rt2 = 12.4 min (Z-1), Rt3 = 18.1 min (2)) for conversion and 
normal-phase chiral HPLC (Daicel Chiralpak OJ-H, 5% 2-propanol in n-hexane, 
0.7 mL/min, 20 °C, 210 nm, Rt1 = 13.8 min ((R)-2), Rt2 = 14.4 min ((S)-2), 
Rt3 = 20.3 min (Z-(S)-1), Rt4 = 26.7 min (E-(S)-1), Rt5 = 30.0 min (Z-(R)-1), 
Rt6 = 31.5 min (E-(R)-1)) for the enantiomeric excess of both product and 
remaining substrate. New E/Z-2-Phenylpropionaldoxime (0.025 mmol, 200 mM 
in DMSO, 125 μL) was added and the reaction was reciprocally shaken for 
another 24 hours at 180 min-1 and 8.0 °C.
Table 87. Subsequent addition of new substrate after the first reaction cycle
Entry Time ie [E] [Z] [CN] ee
1 82 98.9 (E) 5.838 - 4.162 95.6 (S)
2 270 98.9 (E) 5.194 - 4.808 96.1 (S)
3 1395 98.9 (E) 4.527 - 5.470 n.d.
4 82 90.2 (Z) 0.453 3.852 5.695 n.d.
(5)a 270 90.2 (Z) (0.860) (6.936) (2.415) n.d.
6 1395 90.2 (Z) 0.422 1.757 7.822 n.d.
(a) artifact
9.20.2 STANDARD OPERATING PROCEDURE 37 (SOP37): EXCHANGE OF 
AQUEOUS REACTION MIXTURE AFTER FIRST REACTION CYCLE
E/Z-2-Phenylpropionaldoxime (0.025 mmol, 200mM in DMSO, 125 μL) was 
added to the aqueous reaction mixture consisting of flavin mononucleotide 
(FMN, 1M in H2O, 1.25 mL), OxdB (resting cell suspension of recombinant E.coli
HB101/pOxd-90F, 7 U/mL, 0.10 mL) and KPB (50 mM, pH 7.0, 3.525 mL) at 
room temperature. The reaction was reciprocally shaken for 24 hours at 180 
min-1 and 8.0 °C. An aliquot of 0.50 mL was analysed by reversed-phase HPLC
(COSMOSIL C18-MS-II, 30% CH3CN in H2O, 1.0 mL/min, 40 °C, 254 nm, 
Rt1 = 11.0 min (E-1), Rt2 = 12.4 min (Z-1), Rt3 = 18.1 min (2)) for conversion and 
normal-phase chiral HPLC (Daicel Chiralcel OJ-H, 5% 2-propanol in n-hexane, 
0.7 mL/min, 20 °C, 210 nm, Rt1 = 13.8 min ((R)-2), Rt2 = 14.4 min ((S)-2), 
Rt3 = 20.3 min (Z-(S)-1), Rt4 = 26.7 min (E-(S)-1), Rt5 = 30.0 min (Z-(R)-1), 
Rt6 = 31.5 min (E-(R)-1)) for the enantiomeric excess of both product and 
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remaining substrate. The mixture was centrifuged for 5 minutes at 15,000 rpm 
and 4 °C. The supernatant was removed and the cells were resuspended in the 
new reaction mixture. The reaction was reciprocally shaken for 24 hours at 180 
min-1 and 8.0 °C and analysed like the preceding reaction.
Table 88. Recycling of whole-cell biocatalyst by centrifugation and 
resuspending
Entry
Spec. activity
[U/Lculture]
Nitrile conc. (5min)
[mM]
Nitrile conc. 
(24h)
[mM]
1 705 0.705 2.428
2 700 0.700 2.637
3 12 0.012 0.230
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10 EXPERIMENTAL PROCEDURES – ΒETA-HYDROXYCARBONYL
DERIVATIVES
10.1 ETHYL RAC-2-CYANO-3-PHENYLPROPIONATE
Benzyl bromide (1.78 mL, 15.0 mmol), ethyl cyanoacetate (4.76 mL, 45.0 mmol) 
and potassium carbonate (4.15 g, 30.0 mmol) were mixed without solvent and 
stirred for 12 hours at room temperature. The mixture was partitioned between 
MTBE (100 mL) and dist. H2O (100 mL). The aqueous phase was brought to 
pH 1 by titration with hydrochloric acid (12 N) and extracted twice with MTBE 
(2 x 100mL). The combined organic phase was washed once with brine 
(100 mL). After drying over MgSO4, all volatile compounds were removed in 
vacuo. NMR analysis shows quantitative conversion of benzyl bromide and a 
bis-alkylated side-product which could be identified by mass spectrometry. The 
main impurity of the crude product was remaining ethyl cyanoacetate. The 
product was isolated by column chromatography on silica (10% v/v ethyl 
acetate in cyclohexane, d=6cm, h=15cm) to obtain ethyl rac-2-cyano-3-
phenylpropionate (2.46 g, 12.1 mmol, 80.7%) as a colorless oil. The racemic 
compound can be separated on chiral HPLC (Daicel Chiralpak AD-H, 80:18:2 
SC-CO2/n-hexane/iPrOH, 0.8 mL/min, 216 nm, Rt1 = 12.8 min, Rt2 = 18.3 min).
1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.42 – 7.26 (m, 5H, Ar-H), 4.26 (q, J = 7.1 
Hz, 2H, O-CH2), 3.74 (dd, J = 8.4, 5.8 Hz, 1H, CH-CN), 3.26 (qd, J = 13.8, 7.1 Hz, 
2H, CH2-Ph), 1.29 (t, J = 7.1 Hz, 3H, CH2-CH3). 
13C-NMR (75 MHz, CDCl3): δ [ppm] = 165.52, 135.30, 129.04, 128.88, 127.79, 
116.17, 62.94, 39.70, 35.77, 13.95.
The data corresponds to literature-known values.148
10.2 ETHYL RAC-2-BENZYL-4-CHLORO-2-CYANO-3-OXOBUTANOATE
A suspension of sodium hydride (50 mg, 1.25 mmol, 60 % in mineral oil) in dry 
THF (10 mL) was stirred at room temperature. A solution of ethyl 
rac-2-benzyl-2-cyano-acetate (203 mg, 1.0 mmol) in dry THF (10 mL) was 
added dropwise at room temperature. Subsequently, the mixture was heated 
to reflux and stirred for additional two hours. A solution of chloroacetyl 
chloride (200 μL, 2.5 mmol) in dry THF (10 mL) was added dropwise to the 
enolate and the resulting mixture was stirred for 30 minutes at reflux 
temperature and additional three hours while cooling to room temperature. 
The reaction was quenched by the addition of brine (20 mL), the phases were 
[290]
separated, the organic phase was dried over MgSO4 and all volatile compounds
were removed in vacuo. Analysis by 1H-NMR spectroscopy revealed a product-
related conversion of 40.6%. No side-products except chloroacetic acid and 
starting material were observed. The racemic compound can be partially 
separated on chiral HPLC (Daicel ChiralPak OJ-H, 80:18:2 
SC-CO2/n-hexane/iPrOH, 0.8 mL/min, 220 nm, Rt1 = 12.8 min, Rt2 = 18.3 min). 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.40 – 7.25 (m, 5H, Ar-H), 4.33 (s, 2H, Cl-
CH2), 4.24 (q, J = 7.2 Hz, 2H, O-CH2-CH3), 3.40 (d, J = 2.7 Hz, 2H, CH2-Ph), 1.28 
(t, J = 7.1 Hz, 3H, CH2-CH3).
The compound is unknown to literature.
10.3 RAC-3-CYANO-4-PHENYL-2-BUTANONE
The synthesis is based on a condensation procedure from JI et al..149 Potassium 
tert-butoxide (1.68 g, 15.0 mmol, 3.0 eq.) is added to a stirring solution of 
3-phenylpropionitrile (655 mg, 5.0 mmol) in anhydrous THF (20 mL). After 
addition of ethyl acetate (1.97 mL, 20.0 mmol, 4.0 eq.) the mixture is stirred for 
18 hours at room temperature. The reaction is quenched by addition of 
hydrochloric acid (1 N, 25 mL), water (75 mL) and ethyl acetate (100 mL). The 
organic layer is separated, washed with water (2 x 50 mL), brine (2 x 25 mL), 
dried over MgSO4 and concentrated in vacuo. The crude product is purified via 
column chromatography on silica (6:1 v/v ethyl acetate in cyclohexane) to 
obtain a pale yellow oil.
Isolated yield: 742 mg (4.28 mmol, 85.7 %).
1H NMR (300 MHz, CDCl3): δ [ppm] = 7.42 – 7.23 (m, 5H, Ar-H), 3.66 (dd, J = 
8.6, 5.5 Hz, 1H, CH-CN), 3.30 – 3.05 (m, 2H, CH2-Ph), 2.35 (s, 3H, CH3).
13C NMR (75 MHz, CDCl3): δ [ppm] = 198.15, 135.56, 128.99, 128.95, 127.71, 
117.18, 46.42, 34.74, 28.91.
The compound is known to literature.
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10.4 RAC-3-CYANO-4-PHENYL-2-BUTANOL
Sodium borohydride (75.7 mg, 2.0 mmol) is added to a stirring solution of 
rac-3-cyano-4-phenyl-2-butanone (346 mg, 2.0 mmol) in THF (25 mL) at 0-4°C. 
The mixture is stirred for 1.5 hours and quenched by the addition of saturated 
sodium bicarbonate solution (15 mL). The solution is extracted with MTBE (3x 
50 mL) and the combined organic phase is washed with brine (1x 50 mL). After 
drying over MgSO4 all volatile compounds are removed in vacuo and the crude 
product is analyzed by 1H-NMR spectroscopy.
Isolated yield: 278 mg (1.59 mmol, 79.3%).
1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.42 – 7.23 (m, 5H, Ar-H), 3.99 – 3.86 (m, 
1H, CH-OH), 3.09 – 2.73 (m, 1H, CH-CN), 1.43 (dd, J = 10.3, 6.3 Hz, 1H, CH3).
The compound is known to literature.
10.5 STANDARD OPERATING PROCEDURE 38 (SOP38): BIOCATALYTIC 
REDUCTION OF BETA-OXONITRILES WITH ALCOHOL DEHYDROGENASES
A solution of NAD(P)+ (2.5 mol%) and the respective alcohol dehydrogenase in 
KPB (pH 8.0, 50 mM, 7.5 mL) is stirred at room temperature. The corresponding 
-oxonitrile (0.5 mmol) is dissolved in 2-propanol (2.5 mL) and added to the 
stirring biocatalyst solution. The resulting mixture is stirred for 24 hours at 
room temperature. The reaction is quenched by addition of neat sodium 
chloride to saturation and extraction with MTBE (3x 25 mL). The combined 
organic phase is washed with brine (25 mL) and dried over MgSO4. All volatile 
compounds are removed in vacuo and the crude product is analyzed by 1H-
NMR spectroscopy. The products are not purified yet.
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Table 89. Enantio- and diastereoselective reduction of 
3-cyano-4-phenyl-2-butan-one with alcohol dehydrogenases
Entry ADH (amount) Cofactor
Conversion
[%]
dra
(major/minor)
1 Rhodococcus sp. (50 uL) NAD+ >95.0 92:8
2
evocatal 1.1.200 (5.0 
mg)
NAD+ >95.0 70:30
a Identification of syn- and anti- diastereomers not yet established
10.6 STANDARD OPERATING PROCEDURE 39 (SOP39): PHOTOMETRIC 
SCREENING ASSAY OF HYDROLASES FOR THE BIOCATALYTIC 
DECARBOXYLATION OF ΒETA-OXOESTERS 
A solution of the corresponding substrate or mixtures of substrates (20 μL, 
0.2 M in DMSO), containing bromothymol blue (75 nM), was added to a 
solution of hydrolase (1 mg/mL, 180 μL) in aqueous buffer (10 mM, pH 7). The 
solutions were mixed on a 96-well plate and reference mixtures of the 
corresponding hydrolase with bromothymol blue were added. A color change 
from blue to yellow due to formation of carboxylic acids indicates activity for 
the given substrate. The well plate was immediately controlled for active 
enzymes at room temperature and was further mixed by shaking at 40 °C for 4-
24 hours.
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Table 90. Hydrolase-Screening for ethyl rac-2-benzyl-2-cyanoacetate and 
the mixture after chloroacetylation
1 1 1+2a 1+2a BLb 1 1 1+2a 1+2a BLb
A 0.65 0.64 0.88 0.89 0.61 I 0.63 0.61 0.84 0.81 0.56
B 0.67 0.67 0.89 0.90 0.60 J 0.64 0.67 0.89 0.89 0.61
C 0.66 0.66 0.88 0.87 0.60 K 0.80 0.77 0.80 0.89 0.60
D 0.70 0.69 0.89 0.84 0.64 L 0.59 0.59 0.84 0.83 0.55
E 0.76 0.79 0.74 0.75 0.63 M 0.64 0.62 0.87 0.88 0.57
F 0.62 0.61 0.87 0.88 0.56 N 0.55 0.54 0.81 0.79 0.52
G 0.76 0.77 0.79 0.76 0.56 O 0.71 0.69 0.97 0.92 0.67
H 0.57 0.59 0.88 0.88 0.53 P 0.62 0.61 0.70 0.70 0.51
(a) mixture incl. remaining chloroacetic acid, not neutralized (b) blank; hydrolase with indicator, 
no substrate present
A Protease from Rhizopus sp. I Pronase from Streptomyces griseus
B Alcalase ® CLEA J Protease from Aspergillus saitoi
C Protease from Aspergillus sp. (ABCR) K Protease from bovine pancreas
D Amano Acylase (Aspergillus melleus) L Protease S, Pyrococcus furiosus
E Porcine liver esterase (PLE, crude) M Amano Lipase M, Mucor javanicus
F Protease from Bacillus amilolyquefaciens N Protease from Bacillus sp. (Sigma)
G α-Chymotrypsin (Biozym CHY-03) O Protease from Bacillus licheniformis
H Amano Lipase PS (Pseudomonas cepacia) P Protease from Aspergillus oryzae
10.7 STANDARD OPERATING PROCEDURE 40 (SOP40): SYNTHESIS OF 
RACEMIC ΒETA-HYDROXY ESTERS BY REDUCTION OF RACEMIC ΒETA-
OXO ESTERS WITH SODIUM BOROHYDRIDE
A solution of the corresponding β-oxo ester (5.0 – 17.2 mmol) in THF (10-
35 mL) was cooled to 0-4 °C. Sodium borohydride (1.0 eq.) was added in 
portions and the resulting suspension was stirred for 2-3.5 hours at the same 
temperature. The progress of the reaction was monitored via TLC. The reaction 
was quenched by the addition of hydrochloric acid (0.5-1.0 M, 1:1 v/v) and 
MTBE (2:1 v/v). The phases were separated and the aqueous phase was 
extracted with MTBE (2 x 2:1 v/v). The combined organic phase was washed 
with brine (25 mL), filtered over a small silica column and dried over MgSO4. 
After removal of all volatile compounds in vacuo the product was obtained as 
colorless oil and was used without further purification.
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Table 91. Unselective reduction of racemic β-oxo esters with NaBH4
Entry R1 R2
Conv.
[%]
Yielda
[g (%)]
1 Me Bn >95.0 1.02 (91.8)
2 Ph Me >95.0 3.15 (87.9)
a β-Oxo esters were readily reduced to their corresponding 1,3-diols by NaBH4; the crude 
product was always a mixture of β-hydroxy ester and 1,3-diol which can be easily purified by 
recrystallization in the following saponification
10.7.1 ETHYL RAC-2-BENZYL-3-HYDROXYBUTANOATE
The following synthesis was conducted according to SOP35. A solution of ethyl 
rac-2-benzylacetoacetate (1.07 mL, 5.0 mmol) in THF (10 mL) was cooled to 0-
4 °C. Sodium borohydride (187 mg, 5.0 mmol) was added in portions and the 
suspension was stirred for two hours at 0-4 °C. The work-up was done as 
described in SOP35. The enantio- and diastereomers can be separated on 
normal-phase chiral HPLC (Daicel Chiralpak OJ-H, 2 % v/v 2-propanol in n-
hexane, 0.8 mL/min, 220 nm): 23.4 min (2S,3S), 23.5 min (2R,3R), 33.2 min 
(2S,3R), 39.8 min (2R,3S). 
Yield: 1.02 g (4.58 mmol, 91.8 %)
Ethyl syn-2-benzyl-3-hydroxybutanoate 
1H-NMR (400 MHz, CDCl3): δ [ppm] = 7.30 - 7.16 (m, 5H, Ar-H), 4.03 
(q, J = 7.2 Hz, 2H, O-CH2-CH3), 4.04 (m, 1H, CH-OH), 2.97 (d, J = 7.8 Hz, 2H, 
CH2-Ph), 2.74 (m, 1H, CH-COOEt), 1.26 (d, 3H, J = 6.3 Hz, H3C-CH-OH), 1.09 (t, 
J = 7.1 Hz, 3H, CH2-CH3).
13C-NMR (100 MHz, DMSO-d6): δ [ppm] = 173.08, 139.67, 128.57, 128.20, 
126.01, 67.18, 59.47, 55.93, 34.78, 21.44, 13.95.
Ethyl anti-2-benzyl-3-hydroxybutanoate
1H-NMR (400 MHz, CDCl3): δ [ppm] = 7.30 - 7.16 (m, 5H, Ar-H), 4.08 
(q, J = 7.2 Hz, 2H, O-CH2-CH3), 3.87 (m, 1H, CH-OH), 2.97 (d, J = 7.8 Hz, 2H, 
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CH2-Ph), 2.66 (m, 1H, CH-COOEt), 1.25 (d, J = 6.3 Hz, 3H, H3C-CH-OH), 1.13 (t,
J = 7.2 Hz, 3H, CH2-CH3).
13C-NMR (100 MHz, DMSO-d6): δ [ppm] = 173.01, 139.57, 128.68, 128.15, 
126.01, 67.29, 59.32, 55.56, 33.65, 20.89, 13.97.
IR: ṽ [cm-1] = 3442 (O-H), 2977 (C-H), 1720 (C=O), 735 (C-HAr), 
699 (C=CAr).
MS (EI): [m/z] = 204 (M+-H2O), 132 (M+-C3H5O-OH), 131 (M+-C7H7), 104 
(M+-C7H7-C2H4), 91 (C7H7+), 72 (C3H5O+).
EA: C13H18O3
Calculated: 70.24 % C, 8.16 % H, 21.59 % O.
Measured: 69.93 % C, 8.34 % H.
The compound is literature-known. However, no NMR data is available.
10.7.2 ETHYL RAC-3-HYDROXY-2-METHYL-3-PHENYLPROPIONATE
The following synthesis was conducted according to SOP35. A solution of ethyl 
2-methyl-3-oxo-3-phenylpropionate (3.54 g, 17.2 mmol) in dry THF (35 mL)
was cooled to 0-4 °C. Sodium borohydride (649.4 mg, 17.2 mmol, 1.0 eq.) was 
added and the mixture was stirred for 3.5 hours at the same temperature. The 
work-up was done as described in SOP35.
Yield: 3.15 g (15.1 mmol, 87.9 %)
Ethyl syn-3-hydroxy-2-methyl-3-phenylpropionate
1H-NMR (400 MHz, CDCl3): δ [ppm] = 7.40-7.25 (m, 5H, Ar-H), 5.09 (d, 1H,
J = 4.0 Hz, CH-OH), 4.13 (q, 2H, J = 7.1 Hz, O-CH2-CH3), 2.74 (m, 1H, CH-
COOEt), 1.21 (t, 3H, J = 7.1 Hz, CH2-CH3), 1.13 (d, 3H, J = 7.1 Hz, CH-CH3).
13C-NMR (100 MHz, CDCl3): δ [ppm] = 175.50, 141.53, 128.05, 127.30, 125.94, 
73.73, 60.52, 46.52, 13.92, 10.95. 
Ethyl anti-3-hydroxy-2-methyl-3-phenylpropionate
1H-NMR (400 MHz, CDCl3): δ [ppm] = 7.40 - 7.25 (m, 5H, Ar-H), 4.75 (d, 1H,
J = 8.3 Hz, CH-OH), 4.19 (q, 2H, J = 7.1 Hz, O-CH2-CH3), 2.80 (m, 1H, CH-
COOEt), 1.26 (t, 3H, J = 7.1 Hz, CH2-CH3), 1.02 (d, 3H, J = 7.1 Hz, CH-CH3).
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13C-NMR (100 MHz, CDCl3): δ [ppm] = 175.67, 141.58, 128.24, 127.77, 126.53, 
76.13, 60.56, 47.08, 14.27, 13.98.
The data corresponds to literature-known values.[150]
10.8 RAC-2-BENZYL-3-HYDROXYBUTANOIC ACID
The crude product of ethyl rac-2-benzyl-3-hydroxybutanoate (max. 5.0 mmol)
was dissolved in ethanol (5 mL). After addition of aqueous sodium hydroxide 
solution (2.5 M, 5 mL) the mixture was stirred for four hours at 60 °C. The 
solution was diluted with dist. H2O (20 mL), cooled to room temperature and 
saturated with neat sodium chloride. After extraction with MTBE (30 mL) at 
pH 12, the solution was acidified (pH 1-2) with hydrochloric acid (12 M) and 
extracted with MTBE (3 x 30 mL). The combined organic phases of the acidic 
extraction were washed with brine (30 mL), dried over MgSO4 and all volatile 
compounds were removed in vacuo. The crude product was taken up in 2-
propanol (1.5 mL) at reflux temperature. Light petroleum ether (10 mL) was 
added and the solution was slowly cooled to room temperature and further to 
0-4 °C with an ice bath. The precipitate was filtered off and washed with cold 
ether (0-4 °C). After drying in high vacuum the product was obtained as 
colorless solid.
Isolated yield: 201 mg (1.03 mmol, 20.7 %).
syn-2-benzyl-3-hydroxybutanoate 
1H-NMR (500 MHz, Acetone-d6): δ [ppm] = 7.28 - 7.14 (m, 5H, Ar-H), 4.30 –
3.95 (m, 1H, CH-OH), 2.92 (m, 2H, CH2-Ph), 2.74 – 2.69 (m, 1H, CH-COOH), 1.25
(d, 3H, J = 6.3 Hz, H3C-CH-OH).
13C-NMR (125 MHz, Acetone-d6): δ [ppm] = 175.10, 141.00, 129.81, 129.08, 
126.90, 68.41, 55.92, 34.78, 21.33.
anti-2-benzyl-3-hydroxybutanoate
1H-NMR (400 MHz, Acetone-d6): δ [ppm] = 7.28 - 7.14 (m, 5H, Ar-H), 3.95 –
3.89 (m, 1H, CH-OH), 2.92 (m, 2H, CH2-Ph), 2.69 – 2.64 (m, 1H, CH-COOH), 1.25 
(d, 3H, J = 6.3 Hz, H3C-CH-OH).
13C-NMR (125 MHz, Acetone-d6): δ [ppm] = 175.10, 141.00, 129.71, 129.08, 
126.86, 68.64, 56.57, 55.56, 35.51, 21.67.
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The compound is literature-known. However, NMR data is only available for 
D2O.151
10.9 STANDARD OPERATING PROCEDURE 41 (SOP41): PHOTOMETRIC 
SCREENING ASSAY OF HYDROLASES FOR THE BIOCATALYTIC SYNTHESIS
OF ΒETA-HYDROXYCARBOXYLIC ACIDS
A solution of the corresponding substrate or mixtures of substrates (20 μL, 
0.2 M in DMSO), containing bromothymol blue (75 nM), was added to a 
solution of hydrolase (1 mg/mL, 180 μL) in KPB (10 mM, pH 7). The solutions 
were mixed on a 96-well plate and reference mixtures of the corresponding 
hydrolase with bromothymol blue were added. A color change from blue to 
yellow due to formation of carboxylic acids indicates activity for the given 
substrate. The well plate was immediately controlled for active enzymes at 
room temperature and was further mixed by shaking at 40 °C for 4-24 hours.
Table 92. Hydrolase-screening for ethyl rac-2-benzyl-3-oxobutanoate and the 
racemic β-hydroxy ester.
1 1 2 2 BL 1 1 2 2 BL
A 0.83 0.83 0.94 0.91 0.90 I 0.83 0.84 0.95 0.96 0.92
B 1.60 1.23 1.29 1.48 1.37 J 0.93 0.89 1.01 1.02 1.05
C 0.88 0.91 1.00 1.03 1.00 K 0.71 0.72 0.86 0.85 0.85
D 0.89 0.94 1.06 1.01 0.99 L 0.97 0.97 1.08 1.13 0.99
E 0.44 0.45 0.60 0.60 0.88 M 0.87 0.89 1.05 1.02 0.94
F 0.90 0.93 1.03 1.03 0.95 N 0.89 0.92 1.02 0.94 0.91
G 0.83 0.74 1.01 0.94 0.91 O 0.87 0.90 1.04 1.03 0.98
H 1.39 1.30 1.49 1.07 1.58 P 0.93 0.94 1.04 1.08 0.99
A Protease from Rhizopus sp. I Pronase from Streptomyces griseus
B Alcalase ® CLEA J Protease from Aspergillus saitoi
C Protease from Aspergillus sp. (ABCR) K Protease from bovine pancreas
D Amano Acylase (Aspergillus melleus) L Protease S, Pyrococcus furiosus
E Porcine liver esterase (PLE, crude) M Amano Lipase M, Mucor javanicus
F Protease from Bacillus amilolyquefaciens N Protease from Bacillus sp. (Sigma)
G α-Chymotrypsin (Biozym CHY-03) O Protease from Bacillus licheniformis
H Amano Lipase PS (Pseudomonas cepacia) P Protease from Aspergillus oryzae
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10.10 STANDARD OPERATING PROCEDURE 42 (SOP42): PURIFICATION OF 
MIXTURES OF ΒETA-HYDROXY ESTERS BY BIOCATALYTIC 
DECARBOXYLATION VIA HYDROLASES
The corresponding racemic or enriched β-hydroxy or β-oxo ester was 
emulsified in KPB or mixtures of KPB with appropriate cosolvents, e.g. 2-
propanol. A solution of hydrolase in buffer was added and the resulting 
mixture was stirred for 24 hours at room temperature. The pH was maintained 
by titration with aqueous sodium hydroxide solution (0.2 M) by a titrino 
apparatus. The progress of the reaction was monitored by the consumption of 
titer which was equivalent to the amount of product formed during hydrolysis. 
The solution was subsequently saturated with neat sodium chloride and 
extracted with tert-butyl methyl ether (1:1 v/v) at pH 8.0. If necessary, the pH of 
the solution was basified by addition of neat sodium bicarbonate. If the desired 
product was the corresponding decarboxylated ketone, the aqueous phase was 
extracted with additional MTBE (2 x 1:1 v/v) before the combined organic 
phase was washed with brine (1:1 v/v), dried over MgSO4 and all volatile 
compounds were removed in vacuo. In the case of the β-hydroxycarboxylic acid 
as the desired product, the first organic phase was discarded and the aqueous 
phase was brought to pH 1 by the addition of hydrochloric acid (12 M). After 
extraction with MTBE (3x 1:1 v/v) the combined organic phase was treated as 
described before. The crude product was analyzed with 1H-NMR spectroscopy 
and was purified by recrystallization or column chromatography on silica, if 
necessary.
Table 93. Biocatalytic synthesis of β-hydroxycarboxylic acids via hydrolase.
Entry R1 R2 R3 Hydrolase
Conversion
[%]
Isol. Yield
[g (%)]
1 Me Bn H PLE 40.2a 0.19 (39.4)
2
Cl-
Me
Bn CN PLE >95.0b n.d. (< 1.0)c
(a) determined by consumption of titer (b) nearly quantitative conversion to hydrolyzed by-
product (c) not determined
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10.10.1 (2RS,3RS)-2-BENZYL-3-HYDROXYBUTANOIC ACID
The synthesis was conducted according to SOP29. To an emulsion of ethyl rac-
2-benzyl-3-hydroxybutanoate (556 mg, 2.5 mmol) in KPB (pH 7.0, 50 mM, 
25 mL) was added porcine liver esterase (52.4 mg). The mixture was stirred for 
24 hours at room temperature. The pH was maintained by titration with 
aqueous sodium hydroxide solution (0.2M) by a titrino apparatus. The work-up 
was done as described in SOP29.
Isolated yield: 191 mg (0.98 mmol, 39.4%).
syn-2-benzyl-3-hydroxybutanoate 
1H-NMR (500 MHz, Acetone-d6): δ [ppm] = 7.28 - 7.14 (m, 5H, Ar-H), 4.30 –
3.95 (m, 1H, CH-OH), 2.92 (m, 2H, CH2-Ph), 2.74 – 2.69 (m, 1H, CH-COOH), 1.25
(d, 3H, J = 6.3 Hz, H3C-CH-OH).
13C-NMR (125 MHz, Acetone-d6): δ [ppm] = 175.10, 141.00, 129.81, 129.08, 
126.90, 68.41, 55.92, 34.78, 21.33.
anti-2-benzyl-3-hydroxybutanoate
1H-NMR (400 MHz, Acetone-d6): δ [ppm] = 7.28 - 7.14 (m, 5H, Ar-H), 3.95 –
3.89 (m, 1H, CH-OH), 2.92 (m, 2H, CH2-Ph), 2.69 – 2.64 (m, 1H, CH-COOH), 1.25 
(d, 3H, J = 6.3 Hz, H3C-CH-OH).
13C-NMR (125 MHz, Acetone-d6): δ [ppm] = 175.10, 141.00, 129.71, 129.08, 
126.86, 68.64, 56.57, 55.56, 35.51, 21.67.
The data corresponds to literature-known values.
10.10.2 RAC-3-HYDROXY-2-METHYL-3-PHENYLPROPANOIC ACID
Ethyl rac-2-benzyl-3-hydroxybutanoate (1.04 g, 5.0 mmol) was dissolved in 
ethanol (5 mL). After addition of aqueous sodium hydroxide solution (2.5M, 
5mL) the mixture was stirred for four hours at 60°C. The solution was diluted 
with dist. H2O (20 mL), cooled to room temperature and saturated with neat 
sodium chloride. After extraction with MTBE (2x 30 mL) at pH 12, the solution 
was acidified (pH 1-2) with hydrochloric acid (12M) and extracted with MTBE 
(3x 30 mL). The combined organic phases of the acidic extraction were washed 
with brine (30 mL), dried over MgSO4 and all volatile compounds were 
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removed in vacuo. The crude product was a colorless oil which crystallized 
while standing at room temperature. The purification is not finished yet.
10.11 3-METHOXYPROPYLAMINE ACETATE
A mixture of acetic acid (57.2 mL, 1.00 mol) and 3-methoxypropylamine 
(81.6 mL, 0.80 mol) was stirred for six hours at 60 °C. The excess of acetic acid 
was removed in high vacuum (60 °C, 0.02 mbar) to obtain the ionic liquid as 
yellow oil.
Isolated yield: 119.2 g (0.80 mmol, 99.8%).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 3.56 – 3.48 (m, 2H, CH2-NH3), 3.36 – 3.30 
(s, 3H, O-CH3), 3.04 – 2.94 (t, J = 6.6 Hz, 2H, O-CH2), 2.02 – 1.93 (s, 3H, (O=)C-
CH3), 1.94 – 1.84 (m, 2H, CH2-CH2-CH2).
The data corresponds to literature-known values.
10.12 STANDARD OPERATING PROCEDURE 43 (SOP43): KNOEVENAGEL 
CONDENSATION OF BENZALDEHYDE WITH ALPHA-C-H ACIDIC ESTERS 
IN AN IONIC LIQUID
A mixture of the corresponding α-C-H acidic ester (45.0 – 100 mmol), 
benzaldehyde (1.0 - 2.0 eq.) and 3-methoxypropylamine acetate 
(0.08 - 0.17 eq.) was stirred at room temperature. If the viscosity was too high 
for appropriate stirring, additional ethyl acetate (10 mL) was added for dilution. 
The solution was stirred for 3-18 hours at room temperature. The progress of 
the reaction was monitored via TLC. After complete consumption of starting 
material, ethyl acetate (200 mL) was added and the organic phase was washed 
with hydrochloric acid (6 M, 100 mL) and sodium bisulfite solution (40 %, 
100 mL). The organic phase was dried over MgSO4 and all volatile compounds 
were removed in vacuo. The crude product was purified via column 
chromatography or recrystallization, if necessary.
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Table 94. Knoevenagel condensation for the synthesis of 2-substituted ethyl 
cinnamates
Entry R
Time
[h]
Conv.
[%]
Yield
[g(%)]
1 Ac 18.0 68.3 12.2 (56.1)
2 Cl-Ac 4.5 72.4 3.89 (51.3)a
3 CN 3.0 >95.0 6.51 (71.9)
a an aliquot of 6.0 g crude product was purified
10.12.1 ETHYL E/Z-2-BENZYLIDENE-3-OXOBUTANOATE
The following synthesis was conducted according to SOP38. A highly viscous 
mixture of ethyl acetoacetate (12.7 mL, 100 mmol), benzaldehyde (10.1 mL, 
100 mmol) and 3-methoxypropylamine acetate (1.2 g, 8.0 mmol, 0.08 eq.) was 
vigorously stirred for 18 hours at room temperature. The work-up was done as 
described in SOP38. The crude product shows a product content of >95% and
was not further purified. The product was obtained as yellow oil.
Isolated yield: 12.2 g (56.1 mmol, 56.1 %).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 7.86 (s, 1H, Ar-HC=C), 7.45 – 7.35 (m, 5H, 
Ar-H), 4.33 (q, J = 7.1 Hz, 2H, O-CH2-CH3), 4.31 (s, 3H, H3C-C=O), 1.35 (t, J = 7.1 
Hz, 3H, CH3).
The data corresponds to literature values.152
10.12.2 ETHYL E/Z-2-BENZYLIDENE-4-CHLORO-3-OXOBUTANOATE
The following synthesis was conducted according to SOP38. A highly viscous 
mixture of ethyl 4-chloro-3-oxobutanoate (13.6 mL, 100 mmol), benzaldehyde 
(10.1 mL, 100 mmol) and 3-methoxypropylamine acetate (2.4 g, 16.0 mmol, 
0.16 eq.) was diluted with ethyl acetate (10 mL) and vigorously stirred for 4.5 
hours at room temperature. The work-up was done as described in SOP38. An 
aliquot of the crude product (6 g, 30 wt-%) was purified via column 
chromatography on silica (d=6 cm, h=20 cm, 1-10% v/v ethyl acetate in 
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cyclohexane) to yield the product as pure Z-isomer (0.65 g, 2.6 mmol) and an 
E/Z-mixture (3.24 g, 12.8 mmol, E/Z = 78:22).
Isolated yield: 3.89 g (15.4 mmol, 51.3%).
1H-NMR (500 MHz, CDCl3): δ [ppm] = 7.87 (s, 1H, Ar-HC=C), 7.54 – 7.33 (m, 5H, 
Ar-H), 4.34 (q, J = 7.2 Hz, 2H, O-CH2-CH3), 4.31 (s, 3H, H3C-C=O), 1.35 (t, J = 7.2 
Hz, 3H, CH3).
ESI-MS: m/z [fragment] = 275 [M+Na]+(35Cl, 100%), 277 [M+Na] (37Cl, 35%).
The data corresponds to literature-known values.153
10.12.3 ETHYL E-2-CYANOCINNAMATE
The following synthesis was conducted according to SOP38. A highly viscous 
mixture of ethyl cyanoacetate (4.76 mL, 45.0 mmol), benzaldehyde (9.10 mL, 
90 mmol) and 3-methoxypropylamine acetate (2.5 g, 16.7 mmol, 0.17 eq.) was 
vigorously stirred for three hours at room temperature. The work-up was done 
as described in SOP38. The crude product was purified by recrystallization in 
light petroleum ether to obtain the product as colorless solid.
Isolated yield: 6.51 g (32.3 mmol, 71.9%).
1H-NMR (300 MHz, CDCl3): δ [ppm] = 8.27 (s, 1H, C=CH), 8.04 – 7.98 (m, 2H, 
o-Ar-H), 7.62 – 7.48 (m, 3H, m,p-Ar-H), 4.41 (q, J = 7.1 Hz, 2H, O-CH2-CH3), 1.42
(t, J = 7.1 Hz, 3H, O-CH2-CH3).
The data corresponds to literature-known values.154
10.13 BENZYL IODIDE
Sodium iodide (7.79 g, 52.0 mmol) was suspended in acetone (40 mL) at room 
temperature and under exlusion of light. Benzyl bromide (5.95 mL, 50.0 mmol) 
was added dropwise and the resulting suspension was stirred for 60 minutes at 
room temperature. GC analysis reveals a product-related conversion of >98.5%. 
The suspension was filtered and the filtrate was concentrated in vacuo to 
obtain the product as pale yellow oil which was stored under exclusion of light.
Isolated yield: 10.9 g (50.0 mmol, 100%).
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1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.43 – 7.24 (m, 5H, Ar-H), 4.49 (s, 2H, 
CH2-I).
EI-MS (m/z) = 91 [Trp]+, 127 [I]+.
The data corresponds to literature-known values.
10.14 ETHYL RAC-2-BENZYL-4-CHLORO-3-OXOBUTANOATE
The crude product of synthesis 10.8.2 was diluted with ethyl acetate (50 mL). 
Palladium on charcoal (Pd/C, 100 mg) was added to the solution and stirred 
under hydrogen atmosphere at room temperature. Additional hydrogen was 
bubbled through the solution via syringe. Celite (1 g) was added after 12 hours 
and the suspension was filtered. The solvent and all volatile compounds were 
removed in vacuo. The crude product was analyzed by NMR spectroscopy. It 
shows a >95.0% conversion with minor impurities from the previous step. NMR 
analysis reveals dehalogenation of 58.8% under these conditions.
1H-NMR (500 MHz, CDCl3): δ [ppm] = 7.32 – 7.15 (m, 5H, Ar-H), 4.23 (s, 2H, 
CH2-Cl), 4.22 (q, J = 7.2 Hz, 2H, O-CH2-CH3), 4.05 (t, J = 7.0 Hz, 3H, CH-COOEt), 
3.22 (d, J = 7.1 Hz, 2H, CH2-Ph), 1.22 (t, J = 7.2 Hz, 3H, O-CH2-CH3).
The compound is unknown to literature.
10.15 ETHYL RAC-2-BENZYL-4-CHLORO-3-HYDROXYBUTANOATE
Lithium N,N-diisopropylamide (2.0 M in THF/n-heptane/ethylbenzene, 20.0 mL, 
40.0 mmol) was dissolved in abs. THF (40 mL) and cooled to -78 °C
(acetone/dry ice). A solution of ethyl 3-phenylpropionate (7.03 mL, 40.0 mmol) 
in abs. THF (10 mL) was added dropwise under temperature control. The 
resulting mixture was stirred for 60 minutes at -78 °C before a solution of 
chloroacetaldehyde (59% in DCM, 5.32 mL, 40.0 mmol) in abs. THF (10 mL) was 
added dropwise under temperature control. The solution was stirred for 
additional two hours at -78 °C and was subsequently quenched by the addition 
of saturated ammonium chloride solution (20 mL). The phases were separated 
and the organic phase was directly filtrated over silica (20 % v/v ethyl acetate in 
cyclohexane). The filtrate was concentrated in vacuo and the residue was 
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purified via column chromatography on silica (1-10 % v/v ethyl acetate in 
cyclohexane) to obtain the product as colorless oil.
Isolated yield: 1.95 g (7.60 mmol, 19.0 %).
1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.42 – 7.07 (m, 5H, Ar-H), 4.03 – 3.90 (m, 
2H, O-CH2-CH3), 3.32 – 2.72 (m, 5H, Cl-CH2, CH-OH, CH2-Ph), 2.29 – 2.00 (m, 
1H, CH-COOEt), 1.06 – 0.94 (m, 3H, CH2-CH3).
EI-MS (m/z) = 178 [M-C2H2ClO]+, 104 [PhC2H4]+, 91 [Trp]+.
The compound is unknown to literature.
10.16 STANDARD OPERATING PROCEDURE 44 (SOP44): LACTONIZATION OF 
ΒETA-HYDROXYCARBOXYLIC ACIDS UNDER RETENTION OF THE 
ABSOLUTE CONFIGURATION
The corresponding β-hydroxy carbonacid (1.0 – 5.0 mmol) was dissolved in 
pyridine (5 – 25 mL) and cooled to 0-4 °C. After the addition of p-
toluenesulfonyl chloride (2.0 eq.) the reaction was stirred for 4-24 hours at 0-
4 °C. The reaction was quenched by the addition of dist H2O (1:1 v/v) and ethyl 
acetate (2:1 v/v). The phases were separated and the aqueous phase was 
extracted with ethyl acetate (2x 2:1 v/v). The combined organic phase was 
washed with brine (1:1 v/v) and dried over MgSO4 before all volatile 
compounds were removed in vacuo. The crude product was analyzed by NMR 
spectroscopy and purified via column chromatography, if necessary.
Table 95. Lactonization of β-hydroxy carbonacids
Entry R1 R2
Conv.
[%]
Isol. Yield
[g(%)]
1 Me Bn >95.0 n.d.
2 Ph Me >95.0 n.d.
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10.16.1 RAC-3-BENZYL-4-METHYLOXETAN-2-ONE
The following synthesis was conducted according to SOP39. A solution of 
rac-2-benzyl-3-hydroxybutanoic acid (194 mg, 1.0 mmol) in pyridine (5 mL) 
was cooled to 0-4 °C. After the addition of p-toluenesulfonyl chloride (381.3 
mg, 2.0 mmol) the reaction was stirred for 24 hours at 0-4 °C. The work-up was 
done as described in SOP39. NMR analysis of the crude product reveals a 
quantitative conversion of starting material and a change in diastereomeric 
excess, most likely due to racemization by pyridine over the prolonged reaction 
time. The crude product was not further purified.
Yield: 206 mg
syn-3-Benzyl-4-methyl-oxetan-2-one:
1H-NMR (400 MHz, CDCl3): δ [ppm] = 7.32-7.26 (m, 5H, Ar-H), 4.46 (m, 1H, 
H3C-CH-O), 3.46 (m, 1H, CH-Bn), 3.20 – 3.00 (m, 2H, CH2-Ph), 1.45 (d, J = 6.1 Hz,
3H, CH3).
anti-3-Benzyl-4-methyl-oxetan-2-one:
1H-NMR (400 MHz, CDCl3): δ [ppm] = 7.32-7.26 (m, 5H, Ar-H), 4.81 (m, 1H, 
H3C-CH-O), 4.02 (m, 1H, CH-Bn), 3.20 – 3.00 (m, 2H, CH2-Ph), 1.49 (d, J = 6.4 Hz,
3H, CH3).
The compound is literature-known. However, no NMR data is available.
10.17 (2RS,3RS)-2-BENZYL-3-HYDROXYBUTANOIC ACID VIA BIENZYMATIC 
ONE-POT PROCEDURE COMBINING AN ALCOHOL DEHYDROGENASE 
AND A HYDROLASE
An aqueous reaction mixture containing NAD+ (68.2 mg, 0.1 mmol), an alcohol 
dehydrogenase from Rhodococcus sp. (Rsp-ADH, cell-free extract, 1:1 v/v in 
glycerin, 1.00 mL) and porcine liver esterase (crude, 100 mg) in KPB (50 mM, pH 
8.0, 75 mL) was stirred at room temperature. After the addition of a substrate 
solution of ethyl rac-2-benzyl-3-oxobutanoate (551 mg, 2.5 mmol) in 2-
propanol (25 mL) the resulting mixture was stirred for 16 hours at pH 8.0 and 
room temperature. The pH was maintained by titration with sodium hydroxide
solution (0.2 M) to neutralize the carboxylic acid formed during the reaction. 
The consumption of titer stopped at 50 % conversion after 60 minutes. To 
[306]
exclude inactivation of the biocatalysts, additional ethyl rac-2-benzyl-3-
oxobutanoate (551 mg, 2.5 mmol) was added and the mixture was stirred for 
16 hours. The consumption of titer immediately increased up to a conversion 
of 86.5% in relation to 2.5 mmol substrate, corresponding to a total conversion 
of 43.3 %. The solution was brought to saturation with neat sodium chloride 
and acidified to pH 1 with hydrochloric acid (12 M). After extraction with MTBE 
(3x 75 mL) the combined organic phase was washed with brine (100 mL) and 
dried over MgSO4. All volatile compounds were removed in vacuo. The crude 
product was analyzed by 1H-NMR spectroscopy for conversion, 
diastereoselectivity and formation of side-products. It shows 15.2 % ethyl 
rac-2-benzyl-3-oxobutanoate, 44.5 % ethyl rac-2-benzyl-3-hydroxybutanoate, 
11.7 % rac-2-benzyl-3-hydroxybutanoic acid, 8.4 % 4-phenyl-2-butanone and 
20.2 % 4-phenyl-2-butanol. The crude product was not further purified.
Crude yield: 890 mg
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11 EXPERIMENTAL PROCEDURES – CHROMENES
11.1 3,5-DIFLUORSALICYLALDEHYDE 
To a stirring solution of 2,4-difluorphenol (7.64 mL, 10.41 g, 80 mmol) in 
trifluoroacetic acid (65 mL) was added hexamethylentetramine (22.43 g, 160 
mmol) in portions. The mixture was stirred for 18 hours at 75 °C. After addition 
of sulfuric acid (40%, 80 mL) and stirring for additional 2.5 hours at room 
temperature the mixture was poured into ice water (mixture of crushed ice and 
dist. H2O, 0-4 °C). The precipitate was filtered off and dried in high vacuum to 
obtain the product as pale yellow solid. 
Isolated yield: 6.85 g (43.3 mmol, 54.2%). 
1H-NMR (500 MHz, DMSO) δ [ppm] = 10.90 (s, 1H, CHO), 10.26 (d, J = 2.9 Hz, 
1H, OH), 7.63 (ddd, J = 11.3, 8.4, 3.1 Hz, 1H, CF-CH-CF), 7.25 (ddd, J = 8.4, 3.0, 
1.7 Hz, 1H, CF-CH-C). 
13C-NMR (126 MHz, CDCl3) δ [ppm] = 195.2, 155.4, 153.5, 151.9, 149.9, 146.6, 
121.0, 113.2, 112.0. 
19F-NMR (470 MHz, CDCl3) δ [ppm] = -120.41 (s, CH-CF-COH), -131.17 (s, CH-
CF-CH).
The compound was literature-known. However, no NMR data is available.
11.2 2-NITROETHANOL 
Paraformaldehyde (5.04 g, 168 mmol) and potassium carbonate (73 mg, 
0.53 mmol, 0.3 mol%) were suspended in nitromethane (75 mL, 66.37 g, 
1.70 mol) and stirred for three hours at reflux temperature. The mixture was 
cooled to room temperature, acidified with hydrochloric acid (1 M) and 
extracted with MTBE (2x 30 mL). The combined organic phase was washed with 
saline (2x 50 mL) and dried over MgSO4. After removal of all volatile 
compounds the crude product was purified via fractional distillation (80 °C, 8 
mbar) to obtain the product as colorless oil.
Isolated yield: 2.20 g (24.0 mmol, 15.0%).
1H-NMR (500 MHz, CDCl3) δ [ppm] = 4.54 (t, 2H, CH2-OH), 4.15 (t, 2H, CH2-
NO2).
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The compound is literature-known. The data corresponds to a commercial 
reference.
11.3 2-BROMO-1-NITROETHANE
A solution of phosphor tribromide (2.14 mL, 22.8 mmol) in dichloromethane 
(5 mL) was cooled to 0-4 °C. A solution of 2-nitroethanol (5 mL, 70.9 mmol) in 
dichloromethane (10 mL) was added dropwise. The mixture was stirred for 
60 minutes at 0-4 °C. Dist. H2O (10 mL, 0-4 °C) was added and the phases were 
separated. The aqueous phase was extracted with dichloromethane (2x 15 mL) 
and the combined organic phase was washed with saturated sodium 
bicarbonate solution (20 mL). After drying over MgSO4 all volatile compounds 
were removed in vacuo. The crude product was purified by fractional distillation 
(75 °C, 10 mbar) to obtain the product as colorless oil in a mixture with starting 
material.
Isolated yield: 1.25 g (84 % product content, 6.82 mmol, 9.6 %).
1H-NMR (500 MHz, CDCl3) δ [ppm] = 4.77 (t, J = 6.4 Hz, 2H, CH2-NO2), 3.82 (t,
J = 6.3 Hz, 2H, CH2-Br).
The compound is literature-known. However, no NMR data is available.
11.4 NITROETHYLENE
Phthalic anhydride (9.63 g, 65 mmol) was mixed with 2-nitroethanol (3.5 mL, 
49.6 mmol) and stirred at 150 °C. The product was directly distilled from the 
reaction mixture (30-45 °C, 11 mbar) and condensed at -78 °C (acetone/dry 
ice). The distillate was brought to room temperature and consists of two 
phases, one of them being H2O. Dichloromethane (10 mL) was added and the 
phases were separated. After drying the organic phase over MgSO4 all volatile 
compounds were removed under reduced pressure (>150 mbar, 40 °C).i The 
crude product was analyzed by 1H-NMR spectroscopy to be a mixture of 
nitroethylene (40.0 %), nitromethane (44.3 %) and dichloromethane (15.7 %).
Isolated yield: 2.79 g (40 % product content, 15.3 mmol, 30.8 %).
i Due to the low boiling point of the product the pressure was not further decreased.
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1H-NMR (500 MHz, CDCl3) δ [ppm] = 7.14 (dd, J = 14.9, 7.4 Hz, 1H, CH-NO2), 
6.65 (dd, J = 14.9, 2.0 Hz, 1H, HEC=CH-NO2), 5.91 (d, J = 5.9 Hz, 1H, HZC=CH-
NO2).
The data corresponds to literature-known values.155
11.5 STANDARD OPERATING PROCEDURE 45 (SOP45):
CYCLOCONDENSATION OF 3,5-DIFLUOROSALICYLIC ALDEHYDE WITH 
VARIOUS ΑLPHA,ΒETA-UNSATURATED CARBONYL SYNTHONS
The following syntheses were conducted according to different literature 
procedures which will be given in parenthesis. In general, 3,5-difluorosalicylic 
aldehyde (5.0 mmol) and the corresponding Michael acceptor (1.5 – 5.0 eq.)
were dissolved in an adequate organic solvent (10 mL). Different additives were 
added for stabilization of the monomer reagents, in situ formation of the 
monomers or acceleration of the cyclocondensation reaction. The mixtures
were heated to reflux temperature of the solvent and under conditions for the 
irreversible elimination of H2O from the reaction (e.g. azeotrope distillation).
After stirring for 4-24 hours the mixtures were cooled to room temperature 
and the solution was directly chromatographed on silica (dichloromethane / 
light petroleum ether 1:1 v/v) to remove the majority of impurities and to 
obtain the desired product in pure form or in a mixture with the starting 
aldehyde. If starting material was present, extraction with sodium hydroxide 
solution (1 M, 2 x 1:1 v/v), separation of the phases, drying over MgSO4 and 
removal of all volatile compounds in vacuo will give the pure 2H-chromene 
derivative. The starting material can be recycled by acidification and extraction 
with MTBE (3 x 1:1 v/v). In the case of dioxane the solvent was first removed in 
vacuo before extraction or purification of the crude product. In the case of 
PEG400 the solvent was removed by additional washing with dist. H2O (2 x 1:1 
v/v) of the combined organic phase after extractive work-up.
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Table 96. Substrate synthesis of 3-substituted 6,8-difluoro-2H-chromenes
Entry EWGa Solvent Base Isolated yield
1 CHO Dioxane K2CO3 0.15 (15.5)
2 CN - DABCO 0.38 (39.3)
3 NO2 Toluene Bu2NH 0.87 (40.9)
4 CONH2 Toluene Bu2NH n.d. (-)a
(a) Electron-withdrawing group (EWG): aldehyde (CHO), nitrile (CN), nitro (NO2), carbamide 
(CONH2) (b) No product was isolated, probably acrylamide polymerization under the given 
conditions.
11.5.1 6,8-DIFLUORO-2H-CHROMENE-3-CARBALDEHYDE
The following synthesis was conducted according to a literature procedure 
from CONTI and DESIDERI.156 Acrolein (420 μL, 7.50 mmol) was added dropwise 
to a suspension of 3,5-difluorosalicylaldehyde (791 mg, 5.0 mmol) and K2CO3
(1.04 g, 7.5 mmol) in dry dioxane (20 mL). The mixture was refluxed for four 
hours. After cooling, the solvent was removed under reduced pressure and the 
residue was distributed between dichloromethane and 2 M NaOH. The organic 
phase was washed with brine and dried over MgSO4 before all volatile 
compounds were removed in vacuo. The residue was purified by column 
chromatography on silica (1:1 v/v dichloromethane in light petroleum ether).
Isolated yield: 152 mg (0.77 mmol, 15.5 %).
1H-NMR (300 MHz, CDCl3): δ [ppm] = 9.64 (s, 1H, CHO), 7.22 (m, 1H, Ar-CH-C), 
6.91 (ddd, J = 10.3, 8.4, 2.9 Hz, 1H, FC-CH-CF), 6.79 (ddd, J = 7.7, 2.9, 1.8 Hz, 1H, 
FC-CH-C), 5.09 (d, J = 1.4 Hz, 2H, O-CH2).
19F NMR (282 MHz, CDCl3): δ [ppm] = -118.88 (t, J = 8.0 Hz, 1F, p-CF), -131.15 
(d, J = 10.0 Hz, 1F, o-CF).
The compound is literature-known.157 However, no NMR data is available.
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11.5.2 6,8-DIFLUORO-2H-CHROMENE-3-CARBONITRILE
The following synthesis was conducted according to a patent procedure from 
TAUGERBECK et al..158 A solution of 3,5-difluorosalicylaldehyde (791 mg, 5.0 
mmol), 1,4-diazabicyclo[2.2.2]octane (DABCO, 169 mg, 1.5 mmol) and p-
methoxyphenol (9.3 mg, 0.08 mmol) in acrylonitrile (8.0 mL) was stirred for 15 
hours at 75 °C. The solvent was evaporated and the residue was taken up in 
dichloromethane (25 mL) and purified by flash chromatography on silica 
(dichloromethane) to obtain spectroscopically pure product.
Isolated yield: 380 mg (1.97 mmol, 39.3 %).
1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.15 (d, J = 1.5 Hz, 1H, Ar-HC=C), 6.90 
(ddd, J = 10.2, 8.4, 2.9 Hz, 1H, FC-CH-CF), 6.70 (m, 1H, FC-CH-C), 4.89 (d, J = 1.5 
Hz, 2H, O-CH2).
19F NMR (282 MHz, CDCl3): δ [ppm] = -117.70 (t, J = 8.1 Hz, 1F, p-CF), -130.88 
(d, J = 10.9 Hz, 1F, o-CF).
The compound was literature-known.158 However, no NMR data was available.
11.5.3 6,8-DIFLUORO-3-NITRO-2H-CHROMENE
The synthesis was conducted based on the literature procedure from 
NEIRABEYEH et al.159 A mixture of 3,5-difluorosalicylaldehyde (1.58 g, 10.0 mmol), 
phthalic anhydride (2.96 g, 20.0 mmol), 2-nitroethanol (1.41 mL, 20.0 mmol), p-
methoxyphenol (1.24 mg, 0.01 mmol) and di-n-butylamine (843 μL, 5.0 mmol)
was dissolved in toluene (100 mL). The solution was stirred for 24 hours at 
reflux temperature in a Dean-Stark-apparatus. After cooling to room 
temperature the solution was purified directly by column chromatography on 
silica (1:1 v/v dichloromethane in light petroleum ether) to obtain the product 
as orange solid.
Isolated yield: 872 mg (4.09 mmol, 40.9 %).
1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.74 (d, J = 1.4 Hz, 1H, Ar-CH=C), 6.97 
(ddd, J = 10.2, 8.3, 2.9 Hz, 1H, FC-CH-CF), 6.85 (m, 1H, FC-CH-C), 5.32 (d, J = 1.3 
Hz, 2H, O-CH2).
19F NMR (282 MHz, CDCl3): δ [ppm] = -117.36 (t, J = 7.8 Hz, 1F, p-CF), -129.91 
(d, J = 10.3 Hz, 1F, o-CF).
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FT-IR (neat): v [cm-1] = 3080, 2925, 2873, 1655, 1586, 1516, 1322, 1218.
Mp (uncorrected): 114-116 °C.
The compound is unknown to literature.
11.6 STANDARD OPERATING PROCEDURE 46 (SOP46): BIOCATALYTIC 
2H-CHROMENE REDUCTION WITH AN ENOATE REDUCTASE FROM 
GLUCONOBACTER OXYDANS (GOX-ER)
The following synthesis was conducted with enzyme-coupled cofactor 
regeneration with an alcohol dehydrogenase from Lactobacillus kefir and 2-
propanol as cosubstrate and cosolvent. This way the substrate was also 
distributed homogenously in the reaction mixture. A solution of the 
corresponding 3-substituted 6,8-difluoro-2H-chromene (0.1 mmol) in 2-
propanol (2.5 mL) was added to an enzyme solution of Gox-ER (10 mg, 20 U, 
Batch-No. 361), NADP+ (10 mg, 0.014 mmol) and LK-ADH (50 μL, 1:1 v/v in 
glycerin, 3.75 U) in KPB (7.5 mL, 50 mM, pH 6.0). The resulting emulsion was 
stirred for 24 hours at room temperature. The mixture was diluted with brine 
(10 mL) and brought to saturation with neat sodium chloride. After extraction 
with MTBE (3x 25 mL) the combined organic phase was washed with brine 
(20 mL) and dried over MgSO4. All volatile compounds were removed in vacuo
and the crude product was analyzed by NMR spectroscopy for conversion and 
HPLC for enantiomeric excess.
Table 97. Biocatalytic reduction of various 3-substituted 2H-chromenes with 
Gox-ER
Entry EWGa
Conversion 
[%]
Yield 
[mg(%)]
ee
[%]
1 CHO >95.0a n.d. n.d.
2 CN <1.0 - -
3 NO2 >95.0 14.1 (n.d.) < 1.0 (6.7)b
(a) Electron-withdrawing group (EWG): aldehyde (CHO), nitrile (CN), nitro (NO2) (b) LK-ADH-
catalyzed reduction of carbaldehyde; 2H-chromene-3-carbinol and 3-hydroxymethylchroman as 
byproducts (c) racemic product after 24 hours, however, 6.7 % ee after 6 hours reaction time.
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11.6.1 (3RS)-6,8-DIFLUORO-3-NITROCHROMAN
The following synthesis was conducted according to SOP41. A solution of 
6,8-difluoro-3-nitro-2H-chromene (21.2 mg, 0.1 mmol) in 2-propanol (2.5 mL)
was added to an enzyme solution of Gox-ER (10 mg, 20 U, Batch-No. 361), 
NADP+ (10 mg, 0.014 mmol) and LK-ADH (50 μL, 1:1 v/v in glycerin, 3.75 U) in 
KPB (7.5 mL, 50 mM, pH 6.0). The resulting emulsion was stirred for 24 hours at 
room temperature. The work-up was done as described in SOP41. Analysis with 
1H-NMR shows quantitative conversion to the desired product. Chiral HPLC 
(Daicel Chiralcel OJ-H, 95:5 SC-CO2/iPA, 0.8 mL/min, 212 nm, Rt1 = 19.8 min, 
Rt2 = 21.0 min) shows a poor enantioselectivity of 6.7 % ee (6 h) to a racemic 
product (24 h).
116 H. E. Gottlieb, V. Kotlyar, A. Nudelman, J. Org. Chem. 1997, 62, 7512-7515.
117 M. A. Mohamed, K.-i. Yamada, K. Tomioka, Tetrahedron Lett. 2009, 50, 
3436–3438.
118 A. F. Burchat, J. Chong, N. Nielsen, J. Organomet. Chem. 1997, 542, 281–
283.
119 P. L. Coe, M. Löhr, C. Rochin, J. Chem. Soc., Perkin Trans. 1 1998, 2803–2812.
120 G. Bartoli, M. Bosco, A. Carlone, R. Dalpozzo, M. Locatelli, P. Melchiorre, P. 
Palazzi, L. Sambri, Synlett, 2006, 2104-2108.
121 E. Santaniello, M. Chiari, P. Ferraboschi, S. Trave, J. Org. Chem. 1988, 53, 
1567–1569.
122 R. Öhrlein, G. Baisch, Adv. Synth. Catal. 2003, 345, 713-715.
123 WO03004455, 2003, Example 1a, p. 19.
124 C. H. Heathcock, C. R. Hadley, T. Rosen, P. D. Theisen, S. J. Hecker, J. Med. 
Chem. 1987, 30, 1858-1873.
125 A. Holý, Collect. Czech. Chem. Commun. 1978, 43, 3444–3465.
126 M. Baumann, Identifizierung aktiver und enantioselektiver Hydrolasen für 
den industriellen Einsatz. Doctoral dissertation, Greifswald, 2002.
127 E. E. Jacobsen, B. H. Hoff, A. R. Moen, T. Anthonsen, J. Mol. Catal. B: Enzym.
2003, 21, 55–58.
128 WO 2003004456 /A1, 2003, Example 1b, p. 19.
129 H. Schönherr, J. Mollitor, C. Schneider, Eur. J. Org. Chem. 2010, 2010, 3908–
3918.
130 V. M. Sánchez, F. Rebolledo, V. Gotor, J. Org. Chem. 1999, 64, 1464–1470.
131 W. Li, X. Ma, W. Fan, X. Tao, X. Li, X. Xie, Z. Zhang, Org. Lett. 2011, 13, 3876–
3879.
[314]
132 WO 2003004456 /A1, 2003, Example 1c, p. 20.
133 WO 2003004455 /A2, 2003, Example 5a, p. 26.
134 M. Watanabe, H. Koike, T. Ishiba, T. Okada, S. Seo, K. Hirai, Bioorg. Med. 
Chem. 1997, 5, 437–444.
135 R. Touati, V. Ratovelomanana-Vidal, Tetrahedron: Asymmetry 2006, 17, 
3400–3405.
136 WO 2003004455 /A2, 2003, Example 5a, p. 26.
137 J. Kim, K. A. De Castro, M. Lim, H. Rhee, Tetrahedron 2010, 66, 3995-4001.
138 K. Durchschein, B. Ferreira-da Silva, S. Wallner, P. Macheroux, W. Kroutil, S. 
M. Glueck, K. Faber, Green Chem. 2010, 12, 616.
139 P. L. Wu, M. Chu, F. W. Fowler, J. Org. Chem. 1988, 53, 963–972.
140 R. Shang, D.-S. Ji, L. Chu, Y. Fu, L. Liu, Angew. Chem. Int. Ed. 2011, 50, 4470–
4474.
141 P. J. Black, M. G. Edwards, J. M. J. Williams, Eur. J. Org. Chem. 2006, 2006, 
4367–4378.
142 M. M. Salunkhe, R. V. Nair, J. Mol. Catal. B: Enzym. 2000, 10, 535–538.
143 N. Sakai, K. Kawana, R Ikeda, Y. Nakaike, T. Konakahara, Eur. J. Org. Chem. 
2011, 3178–3183.
144 Y. Kato, K. Nakamura, H. Sakiyama, S. G. Mayhew, Y. Asano, Biochemistry
2000, 39, 800–809.
145 Y. Kato, S. Yoshida, S.-X. Xie, J. Biosci. Bioeng. 2004, 97, 250-259.
146 Y. Kato, Y. Asano, Protein Expression Purif. 2003, 28, 131-139.
147 Y. Asano, “Enzymathic Synthesis of (S)-Phenylalanine and Related (S)-Amino 
Acids by Phenylalanine Dehydrogenase” from: Methods in Biotechnology, 
Vol 17: Microbial Enzymes and Biotransformations, 2005, 157-165.
148 J. Che, Y. Lam, Adv. Synth. Catal. 2010, 352, 1752–1758.
149 Y. Ji, W. C. Trenkle, J. V. Vowles, Org. Lett. 2006, 8, 1161–1163.
150 P. J. Jervis, L. R. Cox, Beilstein J. Org. Chem. 2007, 3.
151 J. Zimmermann, D. Seebach, T.-K. Ha, Helv. Chim. Acta. 1988, 71, 1143–
1155.
152 J. Yadav, D. C. Bhunia, V. K. Singh, P. Srihari, Tetrahedron Letters 2009, 50, 
2470–2473.
153 J. M. M. Batista, D. C. Torres, D. M. M. de Jorge, C. E. A. Soares, W. M. 
Bezerra, E. R. Silveira, T. B. Grangeiro, J. Braz. Chem. Soc. 2012, 23, 818–824.
154 M. Zhang, P. Zhao, Y. Leng, G. Chen, J. Wang, J. Huang, Chem. Eur. J. 2012, 
18, 12773–12782.
155 Y. Chi, L. Guo, N. A. Kopf, S. H. Gellman, J. Am. Chem. Soc. 2008, 130, 5608–
5609.
156 C. Conti, N. Desideri, Bioorg. Med. Chem. 2010, 18, 6480–6488.
157 WO2008092491, 2008, Example 2.2.3, p. 43.
[315]
158 WO2008092491, 2008, Example 2.2.2, p. 43
159 M. ai Neirabeyeh, R. Koussini, G. Guillaumet, Synth. Commun. 1990, 20, 
783-788.
[316]
12 LIST OF ABBREVIATIONS
3-DHG diethyl 3-hydroxyglutarate
Ac acetyl
ADH alcohol dehydrogenase
API active pharmaceutical ingredient
CAE cephalosporin C acetylesterase
CHY a-chymotrypsin
DABCO 1,4-diazabicyclo[2.2.2]octane
DCM dichloromethane
DMAP N,N-dimethylaminopyridine
DMF N,N-dimethylformamide
EHG monoethyl 3-hydroxyglutarate
ER enoate reductase
FMN flavin mononucleotide
HPLC high-performance liquid chromatography
HWE HORNER-WADSWORTH-EMMONS
IPA iso-propanol
KPB potassium phosphate buffer
LK Lactobacillus kefir
MTBE tert-butyl methyl ether
NAD(P)+ nicotinamide adenine dinucleotide (phosphate)
NMR nuclear magnetic resonance
NOE Nuclear-OVERHAUSER-Effect
Rsp Rhodococcus sp.
T3P Tris-n-propyltriphosphonic acid anhydride
TBAF tetra-n-butylammonium fluoride
TBS tert-butyldimethylsilyl
TEA triethylamine
THF tetrahydrofurane
THP tetrahydropyran-2-yl
TMEDA tetramethylethylendiamine
TPPO triphenylphosphine oxide
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